Top Pharma Export Products from India Manufacturers Sellers Pharmaceutical Companies Medicine Buyers
Top Pharma Export Products from India Manufacturers Sellers Pharmaceutical Companies Medicine Buyers
INTRODUCTION
India is one of the world’s important pharmaceutical manufacturing and exporting countries.
However, pharmaceutical export is fundamentally different from exporting ordinary commodities.
A pharmaceutical exporter has to understand product quality, manufacturing, regulatory approval, documentation, pricing, logistics, foreign buyers and destination-country requirements.
For example, an Indian manufacturer may legally manufacture a medicine in India, but that does not automatically mean the same medicine can be marketed commercially in the United States, United Kingdom, European Union or another country.
Therefore, the basic export chain should be understood as:
PRODUCT → MANUFACTURER → QUALITY → REGULATORY REQUIREMENTS → BUYER/IMPORTER → DOCUMENTATION → PRICE → LOGISTICS → CUSTOMS → DELIVERY → POST-MARKET RESPONSIBILITIES
PART I — PHARMA EXPORT FUNDAMENTALS
Chapter 1 — Understanding Pharmaceutical Exports
What is pharma export?
Pharmaceutical export is the international supply of pharmaceutical products from one country to another while complying with the applicable laws and regulatory requirements of both countries.
Pharmaceutical exports can include:
- Finished formulations
- APIs
- Intermediates
- OTC medicines
- Prescription medicines
- Certain biological products
- Pharmaceutical raw materials
- Excipients
- Nutraceutical-related products, where legally classified as such
The regulatory treatment differs substantially between these categories.
Chapter 2 — Important Pharma Terms
API
Active Pharmaceutical Ingredient
The pharmacologically active component of a medicine.
Example:
Paracetamol can be the API in a paracetamol tablet.
Excipient
An inactive ingredient used to manufacture a pharmaceutical dosage form.
Examples include:
- Fillers
- Binders
- Disintegrants
- Lubricants
- Preservatives
- Coloring agents
Formulation
A finished medicinal product containing one or more active ingredients together with appropriate excipients.
Tablet
A solid dosage form generally produced by compression or another suitable manufacturing process.
Capsule
A dosage form in which pharmaceutical material is enclosed within a capsule shell.
Syrup
A liquid oral preparation, often containing active pharmaceutical ingredients dissolved or dispersed in a suitable vehicle.
Injection
A sterile pharmaceutical preparation intended for administration by injection.
Cream
A semisolid topical preparation.
Ointment
A semisolid preparation generally intended for application to skin or other appropriate surfaces.
PART II — STARTING A PHARMA EXPORT BUSINESS FROM INDIA
Chapter 3 — Basic Business Setup
Before starting pharmaceutical exports, an entrepreneur should understand:
Business entity → Tax registration → IEC → Bank → Product sourcing → Applicable drug permissions → Manufacturer verification → Buyer → Regulatory assessment → Shipment
Depending on the business model, additional licences and registrations may apply.
Important Indian Authorities
DGFT
Directorate General of Foreign Trade
Deals with India’s foreign-trade framework and export/import procedures.
CDSCO
Central Drugs Standard Control Organisation
India’s central drug regulatory authority.
State Drug Control Authority
State-level authorities perform various drug licensing, inspection and enforcement functions.
PART III — PRODUCT SELECTION
Chapter 4 — How to Select a Pharmaceutical Product
A beginner should not select a medicine merely because:
“It is popular in India.”
Instead, evaluate:
- Product demand
- Target country
- Regulatory status
- Competition
- Manufacturer capability
- Product registration
- Shelf life
- MOQ
- Price
- Freight
- Importer requirements
- Market size
- Intellectual-property considerations
- Label requirements
- Documentation
PRODUCT EVALUATION FORM
Field | Information |
Product | |
Composition | |
Strength | |
Dosage Form | |
Pack Size | |
Manufacturer | |
Manufacturing Licence | |
GMP | |
COA | |
COPP/CPP | |
HS Code | |
Target Country | |
Regulatory Authority | |
Registration Required | |
Importer | |
MOQ | |
EXW | |
FOB | |
CIF | |
Shelf Life | |
Lead Time | |
Private Label | |
OEM | |
Verification |
PART IV — MANUFACTURER DUE DILIGENCE
Before selecting a pharmaceutical manufacturer, verify:
Company
- Legal company name
- Registered address
- Manufacturing location
- Website
- Contact details
Regulatory
- Manufacturing licence
- Product permission
- GMP status
- Applicable certifications
- Export history
Quality
- COA
- Product specifications
- Stability information
- Batch information
- Quality system
Commercial
- MOQ
- Price
- Lead time
- Payment terms
- Packaging
- Private-label capability
- OEM capability
MANUFACTURER VERIFICATION CHECKLIST
□ Company verified
□ Manufacturing facility verified
□ Licence verified
□ Product verified
□ GMP status checked
□ COA obtained
□ Product specification obtained
□ MOQ confirmed
□ Price confirmed
□ Lead time confirmed
□ Export history checked
□ Private-label capability checked
□ Target-country regulatory capability checked
PART V — USA / FDA
This is one of the most important chapters.
FDA
Food and Drug Administration
The US federal agency responsible for regulating drugs and various other products.
Critical distinction
FDA establishment registration is NOT the same as FDA drug approval.
This distinction should be memorized by every pharma exporter.
For applicable foreign establishments, FDA requires registration and drug-listing processes, but a particular drug may also require an appropriate approved marketing application or other applicable regulatory pathway.
Important US Terms
NDA
New Drug Application
ANDA
Abbreviated New Drug Application
BLA
Biologics License Application
IND
Investigational New Drug
NDC
National Drug Code
CGMP
Current Good Manufacturing Practice
US Agent
A US-based representative/contact for applicable foreign establishments.
USA EXPORT CHECKLIST
Before supplying a pharmaceutical product to the USA, investigate:
□ Manufacturer
□ Product
□ Composition
□ FDA establishment status
□ Drug listing
□ Applicable marketing application
□ Importer
□ US Agent
□ Labeling
□ CGMP
□ Product-specific requirements
□ Shipping requirements
□ Customs/FDA import requirements
□ Buyer authorization
PART VI — UK / MHRA
MHRA
Medicines and Healthcare products Regulatory Agency
The UK’s medicines and healthcare-products regulator.
The UK has its own medicines regulatory framework.
Therefore:
India approval ≠ UK approval
and
EU authorization ≠ automatically UK authorization
UK CHECKLIST
□ Product classification
□ Marketing authorization
□ Manufacturer
□ Importer
□ UK regulatory requirements
□ Labeling
□ GMP
□ Pharmacovigilance
□ Product information
□ Regulatory submission requirements
PART VII — UAE & GCC
For Middle Eastern markets, investigate the destination country’s exact regulatory framework.
Important markets include:
- UAE
- Saudi Arabia
- Qatar
- Kuwait
- Oman
- Bahrain
Do not assume that registration in one GCC country automatically permits sale in every other GCC market.
PART VIII — EUROPE
Important concepts include:
- EMA
- National competent authorities
- Marketing authorization
- CTD
- eCTD
- GMP
- Pharmacovigilance
- Product information
- Qualified regulatory responsibilities
The exact authorization procedure depends on the product and intended market.
PART IX — OTHER INTERNATIONAL MARKETS
Important regulatory authorities include:
Country | Authority |
USA | FDA |
UK | MHRA |
Australia | TGA |
Canada | Health Canada |
Saudi Arabia | SFDA |
South Africa | SAHPRA |
European Union | EMA + relevant national authorities |
India | CDSCO + State authorities |
PART X — EXPORT DOCUMENTATION
A pharmaceutical export may involve documents such as:
- Purchase Order
- Proforma Invoice
- Commercial Invoice
- Packing List
- Certificate of Origin
- COA
- GMP certificate
- CPP/COPP where applicable
- Product registration documentation
- Shipping documents
- Insurance documents
- Customs/export documentation
- Regulatory certificates
- Batch documents
The exact list must be determined according to the product and destination.
PART XI — PRICING
Basic pricing model
Product Cost
Packaging
Documentation
Inland Transportation
Freight
Insurance
Other applicable costs
Exporter Margin
=
Export Price
Then determine the appropriate Incoterm.
Important Incoterms
EXW
Ex Works
FOB
Free On Board
CFR
Cost and Freight
CIF
Cost, Insurance and Freight
DDP
Delivered Duty Paid
Always verify the current Incoterms rules and use the correct named place/port.
PART XII — FOREIGN BUYERS
Where can buyers be found?
Potential sources include:
- Pharmaceutical distributors
- Importers
- Wholesalers
- Hospital suppliers
- Government tenders
- Trade fairs
- Industry associations
- Verified B2B platforms
- Business directories
- Professional networks
- Direct company research
BUYER VERIFICATION
Before accepting a large order:
□ Company registration
□ Website
□ Physical address
□ Import licence, where applicable
□ Regulatory status
□ Business references
□ Bank/payment information
□ Product requirement
□ Expected quantity
□ Country
□ Distributor status
PART XIII — PRIVATE LABEL & OEM
Private label can be attractive because the buyer may want:
Indian manufacturing + foreign brand
But the regulatory structure must be understood.
The exporter should identify:
- Manufacturer
- Brand owner
- Marketing authorization holder
- Importer
- Regulatory applicant
- Label owner
- Packaging responsibility
- Pharmacovigilance responsibility, where applicable
PART XIV — LOGISTICS
Air Freight
Advantages:
- Faster
- Useful for urgent/smaller high-value shipments
Disadvantages:
- Higher cost
Sea Freight
Advantages:
- Generally economical for larger shipments
Disadvantages:
- Longer transit time
Cold Chain
Some products require controlled temperatures.
The exporter must consider:
- Storage temperature
- Transport temperature
- Packaging qualification
- Temperature monitoring
- Temperature excursion management
- Stability requirements
PART XV — PAYMENT
Common structures include:
Advance Payment
Buyer pays before shipment.
Letter of Credit
Bank-mediated payment subject to specified terms.
Documentary Collection
Banks facilitate document/payment processes according to agreed arrangements.
Open Account
Buyer pays after shipment under agreed credit terms.
Open-account transactions can create significant credit risk for exporters.
PART XVI — QUALITY
QA
Quality Assurance.
Focuses on the overall quality system.
QC
Quality Control.
Focuses heavily on testing and verification.
CAPA
Corrective and Preventive Action.
Deviation
A departure from an approved procedure or expected requirement.
Change Control
A formal system for evaluating and controlling changes.
Validation
Documented evidence that a process or method consistently achieves its intended purpose.
PART XVII — INTERVIEW QUESTION BANK
The first 200 questions have already been established above in the earlier section of this manuscript.
The next section expands the book into scenario-based interview questions and MCQs.
PART XVIII — PRACTICAL CASE STUDIES
CASE STUDY 1 — India to USA
Situation
An Indian manufacturer offers:
Paracetamol Tablets
A US buyer wants 100,000 boxes.
Questions
- Can the exporter immediately ship?
- Is Indian approval sufficient?
- What FDA requirements apply?
- Who is the US importer?
- What is the applicable US regulatory pathway?
- What labeling is required?
- Is the manufacturer appropriately registered?
- What documentation is required?
- What is the agreed Incoterm?
- What happens if FDA refuses admission?
Lesson
Never treat:
Indian manufacturing licence + Indian market availability
as equivalent to:
US authorization to market the product.
CASE STUDY 2 — UAE Private Label
A UAE company wants 50,000 boxes under its own brand.
Exporter should investigate:
- Product composition
- UAE regulatory status
- Local importer
- Manufacturer
- Private-label agreement
- Brand/trademark
- Packaging
- Labeling
- MOQ
- Registration
- Price
- Payment
- Shipment requirements
CASE STUDY 3 — Suspicious Buyer
A new buyer requests:
“Send 50,000 boxes immediately. We will pay after customs clearance.”
Correct approach
Do not accept automatically.
Perform:
Buyer verification → regulatory verification → commercial risk assessment → payment-risk assessment → contract → shipment
CASE STUDY 4 — Extremely Cheap Manufacturer
Manufacturer A offers $0.20.
Manufacturer B offers $0.55.
Do not automatically choose A.
Compare:
- Licence
- GMP
- Product quality
- Specifications
- COA
- Shelf life
- Packaging
- Regulatory status
- Manufacturing capacity
- Export history
- Documents
Lowest price does not necessarily mean lowest total cost.
PART XIX — MASTER EXPORT CHECKLIST
Before Product Selection
□ Demand research
□ Country research
□ Regulatory research
□ Competitor research
□ Pricing research
Before Manufacturer Selection
□ Licence
□ GMP
□ Product capability
□ Quality documents
□ MOQ
□ Price
□ Lead time
Before Buyer Selection
□ Company verification
□ Importer status
□ Regulatory status
□ Payment risk
□ Market requirement
Before Shipment
□ Product registration
□ Documents
□ Packaging
□ Label
□ Batch details
□ COA
□ Invoice
□ Packing list
□ Transport
□ Insurance
□ Customs
□ Destination requirements
PART XX — READY-TO-USE BUSINESS TEMPLATES
Manufacturer Inquiry Template
Subject: Pharmaceutical Product Manufacturing & Export Inquiry
Dear Sir/Madam,
We are interested in sourcing pharmaceutical products for international markets.
Please provide the following information:
- Product name
- Composition
- Strength
- Dosage form
- Pack size
- MOQ
- Ex-factory price
- FOB price
- Manufacturing licence details
- GMP certification
- COA availability
- CPP/COPP availability, where applicable
- Private-label capability
- OEM capability
- Lead time
- Shelf life
- Export countries
- Available regulatory documents
Regards,
[Company Name]
SECTION 1 — PHARMA EXPORT BASICS
- What is pharmaceutical export?
Answer: Exporting medicines, APIs, formulations, biological products or other pharmaceutical products from India to another country in compliance with Indian and destination-country requirements.
- What is a pharmaceutical formulation?
Answer: A finished medicinal dosage form such as a tablet, capsule, syrup, injection, cream, ointment or suspension.
- What is an API?
Answer: API means Active Pharmaceutical Ingredient, the substance responsible for the pharmacological effect of a medicine.
- What is a finished dosage form?
Answer: A medicine prepared in its final form for administration, such as tablets, capsules, injections or syrups.
- What is a generic medicine?
Answer: A medicine designed to be equivalent to an established/reference medicine according to the regulatory requirements of the target market.
- What is a branded generic?
Answer: A generic medicine marketed under a brand/trade name rather than simply the generic ingredient name.
- What is an OTC medicine?
Answer: OTC means Over-the-Counter, a medicine that can be sold without a prescription where permitted by the applicable country’s rules.
- What is a prescription medicine?
Answer: A medicine that requires a prescription under the laws of the relevant market.
- What is private-label pharma?
Answer: A manufacturer produces the medicine while another company markets it under its own brand, subject to applicable regulatory and licensing requirements.
- What is OEM in pharma?
Answer: OEM generally refers to manufacturing a product for another company according to agreed specifications, branding and regulatory arrangements.
- What is contract manufacturing?
Answer: A company contracts a licensed manufacturer to produce pharmaceutical products on its behalf.
- What is a pharma exporter?
Answer: A business involved in supplying pharmaceutical products from India to international buyers while managing commercial, regulatory and export requirements.
- Can a pharma exporter be different from the manufacturer?
Answer: Yes. An exporter can source products from an appropriately licensed manufacturer, subject to applicable Indian and destination-country requirements.
- What is a pharmaceutical importer?
Answer: A company or entity in the destination country legally responsible for importing pharmaceutical products.
- What is a distributor?
Answer: A company that purchases or receives products and distributes them through a market’s supply chain.
- What is a marketing authorisation?
Answer: Regulatory authorization allowing a medicinal product to be marketed in a particular jurisdiction.
- Is Indian approval automatically valid in the USA?
Answer: No. Approval or marketing in India does not automatically authorize commercial marketing in the USA.
- Is Indian approval automatically valid in the UK?
Answer: No. The UK has its own medicines licensing requirements administered by the MHRA.
- Why is country-specific registration important?
Answer: Because every market can have different requirements for product registration, labeling, manufacturing, importer licensing and pharmacovigilance.
- What is the first thing to identify before exporting a medicine?
Answer: Identify the exact product, composition, strength, dosage form, manufacturer and target country, then determine the applicable regulatory pathway.
SECTION 2 — INDIA EXPORT BASICS
- What is IEC?
Answer: IEC means Importer Exporter Code, issued by DGFT and generally required for carrying out import/export activities in India.
- What is DGFT?
Answer: Directorate General of Foreign Trade, the Indian authority responsible for administering India’s foreign-trade policy and related export/import procedures.
- What is CDSCO?
Answer: Central Drugs Standard Control Organisation, India’s central drug regulatory authority.
- What is a State Drug Control Authority?
Answer: The state-level drug regulatory authority responsible for various licensing, inspection and enforcement functions under applicable Indian drug laws.
- Does every pharma exporter need a manufacturing licence?
Answer: Not necessarily. The requirement depends on whether the business manufactures, wholesales, exports, repacks/relabels, etc., and on the products involved.
- Can a trader export medicines manufactured by another company?
Answer: Potentially yes, provided the business structure, licences, sourcing and export activities comply with applicable requirements.
- What is a drug manufacturing licence?
Answer: Regulatory authorization allowing an eligible facility to manufacture specified pharmaceutical products.
- What is a wholesale drug licence?
Answer: A licence authorizing eligible wholesale activities involving specified drugs, subject to applicable law.
- What is GMP?
Answer: Good Manufacturing Practice, a system of requirements intended to ensure medicines are consistently produced and controlled according to quality standards.
- What is WHO-GMP?
Answer: GMP requirements based on standards/guidance associated with the World Health Organization; the exact certificate and its acceptance depend on the relevant authority and market.
- What is COPP?
Answer: Certificate of Pharmaceutical Product, generally issued within the WHO Certification Scheme framework for pharmaceutical products and used in regulatory processes in various countries.
- What is CPP?
Answer: CPP commonly refers to Certificate of Pharmaceutical Product; terminology and exact format can vary by regulatory framework.
- What is a Certificate of Analysis?
Answer: A COA provides analytical/test results for a product or batch against specified quality requirements.
- What is a batch number?
Answer: A unique identifier assigned to a particular production batch.
- What is batch manufacturing?
Answer: Production of a defined quantity of product under controlled manufacturing conditions.
- What is shelf life?
Answer: The period during which a product is expected to remain within approved specifications when stored under specified conditions.
- What is a product specification?
Answer: A defined set of quality parameters, acceptance criteria and testing requirements for a pharmaceutical product.
- What is a stability study?
Answer: A study evaluating how product quality changes over time under specified storage conditions.
- What is a specification sheet?
Answer: A document describing product characteristics and quality specifications such as assay, dissolution, impurities and other applicable tests.
- Why should an exporter verify the manufacturer?
Answer: To reduce risks involving licences, quality, documentation, regulatory compliance, counterfeit products and shipment problems.
SECTION 3 — PRODUCT EVALUATION
- What information should be collected for every medicine?
Answer: Product name, composition, strength, dosage form, pack size, manufacturer, licence information, shelf life, HS code, regulatory status and target market.
- What is composition?
Answer: The qualitative and quantitative ingredients contained in a pharmaceutical product.
- What is strength?
Answer: The amount/concentration of active ingredient in the specified dosage unit or volume.
- What is dosage form?
Answer: The physical pharmaceutical form in which a medicine is administered—for example tablet, capsule, syrup or injection.
- What is pack size?
Answer: The number/quantity of units contained in a sales or shipping package.
- Why is dosage form important?
Answer: Regulatory classification, manufacturing requirements, stability, labeling and market authorization can depend on dosage form.
- Why is strength important?
Answer: Different strengths may have different regulatory status, registration requirements, product codes and labeling.
- Can the same medicine have different regulatory status in different countries?
Answer: Yes.
- Can the same composition have different brand names?
Answer: Yes. Brand names are often market-specific.
- Can a product registered in one country be exported to another without registration?
Answer: Not necessarily. The destination country’s requirements must be checked.
SECTION 4 — USA / FDA
FDA’s current guidance states that foreign establishments manufacturing, repacking, relabeling or salvaging drugs offered for import into the US generally must register with FDA, list applicable drugs, identify known importers and renew registration annually. FDA also checks applicable marketing applications and labeling at import.
- What is FDA?
Answer: U.S. Food and Drug Administration, the US federal agency regulating drugs, biologics, medical devices, food and other FDA-regulated products.
- Can an Indian medicine simply be shipped to the USA?
Answer: No. The product must meet applicable US requirements before commercial importation.
- What is an NDA?
Answer: New Drug Application, an application used to seek FDA approval for a new drug.
- What is ANDA?
Answer: Abbreviated New Drug Application, commonly used for approval of eligible generic drugs.
- What is BLA?
Answer: Biologics License Application, an application for applicable biological products.
- What is IND?
Answer: Investigational New Drug application, used for applicable investigational drugs in clinical research.
- Does every US medicine require an NDA?
Answer: No. The applicable pathway depends on the product.
- Does every generic medicine require an ANDA?
Answer: Not necessarily. The appropriate regulatory pathway depends on the product and applicable US law.
- What is an FDA-registered establishment?
Answer: An eligible establishment that has completed the applicable FDA drug-establishment registration process.
- Does FDA registration mean FDA approval?
Answer: No. Registration and listing are not the same as approval of a particular drug application.
- What is FDA drug listing?
Answer: The required submission of applicable drug-product information to FDA by establishments subject to drug-listing requirements.
- What is NDC?
Answer: National Drug Code, a US drug identification system/code associated with listed drug products.
- Does an NDC automatically mean FDA approval?
Answer: No. An NDC/listing should not be treated by itself as proof that a product has FDA approval.
- What is a US Agent?
Answer: A US-based representative/contact required for applicable foreign establishments registered with FDA.
- What is CGMP?
Answer: Current Good Manufacturing Practice, the applicable US manufacturing quality requirements.
- What happens if required FDA information does not match at import?
Answer: FDA may request additional information, delay review or detain the shipment.
- Can FDA refuse a drug shipment?
Answer: Yes.
- What happens if a product requiring an NDA/ANDA/BLA/IND does not have the required application?
Answer: It can be subject to refusal of admission.
- Are APIs regulated by FDA?
Answer: Yes. APIs imported into the US are subject to applicable US requirements.
- Are OTC medicines regulated by FDA?
Answer: Yes. Imported OTC medicines must comply with applicable FDA requirements, including applicable labeling and manufacturing requirements.
- Are prescription medicines regulated by FDA?
Answer: Yes.
- Is labeling important for US export?
Answer: Extremely important. US labeling requirements apply to drugs offered for import.
- What is Drug Facts?
Answer: The standardized information panel required for applicable OTC drug labeling.
- What is “Rx only”?
Answer: A labeling designation used for prescription drugs as required by applicable US regulations.
- Does FDA inspect foreign manufacturing facilities?
Answer: FDA can inspect foreign facilities subject to its regulatory authority.
SECTION 5 — UK / MHRA
- What is MHRA?
Answer: Medicines and Healthcare products Regulatory Agency, the UK’s medicines and healthcare-products regulator.
- Can an Indian medicine automatically be sold in the UK?
Answer: No. Applicable UK marketing authorization and supply requirements must be satisfied.
- What is a UK Marketing Authorisation?
Answer: Regulatory authorization permitting a medicinal product to be marketed in the UK.
- Who regulates medicines in Great Britain?
Answer: MHRA is the UK medicines regulator.
- What is PL?
Answer: PL is a Product Licence/marketing authorisation number prefix used in the UK’s current licensing framework.
- Are UK licensing procedures currently the same as EU procedures?
Answer: No. The UK’s regulatory framework has changed following Brexit and has its own requirements.
- What is eCTD?
Answer: Electronic Common Technical Document, a standardized electronic format used for regulatory submissions.
- What is pharmacovigilance?
Answer: The science and activities relating to detecting, assessing, understanding and preventing adverse effects and other medicine-related risks.
- What is an MAH?
Answer: Marketing Authorisation Holder.
- Why is the MAH important?
Answer: The MAH has defined regulatory responsibilities associated with the authorized medicinal product.
The MHRA currently requires UK medicines licensing applications through its regulatory submission processes, with eCTD used for applicable submissions.
SECTION 6 — UAE / GCC / MIDDLE EAST
- Can an Indian medicine automatically be sold in UAE?
Answer: No. UAE registration/import requirements must be satisfied.
- Who is the local importer?
Answer: The UAE-based entity authorized to import the applicable pharmaceutical products.
- Why is a local importer important?
Answer: Pharmaceutical importation and distribution generally require locally compliant entities and regulatory arrangements.
- What should you ask a UAE buyer?
Answer: Ask for importer licence details, product registration status, required documents, target pack size, forecast quantity and regulatory requirements.
- Should UAE registration be checked before quoting?
Answer: Yes, particularly when the buyer expects immediate commercial supply.
- Can one GCC country’s approval automatically cover every GCC country?
Answer: No. Requirements should be checked country by country.
- What is SFDA?
Answer: Saudi Food and Drug Authority, Saudi Arabia’s regulatory authority for medicines and other regulated products.
- What is SAHPRA?
Answer: South African Health Products Regulatory Authority.
- What is TGA?
Answer: Therapeutic Goods Administration, Australia’s regulator of therapeutic goods.
- What is Health Canada?
Answer: Canada’s federal department responsible for regulating health products, including drugs.
SECTION 7 — EUROPE / REGULATORY
- What is the EU?
Answer: European Union.
- Is EU pharmaceutical approval automatically equivalent to UK approval?
Answer: No.
- What is EMA?
Answer: European Medicines Agency.
- What is a Marketing Authorisation?
Answer: Regulatory permission to market a medicinal product in a jurisdiction.
- What is CTD?
Answer: Common Technical Document, a standardized structure for organizing regulatory information.
- What are CTD modules?
Answer: Generally:
- Module 1 – Regional administrative information
- Module 2 – Summaries
- Module 3 – Quality
- Module 4 – Nonclinical
- Module 5 – Clinical
- What is ICH?
Answer: International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use.
- Why is ICH important?
Answer: It promotes harmonization of technical requirements for pharmaceutical development and registration.
- What is dossier?
Answer: A structured collection of regulatory, technical, quality, safety and efficacy information submitted for product authorization.
- What is eCTD?
Answer: An electronic version of the Common Technical Document used for regulatory submissions.
SECTION 8 — QUALITY CONTROL
- What is QA?
Answer: Quality Assurance—the overall system ensuring pharmaceutical quality requirements are consistently achieved.
- What is QC?
Answer: Quality Control—testing and related activities used to verify that products meet specified requirements.
- QA vs QC?
Answer: QA focuses on the quality system and prevention; QC focuses heavily on testing and verification.
- What is assay?
Answer: A quantitative measurement of the amount of active ingredient present.
- What is dissolution?
Answer: A test measuring the rate and extent to which an active ingredient is released into a specified medium.
- What are impurities?
Answer: Unwanted chemical components present in a pharmaceutical substance or product.
- What is microbial testing?
Answer: Testing for microorganisms or microbial characteristics as applicable to the product.
- What is sterility testing?
Answer: Testing used for applicable sterile products to determine whether viable microorganisms are present.
- What is endotoxin?
Answer: A bacterial component that can cause significant biological effects and is particularly important for applicable parenteral products.
- What is validation?
Answer: Documented evidence demonstrating that a process, method or system consistently produces the intended result.
- What is process validation?
Answer: Evidence that a manufacturing process can consistently produce product meeting predetermined specifications.
- What is cleaning validation?
Answer: Evidence that cleaning procedures effectively remove residues to predetermined acceptable levels.
- What is analytical method validation?
Answer: Demonstrating that an analytical method is suitable for its intended purpose.
- What is deviation?
Answer: A departure from an approved procedure, specification or expected process.
- What is CAPA?
Answer: Corrective and Preventive Action—actions taken to correct problems and prevent recurrence.
SECTION 9 — PHARMA DOCUMENTATION
- What is a Commercial Invoice?
Answer: The commercial document showing the transaction, products, quantities, values and other required details.
- What is a Proforma Invoice?
Answer: A preliminary commercial document/quotation issued before the final commercial invoice.
- What is a Packing List?
Answer: A document detailing packages, quantities, weights and shipment packing information.
- What is Certificate of Origin?
Answer: A document certifying the country of origin of goods.
- What is Bill of Lading?
Answer: A transport document commonly used for ocean shipments.
- What is Air Waybill?
Answer: A transport document for air cargo.
- What is COA?
Answer: Certificate of Analysis.
- What is GMP certificate?
Answer: Evidence issued by a competent authority or recognized framework showing compliance with specified GMP requirements.
- What is COPP?
Answer: Certificate of Pharmaceutical Product.
- What is Free Sale Certificate?
Answer: A certificate used in certain regulatory/export contexts to demonstrate that a product is freely sold/marketed in the relevant country, where applicable.
- What is a batch release document?
Answer: Documentation showing that a particular batch has been reviewed/released according to applicable quality procedures.
- What is a product registration certificate?
Answer: Regulatory evidence that the product is authorized/registered in the relevant market.
- What is a manufacturing licence?
Answer: Authorization allowing a facility to manufacture specified products under applicable regulations.
- What is a Certificate of Pharmaceutical Product used for?
Answer: It can support pharmaceutical product registration or regulatory assessment in importing countries, depending on their requirements.
- Can the exporter create a fake certificate if the buyer asks for one?
Answer: Absolutely not. All regulatory and quality documents must be genuine and verifiable.
SECTION 10 — COMMERCIAL QUESTIONS
- What is MOQ?
Answer: Minimum Order Quantity.
- What is FOB?
Answer: Free On Board, an Incoterms rule defining responsibilities, costs and risk transfer according to the agreed shipment point.
- What is CIF?
Answer: Cost, Insurance and Freight, an Incoterms rule applicable to sea/inland-waterway transport under specified conditions.
- What is EXW?
Answer: Ex Works, where the seller’s delivery obligation is generally fulfilled by making the goods available at the named place, subject to the Incoterms rules.
- What is CFR?
Answer: Cost and Freight, an Incoterms rule for sea/inland-waterway transport.
- What is DDP?
Answer: Delivered Duty Paid, an Incoterms rule placing extensive delivery/import obligations on the seller.
- What is landed cost?
Answer: The total cost of getting a product to the relevant destination, including applicable product, freight, insurance, duties, taxes and other costs.
- How do you calculate export price?
Answer: Consider product cost + packaging + documentation + compliance costs + inland transport + freight + insurance + applicable duties/taxes/fees + financing/overhead + profit.
- Should you give the same price to every country?
Answer: No. Freight, regulatory requirements, packaging, taxes, duties, MOQ, payment terms and market conditions differ.
- What is a price quotation?
Answer: A formal offer showing product, specification, quantity, price, Incoterm, validity and applicable commercial conditions.
- What is quotation validity?
Answer: The period during which the quoted price and terms remain valid.
- What is MOQ negotiation?
Answer: Negotiating the minimum order quantity with the manufacturer or buyer.
- What is payment term?
Answer: The agreed method and timing of payment, such as advance payment, LC or agreed credit terms.
- What is LC?
Answer: Letter of Credit, a bank-mediated payment mechanism subject to its specified terms and documentary conditions.
- What is advance payment?
Answer: The buyer pays some or all agreed amount before shipment.
SECTION 11 — BUYER INTERVIEW QUESTIONS
- How do you find pharma buyers?
Answer: Through verified distributors/importers, trade fairs, industry directories, regulatory databases, legitimate B2B platforms, business networks and targeted market research.
- How do you verify a buyer?
Answer: Verify company registration, website/domain, physical address, import licence where applicable, regulatory credentials, business history, references and payment risk.
- Should you trust every buyer who sends an email?
Answer: No.
- What is buyer due diligence?
Answer: Checking whether the prospective buyer is legitimate, authorized and commercially reliable.
- What information should you request from a foreign pharma buyer?
Answer: Company details, country, importer licence where applicable, product requirement, registration status, forecast quantity, packaging requirements and payment terms.
- Should you send your lowest price immediately?
Answer: No. First understand the product specification, quantity, regulatory requirements, Incoterm and payment conditions.
- What is a purchase forecast?
Answer: The buyer’s expected future purchasing quantity over a specified period.
- What is annual volume?
Answer: Expected total quantity purchased during a year.
- What is a distributor agreement?
Answer: A contractual arrangement defining rights and responsibilities between supplier/exporter and distributor.
- What is exclusivity?
Answer: A contractual arrangement giving a particular party exclusive rights to distribute or sell a product in a defined market, subject to the agreement and law.
SECTION 12 — PRIVATE LABEL / OEM
- Can Indian manufacturers manufacture under a foreign buyer’s brand?
Answer: Yes, where legally and regulatorily permissible and subject to the manufacturer’s capabilities and applicable market requirements.
- What is private-label packaging?
Answer: Packaging carrying the buyer’s approved brand and required product information.
- Can the exporter choose any brand name?
Answer: No. Trademark, regulatory, labeling and market-specific requirements must be checked.
- What is artwork approval?
Answer: Review and approval of the product packaging/label artwork before printing and production.
- Who should approve destination-country artwork?
Answer: The responsible regulatory/marketing authorization parties should approve it according to the applicable market requirements.
- Can one label be used worldwide?
Answer: Usually you should not assume that. Label requirements differ between markets.
- What is a master artwork?
Answer: An approved reference design/document used for controlled packaging production.
- What is batch coding?
Answer: Printing identifying information such as batch number, manufacturing date and expiry information as required.
- What is serialization?
Answer: Assigning unique identifiers to individual saleable packs where required by the target market.
- Why is packaging important in pharma export?
Answer: It protects the product and communicates legally required information about identity, use, storage, batch and expiry.
SECTION 13 — LOGISTICS & SHIPPING
- Air freight or sea freight—which is better?
Answer: It depends on urgency, product value, shipment size, stability, temperature requirements and total cost.
- What is cold-chain shipping?
Answer: Controlled-temperature transportation for products requiring specified temperature conditions.
- What is temperature mapping?
Answer: Evaluation of temperature distribution within a storage/transport environment.
- What is a temperature logger?
Answer: A device recording temperature during storage or transportation.
- Why is humidity important?
Answer: Some pharmaceutical products are sensitive to moisture and require controlled storage/transport conditions.
- What is shipping validation?
Answer: Evidence that the selected shipping process can maintain required product conditions throughout transportation.
- What is cargo insurance?
Answer: Insurance covering specified risks associated with goods during transportation.
- Who selects the freight forwarder?
Answer: It depends on the agreed Incoterm and commercial arrangement.
- What is a freight forwarder?
Answer: A logistics service provider that arranges transportation and related shipment services.
- What is customs clearance?
Answer: The process of completing required customs formalities so goods can legally enter or leave a country.
SECTION 14 — COMPLIANCE & RISK
- What is a restricted drug?
Answer: A product subject to additional legal/regulatory restrictions because of its nature, ingredients or intended use.
- Can narcotic/controlled medicines be exported normally?
Answer: No. Controlled substances can be subject to additional licensing, permits, quotas, documentation and destination-country controls.
- Can banned medicines be exported?
Answer: Never assume that a banned/restricted product can be exported. Specific Indian and destination-country rules must be checked.
India’s CDSCO has specific procedures for certain exports involving unapproved/approved new drugs and banned drugs, including a stated NOC procedure in applicable cases.
- What is sanctions screening?
Answer: Checking whether the parties, countries or transactions are subject to applicable sanctions/restrictions.
- What is denied-party screening?
Answer: Checking customers and transaction parties against applicable restricted/denied-party lists.
- What is anti-bribery compliance?
Answer: Following laws and company policies prohibiting bribery and improper payments.
- Why is documentation accuracy important?
Answer: Incorrect information can cause regulatory delays, customs problems, shipment detention, financial loss or legal consequences.
- Can an exporter alter a COA to satisfy a buyer?
Answer: No.
- Can you claim “FDA approved” simply because the factory is FDA registered?
Answer: No. FDA establishment registration and drug approval are different concepts.
- What is the biggest pharma-export mistake?
Answer: Treating a pharmaceutical product as an ordinary commodity and ignoring destination-country regulatory requirements.
SECTION 15 — ADVANCED INTERVIEW QUESTIONS
- A buyer asks for a medicine that is not registered in his country. What do you do?
Answer: Determine whether registration is required and who will hold the authorization. Do not promise immediate commercial supply until the regulatory pathway is confirmed.
- A buyer asks for FDA-approved tablets, but the manufacturer only has FDA establishment registration. What do you say?
Answer: Explain that establishment registration does not by itself establish that the specific drug is FDA-approved. Verify the product’s actual FDA regulatory status.
- A buyer asks for a COA before placing an order. What do you do?
Answer: Obtain an appropriate genuine COA/sample COA from the manufacturer, clearly distinguishing a sample/specification document from a batch-specific certificate.
- A buyer asks for 100,000 boxes. What do you check first?
Answer: Product specification, registration status, manufacturer capacity, MOQ, production lead time, shelf life, packaging, regulatory documents, price, payment terms and logistics.
- A manufacturer offers a very low price. What do you verify?
Answer: Manufacturer identity, licence, GMP status, product quality, specifications, documents, batch history, export experience, packaging and commercial terms.
- A foreign buyer says, “No registration is needed; just ship it.” What do you do?
Answer: Do not rely solely on the buyer’s statement. Verify the destination country’s legal and regulatory requirements independently.
- A buyer asks for a private-label medicine for the USA. What should you ask?
Answer: Ask who will hold the applicable US regulatory authorization, who is the importer, whether the product has the appropriate FDA pathway, who controls labeling, who is responsible for pharmacovigilance where applicable, and whether the manufacturer meets applicable requirements.
- How would you evaluate a new pharma product for export?
Answer:
Product → Composition → Strength → Dosage Form → Manufacturer → Licence → Quality → HS Code → Target Country → Regulatory Status → Registration → Buyer/Importer → Documents → MOQ → Price → Logistics → Payment → Compliance
- What is your biggest responsibility as a pharma exporter?
Answer: To ensure that the product, manufacturer, documentation, transaction and shipment comply with applicable Indian and destination-country requirements.
- Explain your complete pharma export process in an interview.
Strong interview answer:
“First, I identify the product, composition, strength, dosage form and manufacturer. I verify the manufacturer’s licences, GMP status, quality documents and export capability. Then I select the target country and check its regulatory requirements, product registration status, importer requirements and labeling requirements. After confirming regulatory feasibility, I obtain the manufacturer’s price and MOQ and calculate the export price based on the agreed Incoterm. I verify the buyer and importer, agree on specifications, packaging, payment and documentation, arrange production and quality documentation, coordinate freight and customs clearance, and ensure that all applicable regulatory and shipping requirements are satisfied before dispatch.”
CHAPTER: PHARMA MEDICINES, FORMULAS, USES & INTERNATIONAL EXPORT RESTRICTIONS
Nawinza Global Pharma Formula & Export Reference
This chapter provides a practical reference to pharmaceutical active ingredients and formulations relevant to international pharmaceutical trade.
For each medicine/formula, the book should explain:
- Generic / Active Ingredient
The internationally recognized active pharmaceutical ingredient (API) or combination.
- Example Formulation
Examples of common dosage forms and strengths, such as:
- Tablet
- Capsule
- Oral solution
- Oral suspension
- Injection
- Cream
- Gel
- Eye drops
- Inhalation
- Transdermal preparation
- Modified/extended-release formulation
- Therapeutic Category
For example:
- Antibacterial
- Antiviral
- Anthelmintic
- Antidiabetic
- Antihypertensive
- Lipid-lowering
- CNS medicine
- Analgesic
- Dermatological
- Hormonal
- Oncology
- Ophthalmic
- Erectile-dysfunction medicine
- Main Medical Uses
Explain the principal approved/recognized therapeutic uses in plain language.
- Prescription / OTC Status
Indicate whether the medicine is generally:
- Prescription medicine
- OTC/non-prescription in some markets
- Pharmacy-only
- Controlled/restricted
- Hospital/specialist use
- Country-dependent
- Export Classification
Each product will receive a practical status such as:
🟢 REGULAR REGULATED MEDICINE
May be exportable subject to normal product/import/regulatory requirements.
🟡 SPECIAL REGULATORY CHECK
Destination-specific registration, licence, prescription, import permit or other controls may apply.
🟠 CONTROLLED / HIGH-RISK REGULATORY CATEGORY
Additional controlled-substance, narcotics, psychotropic, hormonal, anabolic-steroid or other special controls may apply.
🔴 PROHIBITED / NOT APPROVED FOR THE PROPOSED MARKET OR USE
The product cannot simply be exported/marketed under ordinary pharmaceutical procedures; the exact legal basis must be verified.
⚫ PRODUCT-SPECIFIC INVESTIGATION REQUIRED
The active ingredient may be permitted in one form/use but restricted in another, so the exact formulation, strength, indication and destination must be checked.
COUNTRY RESTRICTION FRAMEWORK
For every formula, the book should separately examine:
🇺🇸 USA
Check:
- FDA establishment registration
- Drug listing
- Applicable NDA/ANDA/BLA/IND or OTC pathway
- Product approval/status
- Import admissibility
- Label requirements
- CGMP
- Controlled-substance requirements where applicable
- Import alerts
- Destination-specific commercial requirements
FDA states that foreign establishments manufacturing, repacking, relabelling or salvaging drugs for U.S. import generally must register with FDA and list their drugs; applicable marketing authorization requirements also apply.
Important:
“Doctor prescribed it” does not mean an Indian exporter can automatically commercially import it into the USA.
🇬🇧 UK
Check:
- MHRA requirements
- Marketing authorisation
- Wholesale/manufacturing/import licensing
- Product classification
- Controlled-drug status
- Labelling
- Importer requirements
- Special/exceptional pathways where applicable
UK guidance states that importing licensed medicines can require appropriate licences, and controlled substances require additional consideration.
For controlled drugs, UK law generally restricts import/export unless an applicable exception or licence applies.
🇦🇪 UAE
Check:
- UAE pharmaceutical registration
- Importer/medical warehouse authorization
- Product registration
- Controlled-drug classification
- Prior approvals
- Prescription requirements
- Quantity restrictions
- Labelling
- Customs documentation
For controlled substances/products, UAE legislation provides for prior approval before import by relevant licensed pharmaceutical establishments.
🇸🇦 Saudi Arabia
Check:
- SFDA requirements
- Product registration
- Importer authorization
- Controlled-drug status
- Prescription classification
- Labelling
- Import permits
- Manufacturer documentation
🇧🇷 Brazil
Check:
- ANVISA requirements
- Product registration/authorization
- Importer authorization
- Prescription classification
- Controlled-substance requirements
- Portuguese labelling
- Import documentation
🇿🇦 South Africa
Check:
- SAHPRA requirements
- Product registration
- Importer authorization
- Scheduled-substance controls
- Prescription status
- Labelling
- Import permit requirements
🇨🇦 Canada
Check:
- Health Canada requirements
- Drug identification/authorization
- Importer requirements
- Prescription classification
- Controlled-substance requirements
- Product and establishment compliance
🇦🇺 Australia
Check:
- TGA requirements
- Australian Register of Therapeutic Goods where applicable
- Import requirements
- Prescription status
- Controlled-drug requirements
- Sponsor/importer requirements
🇯🇵 Japan
Check:
- PMDA/MHLW requirements
- Marketing authorization
- Import notification/permission requirements
- Prescription status
- Controlled substances
- Japanese labelling requirements
🇩🇪 🇫🇷 🇳🇱 EUROPEAN MARKETS
Do not treat Europe as one single pharmaceutical market for every purpose.
For each product, determine:
- EU authorization route
- National requirements
- Marketing authorization
- Importer requirements
- GMP
- Prescription status
- Controlled-substance rules
- Labelling
- Pharmacovigilance
- Country-specific requirements
EXAMPLE 1 — SILDENAFIL
Generic: Sildenafil / sildenafil citrate
Therapeutic category: PDE-5 inhibitor
Principal medical use: Treatment of erectile dysfunction; sildenafil has other approved indications in specific formulations/strengths, such as pulmonary arterial hypertension.
Typical formulation: Oral tablets; other dosage forms may exist depending on market.
Prescription status: Generally prescription medicine in many major markets.
Export classification: 🟡 SPECIAL REGULATORY CHECK
Exporter’s questions
Before exporting, determine:
- Is the product authorized in the destination country?
- Is the specific strength authorized?
- Is the formulation authorized?
- Is the Indian manufacturer appropriately qualified?
- Is the foreign importer authorized?
- Is the destination product registration completed?
- Is the label compliant?
- Are there restrictions on promotional claims?
- Are combination products treated differently?
- Does the destination require a prescription?
Important: Prescription status is not the same as a prohibition on commercial export. The exporter must distinguish between:
Prescription-only → Restricted import → Controlled substance → Unapproved product → Prohibited product
These are different legal concepts.
EXAMPLE 2 — TADALAFIL
Generic: Tadalafil
Category: PDE-5 inhibitor
Uses: Primarily erectile dysfunction; also used for certain other approved indications depending on formulation and market.
Typical formulation: Oral tablets.
Export classification: 🟡 SPECIAL REGULATORY CHECK
Check:
- Product authorization
- Strength
- Manufacturer
- Importer
- Prescription classification
- Labelling
- Advertising restrictions
- Destination registration
Your uploaded list contains tadalafil alone as well as tadalafil + dapoxetine formulations.
Combination products must be checked separately.
EXAMPLE 3 — TADALAFIL + DAPOXETINE
Formula: Tadalafil + dapoxetine
Potential therapeutic positioning: Erectile dysfunction combined with premature-ejaculation treatment.
Export classification: 🟠 HIGHER REGULATORY CHECK
Why?
A combination containing two active ingredients should not automatically be assumed to have the same regulatory status as either ingredient separately.
The exporter should determine:
- Whether the combination is approved
- Whether the exact strength is approved
- Whether the dosage form is approved
- Whether the combination is recognized in the destination market
- Whether separate product registration is required
- Whether both APIs are permitted
- Whether prescription restrictions apply
- Whether promotional claims comply with local law
Business lesson:
A combination product can have a different regulatory pathway from its individual ingredients.
EXAMPLE 4 — MODAFINIL
Generic: Modafinil
Category: CNS medicine / wakefulness-promoting agent
Uses: Certain sleep-related disorders according to applicable approved indications.
Export classification: 🟠 SPECIAL / CONTROLLED-STATUS CHECK
Do not classify modafinil as simply “normal medicine” for every destination.
Check:
- Controlled-drug or psychotropic classification
- Import licence
- Prescription requirement
- Quantity limits
- Importer authorization
- Product registration
- Documentation
- Destination-specific restrictions
Your uploaded list contains multiple modafinil formulations, including 400 mg and other tablet references.
EXAMPLE 5 — TESTOSTERONE
Generic: Testosterone and testosterone esters
Examples in your source:
- Testosterone gel
- Testosterone enanthate injection
- Testosterone propionate
- Testosterone cypionate
- Testosterone combinations
Your source contains several testosterone formulations and strengths.
Category: Androgen / hormone
Uses: Testosterone replacement in appropriately diagnosed patients and other approved indications depending on jurisdiction.
Export classification: 🟠 SPECIAL REGULATORY CHECK
Potential considerations:
- Prescription status
- Controlled-substance/scheduled status
- Import permit
- Quantity controls
- Authorized importer
- Product registration
- Prescription requirements
- Record-keeping
- Anti-diversion controls
Important: A testosterone product must never be treated as an ordinary OTC export merely because it is legally manufactured in India.
EXAMPLE 6 — ISOTRETINOIN
Generic: Isotretinoin
Category: Retinoid / dermatological medicine
Principal use: Severe acne under appropriate medical supervision.
Export classification: 🟠 SPECIAL REGULATORY / SAFETY CHECK
Important considerations can include:
- Prescription status
- Pregnancy-related safety controls
- Risk-management requirements
- Labelling
- Patient counselling
- Product registration
- Destination-specific pregnancy-prevention requirements
Your source contains isotretinoin capsules and multiple references to isotretinoin.
EXAMPLE 7 — IVERMECTIN
Generic: Ivermectin
Category: Antiparasitic
Uses: Treatment of certain parasitic infections according to approved indications and dosage forms.
Export classification: 🟡 PRODUCT- AND COUNTRY-SPECIFIC CHECK
Your source contains numerous ivermectin entries and different strengths, including 12 mg, 15 mg, 24 mg, 40 mg and 80 mg references.
The exporter must not assume that every strength or dosage form is approved in every market.
Check:
- Human vs veterinary product
- Approved indication
- Strength
- Formulation
- Product registration
- Prescription classification
- Import requirements
EXAMPLE 8 — SEMAGLUTIDE
Generic: Semaglutide
Category: GLP-1 receptor agonist
Uses: Depending on the specific product and authorization, treatment of type 2 diabetes and/or weight-management indications.
Export classification: 🟠 HIGH REGULATORY CHECK
Important:
- Exact product
- Route
- Dosage form
- Strength
- Indication
- Marketing authorization
- Manufacturer
- Cold-chain/storage requirements where applicable
- Importer
- Product registration
- Prescription classification
Your source includes semaglutide and an oral semaglutide reference.
Do not assume that an oral semaglutide formulation has the same regulatory status as an injectable product.
EXAMPLE 9 — PREGABALIN
Generic: Pregabalin
Category: CNS / anticonvulsant / neuropathic-pain medicine
Uses: Depending on authorization, neuropathic pain, epilepsy adjunctive therapy and certain other indications.
Export classification: 🟠 SPECIAL REGULATORY CHECK
Potential requirements:
- Prescription
- Controlled/regulated classification in some jurisdictions
- Import authorization
- Quantity limits
- Product registration
- Authorized importer
- Record keeping
Your source contains several pregabalin references.
EXAMPLE 10 — TAPENTADOL
Generic: Tapentadol
Category: Centrally acting analgesic
Uses: Certain moderate-to-severe pain indications depending on the approved product.
Export classification: 🔴/🟠 CONTROLLED-SUBSTANCE CHECK
The exact classification varies by country and formulation.
The exporter should determine:
- Whether it is a controlled drug
- Schedule/classification
- Import licence
- Export authorization
- Quantity limits
- Authorized importer
- Secure transport
- Record keeping
- Prescription requirements
Your source includes tapentadol.
EXAMPLE 11 — ZOPICLONE
Generic: Zopiclone
Category: Hypnotic/sedative
Use: Short-term management of insomnia in appropriate circumstances.
Export classification: 🟠 CONTROLLED / SPECIAL REGULATORY CHECK
The destination country’s controlled-drug classification must be checked before accepting an order.
Your source includes zopiclone and eszopiclone references.
EXAMPLE 12 — AZITHROMYCIN
Generic: Azithromycin
Category: Macrolide antibiotic
Uses: Treatment of susceptible bacterial infections according to approved indications.
Export classification: 🟡 REGULATED MEDICINE
Important checks:
- Prescription status
- Antimicrobial regulations
- Product registration
- Importer authorization
- Label
- Strength
- Dosage form
- Antibiotic stewardship requirements
Your source contains repeated azithromycin entries.
EXAMPLE 13 — DAPAGLIFLOZIN + METFORMIN
Formula: Dapagliflozin + Metformin
Category: Antidiabetic combination
Uses: Glycemic control in appropriate patients according to approved indications.
Your source specifically lists a 10 mg/1000 mg extended-release combination.
Export classification: 🟡 PRODUCT REGISTRATION CHECK
Check:
- Exact strength
- Immediate vs extended release
- Combination authorization
- Manufacturer
- Registration
- Prescription classification
- Labelling
- Importer authorization
EXAMPLE 14 — ADAPALENE + BENZOYL PEROXIDE
Formula: Adapalene + benzoyl peroxide
Category: Topical dermatological / anti-acne
Use: Treatment of acne vulgaris according to approved indications.
Your source contains both 0.1%/2.5% and 0.3%/2.5% formulations.
Important export lesson:
Do not treat:
Adapalene 0.1% + benzoyl peroxide 2.5%
and
Adapalene 0.3% + benzoyl peroxide 2.5%
as automatically interchangeable products.
The exact strength and formulation must be checked against the destination authorization.
EXAMPLE 15 — TRETINOIN
Generic: Tretinoin
Category: Retinoid
Uses: Depending on formulation, commonly dermatological treatment such as acne; oral/other formulations have different indications and much higher regulatory considerations.
Your source includes tretinoin cream and gel formulations.
Export classification: 🟡/🟠 FORMULATION-SPECIFIC CHECK
The exporter must distinguish topical dermatological products from systemic formulations.
EXAMPLE 16 — ISOTRETINOIN vs TRETINOIN
These should be separate entries in the book.
Feature | Isotretinoin | Tretinoin |
Drug family | Retinoid | Retinoid |
Common dermatological use | Severe acne | Acne/other approved uses depending on formulation |
Formulation | Often oral capsules | Often topical |
Pregnancy concerns | Very significant | Significant |
Export classification | Special regulatory check | Product/formulation-specific |
Registration | Destination dependent | Destination dependent |
Important: Similar drug families do not mean identical regulatory treatment.
EXAMPLE 17 — HYDROQUINONE
Generic: Hydroquinone
Category: Dermatological depigmenting agent
Use: Treatment of certain hyperpigmentation disorders depending on jurisdiction.
Your source contains Hydroquinone Cream USP.
Export classification: 🟠 COUNTRY-SPECIFIC CHECK
Hydroquinone is an excellent example for this book because its regulatory status can differ substantially depending on:
- Concentration
- Cosmetic vs medicinal claim
- Product formulation
- Prescription status
- Destination country’s cosmetic/medicine classification
EXAMPLE 18 — CLOMIPHENE
Generic: Clomiphene citrate
Category: Selective estrogen receptor modulator
Use: Fertility treatment in appropriately selected patients.
Your source includes 25 mg and 50 mg references.
Export classification: 🟠 PRESCRIPTION / PRODUCT REGISTRATION CHECK
EXAMPLE 19 — TOFACITINIB
Generic: Tofacitinib
Category: Janus kinase (JAK) inhibitor
Uses: Certain inflammatory/autoimmune diseases depending on approved indication and market.
Your source lists tofacitinib 5 mg.
Export classification: 🟠 HIGH REGULATORY CHECK
The exporter should verify:
- Product authorization
- Indication
- Strength
- Safety warnings
- Prescription status
- Importer authorization
- Pharmacovigilance obligations
EXAMPLE 20 — SORAFENIB
Generic: Sorafenib
Category: Antineoplastic / kinase inhibitor
Use: Certain cancers according to approved indications.
Your source lists sorafenib 200 mg.
Export classification: 🟠 SPECIALIST / PRESCRIPTION / REGULATORY CHECK
Oncology products should receive particularly careful verification of registration, indication, quality, supply chain and pharmacovigilance requirements.
IMPORTANT RULE FOR THE ENTIRE DATABASE
“PRESCRIPTION” DOES NOT MEAN “FREE TO IMPORT.”
A doctor prescribing a medicine is not automatically an import authorization.
For commercial pharmaceutical export, the exporter may need to satisfy:
Manufacturer requirements + product authorization + importer authorization + destination registration + import permit + customs requirements + labelling + quality requirements + controlled-substance requirements, where applicable.
The exact combination depends on the product and country.
COUNTRY STATUS CODES FOR THE BOOK
Use these columns in the master Nawinza database:
Code | Meaning |
🟢 | Generally permitted subject to normal regulatory requirements |
🟡 | Prescription / registration / import requirements |
🟠 | Special control, high regulatory risk or controlled-category check |
🔴 | Prohibited/not approved under the specified circumstances |
⚫ | Exact product/formulation/country investigation required |
Additional column:
“Reason for restriction”
Examples:
- Prescription-only
- Controlled substance
- Psychotropic
- Narcotic
- Hormonal/anabolic
- Product not approved
- Import licence required
- Product registration required
- Special permit required
- Dosage-form restriction
- Strength restriction
- Label restriction
- Veterinary-only
- Cosmetic vs medicine classification
- Unapproved combination
- Cold-chain requirement
- Safety programme
- Country-specific prohibition
This is much more useful than simply writing “BANNED.”
PART XXI — MCQ QUESTION BANK
Questions 201–300
201. What does API stand for?
- Approved Pharmaceutical Import
B. Active Pharmaceutical Ingredient
C. Authorized Product Information
D. Advanced Pharmaceutical Industry
Answer: B
202. Which organization regulates medicines in the USA?
- MHRA
B. FDA
C. TGA
D. CDSCO
Answer: B
203. What does FDA stand for?
- Federal Drug Administration
B. Food and Drug Administration
C. Foreign Drug Authority
D. Food Development Agency
Answer: B
204. What does CDSCO stand for?
- Central Drug Standard Control Organisation
B. Central Drugs Standard Control Organisation
C. Central Drug Supply Control Office
D. Council for Drug Safety Control Organisation
Answer: B
205. Which organization is India’s foreign-trade authority?
- FDA
B. DGFT
C. MHRA
D. EMA
Answer: B
206. What is IEC?
- International Export Certificate
B. Importer Exporter Code
C. Indian Export Code
D. International Excise Certificate
Answer: B
207. What does GMP stand for?
- General Manufacturing Process
B. Good Manufacturing Practice
C. Global Medicine Procedure
D. Government Manufacturing Policy
Answer: B
208. What is COA?
- Certificate of Approval
B. Certificate of Analysis
C. Certificate of Authorization
D. Certificate of Application
Answer: B
209. What does MOQ mean?
- Minimum Order Quantity
B. Maximum Order Quantity
C. Manufacturer Order Quality
D. Minimum Official Quotation
Answer: A
210. Which document commonly contains batch test results?
- COA
B. Packing List
C. Purchase Order
D. Bill of Lading
Answer: A
211. What does NDA mean in US pharmaceutical regulation?
- New Drug Application
B. National Drug Authorization
C. New Distribution Agreement
D. National Drug Application
Answer: A
212. What does ANDA mean?
- Advanced New Drug Application
B. Abbreviated New Drug Application
C. Approved National Drug Application
D. American New Drug Authorization
Answer: B
213. What does BLA stand for?
- Biological Licence Application
B. Biologics License Application
C. Basic Laboratory Authorization
D. Biotech Legal Application
Answer: B
214. Which is NOT automatically equivalent to FDA approval?
- Establishment registration
B. Approved drug application
C. Applicable marketing authorization
D. Regulatory approval
Answer: A
215. What is NDC associated with?
- US drug identification
B. Indian customs
C. UK VAT
D. Indian GST
Answer: A
216. Which authority regulates medicines in the UK?
- FDA
B. MHRA
C. CDSCO
D. TGA
Answer: B
217. What does MHRA stand for?
- Medicines and Healthcare products Regulatory Agency
B. Medical Health Regulatory Authority
C. Medicines Health Registration Agency
D. Medical Healthcare Research Authority
Answer: A
218. Which authority regulates therapeutic goods in Australia?
- FDA
B. TGA
C. MHRA
D. SFDA
Answer: B
219. Which authority regulates medicines in Saudi Arabia?
- SFDA
B. TGA
C. FDA
D. SAHPRA
Answer: A
220. What does SFDA stand for?
- Saudi Food and Drug Authority
B. Saudi Federal Drug Agency
C. Saudi Food Development Authority
D. Saudi Formulation Drug Agency
Answer: A
221. What is SAHPRA?
- South African Health Products Regulatory Authority
B. Saudi Health Products Regulatory Authority
C. South American Health Products Registration Authority
D. South African Hospital Pharmaceutical Regulatory Agency
Answer: A
222. Which document provides product/batch analytical results?
- COA
B. Invoice
C. Packing List
D. Purchase Order
Answer: A
223. Which document primarily describes packages and quantities?
- COA
B. Packing List
C. GMP
D. CPP
Answer: B
224. Which document identifies the commercial value of goods?
- Commercial Invoice
B. COA
C. GMP
D. Stability Report
Answer: A
225. What is a Proforma Invoice?
- Preliminary commercial document/quotation
B. Final customs declaration only
C. Quality certificate
D. GMP certificate
Answer: A
226. What does FOB mean?
- Free On Board
B. Freight On Business
C. Free Overseas Billing
D. Foreign Order Booking
Answer: A
227. What does CIF mean?
- Cost, Insurance and Freight
B. Customs, Import and Freight
C. Cost, Invoice and Finance
D. Cargo Insurance Form
Answer: A
228. What does CFR mean?
- Cost and Freight
B. Customs Freight Rate
C. Cargo Financial Report
D. Certificate Freight Requirement
Answer: A
229. Which Incoterm places extensive import/delivery obligations on the seller?
- EXW
B. DDP
C. FOB
D. FCA
Answer: B
230. What is private-label manufacturing?
- Manufacturing under another company’s brand
B. Manufacturing without quality control
C. Manufacturing only APIs
D. Importing medicines privately
Answer: A
231. What is OEM?
- Original Equipment Manufacturer
B. Overseas Export Medicine
C. Official Export Manufacturer
D. Original Export Market
Answer: A
232. What is QA?
- Quality Assurance
B. Quality Authorization
C. Quantity Assessment
D. Quick Approval
Answer: A
233. What is QC?
- Quality Control
B. Quantity Certificate
C. Quality Customs
D. Quick Compliance
Answer: A
234. What does CAPA stand for?
- Corrective and Preventive Action
B. Certificate Approval and Product Authorization
C. Customs and Pharmaceutical Administration
D. Corrective Approval Process Application
Answer: A
235. What is pharmacovigilance?
- Monitoring medicine safety and related risks
B. Product pricing
C. Freight calculation
D. Customs valuation
Answer: A
236. What is shelf life?
- Period during which product is expected to remain within specifications under specified conditions
B. Manufacturing time
C. Shipping time
D. Registration period only
Answer: A
237. What is batch number?
- Identifier for a production batch
B. Buyer registration number
C. HS code
D. Invoice number only
Answer: A
238. What is HS Code?
- Harmonized System code used for goods classification
B. Health Safety certificate
C. Hospital Supply number
D. Healthcare Standard
Answer: A
239. Why is HS classification important?
- Customs/trade classification
B. It replaces drug approval
C. It replaces GMP
D. It guarantees buyer payment
Answer: A
240. What is an importer?
- Destination-country entity importing goods
B. Indian manufacturer
C. Freight company only
D. Quality laboratory
Answer: A
241. What should an exporter do before accepting a large foreign order?
- Verify the buyer
B. Ignore the buyer’s identity
C. Ship immediately
D. Change the COA
Answer: A
242. What is buyer due diligence?
- Checking buyer legitimacy and business/regulatory status
B. Calculating tablet weight
C. Testing API
D. Printing labels
Answer: A
243. Which is a buyer red flag?
- Refusal to provide company details
B. Proper registration
C. Verified importer licence
D. Clear purchase order
Answer: A
244. Which is a manufacturer red flag?
- Refusal to provide required licence information
B. Valid documentation
C. Verifiable facility
D. Transparent quality system
Answer: A
245. What should you do if a buyer requests a fake certificate?
- Refuse
B. Prepare it
C. Modify an old certificate
D. Ask another exporter to prepare it
Answer: A
246. What is cold-chain logistics?
- Temperature-controlled logistics
B. Sea freight only
C. Air freight only
D. Frozen food logistics only
Answer: A
247. Why are temperature loggers used?
- To record temperature conditions
B. To calculate customs duty
C. To create invoices
D. To determine HS codes
Answer: A
248. What is a freight forwarder?
- Logistics service provider arranging transportation/shipping services
B. Drug regulator
C. Pharmaceutical manufacturer
D. Foreign buyer only
Answer: A
249. What is a Bill of Lading?
- Transport document commonly used for sea shipments
B. GMP certificate
C. Drug licence
D. COA
Answer: A
250. What is an Air Waybill?
- Air cargo transport document
B. Drug registration
C. Manufacturing licence
D. COA
Answer: A
251. Which is generally faster?
- Air freight
B. Sea freight
C. Both always identical
D. Neither
Answer: A
252. What is a Letter of Credit?
- Bank-mediated payment mechanism subject to specified terms
B. Drug licence
C. Manufacturing certificate
D. Shipping label
Answer: A
253. What is advance payment?
- Buyer pays before shipment according to agreed terms
B. Seller pays buyer
C. Customs pays exporter
D. Manufacturer pays importer
Answer: A
254. What is open-account trade?
- Buyer pays later under agreed credit terms
B. Buyer always pays cash
C. No contract is required
D. Government pays seller
Answer: A
255. What is product registration?
- Regulatory authorization/registration process for a product in a market
B. Bank registration
C. Freight registration
D. Trademark only
Answer: A
256. Is trademark registration the same as medicine registration?
- No
B. Yes
C. Always
D. Only in India
Answer: A
257. Can one medicine have different brand names in different countries?
- Yes
B. No
C. Never
D. Only for APIs
Answer: A
258. What is stability testing?
- Testing product quality over time under specified conditions
B. Testing buyer reliability
C. Freight testing
D. Customs testing only
Answer: A
259. What is validation?
- Documented evidence that a process/method consistently achieves its intended purpose
B. Price approval
C. Buyer verification
D. Export promotion
Answer: A
260. What is a deviation?
- Departure from an approved procedure/specification or expected condition
B. Product registration
C. Buyer payment
D. Freight quotation
Answer: A
261. Which department primarily performs laboratory testing?
- QC
B. Sales
C. Finance
D. Logistics
Answer: A
262. Which function focuses on the overall quality system?
- QA
B. Sales
C. Customs
D. Freight
Answer: A
263. What does GMP focus on?
- Consistent pharmaceutical manufacturing and quality systems
B. Buyer acquisition only
C. Freight pricing
D. Currency exchange
Answer: A
264. What is an API manufacturer?
- Manufacturer of active pharmaceutical ingredients
B. Finished-goods distributor only
C. Freight company
D. Customs authority
Answer: A
265. What is a finished formulation manufacturer?
- Manufacturer of finished medicinal dosage forms
B. Shipping company
C. Bank
D. Customs broker
Answer: A
266. What should be checked before selecting a manufacturer?
- Licence and product capability
B. Only website design
C. Only lowest price
D. Only social-media followers
Answer: A
267. What should be checked before private-label production?
- Product, manufacturer, regulatory and packaging requirements
B. Only logo colour
C. Only carton size
D. Only website domain
Answer: A
268. What is artwork approval?
- Approval of packaging/label design and required information
B. Buyer payment
C. Freight booking
D. Customs valuation
Answer: A
269. Why is country-specific labeling important?
- Different countries can have different legal labeling requirements
B. All countries have identical rules
C. Labels never matter
D. Only carton colour matters
Answer: A
270. What is an MAH?
- Marketing Authorisation Holder
B. Manufacturer Approval Holder
C. Medical Application Handler
D. Market Audit Holder
Answer: A
271. What is a regulatory dossier?
- Structured collection of regulatory/technical information
B. Freight invoice
C. Buyer list
D. Packing material
Answer: A
272. What is CTD?
- Common Technical Document
B. Customs Trade Document
C. Certificate Technical Data
D. Commercial Trade Declaration
Answer: A
273. What is eCTD?
- Electronic Common Technical Document
B. Export Customs Trade Document
C. Electronic Customs Tax Declaration
D. Export Certificate Technical Data
Answer: A
274. What is ICH?
- International Council for Harmonisation
B. Indian Customs House
C. International Customs Hub
D. Indian Chemical Health Authority
Answer: A
275. What is a generic medicine?
- Medicine meeting applicable requirements as a generic equivalent of a reference product
B. Counterfeit medicine
C. Medicine without quality standards
D. Unregistered medicine
Answer: A
276. What is counterfeit medicine?
- Falsely represented medicine involving identity/source/composition or other fraudulent characteristics
B. Generic medicine
C. Private-label medicine
D. OTC medicine
Answer: A
277. Should counterfeit products ever be exported?
- No
B. Yes
C. Only with buyer permission
D. Only to developing markets
Answer: A
278. What is an OTC medicine?
- Over-the-Counter medicine
B. Official Trade Certificate
C. Overseas Treatment Certificate
D. Original Tablet Composition
Answer: A
279. What is a prescription medicine?
- Medicine subject to prescription requirements in the relevant market
B. Medicine without regulations
C. Food product
D. Packaging material
Answer: A
280. What should determine whether a medicine can be commercially marketed in another country?
- Applicable destination-country regulatory requirements
B. Indian price only
C. Exporter’s preference
D. Buyer’s WhatsApp message
Answer: A
281. What is a US Agent?
- Applicable US-based representative/contact for a foreign establishment
B. US customs officer
C. US pharmacist
D. Drug manufacturer
Answer: A
282. Does FDA registration automatically prove a product is approved?
- No
B. Yes
C. Always
D. Only for generics
Answer: A
283. What is CGMP?
- Current Good Manufacturing Practice
B. Central Government Medicine Policy
C. Certified Generic Manufacturing Product
D. Current Global Medicine Procedure
Answer: A
284. What is pharmacovigilance primarily concerned with?
- Medicine safety
B. Freight costs
C. Customs duty
D. Marketing design
Answer: A
285. What is a product complaint?
- Report concerning a product’s quality, safety, packaging or other issue
B. Price quotation
C. Freight booking
D. Purchase order
Answer: A
286. What is a product recall?
- Process of removing/returning affected products from the market or supply chain
B. New product launch
C. Buyer acquisition
D. Export quotation
Answer: A
287. What is change control?
- Controlled process for evaluating and managing changes
B. Currency exchange
C. Price negotiation only
D. Buyer selection
Answer: A
288. What is a quality agreement?
- Agreement defining quality responsibilities between relevant parties
B. Purchase order only
C. Freight document
D. Bank statement
Answer: A
289. What is a manufacturing agreement?
- Contract defining manufacturing responsibilities and commercial/legal terms
B. COA
C. Bill of Lading
D. Certificate of Origin
Answer: A
290. What is a Certificate of Origin?
- Document identifying the origin of goods
B. COA
C. GMP certificate
D. Drug registration certificate
Answer: A
291. What is landed cost?
- Total relevant cost of bringing goods to the destination
B. Manufacturing cost only
C. Freight only
D. Product price only
Answer: A
292. What is exporter margin?
- Profit component included in the export price
B. Customs duty
C. Buyer discount
D. Freight cost
Answer: A
293. Should export price be calculated only from factory price?
- No
B. Yes
C. Always
D. Only for tablets
Answer: A
294. Which can affect export price?
- Freight
B. Insurance
C. Packaging
D. All of the above
Answer: D
295. What is lead time?
- Time required to prepare/manufacture an order before shipment
B. Product shelf life
C. Freight insurance
D. Payment method
Answer: A
296. What is MOQ?
- Minimum Order Quantity
B. Maximum Order Quality
C. Manufacturer Official Quotation
D. Medicine Order Qualification
Answer: A
297. What should an exporter do if the buyer says registration is unnecessary?
- Independently verify the requirement
B. Immediately ship
C. Ignore regulations
D. Change the invoice
Answer: A
298. What is the safest approach to regulatory documents?
- Use genuine, current and verifiable documents
B. Edit certificates
C. Copy another manufacturer’s documents
D. Create documents yourself
Answer: A
299. What is the most important principle in pharmaceutical exporting?
- Compliance and product quality
B. Lowest possible price
C. Fastest shipment regardless of regulations
D. Maximum markup
Answer: A
300. What should an exporter do before shipping a pharmaceutical product?
- Confirm applicable regulatory, documentation, commercial and logistics requirements
B. Ship immediately
C. Wait for customs to decide everything
D. Ask the buyer to handle everything
Answer: A
MCQ ANSWER KEY — 201–300
Q | Ans | Q | Ans | Q | Ans | Q | Ans |
201 | B | 226 | A | 251 | A | 276 | A |
202 | B | 227 | A | 252 | A | 277 | A |
203 | B | 228 | A | 253 | A | 278 | A |
204 | B | 229 | B | 254 | A | 279 | A |
205 | B | 230 | A | 255 | A | 280 | A |
206 | B | 231 | A | 256 | A | 281 | A |
207 | B | 232 | A | 257 | A | 282 | A |
208 | B | 233 | A | 258 | A | 283 | A |
209 | A | 234 | A | 259 | A | 284 | A |
210 | A | 235 | A | 260 | A | 285 | A |
211 | A | 236 | A | 261 | A | 286 | A |
212 | B | 237 | A | 262 | A | 287 | A |
213 | B | 238 | A | 263 | A | 288 | A |
214 | A | 239 | A | 264 | A | 289 | A |
215 | A | 240 | A | 265 | A | 290 | A |
216 | B | 241 | A | 266 | A | 291 | A |
217 | A | 242 | A | 267 | A | 292 | A |
218 | B | 243 | A | 268 | A | 293 | A |
219 | A | 244 | A | 269 | A | 294 | D |
220 | A | 245 | A | 270 | A | 295 | A |
221 | A | 246 | A | 271 | A | 296 | A |
222 | A | 247 | A | 272 | A | 297 | A |
223 | B | 248 | A | 273 | A | 298 | A |
224 | A | 249 | A | 274 | A | 299 | A |
225 | A | 250 | A | 275 | A | 300 | A |
PART XXI — ADVANCED MCQs
MCQs 301–400
Regulatory, USA/FDA, UK/MHRA, UAE, EU, Quality & Documentation
- Which statement about FDA establishment registration is correct?
- It automatically approves every medicine manufactured there
B. It is the same as an ANDA approval
C. It is a regulatory registration and does not by itself mean a specific drug is approved
D. It replaces drug listing
Answer: C
- What is the primary purpose of an ANDA?
- To register a manufacturing facility
B. To seek approval for an eligible generic drug
C. To register a trademark
D. To obtain an export licence from India
Answer: B
- Which US application is generally associated with a new drug?
- NDA
B. IEC
C. COPP
D. COA
Answer: A
- Which application is associated with applicable biological products?
- BLA
B. IEC
C. ANDA
D. COA
Answer: A
- What should an Indian exporter do if a US buyer says, “Your Indian licence is enough for the USA”?
- Accept the statement
B. Ship immediately
C. Verify the US regulatory requirements independently
D. Change the country on the invoice
Answer: C
- Which organization regulates medicines in the UK?
- FDA
B. MHRA
C. CDSCO
D. TGA
Answer: B
- Which statement is correct?
- UK and US pharmaceutical regulations are identical
B. UK and Indian approvals are automatically interchangeable
C. The UK has its own regulatory requirements
D. FDA controls the UK market
Answer: C
- What is an MAH?
- Marketing Authorisation Holder
B. Manufacturing Audit Head
C. Medicine Approval Handler
D. Market Analysis Holder
Answer: A
- What is pharmacovigilance concerned with?
- Product pricing
B. Medicine safety and adverse effects
C. Freight calculation
D. Customs valuation
Answer: B
- What is a regulatory dossier?
- A collection of regulatory and technical information
B. A bank statement
C. A packing list
D. A freight invoice
Answer: A
- Which CTD module generally contains quality information?
- Module 1
B. Module 2
C. Module 3
D. Module 5
Answer: C
- Which CTD module generally contains clinical information?
- Module 1
B. Module 3
C. Module 4
D. Module 5
Answer: D
- What is eCTD?
- Electronic Common Technical Document
B. Export Customs Trade Document
C. Electronic Certificate of Trade
D. Export Certificate Technical Data
Answer: A
- What is ICH primarily associated with?
- International harmonisation of pharmaceutical technical requirements
B. Customs valuation
C. Freight forwarding
D. Export banking
Answer: A
- What is GMP primarily concerned with?
- Pharmaceutical manufacturing quality
B. Export pricing
C. Buyer verification
D. Freight booking
Answer: A
- What is GLP?
- Good Laboratory Practice
B. Global Logistics Procedure
C. General Licence Policy
D. Good Label Printing
Answer: A
- What is GCP?
- Good Clinical Practice
B. General Customs Procedure
C. Global Certificate Process
D. Good Commercial Pricing
Answer: A
- What is GDP in pharmaceutical distribution?
- Good Distribution Practice
B. Gross Domestic Product only
C. General Drug Pricing
D. Global Distribution Product
Answer: A
- Why is GDP important?
- It supports appropriate storage and distribution practices
B. It determines the selling price
C. It replaces product registration
D. It replaces GMP
Answer: A
- What is a temperature excursion?
- A temperature condition outside the specified range
B. A customs delay
C. A pricing change
D. A manufacturing licence
Answer: A
- What is a stability-indicating method?
- An analytical method capable of detecting relevant changes in product quality over time
B. A shipping method
C. A pricing method
D. A customs method
Answer: A
- What is assay testing used for?
- Measuring the amount of active ingredient according to the applicable method/specification
B. Checking the buyer’s bank account
C. Calculating freight
D. Checking carton colour
Answer: A
- What is dissolution testing particularly relevant to?
- Drug release from applicable dosage forms
B. Customs clearance
C. Buyer verification
D. Currency conversion
Answer: A
- What are impurities?
- Unwanted components present in a pharmaceutical substance/product
B. Packaging materials only
C. Shipping documents
D. Buyer information
Answer: A
- What is sterility testing particularly relevant to?
- Applicable sterile products
B. All invoices
C. All tablets
D. Customs documents
Answer: A
- What is endotoxin testing particularly important for?
- Applicable parenteral/sterile products
B. Export invoices
C. Cartons
D. Tablets only
Answer: A
- What is CAPA?
- Corrective and Preventive Action
B. Customs Approval and Product Authorization
C. Certificate and Packaging Agreement
D. Commercial Audit and Price Analysis
Answer: A
- What is deviation management?
- Investigation and appropriate handling of departures from approved requirements
B. Buyer acquisition
C. Freight negotiation
D. Currency conversion
Answer: A
- What is change control?
- Controlled evaluation and management of proposed changes
B. Changing the buyer after shipment
C. Changing the invoice value illegally
D. Changing the HS code without assessment
Answer: A
- What is validation?
- Documented evidence that a process/method performs as intended
B. Price negotiation
C. Buyer registration
D. Export promotion
Answer: A
- What is a COA?
- Certificate of Analysis
B. Certificate of Authorization
C. Customs Order Approval
D. Commercial Overseas Agreement
Answer: A
- Should a batch-specific COA be fabricated before manufacturing?
- Yes
B. No
C. Only for large buyers
D. Only for private label
Answer: B
- What is a Certificate of Origin used for?
- Identifying the origin of goods
B. Proving GMP
C. Proving FDA approval
D. Proving product efficacy
Answer: A
- What is a Commercial Invoice?
- Commercial document showing transaction/product/value information
B. Quality certificate
C. Manufacturing licence
D. Regulatory dossier
Answer: A
- What is a Packing List?
- Shipment/package details
B. Product registration
C. GMP certificate
D. Buyer licence
Answer: A
- What is a Purchase Order?
- Buyer’s formal order for specified goods/services
B. Manufacturing licence
C. COA
D. Certificate of Origin
Answer: A
- What is a Proforma Invoice?
- Preliminary commercial document/quotation
B. Laboratory report
C. Drug licence
D. GMP certificate
Answer: A
- What is a Bill of Lading?
- Transport document commonly used for ocean shipments
B. Drug registration certificate
C. COA
D. Manufacturing licence
Answer: A
- What is an Air Waybill?
- Air transportation document
B. Quality certificate
C. Import licence
D. Product registration
Answer: A
- What is a Certificate of Pharmaceutical Product?
- A pharmaceutical regulatory certificate used in applicable regulatory contexts
B. A freight document
C. A bank certificate
D. A trademark certificate
Answer: A
- What is COPP?
- Certificate of Pharmaceutical Product under the applicable certification framework
B. Certificate of Packing Procedure
C. Customs Overseas Product Permit
D. Commercial Order Processing Permit
Answer: A
- Should an exporter assume every country accepts the same CPP/COPP format?
- Yes
B. No
C. Only for generic medicines
D. Only for APIs
Answer: B
- Why must regulatory documents be current?
- Authorities/buyers may require valid/current information
B. Old documents are always accepted
C. Expiry dates do not matter
D. It only affects freight
Answer: A
- What should an exporter do if a GMP certificate has expired?
- Use it anyway
B. Verify and obtain the appropriate current evidence
C. Change the expiry date
D. Ignore it
Answer: B
- What is a Free Sale Certificate?
- A certificate that may demonstrate free sale/marketing status where applicable
B. A freight document
C. A COA
D. A bank guarantee
Answer: A
- What is product registration?
- Regulatory authorization/registration process for a medicinal product in a market
B. Trademark registration only
C. Exporter bank registration
D. Shipping registration
Answer: A
- What is marketing authorization?
- Regulatory permission to market a medicinal product under applicable law
B. A commercial quotation
C. A shipping document
D. A bank document
Answer: A
- Can trademark registration replace medicine registration?
- Yes
B. No
C. Only in Africa
D. Only for OTC products
Answer: B
- What is an importer licence?
- Authorization held by an eligible importing entity where required
B. Exporter’s GST certificate
C. Manufacturer’s GMP
D. COA
Answer: A
- Why should an exporter identify the importer early?
- Regulatory and customs responsibilities may depend on the importer
B. Importers never matter
C. Only freight depends on importer
D. It determines API purity
Answer: A
MCQs 351–400 — Commercial & Export Operations
- What does MOQ stand for?
- Minimum Order Quantity
B. Maximum Order Quantity
C. Manufacturer Order Quality
D. Market Order Quotation
Answer: A
- What is lead time?
- Time required to prepare an order
B. Shelf life
C. Payment period only
D. Freight insurance period
Answer: A
- What does EXW mean?
- Ex Works
B. Export Works
C. External Warehouse
D. Export Without Warranty
Answer: A
- What does FOB mean?
- Free On Board
B. Freight On Board
C. Foreign Order Booking
D. Free Overseas Billing
Answer: A
- What does CIF include under the Incoterms rule?
- Cost, Insurance and Freight
B. Customs, Import and Freight
C. Cost, Invoice and Finance
D. Cargo Insurance Fee
Answer: A
- What does CFR mean?
- Cost and Freight
B. Customs Freight Rate
C. Cargo Financial Report
D. Certificate Freight Requirement
Answer: A
- Which should be specified with an Incoterm?
- Appropriate named place/port as applicable
B. Buyer’s nickname
C. Product colour only
D. Social-media account
Answer: A
- What is landed cost?
- Total relevant cost to bring goods to the destination
B. Factory price only
C. Freight only
D. Insurance only
Answer: A
- What can increase landed cost?
- Freight
B. Insurance
C. Duties/taxes where applicable
D. All of the above
Answer: D
- What is export margin?
- Profit included in export pricing
B. Customs penalty
C. Freight cost
D. Buyer tax
Answer: A
- Should the exporter calculate only the factory purchase price?
- Yes
B. No
C. Only for tablets
D. Only for USA
Answer: B
- What is payment risk?
- Risk that the seller does not receive expected payment
B. Risk of tablet breakage only
C. Risk of customs classification
D. Risk of temperature excursion only
Answer: A
- Which payment method can provide structured bank-backed documentary protection subject to its terms?
- Letter of Credit
B. WhatsApp
C. Verbal promise
D. Social media
Answer: A
- What should you verify before accepting an open-account order?
- Buyer creditworthiness
B. Only buyer logo
C. Only product colour
D. Only freight rate
Answer: A
- What is buyer due diligence?
- Verification of buyer identity, legitimacy and relevant capability
B. Product testing
C. Freight calculation
D. Label design
Answer: A
- What is supplier due diligence?
- Verification of supplier/manufacturer capability and compliance
B. Buyer marketing
C. Freight booking
D. Currency conversion
Answer: A
- What is a red flag?
- Warning sign indicating possible risk
B. Product certificate
C. Export licence
D. Buyer order
Answer: A
- Which is a red flag?
- Buyer refuses to provide basic company information
B. Verified company registration
C. Valid importer documentation
D. Clear purchase order
Answer: A
- Which is a manufacturer red flag?
- Refusal to provide appropriate licence evidence
B. Valid licence
C. Transparent quality documentation
D. Verifiable facility
Answer: A
- What should an exporter do when information is inconsistent?
- Investigate before proceeding
B. Ignore it
C. Alter the documents
D. Ship faster
Answer: A
- What is private label?
- Product marketed under another company’s brand
B. Counterfeit product
C. Product without a manufacturer
D. Unregistered product by definition
Answer: A
- What is OEM in a pharma context?
- Manufacturing for another business under agreed specifications/arrangements
B. Exporting without documents
C. Only API trading
D. Customs brokerage
Answer: A
- Who should approve destination-market artwork?
- Appropriate responsible regulatory/marketing parties
B. Freight driver
C. Customs guard
D. Random buyer employee
Answer: A
- Can the exporter simply copy a competitor’s packaging?
- Yes
B. No
C. Only if cheaper
D. Only for Africa
Answer: B
- What should private-label packaging comply with?
- Applicable regulatory and labeling requirements
B. Only the exporter’s preference
C. Only Indian design preferences
D. Only buyer colour preference
Answer: A
- What is trademark due diligence?
- Checking whether a proposed brand can legally be used/registered
B. Checking freight
C. Checking batch weight
D. Checking COA
Answer: A
- What is a quality agreement?
- Defines quality-related responsibilities between parties
B. Price quotation
C. Packing list
D. Certificate of Origin
Answer: A
- What is a supply agreement?
- Contract governing supply arrangements
B. GMP certificate
C. COA
D. Air Waybill
Answer: A
- What is a distribution agreement?
- Agreement governing distribution rights/responsibilities
B. Manufacturing test
C. Freight document
D. COA
Answer: A
- What is exclusivity?
- Contractual exclusive rights within defined scope/territory
B. Mandatory in every export
C. Same as GMP
D. Same as registration
Answer: A
- What is cold-chain packaging?
- Packaging designed/qualified to maintain required temperature conditions
B. Normal carton
C. Product label
D. Commercial invoice
Answer: A
- What is temperature mapping?
- Assessment of temperature distribution in a defined environment
B. Route mapping only
C. Buyer mapping
D. Price mapping
Answer: A
- What is a temperature logger?
- Device that records temperature over time
B. Customs document
C. Payment instrument
D. Product registration
Answer: A
- Why is shipping validation important for sensitive products?
- To demonstrate that transportation can maintain required conditions
B. To reduce invoice size
C. To create a buyer list
D. To replace product registration
Answer: A
- What is cargo insurance?
- Insurance covering specified transportation risks
B. Drug licence
C. Product registration
D. GMP
Answer: A
- What is customs clearance?
- Completing applicable customs procedures for import/export
B. Product testing
C. Manufacturing
D. Marketing authorization
Answer: A
- Who commonly assists with transportation arrangements?
- Freight forwarder
B. Drug regulator
C. Buyer pharmacist only
D. Laboratory
Answer: A
- What is an HS code used for?
- Classification of goods for customs/trade purposes
B. Product approval
C. GMP
D. Trademark
Answer: A
- Can an exporter deliberately use an incorrect HS code?
- Yes
B. No
C. Only if buyer requests it
D. Only for small shipments
Answer: B
- What should an exporter do if uncertain about classification?
- Obtain appropriate professional/customs guidance and verify the classification
B. Guess
C. Copy another invoice
D. Let the buyer invent one
Answer: A
- What is export documentation reconciliation?
- Checking that key documents contain consistent information
B. Checking only product colour
C. Checking social media
D. Checking employee attendance
Answer: A
- Why should product name and quantity be consistent across documents?
- To reduce customs/regulatory discrepancies
B. To improve website ranking
C. To reduce tablet weight
D. To change the price
Answer: A
- What can happen if shipping documents contain significant discrepancies?
- Delay, inquiry, detention or other problems may occur
B. Guaranteed faster clearance
C. Automatic approval
D. Lower freight
Answer: A
- What is document control?
- Controlled creation, approval, distribution and revision of documents
B. Customs payment only
C. Buyer acquisition
D. Freight calculation
Answer: A
- Why should obsolete documents be controlled?
- To prevent unintended use of outdated information
B. To increase MOQ
C. To reduce freight
D. To increase product strength
Answer: A
- What is a batch record?
- Controlled manufacturing documentation relating to a batch
B. Buyer quotation
C. Freight invoice
D. Certificate of Origin
Answer: A
- What is a product specification?
- Defined quality requirements/criteria for a product
B. Buyer email
C. Freight quotation
D. Payment receipt
Answer: A
- What is a Certificate of Analysis generally linked to?
- Tested batch/material/product results
B. Buyer registration only
C. Freight insurance
D. Trademark registration
Answer: A
- What should be done with a suspected falsified certificate?
- Stop relying on it and investigate/verify through appropriate channels
B. Use it
C. Edit it
D. Send it to another buyer
Answer: A
- What is the correct overall philosophy for pharma exports?
- Sell first and check regulations later
B. Compliance first, then commercial execution
C. Lowest price first
D. Ship first and solve documentation later
Answer: B
MCQs 401–500
Scenario-Based Pharma Export Questions
- An Indian manufacturer has a valid manufacturing licence but no evidence of required destination-country authorization. What should the exporter do?
- Ship immediately
B. Verify destination requirements before shipment
C. Tell the buyer Indian approval is enough
D. Change the product name
Answer: B
- A buyer asks you to put a lower value on the invoice to reduce customs duty. What should you do?
- Agree
B. Refuse and use accurate documentation
C. Split the invoice secretly
D. Use cash
Answer: B
- A buyer asks you to describe a medicine as a different product to avoid restrictions. What should you do?
- Agree
B. Refuse and comply with applicable classification requirements
C. Change only the packing list
D. Ask the driver
Answer: B
- A manufacturer gives you a COA belonging to another batch. What should you do?
- Use it
B. Request the correct applicable documentation
C. Change the batch number
D. Delete the batch number
Answer: B
- A buyer wants immediate shipment but product registration is still pending. What should you do?
- Ship anyway
B. Confirm whether commercial shipment is legally permissible before proceeding
C. Hide the product name
D. Send without labels
Answer: B
- A buyer wants your product under its own brand. What should you investigate?
- Regulatory and private-label requirements
B. Only logo colour
C. Only carton size
D. Only freight
Answer: A
- A manufacturer says “We are FDA approved.” What should you ask?
- What exactly is approved—facility, product, application or another regulatory status?
B. Nothing
C. Only the price
D. Only MOQ
Answer: A
- A buyer asks whether your Indian GMP certificate proves US compliance. What should you say?
- Always yes
B. It should not automatically be treated as proof of all US requirements
C. No documents are needed
D. GMP never matters
Answer: B
- A buyer asks for 1 million tablets. What should you calculate?
- Manufacturing capacity
B. MOQ
C. Lead time
D. All of the above
Answer: D
- A buyer wants a six-month shelf-life product for a two-month international shipment. What should you investigate?
- Remaining shelf life at shipment and destination requirements
B. Only carton colour
C. Only logo
D. Only website
Answer: A
- A medicine requires temperature control. What should be evaluated?
- Shipping qualification and temperature monitoring
B. Only invoice
C. Only HS code
D. Only buyer’s logo
Answer: A
- A buyer refuses to provide importer details. What should you do?
- Investigate why and verify the transaction before proceeding
B. Ship immediately
C. Change the importer yourself
D. Ignore it
Answer: A
- A manufacturer offers a product at half the market price. What should you do first?
- Buy immediately
B. Conduct due diligence
C. Assume it is genuine
D. Advertise it immediately
Answer: B
- A foreign buyer sends an order from a free email address and refuses to provide company registration details. What is this?
- Potential red flag
B. Guaranteed legitimate
C. Proof of large business
D. Regulatory approval
Answer: A
- A buyer wants 100% credit for a first transaction. What should you assess?
- Buyer credit risk
B. Product colour
C. Tablet shape only
D. Social media followers
Answer: A
- A buyer claims to represent a famous pharmaceutical company. What should you do?
- Verify independently using reliable company contacts
B. Trust immediately
C. Send products immediately
D. Share confidential documents
Answer: A
- A manufacturer asks you to pay into a personal bank account. What should you do?
- Investigate and verify the legitimate contracting/payment arrangement before paying
B. Pay immediately
C. Send cash
D. Ignore the invoice
Answer: A
- The buyer’s bank account suddenly changes before payment. What should you do?
- Verify through trusted channels
B. Pay immediately
C. Ignore it
D. Change the invoice
Answer: A
- A product’s registration has expired. Can you automatically continue selling it?
- Yes
B. No—verify current authorization before commercial supply
C. Only if the buyer agrees
D. Only if price is low
Answer: B
- A product is registered under one manufacturer but supplied by another. What should be checked?
- Regulatory and contractual implications
B. Only freight
C. Only packaging colour
D. Nothing
Answer: A
- A buyer asks for an “FDA certificate.” What should you clarify?
- Exactly what FDA document/status they require
B. Send any certificate
C. Send GMP
D. Send COA only
Answer: A
- A buyer asks for “FDA approved factory.” What is the best response?
- Clarify the specific FDA establishment/product status required
B. Say yes automatically
C. Say no documents exist
D. Change the manufacturer
Answer: A
- A buyer asks for “WHO approval.” What should you clarify?
- What specific WHO certificate/standard they mean
B. Send any document
C. Say every WHO-GMP certificate is product approval
D. Ignore them
Answer: A
- Which is stronger evidence?
- Verifiable official regulatory documentation
B. WhatsApp message
C. Marketing brochure
D. Salesperson’s verbal statement
Answer: A
- A buyer asks for a sample before a large order. What should you do?
- Follow a controlled sample process
B. Send random medicine
C. Change batch information
D. Remove labels
Answer: A
- A sample passes the buyer’s test but regulatory approval is absent. Can you automatically sell commercially?
- Yes
B. No
C. Only if the buyer likes it
D. Only if freight is paid
Answer: B
- A product is legally exported from India but prohibited in the destination country. Can it be shipped commercially?
- Automatically yes
B. No—destination-country restrictions must be respected
C. Only by air
D. Only through a trader
Answer: B
- A buyer asks for a product that may be controlled. What should you do?
- Check applicable Indian and destination-country controls before proceeding
B. Ship immediately
C. Hide the ingredient
D. Change the HS code
Answer: A
- Why is country-of-destination screening important?
- Regulations and restrictions can vary by country
B. It only affects colour
C. It only affects freight
D. It never matters
Answer: A
- What is the correct approach to a new country?
- Research regulatory, commercial and import requirements
B. Use another country’s rules
C. Assume India rules apply
D. Ship first
Answer: A
- An exporter wants to enter Africa. Should “Africa” be treated as one regulatory market?
- Yes
B. No
C. Always
D. Only for generic medicines
Answer: B
- Why?
- African countries have different laws and regulatory systems
B. All African countries use identical rules
C. Only freight differs
D. Only language differs
Answer: A
- Should GCC countries automatically be treated as one identical regulatory market?
- Yes
B. No
C. Always
D. Only for tablets
Answer: B
- What should be checked for every target country?
- Regulatory authority
B. Registration
C. Importer requirements
D. All of the above
Answer: D
- A buyer asks for CIF price. What should the exporter consider?
- Product cost, applicable costs, freight and insurance under the agreed CIF transaction
B. Product cost only
C. Freight only
D. Insurance only
Answer: A
- A buyer asks for FOB price. What should you establish?
- Applicable delivery point and costs/responsibilities under FOB
B. Only product cost
C. Only insurance
D. Only destination tax
Answer: A
- Should Incoterms be used without specifying a place?
- Ideally no; the relevant named place/port should be specified
B. Always yes
C. Place is irrelevant
D. Only for pharma
Answer: A
- What is the purpose of a Proforma Invoice?
- Communicate proposed commercial terms before final invoicing
B. Replace all regulatory approvals
C. Replace COA
D. Replace manufacturing licence
Answer: A
- What is a commercial invoice used for?
- Commercial and customs transaction information
B. Product testing only
C. GMP certification
D. Clinical trial approval
Answer: A
- What is a packing list used for?
- Package/quantity/weight information
B. Product approval
C. Pharmacovigilance
D. Trademark registration
Answer: A
- Why should the commercial invoice and packing list be consistent?
- To reduce documentation discrepancies
B. To increase product strength
C. To improve GMP
D. To reduce tablet weight
Answer: A
- What is a product recall?
- Removal of affected product from the market/supply chain
B. Product promotion
C. Export discount
D. Buyer registration
Answer: A
- Who may initiate a recall?
- Responsible parties according to the applicable regulatory and quality framework
B. Only the freight company
C. Only the buyer’s driver
D. Social media users
Answer: A
- What should an exporter do after receiving a serious product complaint?
- Follow the applicable complaint investigation and escalation process
B. Ignore it
C. Delete the complaint
D. Change the batch number
Answer: A
- What is adverse-event reporting related to?
- Medicine safety
B. Freight cost
C. Invoice value
D. HS classification
Answer: A
- What is a quality defect?
- Failure or potential failure to meet applicable quality requirements
B. Price increase
C. Buyer delay
D. Freight delay
Answer: A
- What is traceability?
- Ability to track relevant product/batch information through the supply chain
B. Tracking social media
C. Tracking freight only
D. Tracking buyer calls only
Answer: A
- Why is batch traceability important?
- It supports investigation, quality control and recall activities
B. It changes the product price
C. It replaces registration
D. It replaces GMP
Answer: A
- What is serialization?
- Assigning unique identifiers to individual packs where required
B. Batch testing
C. Freight calculation
D. Product pricing
Answer: A
- Is serialization required identically in every country?
- Yes
B. No
C. Always
D. Only in India
Answer: B
- A buyer asks for a medicine with a new brand name. What should be checked?
- Trademark and regulatory implications
B. Only logo design
C. Only carton colour
D. Only price
Answer: A
- What is the difference between brand registration and product registration?
- Brand/trademark rights and pharmaceutical authorization are different legal/regulatory matters
B. They are always identical
C. Neither matters
D. Only the brand matters
Answer: A
- A manufacturer has no private-label capability. What can the exporter do?
- Find an appropriate manufacturer that can legally and technically support the project
B. Print labels secretly
C. Change the manufacturer’s licence
D. Use another company’s certificate
Answer: A
- A buyer wants a unique dosage form. What should be evaluated?
- Manufacturer capability and regulatory requirements
B. Only price
C. Only freight
D. Only brand
Answer: A
- What is formulation development?
- Development of a suitable pharmaceutical dosage form and composition
B. Freight arrangement
C. Buyer verification
D. Customs classification
Answer: A
- What is bioequivalence?
- A regulatory/scientific assessment used for applicable products to compare relevant performance with a reference product
B. A freight document
C. A payment term
D. A trademark
Answer: A
- What is bioavailability?
- The rate and extent to which an active ingredient becomes available at the relevant site/systemic circulation as applicable
B. Product price
C. Manufacturing licence
D. Customs value
Answer: A
- Why can regulatory requirements differ between dosage forms?
- Risk, administration route, formulation and applicable regulations can differ
B. Dosage form never matters
C. Only price matters
D. Only packaging matters
Answer: A
- Why can sterile products require additional controls?
- Sterility and contamination risks are critical
B. They are always cheaper
C. They require no documentation
D. They are always OTC
Answer: A
- What is a parenteral product?
- Product administered by a route other than the gastrointestinal tract, such as injection
B. Tablet only
C. Syrup only
D. Cream only
Answer: A
- A manufacturer has excellent prices but poor documentation. Should you select it?
- Yes
B. No, documentation/compliance must be properly evaluated
C. Always
D. Only for Africa
Answer: B
- A buyer offers a huge order but refuses normal verification. What should you do?
- Proceed immediately
B. Perform due diligence before committing
C. Send products first
D. Provide confidential documents
Answer: B
- What is the purpose of a written supply contract?
- Define rights, responsibilities, specifications and commercial terms
B. Replace regulatory approval
C. Replace GMP
D. Replace customs clearance
Answer: A
- What should a contract specify for a pharma supply?
- Product specifications and applicable responsibilities
B. Only company logo
C. Only email address
D. Only social-media account
Answer: A
- What is dispute resolution?
- Contractual mechanism for handling disputes
B. Product testing
C. Freight booking
D. GMP inspection
Answer: A
- What is force majeure?
- Contractual concept concerning specified extraordinary events beyond a party’s reasonable control
B. Product registration
C. Quality test
D. Buyer verification
Answer: A
- Why should confidential technical information be protected?
- It may contain commercially sensitive or proprietary information
B. It is always public
C. It has no value
D. It is only needed for customs
Answer: A
- What is an NDA in a business-contract context?
- Non-Disclosure Agreement
B. New Drug Application
C. National Drug Authorization
D. New Distribution Agreement
Answer: A
- Why must the context of “NDA” be understood?
- NDA can mean different things in pharma regulatory and business-contract contexts
B. It always has one meaning
C. It only means New Drug Application
D. It only means Non-Disclosure Agreement
Answer: A
- What is due diligence before investment in a manufacturer?
- Verification of legal, commercial, financial, regulatory and operational information as appropriate
B. Only checking price
C. Only checking website
D. Only checking logo
Answer: A
- What is a forecast?
- Expected future demand/order quantity
B. Final invoice
C. COA
D. GMP
Answer: A
- Why is a buyer forecast useful?
- It helps production and supply planning
B. It replaces product registration
C. It replaces payment
D. It replaces customs
Answer: A
- What is annual purchase volume?
- Expected quantity purchased over a year
B. Single shipment quantity only
C. MOQ
D. Shelf life
Answer: A
- What is a distributor margin?
- Difference/percentage between distributor acquisition cost and selling economics as applicable
B. GMP fee
C. Customs duty
D. COA cost
Answer: A
- What is market research?
- Systematic study of market demand, competition, customers and conditions
B. Product testing only
C. Customs clearance
D. Freight forwarding
Answer: A
- Why should exporters study competitors?
- To understand pricing, positioning, products and market conditions
B. To copy documents
C. To copy certificates
D. To falsify products
Answer: A
- What should an exporter never copy from a competitor?
- Confidential/proprietary documents or misleading certifications
B. Public market observations
C. General industry information
D. Publicly available market prices
Answer: A
- What is market positioning?
- How a product is presented relative to competitors and customer needs
B. Customs location
C. Warehouse location only
D. Freight route
Answer: A
- What is a target market?
- Specific country/customer segment selected for business development
B. Manufacturing facility
C. Customs office
D. Freight company
Answer: A
- What is market entry strategy?
- Plan for entering and developing a specific market
B. COA preparation
C. Batch manufacturing
D. Freight insurance
Answer: A
- What should an exporter consider before selecting a target country?
- Demand
B. Regulation
C. Competition
D. All of the above
Answer: D
- What is regulatory risk?
- Risk arising from failure to meet applicable laws/regulatory requirements
B. Only freight risk
C. Only currency risk
D. Only buyer risk
Answer: A
- What is currency risk?
- Risk caused by changes in exchange rates
B. Product contamination
C. GMP failure
D. Customs classification
Answer: A
- What is logistics risk?
- Risk associated with transportation, storage and delivery
B. Product trademark
C. Product registration only
D. Buyer identity only
Answer: A
- What is credit risk?
- Risk that a buyer may fail to pay
B. Risk of tablet dissolution
C. Risk of temperature excursion only
D. Risk of product registration only
Answer: A
- What is quality risk?
- Risk that product may fail to meet applicable quality requirements
B. Currency fluctuation
C. Buyer delay only
D. Freight price
Answer: A
- What is supply-chain risk?
- Risk of interruption or failure in sourcing, manufacturing, storage or distribution
B. Trademark risk only
C. Currency risk only
D. Customs risk only
Answer: A
- What is contingency planning?
- Preparing alternatives for potential disruptions
B. Changing certificates
C. Avoiding documentation
D. Ignoring risks
Answer: A
- What is business continuity?
- Ability to continue critical operations during disruptions
B. Product registration
C. Freight discount
D. Buyer discount
Answer: A
- Why should an exporter maintain backup suppliers?
- To reduce supply interruption risk where appropriate
B. To avoid quality checks
C. To avoid regulations
D. To change certificates
Answer: A
- A supplier suddenly cannot manufacture an order. What should you do?
- Assess alternatives while maintaining regulatory and quality controls
B. Send an unrelated product
C. Change batch details
D. Ignore the buyer
Answer: A
- A shipment is delayed. What should the exporter do?
- Communicate transparently and assess regulatory/product implications
B. Hide the delay
C. Change the shipping date on documents
D. Blame the buyer automatically
Answer: A
- A temperature-sensitive product experiences a temperature excursion. What should happen?
- Follow the applicable excursion investigation and product-disposition procedure
B. Ignore it
C. Immediately sell it
D. Change the temperature record
Answer: A
- What is the worst response to a quality problem?
- Hiding or falsifying the problem
B. Investigating it
C. Documenting it
D. Escalating it appropriately
Answer: A
- What is the best response to a suspected counterfeit product?
- Stop relying on it and investigate through appropriate channels
B. Export it
C. Rebrand it
D. Mix it with genuine products
Answer: A
- What is the best response to a suspected forged certificate?
- Verify and investigate before relying on it
B. Use it
C. Edit it
D. Sell it
Answer: A
- What is the strongest foundation for long-term pharma export business?
- Compliance, quality, reliable supply and trustworthy relationships
B. Lowest price only
C. Aggressive sales only
D. Fast shipment without documentation
Answer: A
- What makes a pharma exporter different from an ordinary commodity exporter?
- Greater regulatory, quality and product-safety considerations
B. Nothing
C. Only packaging
D. Only freight
Answer: A
- What should an exporter prioritize when there is a conflict between an illegal buyer request and a commercial opportunity?
- Compliance
B. Sales
C. Profit
D. Speed
Answer: A
- What is the best summary of pharmaceutical exporting?
- Buy cheaply and sell internationally
B. Identify a compliant product and manufacturer, satisfy applicable regulatory requirements, verify the buyer, execute correct documentation and logistics, and manage the product responsibly
C. Find a buyer and ship immediately
D. Focus only on price
Answer: B
MCQ ANSWER KEY — 301–500
301–350
301-C | 302-B | 303-A | 304-A | 305-C
306-B | 307-C | 308-A | 309-B | 310-A
311-C | 312-D | 313-A | 314-A | 315-A
316-A | 317-A | 318-A | 319-A | 320-A
321-A | 322-A | 323-A | 324-A | 325-A
326-A | 327-A | 328-A | 329-A | 330-A
331-A | 332-B | 333-A | 334-A | 335-A
336-A | 337-A | 338-A | 339-A | 340-A
341-A | 342-B | 343-A | 344-B | 345-A
346-A | 347-A | 348-B | 349-A | 350-A
351–400
351-A | 352-A | 353-A | 354-A | 355-A
356-A | 357-A | 358-A | 359-D | 360-A
361-B | 362-A | 363-A | 364-A | 365-A
366-A | 367-A | 368-A | 369-A | 370-A
371-A | 372-A | 373-A | 374-B | 375-A
376-A | 377-A | 378-A | 379-A | 380-A
381-A | 382-A | 383-A | 384-A | 385-A
386-A | 387-A | 388-A | 389-B | 390-A
391-A | 392-A | 393-A | 394-A | 395-A
396-A | 397-A | 398-A | 399-A | 400-B
401–450
401-B | 402-B | 403-B | 404-B | 405-B
406-A | 407-A | 408-B | 409-D | 410-A
411-A | 412-A | 413-B | 414-A | 415-A
416-A | 417-A | 418-A | 419-B | 420-A
421-A | 422-A | 423-A | 424-A | 425-A
426-B | 427-B | 428-A | 429-A | 430-A
431-B | 432-A | 433-B | 434-D | 435-A
436-A | 437-A | 438-A | 439-A | 440-A
441-A | 442-A | 443-A | 444-A | 445-A
446-A | 447-A | 448-A | 449-A | 450-B
451–500
451-A | 452-A | 453-A | 454-A | 455-A
456-A | 457-A | 458-A | 459-A | 460-A
461-B | 462-B | 463-A | 464-A | 465-A
466-A | 467-A | 468-A | 469-A | 470-A
471-A | 472-A | 473-A | 474-A | 475-A
476-A | 477-A | 478-A | 479-A | 480-A
481-D | 482-A | 483-A | 484-A | 485-A
486-A | 487-A | 488-A | 489-A | 490-A
491-A | 492-A | 493-A | 494-A | 495-A
496-A | 497-A | 498-A | 499-A | 500-B
Top Pharma Export Products from India Manufacturers Sellers Pharmaceutical Companies Medicine Buyers
PART XXII — PRACTICAL CASE STUDIES
CASE STUDY 5 — INDIA → USA GENERIC MEDICINE
Situation
An Indian pharmaceutical company manufactures a generic tablet. A US distributor contacts an Indian exporter.
The buyer says:
“Send 20,000 boxes. We will handle everything after arrival.”
Questions
- Should the exporter immediately ship?
Answer: No.
First establish the applicable US regulatory pathway and responsibilities of the manufacturer, importer and other parties.
- Is the Indian manufacturing licence sufficient?
Answer: No. The US has its own applicable requirements.
- What should be verified?
- Product identity
- Manufacturer
- FDA establishment requirements
- Drug listing
- Applicable marketing authorization
- US importer
- US Agent where applicable
- Labeling
- CGMP
- Documentation
- Shipment requirements
Lesson
Never confuse Indian authorization with US authorization.
CASE STUDY 6 — INDIA → UK
An Indian manufacturer sells a medicine in India. A UK distributor wants the same medicine.
The distributor says:
“It is already approved in India, so we can sell it in the UK.”
Correct response
The exporter should explain that Indian approval does not automatically authorize commercial marketing in the UK.
The UK regulatory requirements must be assessed.
Checklist
Product → UK classification → Marketing authorization → Manufacturer → Importer → Label → GMP → Regulatory responsibilities → Supply
CASE STUDY 7 — PRIVATE LABEL UAE
A UAE company wants:
100,000 tablets under its own brand.
Exporter must investigate:
- Manufacturer
- Product composition
- UAE regulatory status
- Importer
- Brand
- Trademark
- Packaging
- Artwork
- Registration
- MOQ
- Production capacity
- Price
- Payment
- Shipping
- Quality agreement
- Supply agreement
Important lesson
Private label is not simply putting a new sticker on an existing medicine.
It may involve regulatory, contractual, quality and intellectual-property responsibilities.
CASE STUDY 8 — BUYER REQUESTS FALSE DOCUMENT
A buyer says:
“Your product does not have the required certificate. Just make one.”
Correct answer
Refuse.
Never manufacture, alter or falsify:
- GMP certificates
- COA
- CPP/COPP
- Manufacturing licences
- Regulatory approvals
- Test reports
- Customs documents
Lesson
A short-term sale can create long-term regulatory and criminal/legal risk.
CASE STUDY 9 — LOW PRICE
Manufacturer A:
$0.20/unit
Manufacturer B:
$0.35/unit
Manufacturer C:
$0.50/unit
Manufacturer A has poor documentation.
Manufacturer B has acceptable documentation and GMP evidence.
Manufacturer C has strong export experience.
Question
Which is automatically the best?
Answer: None automatically.
The exporter should perform a total assessment:
Quality + compliance + reliability + capacity + documents + price + lead time + market suitability
The cheapest quote is not necessarily the best supplier.
CASE STUDY 10 — LARGE BUYER, NO IMPORT LICENCE
A buyer claims:
“We are a very large distributor. We don’t need to give you our importer details.”
What should you do?
Do not proceed blindly.
Verify:
- Legal entity
- Importer status
- Regulatory authorization
- Destination-country requirements
- Product registration
- Payment risk
- Contract
Lesson
Large order ≠ legitimate buyer.
CASE STUDY 11 — SHELF-LIFE PROBLEM
A manufacturer offers a product with:
12 months total shelf life
The shipment will take several months to arrive.
Questions
- What is the remaining shelf life at shipment?
- What does the destination market require?
- What does the buyer require?
- Can the manufacturer produce a fresh batch?
- Is the product stable under the transportation conditions?
Lesson
Do not look only at total shelf life.
Look at:
Manufacturing date → shipment date → transit → customs → warehouse → distribution → required remaining shelf life
CASE STUDY 12 — TEMPERATURE EXCURSION
A temperature-sensitive pharmaceutical shipment experiences temperatures outside the specified range.
What should NOT happen?
❌ Change the temperature record
❌ Ignore the event
❌ Automatically release the product
❌ Tell the buyer nothing happened
Correct approach
Follow the applicable:
Excursion investigation → product assessment → quality decision → documentation → communication
CASE STUDY 13 — WRONG HS CODE
An exporter discovers that the HS code used on a previous shipment may have been incorrect.
What should the exporter do?
Do not simply repeat it.
Seek appropriate customs/trade classification advice and determine the correct classification for future transactions, while assessing whether previous shipments require correction or other action.
CASE STUDY 14 — BUYER CHANGES BANK ACCOUNT
A regular buyer suddenly sends:
“Please make today’s payment to this new bank account.”
What should happen?
Stop and verify.
Use trusted contact information already on file, not merely the contact information contained in the new message.
Lesson
This is a common business-fraud warning sign.
CASE STUDY 15 — PRODUCT REGISTRATION EXPIRING
A buyer wants a large order, but the product authorization is approaching expiry.
What should be checked?
- Current authorization
- Renewal status
- Expected renewal date
- Import requirements
- Remaining shelf life
- Buyer requirements
- Shipment timing
Lesson
Do not plan a large shipment based only on an authorization that may no longer be valid at the relevant time.
CASE STUDY 16 — NEW BRAND NAME
A buyer asks:
“Can you manufacture this medicine under the brand ‘XYZ’?”
Check:
Trademark → Product registration → Regulatory acceptability → Label → Packaging → Manufacturer agreement → Marketing authorization responsibilities
Lesson
A brand name is not merely a graphic design issue.
CASE STUDY 17 — API EXPORT
A buyer wants an API rather than finished tablets.
What changes?
The exporter must evaluate:
- API manufacturer
- API specification
- DMF/technical documentation where applicable
- GMP
- COA
- Impurity profile
- Stability
- Target-country requirements
- Packaging
- Storage
- Transport
- Importer requirements
Lesson
API export and finished-formulation export have overlapping but different regulatory and commercial considerations.
CASE STUDY 18 — GOVERNMENT TENDER
A foreign government or government-linked buyer requests:
500,000 units
Before bidding, evaluate:
- Tender eligibility
- Product registration
- Required certificates
- Manufacturer qualification
- Pricing
- Bid security
- Delivery schedule
- Payment terms
- Penalties
- Local representative
- Regulatory requirements
- Past supply requirements
Lesson
A huge quantity does not automatically mean a profitable order.
CASE STUDY 19 — BUYER WANTS EXCLUSIVITY
A distributor asks:
“Give us exclusive rights for the entire country.”
Before agreeing, consider:
- Minimum annual purchase
- Registration responsibility
- Marketing obligations
- Territory
- Contract period
- Performance targets
- Payment history
- Termination rights
- Regulatory responsibilities
Better commercial structure
Instead of unconditional exclusivity, consider performance-based exclusivity, where legally appropriate.
CASE STUDY 20 — FIRST EXPORT ORDER
A new exporter receives the first small order.
Recommended workflow
Step 1: Verify buyer
↓
Step 2: Verify product
↓
Step 3: Verify manufacturer
↓
Step 4: Verify destination regulatory requirements
↓
Step 5: Confirm product registration/authorization
↓
Step 6: Confirm specifications
↓
Step 7: Confirm price and Incoterm
↓
Step 8: Confirm payment
↓
Step 9: Prepare documentation
↓
Step 10: Manufacture/procure
↓
Step 11: Quality review
↓
Step 12: Shipment
↓
Step 13: Customs/import clearance
↓
Step 14: Delivery
↓
Step 15: Post-shipment follow-up
PART XXIII — 10 GOLDEN RULES FOR PHARMA EXPORTERS
Rule 1
Never assume Indian approval equals foreign approval.
Rule 2
Never confuse establishment registration with product approval.
Rule 3
Never use false or altered certificates.
Rule 4
Verify the manufacturer.
Rule 5
Verify the foreign buyer.
Rule 6
Check the destination country’s requirements product-by-product.
Rule 7
Do not calculate price using factory cost alone.
Rule 8
Do not ignore shelf life and transportation conditions.
Rule 9
Put commercial responsibilities in writing.
Rule 10
Compliance comes before shipment.
PART 1: ADVANCED PHARMA EXPORT MCQs (501–600)
Section A: Regulatory Affairs and Market Authorization
- What should an exporter confirm before offering a finished medicine to a foreign buyer?
- Only the selling price
B. Product authorization requirements in the destination market
C. Only the packaging colour
D. Only the transport company - What is the main purpose of a pharmaceutical regulatory dossier?
- To advertise the product
B. To provide evidence of product quality, safety and efficacy, as applicable
C. To calculate customs duty only
D. To replace the commercial invoice - What does a Certificate of Analysis (COA) generally report?
- Buyer credit rating
B. Test results for a specified sample or batch against relevant specifications
C. Freight charges
D. Trademark ownership only - Which statement about GMP is most accurate?
- GMP guarantees sales in every country
B. GMP concerns manufacturing quality systems and controls
C. GMP replaces product registration
D. GMP eliminates the need for testing - What is the appropriate approach when a buyer requests a medicine that is not authorized for sale in its country?
- Ship immediately
B. Change the product name to avoid regulation
C. Establish a lawful regulatory pathway before proceeding
D. Remove the manufacturer’s name - What does pharmacovigilance primarily concern?
- Monitoring and assessing medicine-related safety information
B. Advertising campaigns
C. Freight negotiation
D. Export incentive calculations - What is the purpose of stability studies?
- To determine the product’s shelf life and storage conditions under defined conditions
B. To calculate the buyer’s profit
C. To establish customs duty
D. To select the freight forwarder - Which statement about a foreign marketing authorization is correct?
- It automatically covers all countries
B. It applies according to the authorization’s scope and jurisdiction
C. It replaces customs documentation
D. It is unnecessary for all generic medicines - What should an exporter do if the registered product’s composition changes?
- Ship without informing anyone
B. Assess the change under applicable regulatory and quality requirements
C. Change only the invoice description
D. Assume no approval is needed - Why are approved product specifications important?
- They define relevant quality requirements and acceptance criteria
B. They determine the exchange rate
C. They replace the purchase order
D. They guarantee immediate customs clearance
Section B: Manufacturing and Quality Assurance
- What is a deviation in a pharmaceutical quality system?
- A departure from an approved procedure, instruction, specification or expected condition
B. A change in currency
C. A buyer’s discount request
D. A shipping quotation - What does CAPA stand for?
- Customs Approval and Product Assessment
B. Corrective and Preventive Action
C. Commercial Account and Payment Agreement
D. Certificate Approval and Packaging Authorization - What is the main objective of batch traceability?
- To identify and follow a batch through relevant manufacturing and distribution records
B. To reduce the number of invoices
C. To eliminate regulatory requirements
D. To guarantee buyer payment - Why is data integrity important in pharmaceutical manufacturing?
- It supports reliable, complete and trustworthy records
B. It makes product registration unnecessary
C. It guarantees a higher selling price
D. It removes the need for audits - What should happen when a batch fails a critical quality test?
- Ship it at a lower price
B. Release it if the buyer agrees
C. Follow the quality system’s investigation and disposition procedures
D. Alter the COA - What is the purpose of change control?
- To assess, authorize and document proposed changes appropriately
B. To change the buyer’s name
C. To avoid maintaining records
D. To replace stability studies automatically - What is a product recall?
- A process to remove or address a product that presents a quality, safety, compliance or other justified concern
B. A discount campaign
C. A freight refund
D. A marketing strategy only - Why is supplier qualification important for pharmaceutical exporters?
- It helps assess supplier capability, quality systems and compliance
B. It guarantees the lowest possible price
C. It eliminates the need for incoming checks
D. It replaces buyer verification - What is the purpose of an audit trail in an electronic system?
- To record relevant system activities and changes
B. To calculate freight
C. To replace the product label
D. To confirm the buyer’s bank balance - What is the most appropriate response to a suspected counterfeit medicine?
- Continue distribution
B. Investigate, preserve evidence, notify appropriate parties and follow applicable procedures
C. Change the batch number
D. Sell it in another country
Section C: Export Documentation and Customs
- What is the principal purpose of a commercial invoice?
- To describe the transaction and relevant goods and charges for commercial and customs purposes
B. To certify clinical efficacy
C. To replace a manufacturing licence
D. To approve a medicine for sale - What is the purpose of a packing list?
- To detail package contents, quantities, weights and related packing information
B. To prove product efficacy
C. To authorize a new drug
D. To certify the buyer’s creditworthiness - What should an exporter do if the commercial invoice and packing list show inconsistent quantities?
- Ignore the difference
B. Correct and reconcile the documents before shipment or through the appropriate amendment process
C. Ask customs to guess the correct quantity
D. Change the batch number - What is an HS code used for?
- Classification of goods for customs and trade purposes
B. Determining a medicine’s clinical effectiveness
C. Establishing a trademark
D. Calculating the product’s expiry date - Who generally issues an air waybill in an air shipment arrangement?
- An airline or its authorized agent
B. The drug regulator
C. The trademark office
D. The retail pharmacy - Which document may provide evidence of the country of origin when required?
- Certificate of Origin
B. Sales brochure
C. Staff attendance register
D. Marketing calendar - Why should exporters retain shipping and transaction records?
- For traceability, accounting, compliance, audits and dispute resolution
B. Only for decoration
C. To avoid paying taxes
D. To replace all regulatory filings - What is the purpose of a proforma invoice?
- To communicate a proposed transaction and its commercial terms before the final commercial invoice
B. To prove delivery has already occurred
C. To replace a COA
D. To grant product authorization - What is a bill of lading commonly associated with?
- Sea transport and the relevant carriage documentation
B. Product stability testing
C. Pharmacovigilance reporting
D. Clinical trial approval - What is the best approach to a request for false customs or regulatory documents?
- Agree to protect the relationship
B. Refuse and follow lawful compliance procedures
C. Change the documents after customs inspection
D. Use another company’s certificate
Section D: Incoterms, Logistics and Cold Chain
- What does FOB generally mean under Incoterms 2020?
- Free on Board
B. Freight on Balance
C. Foreign Order Booking
D. Final Overseas Billing - Under CIF, which costs are generally arranged by the seller for sea or inland waterway transport?
- Cost, insurance and freight to the named destination port
B. All import duties and taxes in every case
C. The buyer’s entire distribution network
D. The buyer’s retail advertising - Why must the named place or port be clearly specified in an Incoterms rule?
- It helps define delivery obligations, cost allocation and risk transfer under the chosen rule
B. It determines the medicine’s dosage
C. It replaces the sales contract
D. It determines the country’s drug approval automatically - What is the purpose of a temperature data logger?
- To record temperature conditions over time
B. To certify product registration
C. To calculate export commission
D. To replace the shipping label - What should happen if a temperature-sensitive shipment experiences an excursion?
- Ignore it if the goods look normal
B. Assess the excursion against approved procedures and product-specific stability information, document it and determine disposition
C. Delete the logger data
D. Immediately resell it - Why is cargo insurance considered in export planning?
- To manage certain financial risks associated with covered loss or damage
B. To guarantee product authorization
C. To replace customs clearance
D. To guarantee the buyer’s payment - What is a freight forwarder generally responsible for?
- Coordinating transport and related logistics services within the agreed scope
B. Approving medicines for sale
C. Issuing manufacturing licences
D. Guaranteeing clinical outcomes - What should be checked before booking a refrigerated shipment?
- Required temperature range, packaging qualification, route, transit time and handling capability
B. Only the colour of the carton
C. Only the buyer’s website
D. Only the exchange rate - What is the purpose of a shipping validation or qualification programme where applicable?
- To establish that defined shipping arrangements can maintain required conditions
B. To eliminate the need for quality control
C. To approve a trademark
D. To establish a distributor’s credit limit - What is demurrage commonly associated with?
- Charges relating to extended use of containers or port/terminal equipment beyond the applicable free time, depending on the charge
B. Clinical trial fees
C. Product registration fees
D. Manufacturing validation
Section E: Commercial Negotiation and Finance
- What is MOQ?
- Minimum Order Quantity
B. Maximum Overseas Quotation
C. Monthly Order Quality
D. Manufacturing Operations Qualification - What is landed cost?
- The total cost of getting goods to the relevant destination point, including applicable transport, insurance, duties, taxes and other costs as relevant
B. Only the ex-factory price
C. Only the marketing budget
D. Only the exporter’s profit - Why should exporters evaluate payment terms before accepting an order?
- To understand cash-flow needs, payment risk and financing requirements
B. To avoid product testing
C. To replace product registration
D. To guarantee currency appreciation - What is a letter of credit (LC)?
- A bank instrument under which payment is made against specified terms and compliant documents, subject to its conditions
B. A product registration certificate
C. A manufacturer’s quality manual
D. A freight quotation - What is the purpose of buyer credit verification?
- To assess the buyer’s ability and willingness to meet payment obligations
B. To establish the product’s shelf life
C. To replace the import licence
D. To determine clinical efficacy - Why is currency risk relevant to exporters?
- Exchange-rate movements may affect the value of receipts, costs and profit
B. It determines the batch number
C. It eliminates customs duties
D. It guarantees sales growth - What should be included in a sound export quotation?
- Product details, specifications, quantity, price, currency, Incoterm, delivery timeline, payment terms and validity
B. Only the product name
C. Only the manufacturer’s logo
D. Only the buyer’s telephone number - Why should an exporter specify quotation validity?
- To define the period during which the quoted commercial terms remain available
B. To extend the product expiry date
C. To waive all regulatory requirements
D. To guarantee unlimited stock - What is a practical way to manage an overseas buyer requesting an unusually large first order?
- Ship immediately without checks
B. Conduct due diligence, assess payment security, confirm compliance and evaluate supply capability
C. Ignore the purchase order
D. Provide unverified certificates - What should an exporter do when a buyer requests payment to a new bank account by email?
- Transfer funds immediately
B. Independently verify the change through a trusted, previously established contact channel
C. Ignore all fraud risk
D. Send confidential information to any address provided
Section F: Private Label, OEM and Distribution
- What does private labelling generally mean in pharmaceutical business?
- A product is marketed under a customer’s or brand owner’s label, subject to applicable law and agreements
B. A product is automatically exempt from registration
C. A product can use any manufacturer’s licence
D. A product has no quality requirements - What should be clarified before entering an OEM arrangement?
- Product specifications, responsibilities, ownership, quality, regulatory obligations, pricing and supply terms
B. Only the carton colour
C. Only the exporter’s personal preference
D. Only the first shipment date - Why should trademark ownership be verified before using a brand name?
- To reduce intellectual property disputes and unauthorized use
B. To avoid testing
C. To replace import authorization
D. To eliminate customs documentation - What is the main purpose of a distribution agreement?
- To define commercial rights, responsibilities and operating terms between the parties
B. To replace all national laws
C. To certify batch quality
D. To authorize every medicine worldwide - What is an important risk of granting broad territorial exclusivity?
- The exporter may lose access to other buyers without receiving adequate sales performance
B. The medicine becomes automatically approved worldwide
C. The buyer no longer needs to pay
D. The manufacturer loses all quality obligations - Which provision can help make exclusivity more commercially balanced?
- Minimum purchase commitments, performance targets, reporting and termination provisions
B. Unlimited rights without conditions
C. No payment deadlines
D. No quality obligations - What should be agreed upon for artwork and packaging changes?
- Approval workflow, legal review, regulatory review, version control and responsibilities
B. Verbal agreement only in every situation
C. No documentation
D. Changes after printing without review - Why is it important to clarify who holds the product marketing authorization?
- To understand legal responsibilities and control over regulatory maintenance in the market
B. To decide the colour of the shipping container
C. To eliminate adverse-event reporting
D. To determine freight charges only - What is an important consideration when selecting a foreign distributor?
- Relevant licences, market reach, regulatory capability, financial reliability and distribution controls
B. Only the number of social media followers
C. Only the lowest requested price
D. Only the office size - What should be done before approving a customer-specific product label?
- Check applicable regulatory requirements, accuracy, language, artwork and authorization responsibilities
B. Print immediately without review
C. Remove the batch number
D. Use a competitor’s approval number
Section G: Risk Management and Business Development
- What is the purpose of export market research?
- To evaluate demand, competition, regulation, pricing, distribution and commercial feasibility
B. To avoid checking the destination country’s laws
C. To replace product registration
D. To guarantee a specific profit - What is a red flag during buyer due diligence?
- A buyer refuses reasonable verification and requests false documents
B. A buyer asks for a valid COA
C. A buyer requests a quotation
D. A buyer asks about lead time - Why should an exporter assess the shelf life remaining at delivery?
- To ensure it meets contractual, regulatory and distribution requirements
B. To calculate the buyer’s tax return
C. To replace stability studies
D. To determine the freight forwarder’s licence - What is the purpose of a product complaint procedure?
- To receive, investigate, document and appropriately address product complaints
B. To automatically blame the customer
C. To avoid quality investigations
D. To delete records - What is the main purpose of a risk register?
- To document identified risks, assessments, owners and mitigation actions
B. To record only sales revenue
C. To replace a manufacturing licence
D. To calculate medicine dosage - Why should exporters screen relevant parties for sanctions and restricted-party risks where applicable?
- To assess legal and financial restrictions on transactions
B. To increase shelf life
C. To eliminate product testing
D. To determine packaging dimensions - What is a reasonable first step if a buyer asks for a certificate that the manufacturer does not possess?
- Create a certificate using another company’s details
B. Clarify the exact requirement and determine whether an authorized, legitimate alternative is available
C. Ignore the buyer’s request
D. Use an expired certificate without disclosure - What is a key advantage of maintaining a document-control system?
- It helps ensure that current, approved versions are used and records remain traceable
B. It guarantees customs clearance in every country
C. It eliminates all audits
D. It removes the need for contracts - Why should an exporter have a contingency plan for supply disruption?
- To prepare for production delays, material shortages, transport disruption and other risks
B. To avoid communicating with buyers
C. To eliminate the need for quality controls
D. To guarantee uninterrupted global shipping - What is a sensible way to evaluate a new export market?
- Compare regulatory feasibility, market demand, competition, costs, payment risks and distribution capability
B. Select the country only by population
C. Assume all countries have identical medicine regulations
D. Ship samples without checking requirements
Section H: Scenario-Based Questions
- A buyer claims that its country’s registration is unnecessary because the product is generic. What should the exporter do?
- Accept the claim
B. Verify the applicable rules for that product and market
C. Remove the product name from the invoice
D. Ship under a different HS code - A supplier offers a very low price but refuses to provide manufacturing and quality documents. What is the best response?
- Place a large order
B. Treat this as a significant due-diligence concern and investigate before proceeding
C. Pay cash immediately
D. Ignore quality considerations - A buyer asks the exporter to declare a lower value than the actual transaction value. What should the exporter do?
- Agree to reduce duties
B. Refuse inaccurate declarations and follow applicable customs valuation rules
C. Change the invoice after shipment
D. Use another company’s invoice - A product is approved in one country but not in the intended destination. What should the exporter do?
- Assume the existing approval applies globally
B. Establish the destination market’s lawful authorization pathway
C. Remove the manufacturer’s name
D. Ship under a different product category - A shipment arrives with damaged secondary packaging. What is the appropriate response?
- Release it without assessment
B. Follow the quality agreement and applicable procedures to assess product integrity, documentation and disposition
C. Change the expiry date
D. Hide the damage from the buyer - The buyer asks for a longer expiry date than the approved shelf life. What should the exporter do?
- Print the requested date
B. Refuse and use only properly supported, approved shelf-life information
C. Change the batch number
D. Send the goods without labels - A distributor wants to change the approved product leaflet. What is the correct approach?
- Approve the change informally
B. Assess the proposed change against applicable regulatory and quality requirements before implementation
C. Make the change after shipment
D. Remove warnings from the leaflet - A potential buyer sends a purchase order but refuses to identify the importing entity. What should the exporter do?
- Ship immediately
B. Obtain sufficient information to verify the buyer, importer and transaction
C. Ignore all compliance concerns
D. Send the original certificates without verification - A shipment is delayed and the remaining shelf life may fall below the contractual requirement. What should the exporter do?
- Ignore the contract
B. Assess the situation, notify relevant parties and agree on a lawful, documented resolution
C. Change the expiry date
D. Hide the delay - A buyer requests an unapproved substitution of an active ingredient. What should the exporter do?
- Substitute it to save money
B. Reject the change unless it is properly assessed, authorized and documented under applicable requirements
C. Update only the invoice
D. Keep the same label regardless of composition
Section I: Advanced Commercial and Operational Questions
- What is a purchase order (PO)?
- A buyer’s document setting out an order and its terms
B. A certificate of product efficacy
C. A manufacturing licence
D. A customs inspection report - What is the purpose of a quality agreement?
- To define relevant quality responsibilities and procedures between parties
B. To determine currency exchange rates
C. To guarantee marketing success
D. To replace all commercial terms - What should be considered when selecting air freight instead of sea freight for a pharmaceutical shipment?
- Transit time, temperature control, cost, product sensitivity and destination handling capability
B. Only the colour of the cartons
C. Only the exporter’s preferred airline
D. Only the buyer’s brand name - What is a key objective of shipment-document reconciliation?
- To ensure relevant quantities, product details, batch references and other information are consistent
B. To increase the invoice value artificially
C. To remove all product identifiers
D. To replace the export contract - Why should the exporter calculate the cost of rejected or returned goods?
- To understand potential financial exposure and contract responsibilities
B. To determine product efficacy
C. To eliminate quality investigations
D. To replace insurance - What should an exporter consider when accepting a government tender?
- Eligibility, technical requirements, pricing, bid security, delivery, payment, penalties and compliance
B. Only the tender’s title
C. Only the buyer’s logo
D. Only the lowest price, regardless of feasibility - Why should sample shipments be planned carefully?
- Samples may still be subject to import, customs, product and documentation requirements
B. Samples are always exempt from regulation
C. Samples never need an invoice or declaration
D. Samples can always be sent as gifts without restrictions - What is a practical use of a customer relationship management (CRM) system?
- Tracking leads, quotations, communication, follow-ups and opportunities
B. Approving medicines for sale
C. Issuing GMP certificates
D. Replacing product quality systems - What should an exporter do if the actual shipping cost is higher than the quotation estimate?
- Review the contract, determine responsibility for the difference and communicate transparently
B. Hide the cost
C. Change the product composition
D. Alter customs documents - Why is a written sales contract useful?
- It documents key commercial obligations, responsibilities, payment terms and remedies
B. It replaces all local law
C. It guarantees that no dispute can occur
D. It automatically authorizes the product
Section J: Final Examination Questions
- Which is the strongest approach to selecting a manufacturer for export?
- Choose the cheapest supplier without verification
B. Assess quality systems, regulatory status, capacity, specifications, reliability and commercial terms
C. Choose the supplier with the most attractive logo
D. Choose only by distance - What is the most appropriate response when a foreign buyer asks whether a medicine is “FDA approved”?
- Say yes because the manufacturer is registered
B. Clarify the exact product and authorization status, then provide accurate evidence
C. Say all Indian medicines are automatically approved
D. Avoid answering and ship anyway - What is the most important principle when preparing a COA?
- Report genuine, authorized test results for the relevant sample or batch
B. Copy another batch’s results
C. Adjust results to match buyer expectations
D. Remove failed tests - What is a key factor when calculating export profit?
- Revenue minus all relevant costs and expenses, with assumptions clearly defined
B. Revenue alone
C. The factory price alone
D. Freight alone - Which action best supports responsible market entry?
- Verify regulatory requirements, buyer credentials, product suitability, logistics and commercial viability
B. Ship first and investigate later
C. Assume neighbouring countries have identical laws
D. Rely exclusively on verbal promises - What should be checked before appointing a local representative?
- Credentials, legal authority, experience, conflicts of interest, contractual terms and compliance risks
B. Only their preferred commission
C. Only their office decoration
D. Only their personal social media account - What is a key benefit of conducting a mock export-document review before shipment?
- It may identify inconsistencies and missing documents before dispatch
B. It replaces customs requirements
C. It guarantees payment
D. It eliminates all shipping risks - What is the correct response to an adverse event report received from a distributor?
- Ignore it because the exporter is outside the destination country
B. Follow applicable pharmacovigilance, contractual escalation and reporting procedures
C. Delete the email
D. Stop maintaining product records - What is the purpose of a post-shipment review?
- To evaluate delivery, documentation, costs, complaints, payment and lessons for future orders
B. To change the batch number
C. To avoid reviewing costs
D. To replace the commercial contract - What is the best overall principle for pharmaceutical exporting?
- Price is more important than compliance
B. Compliance, product quality, truthful documentation and responsible commercial practice must work together
C. Verbal promises replace written records
D. Product registration is unnecessary for generic medicines
PART 2: ANSWER KEY — MCQs 501–600
Question | Answer | Question | Answer |
501 | B | 551 | A |
502 | B | 552 | A |
503 | B | 553 | A |
504 | B | 554 | A |
505 | C | 555 | A |
506 | A | 556 | A |
507 | A | 557 | A |
508 | B | 558 | A |
509 | B | 559 | A |
510 | A | 560 | A |
511 | A | 561 | A |
512 | B | 562 | A |
513 | A | 563 | A |
514 | A | 564 | A |
515 | C | 565 | A |
516 | A | 566 | A |
517 | A | 567 | B |
518 | A | 568 | A |
519 | A | 569 | A |
520 | B | 570 | A |
521 | A | 571 | B |
522 | A | 572 | B |
523 | B | 573 | B |
524 | A | 574 | B |
525 | A | 575 | B |
526 | A | 576 | B |
527 | A | 577 | B |
528 | A | 578 | B |
529 | A | 579 | B |
530 | B | 580 | B |
531 | A | 581 | A |
532 | A | 582 | A |
533 | A | 583 | A |
534 | A | 584 | A |
535 | B | 585 | A |
536 | A | 586 | A |
537 | A | 587 | A |
538 | A | 588 | A |
539 | A | 589 | A |
540 | A | 590 | A |
541 | A | 591 | B |
542 | A | 592 | B |
543 | A | 593 | A |
544 | A | 594 | A |
545 | A | 595 | A |
546 | A | 596 | A |
547 | A | 597 | A |
548 | A | 598 | B |
549 | B | 599 | A |
550 | B | 600 | B |
PART 3: PRACTICAL PHARMA EXPORT CASE STUDIES (21–30)
Case Study 21: Buyer Requests an Unregistered Product
Situation: An Indian exporter receives an order for a generic tablet from a distributor in another country. The buyer says that product registration can be completed after shipment.
Questions:
- Should the exporter ship immediately?
- What must be verified?
- How can the exporter protect the business relationship?
Suggested answer:
The exporter should not assume that shipment or marketing is lawful simply because the buyer has placed an order. Determine the destination country’s requirements for import, product registration, permits, samples and any applicable exemptions. Confirm who is responsible for registration, what activities are permitted before authorization, and whether the product can legally be imported for the stated purpose.
Put responsibilities, payment milestones and cancellation terms in writing. If lawful shipment is not possible, defer the order until the required pathway is confirmed.
Learning point: A purchase order does not override regulatory requirements.
Case Study 22: A Supplier Offers an Attractive Price
Situation: A new manufacturer offers a medicine at a price significantly below competing quotations. It refuses an audit and provides only a promotional brochure.
Questions:
- Is price sufficient to select the supplier?
- Which documents should be requested?
- When should the exporter walk away?
Suggested answer:
The exporter should conduct appropriate due diligence before making a commitment. Depending on the product and transaction, this may include verifying the manufacturer’s legal identity, manufacturing authorization, relevant GMP status, product specifications, quality documentation, production capacity, batch testing arrangements, supply history and references.
An audit or alternative quality assessment may be necessary based on the product and risk. If the supplier refuses reasonable verification or requests inaccurate documentation, do not proceed until the concerns are resolved.
Learning point: A low quotation is not proof of a commercially sound or compliant supply source.
Case Study 23: Buyer Requests a False Certificate
Situation: A buyer insists that the exporter provide a certificate claiming an approval that the product does not possess.
Questions:
- What should the exporter do?
- Can the exporter use another company’s certificate?
- How can the exporter continue the discussion professionally?
Suggested answer:
The exporter must refuse to issue, alter or misrepresent certificates. Another company’s certificate must not be presented as evidence for the exporter or product unless its use is legitimate, authorized and applicable to the specific claim.
The exporter can ask the buyer to clarify the exact requirement, explain which documents are genuinely available, and investigate whether a lawful alternative meets the market’s requirements.
Learning point: Never compromise document integrity to secure an order.
Case Study 24: Temperature Excursion During Transit
Situation: A shipment requiring controlled temperature is delayed at a transit airport. The logger records temperatures outside the specified range.
Questions:
- Can the shipment automatically be released?
- What information is needed?
- Who should be informed?
Suggested answer:
The product should be assessed under the applicable quality procedures. Relevant information includes the duration and magnitude of the excursion, the product’s stability information, packaging performance, logger calibration and data integrity, transport conditions, and any approved excursion-handling procedure.
Notify the appropriate quality personnel and other parties according to the quality agreement and applicable requirements. Document the assessment and disposition. Do not delete data or release the product solely because the packaging looks undamaged.
Learning point: Temperature excursion management requires documented, product-specific assessment.
Case Study 25: A Large Order With Unclear Payment Terms
Situation: A foreign buyer offers a large initial order but requests extended credit without providing trade references or financial information.
Questions:
- What risks are involved?
- How can payment risk be reduced?
- Should the exporter accept the order?
Suggested answer:
The exporter should assess buyer identity, financial standing, references, transaction history, country risk, payment arrangements and potential loss exposure. Options may include advance payment, an appropriately structured letter of credit, credit insurance where available, staged deliveries or a smaller initial order.
The decision should reflect the exporter’s risk tolerance and financing capacity. No payment method removes every risk, so its terms and conditions must be reviewed carefully.
Learning point: A large order is not necessarily a safe order.
Case Study 26: Wrong Product Quantity in Documents
Situation: The commercial invoice states 10,000 packs, while the packing list and physical shipment indicate 9,800 packs.
Questions:
- Should the documents be submitted unchanged?
- What should be checked?
- How should the discrepancy be handled?
Suggested answer:
The exporter should reconcile the documents against the purchase order, manufacturing or packing records, final packing count and shipment instructions. Correct the affected documents using the appropriate procedure before submission wherever possible. If the goods have already shipped, consult the customs broker, freight forwarder and relevant parties about the proper amendment or correction process.
Learning point: Consistent documentation supports customs clearance, payment processing and traceability.
Case Study 27: Private-Label Medicine for a Foreign Distributor
Situation: A distributor wants an Indian manufacturer to supply a medicine under the distributor’s brand name.
Questions:
- Which commercial points should be negotiated?
- Which regulatory points must be clarified?
- How can the parties reduce disputes?
Suggested answer:
The parties should define brand ownership and permitted use, product specifications, manufacturing responsibilities, batch release, packaging artwork, minimum order quantity, price, payment, lead time, complaints, recalls, pharmacovigilance responsibilities, confidentiality, intellectual property, registration responsibilities and termination terms.
Before printing labels or shipping, verify that the proposed branding and product presentation are allowed in the destination market and that the appropriate authorization pathway is in place.
Learning point: Private labelling does not remove product-quality or regulatory responsibilities.
Case Study 28: Product Registration Is Near Expiry
Situation: A distributor requests a shipment, but the product’s marketing authorization is close to expiry.
Questions:
- What should be checked before shipment?
- Who is responsible for renewal?
- How should the order be managed?
Suggested answer:
Verify the authorization’s current status, renewal timeline, permitted import and marketing activities, shipment and customs-clearance timing, and any applicable transitional arrangements. Confirm contractual responsibilities for renewal and any required documentation.
Do not assume that an application for renewal automatically permits every activity. If the status is uncertain, obtain written clarification from the responsible regulatory party or competent authority before proceeding.
Learning point: Regulatory validity must be assessed at the relevant stage of the transaction.
Case Study 29: The Buyer Requests Exclusive Distribution
Situation: A distributor wants exclusive rights to sell a medicine throughout an entire country but offers no minimum purchase commitment.
Questions:
- What are the commercial risks?
- What terms could make exclusivity more balanced?
- When might exclusivity be inappropriate?
Suggested answer:
Exclusivity can restrict the exporter’s ability to appoint other distributors. The exporter should assess market size, registration investment, distribution capability, competing products, expected sales and the distributor’s financial strength.
Possible safeguards include defined territories, minimum annual purchases, performance targets, reporting obligations, marketing commitments, payment protections, review periods and termination rights. Any arrangement must also comply with applicable competition and commercial laws.
Learning point: Exclusivity should be based on measurable performance and clearly defined responsibilities.
Case Study 30: First Export Order — From Enquiry to Delivery
Situation: A distributor in a new market requests a quotation for a medicine manufactured in India. The exporter has not previously shipped that product to the destination.
Recommended workflow:
- Verify the buyer and importing entity.
- Confirm the product, dosage form, strength and intended use.
- Identify the destination’s applicable product authorization and import requirements.
- Verify the manufacturer’s capability and quality documentation.
- Confirm product specifications, packaging and remaining shelf-life requirements.
- Establish pricing, currency, MOQ, lead time and payment terms.
- Agree on the appropriate Incoterm and precisely named place or port.
- Confirm shipping route, insurance, temperature controls and handling requirements where applicable.
- Prepare and review the commercial and regulatory documentation.
- Confirm order acceptance and manufacturing or procurement arrangements.
- Complete the required quality release and shipment checks.
- Coordinate customs and logistics documentation.
- Monitor dispatch, transit and delivery.
- Confirm receipt and address any discrepancies or complaints.
- Reconcile costs, payment and lessons learned.
Learning point: A repeatable export process reduces avoidable errors and improves business control.
PART 4: PHARMA EXPORT PRE-SHIPMENT CHECKLIST
Use this checklist as an internal review tool. Adapt it to the product, transaction, destination and applicable law.
- Buyer Verification
Legal name and registered address verified
Importer/distributor identity confirmed
Relevant licences or authorizations checked
Business references assessed where appropriate
Payment terms and credit risk reviewed
Sanctions or restricted-party screening completed where applicable
Authorized contact and bank details independently verified
- Product and Regulatory Review
Product name, composition, strength and dosage form confirmed
Destination market identified
Applicable product authorization verified
Import permit or other applicable permissions checked
Label and packaging requirements confirmed
Language and patient-information requirements assessed
Remaining shelf-life requirement confirmed
Applicable controlled-substance restrictions assessed, if relevant
Regulatory responsibilities allocated in writing
- Manufacturer and Quality Review
Manufacturer’s legal identity verified
Relevant manufacturing authorization and quality status checked
Product specifications agreed
Batch documentation and COA arrangements confirmed
Packaging and labelling specifications approved
Quality agreement reviewed where needed
Batch traceability and complaint procedures established
Recall and escalation arrangements understood
Storage and transport conditions confirmed
- Commercial Review
Purchase order received and reviewed
Quotation and contract terms consistent
Price and currency confirmed
MOQ and quantity confirmed
Payment method and due dates agreed
Incoterm and named place or port stated
Freight, insurance and other costs allocated
Taxes, duties and other relevant charges assessed
Quotation validity and delivery timeline confirmed
Cancellation, delay and dispute terms reviewed
- Shipping Documentation
Commercial invoice checked
Packing list checked
COA and batch references checked, where applicable
Certificate of Origin arranged where required
Transport document requirements confirmed
Export and import declarations reviewed
Required regulatory certificates verified
HS classification checked
Quantities, descriptions and values reconciled
Shipping instructions and consignee details verified
Insurance arrangements confirmed where applicable
Temperature logger and cold-chain records arranged, if required
- Post-Shipment Review
Dispatch details sent to the buyer
Shipment tracked
Delivery confirmed
Customs or delivery issues documented
Buyer receipt and product condition confirmed
Payment tracked and reconciled
Complaints or discrepancies escalated
Actual costs compared with the quotation
Records archived according to applicable requirements
Lessons learned recorded for the next shipment
PART 5: KEY LESSONS FROM THIS SECTION
- A buyer’s request does not override regulatory requirements.
- Manufacturer verification should include quality and operational capability, not just price.
- Certificates and shipping documents must be accurate and applicable to the actual transaction.
- Temperature-sensitive medicines require suitable handling and documented assessment of excursions.
- Payment security should be evaluated before accepting large orders.
- Private-label arrangements need clear brand, quality, regulatory and contractual responsibilities.
- Distribution exclusivity should be carefully negotiated.
- Registration status and import permissions should be verified at the relevant stage.
- Pre-shipment document reconciliation can prevent avoidable customs and payment problems.
- A documented export workflow improves consistency and helps the exporter learn from each shipment.
PHARMA MEDICINE EXPORT FROM INDIA
Nawinza Global Export Guide
Formula Database — Part 2
Additional Medicines, Uses, Dosage Forms & Export-Regulatory Considerations
Important: The information in this section is intended for pharmaceutical export research and education. A medicine being legally manufactured or exported from India does not automatically mean that it can be marketed or imported in another country. Product registration, marketing authorization, importer licensing, prescription classification, controlled-drug requirements, labeling, GMP requirements and destination-country rules must be checked separately.
- Vardenafil + Dapoxetine
Therapeutic category: Erectile dysfunction / sexual-health medicine
Description:
Vardenafil is a phosphodiesterase type-5 (PDE5) inhibitor. Dapoxetine is a short-acting selective serotonin reuptake inhibitor used in certain markets for premature ejaculation. A combination therefore targets two different sexual-health conditions.
Common intended uses:
- Erectile dysfunction
- Premature ejaculation, where the combination is specifically authorized
Dosage forms: Usually oral tablets.
Export consideration:
The combination should not be treated as automatically approved merely because both individual ingredients are available in a country. The exact combination, strength, indication and manufacturer must be checked.
Regulatory flag: 🟠 Special product-registration check.
- Lamotrigine
Therapeutic category: Antiepileptic / mood stabilizer
Description:
Lamotrigine is an anticonvulsant that affects voltage-sensitive sodium channels and reduces abnormal neuronal activity.
Common uses:
- Epilepsy
- Certain seizure disorders
- Maintenance treatment of bipolar disorder in approved markets
Dosage forms:
- Immediate-release tablets
- Chewable/dispersible tablets
- Extended-release formulations in some markets
Important safety consideration:
Lamotrigine requires careful dose escalation because serious skin reactions, including Stevens-Johnson syndrome, can occur.
Export consideration:
Usually treated as a prescription medicine. Exact registration and labeling requirements vary by market.
Regulatory flag: 🟡 Prescription/product-registration check.
- Gabapentin
Therapeutic category: Antiepileptic / neuropathic-pain medicine
Description:
Gabapentin is structurally related to GABA but does not act simply as a conventional GABA agonist. It is widely used for neurological conditions and neuropathic pain.
Common uses:
- Neuropathic pain
- Epilepsy/seizure disorders
- Other approved indications depending on country
Dosage forms:
- Capsules
- Tablets
- Oral solution
Export consideration:
Its legal classification differs between countries. Some jurisdictions have introduced tighter controls because of misuse and dependence concerns.
Regulatory flag: 🟠 Special regulatory check.
- Telmisartan
Therapeutic category: Antihypertensive / angiotensin II receptor blocker
Description:
Telmisartan blocks the angiotensin II AT1 receptor and reduces vasoconstriction and aldosterone-related effects.
Common uses:
- Hypertension
- Cardiovascular-risk reduction in selected patients/products
Dosage forms: Oral tablets.
Common strengths: Market-dependent, commonly including 20 mg, 40 mg and 80 mg.
Export consideration:
Generally a conventional prescription medicine, but the exact strength, indication and combination product must be registered where required.
Regulatory flag: 🟡 Standard prescription/product-registration check.
- Sildenafil + Tadalafil
Therapeutic category: PDE5 inhibitor combination
Description:
This combines two PDE5 inhibitors. Although both drugs individually have established medical uses, combining them is not automatically an accepted or authorized therapeutic product.
Export warning:
This is an important example for exporters:
Individual drug approval ≠ combination-product approval.
The exporter must verify whether the exact combination and strength has regulatory authorization in the destination market.
Regulatory flag: 🟠 Combination-specific investigation required.
- Liothyronine Sodium
Therapeutic category: Thyroid hormone
Description:
Liothyronine is synthetic triiodothyronine (T3), a thyroid hormone used when thyroid-hormone replacement is medically indicated.
Common use:
- Certain forms of hypothyroidism
- Selected thyroid-related clinical situations
Dosage form: Oral tablets; other formulations may exist in selected markets.
Important:
Thyroid hormones should not be treated as ordinary nutritional supplements.
Export consideration:
Prescription status and approved indications must be checked for the destination country.
Regulatory flag: 🟡 Prescription/product-registration check.
- Danazol
Therapeutic category: Hormonal / androgenic medicine
Description:
Danazol is a synthetic steroid with androgenic activity.
Historical/approved uses may include:
- Endometriosis
- Certain hereditary angioedema indications
- Other specialized hormonal conditions depending on market
Export consideration:
Because of its hormonal and androgenic effects, the product requires careful regulatory review.
Regulatory flag: 🟠 Special regulatory check.
- Empagliflozin
Therapeutic category: Antidiabetic / SGLT2 inhibitor
Description:
Empagliflozin reduces renal glucose reabsorption by inhibiting sodium-glucose cotransporter 2.
Common uses:
- Type 2 diabetes
- Heart-failure indications for authorized products
- Chronic kidney disease indications for authorized products
Dosage form: Oral tablets.
Common strengths: 10 mg and 25 mg in many markets.
Export consideration:
The approved indications can differ by country and product label.
Regulatory flag: 🟡 Prescription/product-registration check.
- Memantine Hydrochloride
Therapeutic category: Neurological / NMDA receptor antagonist
Description:
Memantine is an NMDA receptor antagonist used in the management of certain patients with moderate-to-severe Alzheimer’s disease.
Common use:
- Alzheimer’s disease
Dosage forms:
- Tablets
- Oral solution
- Extended-release formulations in some markets
Export consideration:
Prescription medicine; product registration and approved indication should be verified.
Regulatory flag: 🟡 Prescription/product-registration check.
- Bempedoic Acid
Therapeutic category: Lipid-lowering medicine
Description:
Bempedoic acid reduces cholesterol synthesis through inhibition of ATP-citrate lyase.
Common use:
- Reduction of LDL cholesterol
- Management of hypercholesterolemia in appropriate patients
Combination:
Bempedoic acid + ezetimibe is an important combination product.
Export consideration:
Exact combination products and indications must be checked against the destination-country authorization.
Regulatory flag: 🟡 Product-registration check.
- Baclofen
Therapeutic category: Skeletal-muscle relaxant / antispasticity medicine
Description:
Baclofen acts primarily through GABA-B receptors and reduces muscle spasticity.
Common uses:
- Muscle spasticity
- Neurological conditions associated with increased muscle tone
Dosage forms:
- Tablets
- Oral liquid
- Intrathecal formulations for specialized use
Export consideration:
Prescription status and controlled-drug classification should be checked by jurisdiction.
Regulatory flag: 🟠 Special regulatory check.
- Tropicamide + Phenylephrine
Therapeutic category: Ophthalmic diagnostic preparation
Description:
Tropicamide produces mydriasis by blocking muscarinic receptors, while phenylephrine produces pupil dilation through alpha-adrenergic activity.
Common use:
- Pupil dilation for ophthalmic examination
Dosage form: Sterile ophthalmic solution.
Export considerations:
- Sterility requirements
- Ophthalmic manufacturing controls
- Labeling
- Product registration
- Storage requirements
Regulatory flag: 🟡 Sterile-product/product-registration check.
- Propranolol Hydrochloride
Therapeutic category: Beta-blocker
Description:
Propranolol is a non-selective beta-adrenergic receptor blocker.
Common uses:
- Hypertension
- Certain cardiac conditions
- Migraine prevention
- Tremor
- Other approved indications
Dosage forms:
- Tablets
- Extended-release capsules/tablets
- Oral liquid
- Injectable forms in selected markets
Export consideration:
Prescription medicine in many markets.
Regulatory flag: 🟡 Prescription/product-registration check.
- Metformin Hydrochloride
Therapeutic category: Antidiabetic / biguanide
Description:
Metformin improves insulin sensitivity and reduces hepatic glucose production.
Common use:
- Type 2 diabetes mellitus
Dosage forms:
- Immediate-release tablets
- Extended-release tablets
- Oral solutions in selected markets
Important export distinction:
Metformin alone and combinations such as metformin + SGLT2 inhibitor, metformin + DPP-4 inhibitor, or metformin + sulfonylurea should be listed as separate products in an export database.
Regulatory flag: 🟡 Standard prescription/product-registration check.
- Armodafinil
Therapeutic category: CNS / wakefulness-promoting medicine
Description:
Armodafinil is the R-enantiomer associated with modafinil and is used for certain excessive-sleepiness disorders.
Common uses:
- Narcolepsy-associated excessive sleepiness
- Obstructive sleep apnea-associated excessive sleepiness
- Shift-work sleep disorder, where approved
Export consideration:
Regulatory classification varies considerably. It should receive a separate regulatory assessment rather than being assumed to have identical status to modafinil.
Regulatory flag: 🟠 Special/controlled-status check.
- Meloxicam
Therapeutic category: NSAID
Description:
Meloxicam is a non-steroidal anti-inflammatory drug that inhibits cyclooxygenase enzymes and reduces pain and inflammation.
Common uses:
- Osteoarthritis
- Rheumatoid arthritis
- Musculoskeletal pain/inflammation
Dosage form: Oral tablets/capsules and other formulations depending on market.
Export consideration:
Check prescription/OTC classification, maximum strength, labeling and approved indications.
Regulatory flag: 🟡 Product classification check.
- Tamoxifen
Therapeutic category: Selective estrogen receptor modulator
Description:
Tamoxifen blocks or modifies estrogen-receptor activity in breast tissue.
Main medical use:
- Treatment of hormone-receptor-positive breast cancer
- Prevention of breast cancer in selected high-risk populations
Export consideration:
Prescription oncology medicine. It should not be marketed for unapproved bodybuilding or performance-enhancement purposes.
Regulatory flag: 🟠 Prescription/specialist-use check.
- Exemestane
Therapeutic category: Aromatase inhibitor
Description:
Exemestane reduces estrogen production by irreversibly inhibiting aromatase.
Main use:
- Hormone-sensitive breast cancer in appropriate patients
Export consideration:
Prescription oncology medicine. The indication and patient population should follow the destination-market authorization.
Regulatory flag: 🟠 Prescription/oncology registration check.
- Cyanocobalamin
Therapeutic category: Vitamin B12
Description:
Cyanocobalamin is a form of vitamin B12 used to treat or prevent vitamin B12 deficiency.
Common uses:
- Vitamin B12 deficiency
- Certain megaloblastic anemia conditions caused by B12 deficiency
Dosage forms:
- Injection
- Oral preparations
- Other formulations depending on market
Export consideration:
Classification can vary between medicine and supplement depending on formulation, dose and claims.
Regulatory flag: 🟡 Product classification check.
- Dutasteride
Therapeutic category: 5-alpha-reductase inhibitor
Description:
Dutasteride inhibits both type 1 and type 2 5-alpha-reductase enzymes, reducing conversion of testosterone to dihydrotestosterone.
Common medical use:
- Benign prostatic hyperplasia
Other use:
Dutasteride is also used for hair-loss treatment in some jurisdictions, but the regulatory status and approved indication must be checked.
Dosage form: Oral capsules.
Common strength: 0.5 mg.
Export consideration:
Indication-specific registration is important.
Regulatory flag: 🟡 Prescription/product-registration check.
- Finasteride
Therapeutic category: 5-alpha-reductase inhibitor
Description:
Finasteride reduces conversion of testosterone to dihydrotestosterone.
Common uses:
- Benign prostatic hyperplasia at higher approved strengths
- Male pattern hair loss at lower approved strength
Important:
The 1 mg and 5 mg products should be treated as distinct products because their approved indications differ.
Export consideration:
Country-specific labeling and indication requirements must be checked.
Regulatory flag: 🟡 Prescription/product-registration check.
- Finasteride + Minoxidil
Therapeutic category: Hair-loss treatment
Description:
This combination targets androgen-related hair loss through two different mechanisms.
Potential use:
- Male pattern hair loss, where the exact combination is authorized
Important export point:
The existence of individual approvals for finasteride and minoxidil does not automatically establish approval for the combination.
Regulatory flag: 🟠 Combination-product investigation.
- Dutasteride + Minoxidil
Therapeutic category: Hair-loss treatment
Description:
Dutasteride reduces dihydrotestosterone production, while minoxidil promotes hair growth through a different mechanism.
Export consideration:
This combination requires particularly careful verification because the exact combination may not have the same regulatory status as the individual ingredients in a particular market.
Regulatory flag: 🟠 Combination-specific check.
- Azelaic Acid
Therapeutic category: Dermatological medicine
Description:
Azelaic acid has antimicrobial, anti-inflammatory and keratinization-modifying effects.
Common uses:
- Acne vulgaris
- Rosacea
- Post-inflammatory hyperpigmentation in some clinical uses
Dosage forms:
- Cream
- Gel
- Foam in selected markets
Common concentration: 15–20%, depending on formulation and market.
Export consideration:
Classification can differ between medicine and cosmetic/dermatological product depending on concentration, claims and local rules.
Regulatory flag: 🟡 Product classification check.
- Sirolimus
Therapeutic category: Immunosuppressant / mTOR inhibitor
Description:
Sirolimus inhibits the mTOR pathway and suppresses immune-cell proliferation.
Common medical uses:
- Prevention of organ-transplant rejection
- Certain specialized diseases/conditions depending on formulation and authorization
Dosage forms:
- Tablets
- Oral solution
- Other specialized formulations
Export consideration:
Prescription/specialist medicine. Cold-chain or storage requirements depend on the specific product.
Regulatory flag: 🟠 Specialist prescription/product-registration check.
- Ambrisentan
Therapeutic category: Endothelin receptor antagonist
Description:
Ambrisentan selectively blocks endothelin A receptors.
Main use:
- Pulmonary arterial hypertension
Important safety consideration:
Pregnancy-related safety requirements are particularly important for this class of medicine.
Export consideration:
Specialist prescription medicine requiring destination-country authorization.
Regulatory flag: 🟠 High regulatory-check category.
- Oxandrolone
Therapeutic category: Anabolic androgenic steroid
Description:
Oxandrolone is an anabolic steroid with androgenic activity and has had medical uses in selected conditions involving weight or tissue loss.
Export consideration:
This is not an ordinary nutritional supplement. Anabolic-steroid controls differ significantly between countries and may include controlled-substance or special-prescription requirements.
Regulatory flag: 🔴/🟠 Country-specific controlled-substance investigation.
- Mesterolone
Therapeutic category: Androgenic hormonal medicine
Description:
Mesterolone is an orally active androgenic steroid.
Export consideration:
Hormonal/anabolic medicines can have significantly different legal classifications across countries. The exact destination must be checked before quotation or shipment.
Regulatory flag: 🟠 Special hormonal/controlled-status check.
- Drostanolone Enanthate
Therapeutic category: Anabolic androgenic steroid
Description:
Drostanolone is an androgenic/anabolic steroid derivative.
Export consideration:
This product should not be treated like a routine prescription medicine. The legal status, import authorization and controlled-substance rules must be checked in the destination market before export.
Regulatory flag: 🔴/🟠 High-risk regulatory category.
- Nandrolone Phenylpropionate
Therapeutic category: Anabolic androgenic steroid
Description:
Nandrolone phenylpropionate is an injectable anabolic-androgenic steroid.
Medical context:
Nandrolone products have had limited medical uses in certain jurisdictions, but their regulatory status is highly jurisdiction-dependent.
Export consideration:
Exporter must verify:
- controlled-substance classification
- import permit requirements
- manufacturer authorization
- destination product registration
- prescription requirements
- permitted medical indication
Regulatory flag: 🔴/🟠 High-risk regulatory category.
- Exemestane
Note: Already included above and therefore not counted as a new formula if it appears repeatedly in the source list.
- Testosterone Cypionate
Therapeutic category: Androgen / hormone replacement
Description:
Testosterone cypionate is a long-acting testosterone ester administered by injection.
Medical use:
- Testosterone replacement in appropriately diagnosed patients
Export consideration:
Because testosterone products may be controlled or specially regulated, exporters must verify destination-country requirements before shipment.
Regulatory flag: 🟠/🔴 Country-specific controlled-substance check.
- Estradiol
Therapeutic category: Estrogen hormone
Description:
Estradiol is a naturally occurring estrogen hormone used in hormone-replacement and other gynecological/endocrine indications.
Dosage forms:
- Gel
- Tablets
- Patches
- Vaginal preparations
- Injectable preparations depending on market
Export consideration:
Exact formulation matters. Hormonal medicines require appropriate prescription/product registration and labeling.
Regulatory flag: 🟠 Hormonal prescription-product check.
- Estriol
Therapeutic category: Estrogen hormone
Description:
Estriol is an estrogen used in selected hormone-related and local vaginal indications.
Dosage form: Cream and other formulations.
Export consideration:
Classification and approved indications vary by country. The exact formulation and concentration should be checked.
Regulatory flag: 🟡/🟠 Hormonal product check.
- Salbutamol
Therapeutic category: Bronchodilator / beta-2 agonist
Description:
Salbutamol relaxes bronchial smooth muscle and improves airflow.
Common uses:
- Asthma
- Bronchospasm
- Chronic obstructive airway disease in appropriate patients
Dosage forms:
- Metered-dose inhaler
- Nebulizer solution
- Tablets
- Syrup in some markets
Export consideration:
The inhaled product and oral product should be treated as separate regulatory products.
Regulatory flag: 🟡 Product/formulation check.
- Salbutamol Sulphate
Note: This is the salt form used in pharmaceutical formulations of salbutamol. When building the final export database, it should be standardized under the active ingredient while preserving the exact formulation name.
Important database rule:
Generic/API name: Salbutamol
Salt: Salbutamol sulphate
Dosage form: Must be recorded separately.
- Cyclosporine Ophthalmic
Therapeutic category: Ophthalmic immunomodulator
Description:
Topical cyclosporine ophthalmic preparations reduce ocular-surface inflammation and may increase tear production in appropriate dry-eye conditions.
Dosage form: Sterile ophthalmic emulsion/solution depending on product.
Export consideration:
- Sterility
- Container-closure system
- Stability
- Ophthalmic manufacturing requirements
- Product registration
Regulatory flag: 🟠 Sterile ophthalmic product check.
- Fluoxymesterone
Therapeutic category: Androgenic steroid
Description:
Fluoxymesterone is a synthetic androgen.
Export consideration:
It belongs to a category requiring careful controlled-substance and hormonal regulatory assessment.
Regulatory flag: 🔴/🟠 High-risk regulatory category.
- Oxymetholone
Therapeutic category: Anabolic androgenic steroid
Description:
Oxymetholone is an oral anabolic-androgenic steroid historically used for selected forms of anemia.
Export consideration:
The product may be subject to controlled-drug or special prescription rules depending on destination.
Regulatory flag: 🔴/🟠 Special controlled-substance check.
- L-Carnitine / Levocarnitine
Therapeutic category: Metabolic/nutritional medicine
Description:
Levocarnitine is involved in fatty-acid transport into mitochondria and is used medically for certain carnitine-deficiency states.
Dosage forms:
- Oral solution
- Tablets/capsules
- Injection
Export consideration:
Classification varies between medicine, nutritional product and supplement depending on country, formulation and claims.
Regulatory flag: 🟡 Product classification check.
- Azithromycin
Duplicate rule: Already covered in the previous batch/source analysis. Do not create another separate formula entry merely because the uploaded file contains multiple strengths or repeated rows.
- Pentoxifylline
Therapeutic category: Hemorheologic / peripheral vascular medicine
Description:
Pentoxifylline improves red-cell flexibility and blood-flow characteristics.
Common use:
- Intermittent claudication associated with peripheral arterial disease in markets where approved
Dosage form: Extended-release tablets are common.
Export consideration:
Prescription status and approved indications should be checked.
Regulatory flag: 🟡 Product-registration check.
- Niclosamide
Therapeutic category: Anthelmintic
Description:
Niclosamide is an antiparasitic medicine used against certain intestinal tapeworm infections.
Dosage form: Oral tablets.
Export consideration:
Antiparasitic products require verification of:
- human versus veterinary use
- approved indication
- formulation
- destination registration
- labeling
Regulatory flag: 🟡/🟠 Product-specific check.
- Rifaximin
Therapeutic category: Gastrointestinal antibiotic
Description:
Rifaximin is a minimally absorbed rifamycin-class antibacterial medicine used for selected gastrointestinal conditions.
Common uses:
Depending on market authorization:
- Certain infectious diarrhea conditions
- Hepatic encephalopathy recurrence reduction
- Irritable bowel syndrome with diarrhea
Export consideration:
The approved indications differ between jurisdictions.
Regulatory flag: 🟡 Prescription/product-registration check.
- Nebivolol
Therapeutic category: Beta-blocker / antihypertensive
Description:
Nebivolol is a beta-1 selective adrenergic blocker with nitric-oxide-mediated vasodilatory properties.
Common use:
- Hypertension
Dosage form: Oral tablets.
Export consideration:
Prescription classification and approved indications should be checked in the destination market.
Regulatory flag: 🟡 Standard prescription check.
- Mebendazole
Therapeutic category: Anthelmintic
Description:
Mebendazole interferes with parasite microtubule formation and is used to treat several intestinal worm infections.
Common uses:
- Pinworm infection
- Roundworm
- Whipworm
- Hookworm and other susceptible helminth infections
Dosage form: Tablets and chewable formulations depending on market.
Export consideration:
Classification may differ by country, and some markets permit selected strengths through non-prescription channels.
Regulatory flag: 🟡 Country/product classification check.
- Metronidazole
Therapeutic category: Nitroimidazole antimicrobial/antiprotozoal
Description:
Metronidazole is active against certain anaerobic bacteria and protozoa.
Common uses:
- Anaerobic bacterial infections
- Trichomoniasis
- Giardiasis
- Amoebiasis
- Other approved infections
Dosage forms:
- Tablets
- Oral suspension
- IV infusion
- Topical preparations
- Vaginal formulations
Export consideration:
Different dosage forms may have different registration and prescription classifications.
Regulatory flag: 🟡 Product/formulation check.
- Atomoxetine
Therapeutic category: ADHD medicine / selective norepinephrine reuptake inhibitor
Description:
Atomoxetine increases norepinephrine activity and is used for attention-deficit/hyperactivity disorder.
Common use:
- ADHD
Export consideration:
Prescription-only classification and special monitoring requirements may apply. It should not automatically be grouped with stimulant ADHD medicines.
Regulatory flag: 🟠 Special prescription/regulatory check.
- Cyproheptadine
Therapeutic category: Antihistamine
Description:
Cyproheptadine is an H1 antihistamine with antiserotonergic properties.
Common uses:
- Allergic conditions
- Urticaria
- Other approved indications depending on country
Important export point:
Some markets have different restrictions or warnings concerning pediatric use and appetite/weight-gain claims.
Regulatory flag: 🟡 Country-specific classification check.
- Ketorolac Tromethamine
Therapeutic category: NSAID analgesic
Description:
Ketorolac is a potent non-steroidal anti-inflammatory analgesic intended primarily for short-term treatment of moderate-to-severe acute pain.
Dosage forms:
- Injection
- Tablets
- Ophthalmic preparations
Important:
Ketorolac has significant gastrointestinal, renal and bleeding risks and is generally intended for short-duration use.
Export consideration:
Exact dosage form and approved duration/indication should be checked.
Regulatory flag: 🟠 Prescription/high-risk-use check.
EXPORTER’S GOLDEN RULE
Never ask only: “Can I export this medicine from India?”
Ask five questions:
- Can it legally be manufactured/supplied in India?
- Can it legally be exported from India under the applicable Indian requirements?
- Is the exact product registered/authorized in the destination country?
- Can the foreign importer legally import and distribute it?
- Does the exact formulation, strength, indication and dosage form comply with destination-country rules?
MASTER STATUS SYSTEM FOR THE BOOK
🟢 Routine regulated medicine — normal pharmaceutical regulatory pathway.
🟡 Prescription/product-registration check — authorization and prescription classification must be verified.
🟠 Special regulatory check — controlled substances, hormones, high-risk medicines, specialist medicines, sterile products or unusual combinations.
🔴 High-risk/prohibited-status investigation — do not quote or ship until destination-country legality and import authorization are confirmed.
⚫ Product-specific investigation — exact formulation, strength, indication or combination requires individual verification.
EXPORT DATABASE RULE
For the final database, the same API should not be counted repeatedly simply because the source contains:
- multiple strengths
- repeated rows
- spelling variations
- IP/BP/USP variations
- duplicate manufacturer entries
- duplicate dosage forms copied from different sources
However, these should remain separate where they have meaningful regulatory or commercial differences:
Example:
API | Formulation | Should it be separate? |
Finasteride | 1 mg tablet | Yes |
Finasteride | 5 mg tablet | Yes |
Tretinoin | 0.025% cream | Yes |
Tretinoin | 0.1% microsphere gel | Yes |
Salbutamol | Inhaler | Yes |
Salbutamol | Tablet | Yes |
Metformin | Immediate-release | Yes |
Metformin | Extended-release | Yes |
Ivermectin | Different tablet strengths | Usually separate SKU/formulation records |
Azithromycin | Multiple repeated rows | No — deduplicate |
Testosterone | Different esters | Yes |
Testosterone | Same ester, repeated strength | No — deduplicate |
Prescription medicine
Product registration required
Controlled/special licence check
Combination-product approval check
Import permit may be required
Not approved for the proposed indication
Destination-country verification required
The strongest structure would make every medicine commercially useful to an exporter, manufacturer, buyer, regulatory person, and student.
1. Complete medicine profile
For every unique formula, add:
- Generic/API name
- Salt form
- Chemical/class name
- Therapeutic category
- Pharmacological class
- Mechanism of action
- Main indications
- Secondary indications
- Dosage forms
- Common strengths
- Route of administration
- Typical prescription status
- OTC status where applicable
- Pediatric/adult considerations
- Major contraindications
- Major warnings
- Common adverse effects
- Serious adverse effects
- Major drug interactions
- Storage requirements
- Shelf-life considerations
2. Export-specific information
This is where your book can become much more valuable than an ordinary medicine book:
- India export status
- HS code
- Whether API or finished formulation
- Tablet/capsule/injection/cream/ophthalmic/etc.
- Prescription medicine
- OTC medicine
- Controlled substance
- Narcotic/psychotropic status
- Hormonal medicine
- Antibiotic/antimicrobial
- Oncology medicine
- Biologic
- Sterile product
- Cold-chain requirement
- Dangerous-goods consideration, where applicable
- Import permit requirement
- Manufacturer licence requirement
- Product registration requirement
- Marketing authorization requirement
- Local representative requirement
- Importer/distributor licence
- Special certificate requirement
- GMP requirement
- CPP/COPP requirement where applicable
- Certificate of Analysis
- Stability data
- Bioequivalence requirement where applicable
- Pharmacovigilance requirements
3. Country-by-country matrix
For your selected countries, I would make a separate row for every formula:
Formula | USA | UK | Brazil | South Africa | Netherlands | France | Germany | Russia | Canada | Australia | Bangladesh | Nigeria | UAE | Indonesia | Turkey | Egypt | Japan | Philippines | Vietnam | Malaysia | Kenya | Tanzania | Uganda | Ghana | Saudi Arabia |
But don’t simply put “Allowed/Banned.”
Use:
🟢 Authorized/normal pathway
🟡 Registration required
🟠 Special licence/control check
🔴 Prohibited/not authorized for proposed use
⚫ Exact product verification required
And add reason + official authority/source.
4. Regulatory authority
For each country, mention the relevant authority, for example:
- USA — FDA
- UK — MHRA / relevant UK authorities
- UAE — Ministry of Health and Prevention / applicable emirate or federal requirements
- Australia — TGA
- Canada — Health Canada
- Japan — PMDA/MHLW
- Saudi Arabia — SFDA
- Brazil — ANVISA
- South Africa — SAHPRA
This makes the book much more useful for exporters.
5. Registration pathway
For each important market, explain:
Manufacturer → Product dossier → Regulatory application → Registration/marketing authorization → Importer → Customs → Distribution → Pharmacovigilance
Then explain what changes for:
- Generic medicine
- New chemical entity
- Combination product
- Biosimilar
- Vaccine
- Injectable
- Controlled medicine
- OTC medicine
- Herbal/Ayurvedic product
6. Buyer information
Since your book is specifically about export, add:
Who buys this product?
Examples:
- Pharmaceutical importer
- National distributor
- Hospital supplier
- Government procurement agency
- Pharmacy chain
- Wholesaler
- Private hospital
- Specialty distributor
- Oncology distributor
- Dermatology distributor
- Fertility distributor
And:
What type of buyer should NOT be approached?
This can help readers avoid unsuitable or fraudulent buyers.
7. Commercial information
For each major medicine category:
- Typical MOQ
- Bulk-pack possibilities
- Private-label possibility
- Contract manufacturing
- OEM possibility
- Packaging options
- Blister/bottle/vial/ampoule
- Carton requirements
- Serialization
- Artwork/label customization
- Sample availability
- Approximate lead-time factors
- Shelf-life requirements
- Payment terms
- LC / advance / CAD considerations
- FOB
- CIF
- insurance
- freight
- landed-cost calculation
Don’t publish unsupported “market prices” as universal prices; instead explain how to calculate the quotation.
8. Formula combinations
This is very important for your book.
Create a separate section:
Common Pharmaceutical Combinations
For example:
- Aceclofenac + Paracetamol
- Amoxicillin + Clavulanic acid
- Dapagliflozin + Metformin
- Telmisartan + Amlodipine
- Losartan + Hydrochlorothiazide
- Rosuvastatin + Ezetimibe
- Sitagliptin + Metformin
- Empagliflozin + Metformin
- Pantoprazole + Domperidone
- Levocetirizine + Montelukast
For each:
Formula → Drug classes → Why combined → Main indications → Dosage forms → Regulatory considerations → Major markets → Prescription status
And, importantly, don’t assume that approval of two individual ingredients means the combination itself is approved.
9. Dosage-form chapter
Another useful chapter:
Same API, Different Product
Example:
Salbutamol
- Tablet
- Syrup
- Inhaler
- Nebulizer solution
Then explain that the regulatory requirements can differ substantially.
Likewise:
Tretinoin
- Cream
- Gel
- Microsphere gel
Testosterone
- Gel
- Injection
- Different esters
Estradiol
- Tablet
- Gel
- Patch
- Vaginal formulation
This will teach exporters why they cannot quote simply by API name.
10. Red-flag medicines
I strongly recommend a dedicated chapter:
Medicines Requiring Extra Regulatory Caution
Include categories such as:
- Narcotic/controlled medicines
- Psychotropic medicines
- Anabolic steroids
- Testosterone/hormones
- Sedative/hypnotics
- Strong analgesics
- ADHD/CNS medicines
- Oncology medicines
- Immunosuppressants
- Fertility medicines
- Retinoids
- High-risk injectables
- Biologics
- Peptides
- GLP-1 medicines
- Certain antibiotics
- Veterinary medicines mistakenly offered as human medicines
Then explain why exporters need additional verification.
11. Human vs veterinary
This is especially important because your source list contains substances that may be encountered in both human and veterinary contexts.
Add:
Human pharmaceutical
vs
Veterinary pharmaceutical
vs
Research/experimental product
A product should never be marketed for human use merely because the active ingredient exists in veterinary products.
12. “Banned” vs “not approved” vs “controlled”
I would make this a dedicated educational section.
These are not the same thing:
Banned ≠ Not approved ≠ Prescription-only ≠ Controlled ≠ Import-restricted ≠ Registration-required
This distinction can become one of the most valuable parts of your book.
13. Export documentation
Create a complete checklist:
- Purchase Order
- Proforma Invoice
- Commercial Invoice
- Packing List
- Certificate of Origin
- Certificate of Analysis
- GMP certificate
- CPP/COPP where applicable
- Batch documents
- Manufacturing licence
- Product registration
- Import permit
- Insurance
- Bill of Lading/Air Waybill
- Shipping Bill
- Customs documentation
- Export declaration
- Stability documentation
- MSDS/SDS where applicable
- Temperature records where required
14. Pharmaceutical costing formula
Include practical formulas such as:
Product Cost + Packaging + Documentation + Testing + Inland Transport + Port Charges + Freight + Insurance + Other Export Costs = Export Cost
Then:
Export Selling Price − Total Export Cost = Gross Export Margin
And explain FOB/CIF carefully.
15. Buyer verification chapter
This is essential for Nawinza.
Explain how to verify:
- Company registration
- Import licence
- Pharmaceutical licence
- Website
- Physical address
- Regulatory registration
- Business email
- Bank details
- Previous shipment history
- Trade references
- Distributor authorization
- Beneficial ownership where appropriate
And include a:
“10 Red Flags of a Fake Pharma Buyer”
16. Manufacturer verification
Likewise:
- Manufacturing licence
- GMP
- WHO-related certifications where actually applicable
- Product list
- Inspection history where publicly available
- Export experience
- Batch documentation
- COA
- Stability data
- Manufacturing capacity
- MOQ
- Private-label capability
- Packaging capability
17. Country-specific chapters
Instead of only putting country restrictions into tables, create individual chapters:
USA Pharma Export Guide
UK Pharma Export Guide
UAE Pharma Export Guide
Saudi Arabia Pharma Export Guide
Australia Pharma Export Guide
etc.
Each can contain:
Authority → Registration → Importer → Product dossier → Label → GMP → Controlled medicines → Documentation → Typical exporter mistakes → Checklist
18. Real export case studies
For example:
Case Study 1: Indian manufacturer → UAE distributor
Case Study 2: Indian generic → African market
Case Study 3: Controlled medicine inquiry rejected because importer lacked authorization
Case Study 4: Product available in India but not authorized in destination market
Case Study 5: Buyer asks for private label
Case Study 6: Buyer asks for exclusivity
Case Study 7: Buyer wants 100,000 tablets but has no import licence
Case Study 8: Product registration exists but formulation/strength differs
19. Export email templates
This would make the book much more practical.
Include:
- First buyer introduction
- Manufacturer inquiry
- RFQ
- Product availability request
- MOQ request
- Private-label inquiry
- OEM inquiry
- Registration-document request
- COA/GMP request
- Importer verification
- Price negotiation
- Follow-up after quotation
- Payment follow-up
- Shipment follow-up
- Complaint handling
- Exclusivity negotiation
20. Final “Exporter Decision Sheet”
For every medicine, the reader could complete:
PRODUCT EXPORT CHECK
☐ Formula verified
☐ Manufacturer verified
☐ Human-use product confirmed
☐ Strength verified
☐ Dosage form verified
☐ Indian legal/export requirements checked
☐ Destination-country registration checked
☐ Importer licence verified
☐ Prescription/OTC status checked
☐ Controlled status checked
☐ Label checked
☐ GMP checked
☐ COA checked
☐ Shelf life checked
☐ Storage checked
☐ Import permit checked
☐ Price calculated
☐ FOB calculated
☐ CIF calculated
☐ Buyer verified
☐ Documents complete
☐ Shipment cleared for execution
Master sequence for every medicine
- Medicine / Product Name
2. Generic / API / Composition
3. Salt / Strength
4. Therapeutic Category
5. Pharmacological / Drug Class
6. Main Uses / Indications
7. Mechanism / Basic Description
8. Dosage Form & Route
9. Prescription / OTC Status
10. Major Warnings / Contraindications / Key Interactions
11. India Export Considerations
12. HS Code / Customs Classification – to be verified
13. 26-Country Regulatory Status
14. Country Regulatory Authority
15. Registration / Marketing Authorization Requirements
16. Export Requirements & Special Restrictions
17. Buyer Type
18. Required Export / Regulatory Documentation
19. Commercial Considerations
20. Exporter Decision / Verification Checklist
And the 26-country section will be standardized as:
- USA
- UK
- UAE
- Saudi Arabia
- Canada
- Australia
- Germany
- France
- Netherlands
- Brazil
- South Africa
- Nigeria
- Kenya
- Tanzania
- Uganda
- Ghana
- Egypt
- Turkey
- Russia
- Bangladesh
- Indonesia
- Malaysia
- Philippines
- Vietnam
- Japan
- New Zealand
Overall master structure
1000+ Medicines × 26 Countries × Regulatory Status × Uses × Dosage Forms × Export Requirements × Buyer Type × Documentation × Commercial Considerations
For each medicine, I will not simply write “approved/banned”. Where applicable, I will distinguish:
- 🟢 Generally permissible/standard regulatory pathway
- 🟡 Registration/approval required
- 🟠 Special regulatory review
- 🔴 Controlled/restricted/high-risk — verify before export
- ⚫ Product/formulation-specific investigation required
I will also flag duplicate medicines, unusual strengths, human vs veterinary products, controlled substances, hormones/anabolic steroids, oncology medicines, biologics/peptides, injectables, antibiotics and other high-risk products rather than silently treating everything as an ordinary export product.
For country-specific regulatory claims, we should use the current official authority/source and verification date, because regulations can change.
Starting point
We already covered medicines 1–20 in the earlier sequence. So the next continuation should begin with 21 and proceed forward without repeating the previous formulas.
MEDICINE 21 — VARDENAFIL + DAPOXETINE
- Medicine / Product Name
Vardenafil + Dapoxetine - Generic / API / Composition
- Vardenafil — PDE5 inhibitor used for erectile dysfunction
- Dapoxetine — short-acting SSRI used for premature ejaculation in markets where approved
- Combination = erectile dysfunction + premature ejaculation positioning
- Salt / Strength
Source file identifies the combination but does not provide a strength.
Export rule: do not assume the strength. Obtain the manufacturer’s exact formulation, strength, dosage form and specification before quotation. - Therapeutic Category
Sexual-health medicine / erectile dysfunction / premature ejaculation. - Pharmacological / Drug Class
- Vardenafil: PDE5 inhibitor
- Dapoxetine: SSRI
- Main Uses / Indications
Potentially intended for adult males with erectile dysfunction and premature ejaculation. The exact approved indication depends on the destination country’s product authorization. - Mechanism / Basic Description
Vardenafil enhances erectile response by inhibiting PDE5 and increasing cGMP-mediated penile blood flow. Dapoxetine increases serotonergic activity and can delay ejaculation. - Dosage Form & Route
Usually oral tablets/capsules depending on manufacturer.
Exact dosage form must be verified from the finished-product specification. - Prescription / OTC Status
Treat as prescription/regulatory-controlled medicine unless the destination authority specifically classifies the product otherwise. - Major Warnings / Contraindications / Key Interactions
Important issues include cardiovascular risk, nitrate interactions with PDE5 inhibitors, blood-pressure effects and potential serotonergic adverse effects/interactions from dapoxetine. Medical supervision is appropriate. - India Export Considerations
Verify:
- finished formulation authorization/licence
- manufacturer licence
- composition and strength
- export documentation
- destination registration
- importer authorization
- labeling
- stability/shelf-life data
- HS Code / Customs Classification — TO BE VERIFIED
Do not assign a final HS code solely from the API name. Classification depends on the finished pharmaceutical product, presentation and applicable customs rules. - 26-Country Regulatory Status
Country | Export status for this exact combination |
USA | 🔴 Product-specific approval required; do not assume marketing authorization |
UK | 🟠 Combination-specific authorization/registration must be verified |
UAE | 🟠 Product registration/import authorization check |
Saudi Arabia | 🟠 Product registration/importer authorization check |
Canada | 🟠 Product-specific authorization check |
Australia | 🟠 TGA product pathway check |
Germany | 🟠 EU/German authorization check |
France | 🟠 EU/French authorization check |
Netherlands | 🟠 EU/Dutch authorization check |
Brazil | 🟠 ANVISA authorization check |
South Africa | 🟠 SAHPRA registration check |
Nigeria | 🟠 NAFDAC registration/import requirements |
Kenya | 🟠 Pharmacy & Poisons Board requirements |
Tanzania | 🟠 TMDA registration/import requirements |
Uganda | 🟠 NDA Uganda requirements |
Ghana | 🟠 FDA Ghana registration/import requirements |
Egypt | 🟠 Egyptian pharmaceutical registration |
Turkey | 🟠 Turkish product authorization |
Russia | 🟠 Russian pharmaceutical registration |
Bangladesh | 🟠 DGDA registration/import requirements |
Indonesia | 🟠 BPOM registration |
Malaysia | 🟠 NPRA registration |
Philippines | 🟠 FDA Philippines registration |
Vietnam | 🟠 DAV/MOH registration |
Japan | 🟠 PMDA/MHLW pathway |
New Zealand | 🟠 Medsafe regulatory pathway |
Important: this table is a screening classification, not a statement that the combination is approved or banned in each country. The exact finished product must be checked against each country’s current database before export.
- Country Regulatory Authority
Examples include FDA (USA), MHRA (UK), TGA (Australia), Health Canada, ANVISA (Brazil), SAHPRA (South Africa), NAFDAC (Nigeria), NPRA (Malaysia), BPOM (Indonesia), PMDA/MHLW (Japan). - Registration / Marketing Authorization Requirements
Combination products normally require destination-specific assessment. The fact that each individual ingredient exists as an approved medicine does not automatically mean that their fixed-dose combination is authorized. - Export Requirements & Special Restrictions
Special attention to:
- combination authorization
- prescription status
- pharmacovigilance
- label claims
- importer licence
- advertising claims
- product registration
- certificate requirements
- Buyer Type
Suitable buyer categories may include:
- licensed pharmaceutical importers
- registered distributors
- pharmaceutical wholesalers
- licensed healthcare companies
- registered private-label pharmaceutical companies where permitted
- Required Export / Regulatory Documentation
Potential documentation:
- Commercial Invoice
- Packing List
- Certificate of Origin
- GMP certificate
- COA
- manufacturing licence
- product specification
- stability data
- product registration/MA
- CPP where applicable
- import permit
- shipping documents
- Commercial Considerations
Evaluate:
- MOQ
- tablet/capsule strength
- blister/bottle packaging
- private-label possibility
- artwork
- registration cost
- shelf life
- payment terms
- FOB/CIF
- freight
- insurance
- destination registration cost
- Exporter Decision / Verification Checklist
☐ Exact strength confirmed
☐ Exact dosage form confirmed
☐ Combination legally permitted
☐ Manufacturer verified
☐ Buyer/importer licence verified
☐ Destination registration checked
☐ Prescription/controlled status checked
☐ Label checked
☐ GMP/COA available
☐ Import permit requirement checked
☐ Commercial feasibility calculated
MEDICINE 22 — LAMOTRIGINE
- Medicine / Product Name
Lamotrigine - Generic / API / Composition
Lamotrigine - Salt / Strength
Source file specifically lists Lamotrigine Dispersible; strength is not stated in the extracted source. - Therapeutic Category
Antiepileptic / anticonvulsant; also used in certain bipolar-disorder treatment regimens. - Pharmacological / Drug Class
Antiseizure medication; sodium-channel modulating anticonvulsant. - Main Uses / Indications
Depending on country and authorization:
- epilepsy/seizure disorders
- maintenance treatment of bipolar disorder
- Mechanism / Basic Description
Lamotrigine primarily reduces neuronal excitability through inhibition of voltage-sensitive sodium channels and reduction of excitatory neurotransmitter release. - Dosage Form & Route
- Tablets
- chewable/dispersible tablets
- oral route
The exact formulation must match the destination registration.
- Prescription / OTC Status
Generally prescription medicine. - Major Warnings / Contraindications / Key Interactions
Major concern: serious skin reactions, including Stevens-Johnson syndrome/toxic epidermal necrolysis. Dose escalation is important. Interactions include valproate and certain enzyme-inducing medicines. - India Export Considerations
Verify:
- manufacturer’s drug licence
- finished-product specification
- dispersible-tablet formulation
- dissolution specifications
- stability
- GMP
- destination registration
- HS Code — TO BE VERIFIED
Pharmaceutical medicament classification must be confirmed according to the finished product and destination customs requirements. - 26-Country Regulatory Status
Market group | Screening status |
USA | 🟡 Regulated prescription medicine; product authorization required |
UK | 🟡 Prescription medicine; MA/product requirements |
EU markets — Germany, France, Netherlands | 🟡 Prescription/authorized medicinal product pathway |
Canada | 🟡 Product authorization required |
Australia | 🟡 TGA/Australian Register pathway |
Japan | 🟡 PMDA/MHLW pathway |
New Zealand | 🟡 Medsafe pathway |
UAE | 🟡 Local registration/importer authorization |
Saudi Arabia | 🟡 SFDA registration/import pathway |
Brazil | 🟡 ANVISA pathway |
South Africa | 🟡 SAHPRA pathway |
Nigeria | 🟡 NAFDAC pathway |
Kenya | 🟡 PPB pathway |
Tanzania | 🟡 TMDA pathway |
Uganda | 🟡 NDA pathway |
Ghana | 🟡 FDA Ghana pathway |
Egypt | 🟡 Local pharmaceutical registration |
Turkey | 🟡 Product authorization |
Russia | 🟡 Product registration |
Bangladesh | 🟡 DGDA pathway |
Indonesia | 🟡 BPOM pathway |
Malaysia | 🟡 NPRA pathway |
Philippines | 🟡 FDA Philippines pathway |
Vietnam | 🟡 DAV/MOH pathway |
- Country Regulatory Authority
Destination authority must be checked before shipment; the U.S. FDA, UK MHRA, Health Canada, TGA, SFDA, UAE authority and corresponding national agencies regulate medicinal products in their respective markets. - Registration / Marketing Authorization Requirements
The exact lamotrigine dosage form, strength, manufacturer and indication must correspond to the destination authorization. - Export Requirements & Special Restrictions
Check:
- prescription classification
- product registration
- importer licence
- GMP
- stability
- labeling
- pharmacovigilance
- batch-release requirements
- Buyer Type
Licensed pharmaceutical:
- importer
- distributor
- wholesaler
- hospital-supply distributor
- government/NGO procurement organization where eligible
- Required Documentation
COA, GMP, manufacturing licence, product specification, stability data, CPP where applicable, Certificate of Origin, invoice, packing list, registration/MA and import permit where applicable. - Commercial Considerations
Dispersible formulation may have different:
- packaging
- stability
- dissolution
- moisture-protection
- registration
- MOQ
requirements compared with ordinary tablets.
- Exporter Decision
☐ Strength confirmed
☐ Dispersible formulation confirmed
☐ Manufacturer GMP verified
☐ Product registered in target market
☐ Importer licensed
☐ Label approved
☐ Stability data available
☐ COA available
☐ Shelf life acceptable
☐ Price calculated on FOB/CIF basis
MEDICINE 23 — GABAPENTIN
- Medicine / Product Name
Gabapentin - Generic / API / Composition
Gabapentin - Salt / Strength
Gabapentin; source file contains multiple repeated entries and strengths. These should be consolidated after exact-strength verification. - Therapeutic Category
Antiepileptic / neuropathic-pain medicine. - Pharmacological / Drug Class
Antiseizure medicine / gabapentinoid. - Main Uses / Indications
Depending on country:
- certain seizure disorders
- neuropathic pain
- other authorized indications
- Mechanism / Basic Description
Gabapentin binds to the α2δ subunit of voltage-gated calcium channels and reduces excitatory neurotransmitter release. - Dosage Form & Route
Commonly:
- capsules
- tablets
- oral solution
Exact dosage form must be matched to the registered product.
- Prescription / OTC Status
Generally prescription medicine. Regulatory/control classification varies by country. - Major Warnings / Contraindications / Key Interactions
Potential concerns:
- dizziness
- sedation
- impaired coordination
- respiratory-depression risk in susceptible patients, especially with CNS depressants
- renal-dose considerations
- India Export Considerations
Check the exact strength and dosage form because the source list contains repeated gabapentin entries. - HS Code — TO BE VERIFIED
Do not use a generic HS code without confirming the finished-product classification. - 26-Country Regulatory Status
Overall screening: 🟡 regulated prescription medicine in the listed markets; additional controlled-drug checks are necessary in certain jurisdictions.
Countries | Screening |
USA | 🟡 Prescription; federal/state requirements must be checked |
UK | 🟠 Controlled-drug requirements apply; verify current classification and import requirements |
Canada | 🟡 Controlled/substance regulatory check required |
Australia | 🟠 State/federal controlled-medicine requirements |
New Zealand | 🟠 Controlled-medicine classification check |
EU countries | 🟡 Prescription/product authorization |
UAE | 🟠 Controlled/prescription/import check |
Saudi Arabia | 🟠 Controlled/prescription/import check |
Japan | 🟠 Import/prescription requirements |
Other listed markets | 🟡/🟠 Destination-specific medicine and controlled-substance checks |
- Country Regulatory Authority
FDA, MHRA, Health Canada, TGA, Medsafe and respective national authorities. - Registration / Marketing Authorization Requirements
Exact product authorization, importer authorization and prescription/controlled classification must be confirmed before commercial shipment. - Export Requirements & Special Restrictions
Because gabapentin can have additional controls depending on jurisdiction, do not treat it like an unrestricted OTC product. - Buyer Type
Only verified:
- licensed pharmaceutical importers
- authorized distributors
- hospital suppliers
- licensed wholesalers
- Required Documentation
Manufacturer licence, GMP, COA, product specification, stability data, CPP where applicable, import permit/authorization where required, invoice, packing list and certificate of origin. - Commercial Considerations
Important commercial variables:
- strength
- capsule/tablet format
- pack size
- controlled-medicine handling
- importer licence
- destination registration
- MOQ
- shelf life
- FOB/CIF
- Exporter Decision
☐ Exact strength confirmed
☐ Controlled status checked in destination
☐ Importer licence verified
☐ Product registration verified
☐ Manufacturer verified
☐ GMP verified
☐ COA verified
☐ Label checked
☐ Import permit checked
☐ Shipment documentation complete
MEDICINE 24 — TELMISARTAN
- Medicine / Product Name
Telmisartan - Generic / API / Composition
Telmisartan - Salt / Strength
Telmisartan; exact strength must be taken from the finished-product specification. - Therapeutic Category
Cardiovascular medicine / antihypertensive. - Pharmacological / Drug Class
Angiotensin II receptor blocker (ARB). - Main Uses / Indications
Primarily used for:
- hypertension
- cardiovascular-risk reduction in appropriate patients where authorized
- Mechanism / Basic Description
Telmisartan blocks angiotensin II AT1 receptors, reducing vasoconstriction and aldosterone-related effects. - Dosage Form & Route
Primarily:
- oral tablets
Combination products may contain telmisartan with other antihypertensive agents.
- Prescription / OTC Status
Generally prescription medicine. - Major Warnings / Contraindications / Key Interactions
Important considerations include:
- pregnancy contraindication/warnings
- renal function
- potassium elevation
- interactions with certain medicines affecting renal function or potassium
- India Export Considerations
Verify:
- strength
- tablet formulation
- manufacturer licence
- GMP
- stability
- destination registration
- labeling
- HS Code — TO BE VERIFIED
Finished medicament HS classification must be verified according to the exact product and customs requirements. - 26-Country Regulatory Status
Market | Screening status |
USA | 🟡 Prescription/product authorization |
UK | 🟡 Prescription/product authorization |
UAE | 🟡 Product registration/import authorization |
Saudi Arabia | 🟡 SFDA/product registration |
Canada | 🟡 Product authorization |
Australia | 🟡 TGA pathway |
Germany | 🟡 EU/German authorization |
France | 🟡 EU/French authorization |
Netherlands | 🟡 EU/Dutch authorization |
Brazil | 🟡 ANVISA pathway |
South Africa | 🟡 SAHPRA pathway |
Nigeria | 🟡 NAFDAC pathway |
Kenya | 🟡 PPB pathway |
Tanzania | 🟡 TMDA pathway |
Uganda | 🟡 NDA pathway |
Ghana | 🟡 FDA Ghana pathway |
Egypt | 🟡 Pharmaceutical registration |
Turkey | 🟡 Product authorization |
Russia | 🟡 Product registration |
Bangladesh | 🟡 DGDA pathway |
Indonesia | 🟡 BPOM pathway |
Malaysia | 🟡 NPRA pathway |
Philippines | 🟡 FDA Philippines pathway |
Vietnam | 🟡 DAV/MOH pathway |
Japan | 🟡 PMDA/MHLW pathway |
New Zealand | 🟡 Medsafe pathway |
- Country Regulatory Authority
National pharmaceutical authority of the importing country; examples include FDA, MHRA, TGA, Health Canada, SFDA, SAHPRA, NAFDAC, NPRA and PMDA/MHLW. - Registration / Marketing Authorization Requirements
The finished telmisartan product must satisfy the destination’s pharmaceutical registration requirements. Do not confuse API availability with authorization to sell a finished medicine. - Export Requirements & Special Restrictions
Check:
- product registration
- prescription status
- importer licence
- GMP
- stability
- approved label
- batch documentation
- Buyer Type
Licensed:
- pharmaceutical importers
- distributors
- wholesalers
- hospital suppliers
- institutional procurement organizations
- Required Documentation
COA, GMP, manufacturing licence, specifications, stability information, registration/MA, CPP where applicable, invoice, packing list, COO and import authorization where required. - Commercial Considerations
Potentially strong generic-market category because hypertension treatment is widely used, but competition, registration, local reference pricing, pack size and reimbursement environment should be assessed. - Exporter Decision
☐ Strength confirmed
☐ Manufacturer verified
☐ GMP verified
☐ Destination MA verified
☐ Importer verified
☐ Label verified
☐ COA available
☐ Stability available
☐ MOQ obtained
☐ FOB/CIF calculated
MEDICINE 25 — SILDENAFIL CITRATE + TADALAFIL
- Medicine / Product Name
Sildenafil citrate + Tadalafil - Generic / API / Composition
- Sildenafil citrate
- Tadalafil
Both are PDE5 inhibitors.
- Salt / Strength
Source file identifies Sildenafil Citrate and Tadalafil but does not provide the exact strengths in this entry. - Therapeutic Category
Sexual-health / erectile-dysfunction product. - Pharmacological / Drug Class
Both ingredients are PDE5 inhibitors. - Main Uses / Indications
The proposed combination is intended commercially for erectile dysfunction, but the exact combination must be treated as a separate regulatory product from either sildenafil or tadalafil alone. - Mechanism / Basic Description
Both medicines inhibit PDE5. Combining two PDE5 inhibitors is not automatically an approved or clinically appropriate regimen. - Dosage Form & Route
Likely oral dosage form based on the source entry. Exact form and strength must be verified. - Prescription / OTC Status
Treat as prescription/regulatory medicine unless the destination authority specifically determines otherwise. - Major Warnings / Contraindications / Key Interactions
Major concern is duplication of PDE5 pharmacological activity and increased risk of adverse effects such as hypotension. Nitrate interactions are particularly important with PDE5 inhibitors. - India Export Considerations
Before exporting, verify whether the specific fixed-dose combination is legally manufactured, licensed and exportable. - HS Code — TO BE VERIFIED
Final HS classification requires exact finished-product details. - 26-Country Regulatory Status
Critical rule: Do not infer authorization of this combination from authorization of sildenafil or tadalafil individually.
Country | Screening status |
USA | 🔴 Combination-specific FDA authorization required; do not assume approved |
UK | 🟠 Combination-specific authorization required |
UAE | 🟠 Product registration/import authorization |
Saudi Arabia | 🟠 SFDA product registration |
Canada | 🟠 Combination-specific authorization |
Australia | 🟠 TGA product pathway |
Germany | 🟠 EU/German authorization |
France | 🟠 EU/French authorization |
Netherlands | 🟠 EU/Dutch authorization |
Brazil | 🟠 ANVISA authorization |
South Africa | 🟠 SAHPRA registration |
Nigeria | 🟠 NAFDAC registration |
Kenya | 🟠 PPB registration |
Tanzania | 🟠 TMDA registration |
Uganda | 🟠 NDA registration |
Ghana | 🟠 FDA Ghana registration |
Egypt | 🟠 Local pharmaceutical authorization |
Turkey | 🟠 Product authorization |
Russia | 🟠 Product registration |
Bangladesh | 🟠 DGDA registration |
Indonesia | 🟠 BPOM registration |
Malaysia | 🟠 NPRA registration |
Philippines | 🟠 FDA Philippines registration |
Vietnam | 🟠 DAV/MOH registration |
Japan | 🟠 PMDA/MHLW pathway |
New Zealand | 🟠 Medsafe pathway |
- Country Regulatory Authority
The applicable national medicines authority must assess the combination product, not merely the individual APIs. - Registration / Marketing Authorization Requirements
A fixed-dose combination requires its own regulatory justification/authorization where applicable. The existence of approved sildenafil and tadalafil products does not establish authorization of this combination. - Export Requirements & Special Restrictions
High-priority checks:
- fixed-dose combination legality
- clinical/regulatory justification
- product licence
- prescription classification
- label claims
- importer authorization
- pharmacovigilance
- destination registration
- Buyer Type
Only verified pharmaceutical:
- importers
- distributors
- wholesalers
- registered private-label companies
- licensed healthcare suppliers
- Required Documentation
Potential requirements:
- manufacturing licence
- GMP
- product specification
- COA
- stability
- pharmaceutical dossier
- registration/MA
- CPP where applicable
- import authorization
- invoice
- packing list
- certificate of origin
- Commercial Considerations
Do not price this product simply by adding sildenafil and tadalafil API costs. Include:
- formulation development
- regulatory/registration cost
- stability studies
- packaging
- testing
- artwork
- MOQ
- freight
- insurance
- importer/distributor margin
- potential registration/exclusivity costs
- Exporter Decision
☐ Exact formulation confirmed
☐ Exact strength confirmed
☐ Combination legally authorized in India
☐ Destination authorization confirmed
☐ Manufacturer verified
☐ Buyer/importer verified
☐ Prescription status checked
☐ Label reviewed
☐ COA/GMP available
☐ Import permit checked
☐ Commercial feasibility approved
U.S. regulatory principle for the entire database: FDA states that foreign establishments manufacturing drugs offered for import into the U.S. generally must register, commercially distributed drugs must be listed, applicable drug applications/approval requirements must be satisfied, labeling must comply, and drugs must meet CGMP requirements.
For the UK, the MHRA states that importing licensed human medicines can involve a WDA(H), manufacturer licence and marketing authorization, with additional requirements for controlled substances and certain import routes.
MEDICINE 26 — LIOTHYRONINE SODIUM
- Medicine / Product Name
Liothyronine Sodium - Generic / API / Composition
Liothyronine sodium — synthetic sodium salt of liothyronine (T3).
FDA’s substance database identifies liothyronine sodium as the sodium salt of 3,3′,5-triiodo-L-thyronine.
- Salt / Strength
Source file contains:
- Liothyronine Sodium
- Liothyronine Sodium BP 25 mcg
Therefore, 25 mcg should be recorded as one confirmed source-file strength, while any other strength must be verified from the manufacturer.
- Therapeutic Category
Thyroid hormone / endocrine medicine. - Pharmacological / Drug Class
Thyroid hormone; synthetic T3. - Main Uses / Indications
Used for thyroid-hormone replacement in appropriate thyroid disorders according to the approved indication and local label. - Mechanism / Basic Description
Liothyronine is the active thyroid hormone T3 and acts through thyroid-hormone receptors to regulate gene transcription and metabolic activity. - Dosage Form & Route
Common pharmaceutical forms include:
- oral tablets
- injectable formulations for specific indications
Your source specifically identifies the oral ingredient/tablet context.
- Prescription / OTC Status
Treat as a prescription medicine unless the destination authority explicitly classifies the particular product otherwise. - Major Warnings / Contraindications / Key Interactions
Important issues include:
- cardiovascular effects
- excessive thyroid-hormone exposure
- arrhythmia risk
- interaction with anticoagulants
- interaction with medicines affecting thyroid absorption/metabolism
FDA labeling for Cytomel specifically warns that thyroid hormones should not be used for obesity or weight loss and that excessive doses can cause serious or life-threatening toxicity.
- India Export Considerations
Verify:
- exact strength
- finished dosage form
- manufacturer licence
- GMP
- stability
- label
- destination registration
- importer authorization
- HS Code / Customs Classification — VERIFY
Do not assign the final HS code from the API name alone. Confirm the finished pharmaceutical presentation. - 26-Country Regulatory Status
Country | Screening status |
USA | 🟡 Prescription/product authorization |
UK | 🟡 Prescription/product authorization |
UAE | 🟡 Product registration/import authorization |
Saudi Arabia | 🟡 Product registration/import authorization |
Canada | 🟡 Product authorization |
Australia | 🟡 TGA pathway |
Germany | 🟡 EU/German authorization |
France | 🟡 EU/French authorization |
Netherlands | 🟡 EU/Dutch authorization |
Brazil | 🟡 ANVISA pathway |
South Africa | 🟡 SAHPRA pathway |
Nigeria | 🟡 NAFDAC pathway |
Kenya | 🟡 PPB pathway |
Tanzania | 🟡 TMDA pathway |
Uganda | 🟡 NDA pathway |
Ghana | 🟡 FDA Ghana pathway |
Egypt | 🟡 Pharmaceutical registration |
Turkey | 🟡 Product authorization |
Russia | 🟡 Product registration |
Bangladesh | 🟡 DGDA pathway |
Indonesia | 🟡 BPOM pathway |
Malaysia | 🟡 NPRA pathway |
Philippines | 🟡 FDA Philippines pathway |
Vietnam | 🟡 DAV/MOH pathway |
Japan | 🟡 PMDA/MHLW pathway |
New Zealand | 🟡 Medsafe pathway |
- Country Regulatory Authority
The applicable national medicines authority must be checked for the exact product. - Registration / Marketing Authorization Requirements
The finished product must meet the destination’s thyroid-medicine requirements, including approved strength, indications, labeling and manufacturing standards. - Export Requirements & Special Restrictions
Special attention:
- prescription status
- hormone/thyroid-medicine classification
- approved indications
- anti-weight-loss claims
- importer licence
- destination registration
- Buyer Type
- Licensed pharmaceutical importer
- Distributor
- Hospital supplier
- Licensed wholesaler
- Institutional procurement organization
- Required Export / Regulatory Documentation
Potential documents:
- GMP
- manufacturing licence
- COA
- product specification
- stability data
- CPP where applicable
- registration/MA
- Certificate of Origin
- Commercial Invoice
- Packing List
- import authorization where applicable
- Commercial Considerations
Check:
- 25 mcg or other strength
- blister/bottle
- MOQ
- shelf life
- registration cost
- freight
- importer margin
- FOB/CIF
- Exporter Decision / Verification Checklist
☐ Strength confirmed
☐ Dosage form confirmed
☐ Manufacturer verified
☐ GMP verified
☐ Destination registration checked
☐ Prescription status checked
☐ Label/claims checked
☐ Importer verified
☐ COA available
☐ Commercial costing completed
MEDICINE 27 — DANAZOL
- Medicine / Product Name
Danazol - Generic / API / Composition
Danazol. - Salt / Strength
Source file identifies Danazol but does not specify the strength. - Therapeutic Category
Hormonal medicine / androgenic-anabolic steroid derivative. - Pharmacological / Drug Class
Synthetic androgen with antigonadotropic activity. - Main Uses / Indications
Historically/depending on jurisdiction:
- endometriosis
- hereditary angioedema
- certain other hormone-related conditions
The exact indication must follow the destination-approved label.
- Mechanism / Basic Description
Danazol suppresses pituitary-gonadal hormone activity and has androgenic effects. - Dosage Form & Route
Primarily:
- oral capsules
- Prescription / OTC Status
Prescription medicine.
An FDA danazol label explicitly states that dispensing is prohibited without prescription.
- Major Warnings / Contraindications / Key Interactions
Important considerations include:
- androgenic effects
- liver-related adverse effects
- lipid changes
- pregnancy/fetal-risk concerns
- interaction with anticoagulants and certain other medicines
- India Export Considerations
Because this is a hormone-related medicine, verify:
- manufacturer authorization
- exact strength
- formulation
- export classification
- destination restrictions
- importer licence
- HS Code — VERIFY
Final classification depends on the finished medicament. - 26-Country Regulatory Status
Market | Screening |
USA | 🟡 Prescription medicine; product authorization required |
UK | 🟠 Hormonal/special regulatory check |
UAE | 🟠 Product registration + importer authorization |
Saudi Arabia | 🟠 Product registration/import check |
Canada | 🟠 Product authorization |
Australia | 🟠 TGA/product pathway |
Germany | 🟠 EU/German authorization |
France | 🟠 EU/French authorization |
Netherlands | 🟠 EU/Dutch authorization |
Brazil | 🟠 ANVISA check |
South Africa | 🟠 SAHPRA check |
Nigeria | 🟠 NAFDAC check |
Kenya | 🟠 PPB check |
Tanzania | 🟠 TMDA check |
Uganda | 🟠 NDA check |
Ghana | 🟠 FDA Ghana check |
Egypt | 🟠 Pharmaceutical registration |
Turkey | 🟠 Product authorization |
Russia | 🟠 Product registration |
Bangladesh | 🟠 DGDA check |
Indonesia | 🟠 BPOM check |
Malaysia | 🟠 NPRA check |
Philippines | 🟠 FDA Philippines check |
Vietnam | 🟠 DAV/MOH check |
Japan | 🟠 PMDA/MHLW check |
New Zealand | 🟠 Medsafe check |
- Country Regulatory Authority
Destination-specific pharmaceutical authority. - Registration / Marketing Authorization Requirements
Exact indication, formulation, strength and manufacturer must be covered by the destination authorization. - Export Requirements & Special Restrictions
Treat as a special-regulatory hormonal product, not as an ordinary OTC product. - Buyer Type
Only:
- licensed pharmaceutical importer
- authorized distributor
- hospital/medical supplier
- regulated pharmaceutical wholesaler
- Required Documentation
GMP, manufacturing licence, COA, specifications, stability, product registration/MA, CPP where applicable, import permit, invoice, packing list and COO. - Commercial Considerations
Consider:
- hormone-product demand
- registration barriers
- MOQ
- strength
- capsule packaging
- shelf life
- importer authorization
- regulatory cost
- Exporter Decision
☐ Hormonal classification checked
☐ Strength verified
☐ Destination authorization checked
☐ Importer licence verified
☐ Manufacturer verified
☐ GMP/COA verified
☐ Label approved
☐ Import permit checked
☐ Commercial viability confirmed
MEDICINE 28 — EMPAGLIFLOZIN
- Medicine / Product Name
Empagliflozin - Generic / API / Composition
Empagliflozin. - Salt / Strength
Source file identifies Empagliflozin but does not state the strength in the relevant entry. - Therapeutic Category
Antidiabetic / cardiovascular / renal medicine. - Pharmacological / Drug Class
SGLT2 inhibitor. - Main Uses / Indications
Depending on jurisdiction and current label:
- type 2 diabetes management
- cardiovascular-risk reduction in appropriate patients
- heart-failure indications
- chronic-kidney-disease-related indications in applicable labels
- Mechanism / Basic Description
Empagliflozin inhibits sodium-glucose cotransporter 2 in the renal proximal tubule, increasing urinary glucose and sodium excretion. - Dosage Form & Route
Primarily:
- film-coated oral tablets
FDA labeling records Jardiance as an oral film-coated tablet and identifies empagliflozin as an SGLT2 inhibitor.
- Prescription / OTC Status
Prescription medicine. - Major Warnings / Contraindications / Key Interactions
Key concerns can include:
- dehydration/volume depletion
- genital mycotic infections
- urinary infections
- ketoacidosis
- renal-function considerations
- hypoglycemia when combined with certain glucose-lowering medicines
- India Export Considerations
Verify:
- exact strength
- formulation
- finished-product licence
- GMP
- stability
- bioequivalence requirements where applicable
- destination registration
- HS Code — VERIFY
Use the finished pharmaceutical classification, not merely the API classification. - 26-Country Regulatory Status
Country | Screening |
USA | 🟢 Approved prescription product pathway exists; specific generic/product authorization required |
UK | 🟡 Prescription/product authorization |
UAE | 🟡 Registration/import authorization |
Saudi Arabia | 🟡 SFDA registration |
Canada | 🟡 Product authorization |
Australia | 🟡 TGA pathway |
Germany | 🟡 EU/German authorization |
France | 🟡 EU/French authorization |
Netherlands | 🟡 EU/Dutch authorization |
Brazil | 🟡 ANVISA pathway |
South Africa | 🟡 SAHPRA pathway |
Nigeria | 🟡 NAFDAC pathway |
Kenya | 🟡 PPB pathway |
Tanzania | 🟡 TMDA pathway |
Uganda | 🟡 NDA pathway |
Ghana | 🟡 FDA Ghana pathway |
Egypt | 🟡 Pharmaceutical registration |
Turkey | 🟡 Product authorization |
Russia | 🟡 Product registration |
Bangladesh | 🟡 DGDA pathway |
Indonesia | 🟡 BPOM pathway |
Malaysia | 🟡 NPRA pathway |
Philippines | 🟡 FDA Philippines pathway |
Vietnam | 🟡 DAV/MOH pathway |
Japan | 🟡 PMDA/MHLW pathway |
New Zealand | 🟡 Medsafe pathway |
FDA records show an approved U.S. NDA for Jardiance/empagliflozin and also authorized combination products such as empagliflozin/metformin and empagliflozin/linagliptin.
- Country Regulatory Authority
National medicines authority of the destination country. - Registration / Marketing Authorization Requirements
For generic export, the exporter must distinguish:
- API availability
- finished-product manufacturing authorization
- product registration
- bioequivalence/dossier requirements
- local importer/MA holder
- Export Requirements & Special Restrictions
Check:
- prescription status
- diabetes/cardiovascular/renal indication claims
- product registration
- stability
- bioequivalence
- approved label
- importer authorization
- Buyer Type
- Pharmaceutical importer
- Diabetes-care distributor
- Hospital supplier
- Pharmaceutical wholesaler
- Government/institutional procurement where permitted
- Required Documentation
GMP, COA, manufacturing licence, product dossier, stability, bioequivalence data where required, CPP where applicable, MA/registration, COO, invoice, packing list and import authorization. - Commercial Considerations
Important:
- strength
- tablet count
- generic competition
- reference-product pricing
- registration cost
- MOQ
- private label/OEM
- shelf life
- FOB/CIF
- local distributor margin
- Exporter Decision
☐ Strength confirmed
☐ Generic authorization pathway confirmed
☐ Manufacturer verified
☐ GMP verified
☐ BE requirements checked
☐ Destination registration checked
☐ Importer verified
☐ Label approved
☐ COA/stability available
☐ Commercial calculation completed
MEDICINE 29 — MEMANTINE HYDROCHLORIDE
- Medicine / Product Name
Memantine Hydrochloride - Generic / API / Composition
Memantine hydrochloride. - Salt / Strength
Source file includes memantine hydrochloride and specifically 5 mg tablets in another entry. - Therapeutic Category
Neurology / dementia medicine. - Pharmacological / Drug Class
NMDA receptor antagonist. - Main Uses / Indications
Moderate-to-severe Alzheimer’s-type dementia, subject to local authorization.
FDA labeling identifies memantine hydrochloride as indicated for moderate-to-severe dementia of the Alzheimer’s type.
- Mechanism / Basic Description
Memantine is an NMDA receptor antagonist that modulates glutamatergic activity. - Dosage Form & Route
- immediate-release tablets
- extended-release capsules
- oral solution in some markets/products
FDA labeling identifies 5 mg and 10 mg immediate-release tablets for oral use.
- Prescription / OTC Status
Prescription medicine. - Major Warnings / Contraindications / Key Interactions
Important considerations include:
- renal impairment
- dizziness/confusion
- urine-pH-related changes in elimination
- interactions with other NMDA antagonists
- India Export Considerations
Verify:
- 5 mg/10 mg or other strength
- dosage form
- manufacturer
- GMP
- stability
- registration requirements
- HS Code — VERIFY
Final HS classification must be confirmed for the finished medicament. - 26-Country Regulatory Status
Country | Screening |
USA | 🟢 Established prescription-product pathway; specific product authorization required |
UK | 🟡 Prescription/product authorization |
UAE | 🟡 Registration/import authorization |
Saudi Arabia | 🟡 SFDA pathway |
Canada | 🟡 Product authorization |
Australia | 🟡 TGA pathway |
Germany | 🟡 EU/German authorization |
France | 🟡 EU/French authorization |
Netherlands | 🟡 EU/Dutch authorization |
Brazil | 🟡 ANVISA pathway |
South Africa | 🟡 SAHPRA pathway |
Nigeria | 🟡 NAFDAC pathway |
Kenya | 🟡 PPB pathway |
Tanzania | 🟡 TMDA pathway |
Uganda | 🟡 NDA pathway |
Ghana | 🟡 FDA Ghana pathway |
Egypt | 🟡 Pharmaceutical registration |
Turkey | 🟡 Product authorization |
Russia | 🟡 Product registration |
Bangladesh | 🟡 DGDA pathway |
Indonesia | 🟡 BPOM pathway |
Malaysia | 🟡 NPRA pathway |
Philippines | 🟡 FDA Philippines pathway |
Vietnam | 🟡 DAV/MOH pathway |
Japan | 🟡 PMDA/MHLW pathway |
New Zealand | 🟡 Medsafe pathway |
- Country Regulatory Authority
National pharmaceutical authority applicable to the destination. - Registration / Marketing Authorization Requirements
The exact strength and dosage form must be included in the product authorization. - Export Requirements & Special Restrictions
Check:
- prescription status
- dementia indication
- importer authorization
- label
- pharmacovigilance
- stability
- registration
- Buyer Type
- Pharmaceutical importer
- Neurology/geriatric medicine distributor
- Hospital supplier
- Licensed wholesaler
- Institutional purchaser
- Required Documentation
GMP, COA, manufacturing licence, product specifications, stability, registration/MA, CPP where applicable, COO, invoice, packing list and import permit where required. - Commercial Considerations
Evaluate:
- 5 mg/10 mg
- IR vs ER
- tablet vs oral solution
- MOQ
- generic competition
- private-label opportunity
- shelf life
- registration expense
- FOB/CIF
- Exporter Decision
☐ Strength confirmed
☐ Dosage form confirmed
☐ Manufacturer verified
☐ GMP verified
☐ Registration checked
☐ Importer verified
☐ Label checked
☐ COA available
☐ Stability available
☐ Commercial feasibility calculated
MEDICINE 30 — BEMPEDOIC ACID
- Medicine / Product Name
Bempedoic Acid - Generic / API / Composition
Bempedoic acid. - Salt / Strength
Source file identifies Bempedoic Acid without a strength in the entry.
For the U.S. reference product Nexletol, the tablet strength is 180 mg.
- Therapeutic Category
Lipid-lowering / cardiovascular medicine. - Pharmacological / Drug Class
ATP-citrate lyase (ACL) inhibitor. - Main Uses / Indications
Depending on current destination authorization:
- LDL-cholesterol reduction in hypercholesterolemia
- cardiovascular-risk reduction in eligible patients
The current FDA Nexletol label includes cardiovascular-risk reduction and LDL-C lowering indications.
- Mechanism / Basic Description
Bempedoic acid inhibits ACL, an enzyme upstream of HMG-CoA reductase in hepatic cholesterol synthesis, thereby reducing LDL-C. - Dosage Form & Route
- oral film-coated tablet
- U.S. Nexletol reference strength: 180 mg
- Prescription / OTC Status
Prescription medicine. - Major Warnings / Contraindications / Key Interactions
Current FDA labeling highlights:
- hyperuricemia
- gout risk
- tendon rupture
- pregnancy considerations
- interactions with simvastatin and pravastatin at specified doses.
- India Export Considerations
Verify:
- 180 mg formulation
- Indian manufacturing authorization
- product registration
- GMP
- stability
- bioequivalence requirements
- destination-specific dossier
- HS Code — VERIFY
Final HS code must be established from the finished medicament classification. - 26-Country Regulatory Status
Country | Screening |
USA | 🟢 Established FDA-approved prescription pathway; generic product still requires applicable authorization |
UK | 🟡 Product/MA pathway |
UAE | 🟡 Product registration/import authorization |
Saudi Arabia | 🟡 SFDA pathway |
Canada | 🟡 Product authorization |
Australia | 🟡 TGA pathway |
Germany | 🟡 EU/German authorization |
France | 🟡 EU/French authorization |
Netherlands | 🟡 EU/Dutch authorization |
Brazil | 🟡 ANVISA pathway |
South Africa | 🟡 SAHPRA pathway |
Nigeria | 🟡 NAFDAC pathway |
Kenya | 🟡 PPB pathway |
Tanzania | 🟡 TMDA pathway |
Uganda | 🟡 NDA pathway |
Ghana | 🟡 FDA Ghana pathway |
Egypt | 🟡 Pharmaceutical registration |
Turkey | 🟡 Product authorization |
Russia | 🟡 Product registration |
Bangladesh | 🟡 DGDA pathway |
Indonesia | 🟡 BPOM pathway |
Malaysia | 🟡 NPRA pathway |
Philippines | 🟡 FDA Philippines pathway |
Vietnam | 🟡 DAV/MOH pathway |
Japan | 🟡 PMDA/MHLW pathway |
New Zealand | 🟡 Medsafe pathway |
- Country Regulatory Authority
Destination-specific pharmaceutical regulator. - Registration / Marketing Authorization Requirements
A generic manufacturer must establish the applicable regulatory pathway rather than assuming that U.S. approval automatically permits export to another country. - Export Requirements & Special Restrictions
Check:
- prescription status
- product registration
- bioequivalence requirements
- quality dossier
- stability
- label
- importer authorization
- pharmacovigilance
- Buyer Type
- Pharmaceutical importer
- Cardiovascular/lipid-management distributor
- Hospital supplier
- Licensed wholesaler
- Institutional procurement organization
- Required Documentation
Potentially:
- GMP
- manufacturing licence
- COA
- specifications
- stability data
- BE data where required
- CPP
- product registration/MA
- COO
- invoice
- packing list
- import authorization
- Commercial Considerations
This is a more specialized/high-value cardiovascular product than many established generic medicines. Evaluate:
- local registration status
- patent/exclusivity considerations
- reference-product pricing
- generic competition
- MOQ
- private label/OEM
- shelf life
- registration costs
- FOB/CIF
- distributor margin
- Exporter Decision
☐ 180 mg strength confirmed
☐ Patent/exclusivity situation checked
☐ Manufacturer verified
☐ GMP verified
☐ Destination MA pathway verified
☐ BE/dossier requirements checked
☐ Importer verified
☐ Label checked
☐ COA/stability available
☐ Commercial feasibility calculated
SOURCE / BOOK RULE FOR THIS BATCH
For the final published book, these entries should carry a “Regulatory status verified on: October 2026” field and a source field. The current FDA evidence confirms, for example, that empagliflozin has an established U.S. prescription-product pathway, liothyronine sodium is an identified pharmaceutical substance with U.S. product history, memantine has an established prescription indication, and bempedoic acid has a current FDA label.
31. BEMPEDOIC ACID 180 mg + EZETIMIBE 10 mg
- Medicine / Product Name
Bempedoic Acid 180 mg + Ezetimibe 10 mg - Generic / API / Composition
Bempedoic acid 180 mg + Ezetimibe 10 mg. - Salt / Strength
Fixed-dose oral combination: 180 mg + 10 mg. - Therapeutic Category
Lipid-lowering / antihyperlipidemic medicine. - Pharmacological / Drug Class
Bempedoic acid: ATP-citrate lyase inhibitor.
Ezetimibe: cholesterol absorption inhibitor. - Main Uses / Indications
Used to reduce LDL cholesterol in appropriate patients, generally as an adjunct to diet and other lipid-management measures. - Mechanism / Basic Description
Bempedoic acid reduces cholesterol synthesis in the liver by inhibiting ATP-citrate lyase. Ezetimibe reduces intestinal absorption of cholesterol. - Dosage Form & Route
Usually oral tablet. - Prescription / OTC Status
Prescription medicine in major regulated markets. Do not assume OTC status in an importing country. - Major Warnings / Contraindications / Key Interactions
Important considerations include hyperuricemia/gout, tendon-related adverse effects and drug interactions. Product-specific labeling must be checked.
For export, the exact formulation and local label should be verified. - India Export Considerations
Verify that the Indian manufacturer has the appropriate manufacturing licence, product permission/approval and GMP documentation for the finished formulation. Confirm whether the exporter is exporting a registered finished formulation or an API/intermediate. - HS Code / Customs Classification — TO BE VERIFIED
Likely pharmaceutical medicament classification, but the final HS/ITC-HS code must be confirmed according to formulation, packing and Indian customs classification. - 26-Country Regulatory Status
USA 🟡 Registration/marketing authorization pathway required.
UK 🟡 Marketing authorization/import requirements apply.
UAE 🟡 Registration/import authorization required.
Saudi Arabia 🟡 SFDA registration pathway required.
Canada 🟡 Health Canada authorization required.
Australia 🟡 TGA pathway required.
Germany 🟡 EU marketing authorization requirements apply.
France 🟡 EU/French requirements apply.
Netherlands 🟡 EU/Dutch requirements apply.
Brazil 🟡 ANVISA requirements apply.
South Africa 🟡 SAHPRA requirements apply.
Nigeria 🟡 NAFDAC requirements apply.
Kenya 🟡 Pharmacy and Poisons Board requirements apply.
Tanzania 🟡 TMDA requirements apply.
Uganda 🟡 NDA requirements apply.
Ghana 🟡 FDA Ghana requirements apply.
Egypt 🟡 Egyptian pharmaceutical registration requirements apply.
Turkey 🟡 Turkish regulatory requirements apply.
Russia 🟡 Russian registration requirements apply.
Bangladesh 🟡 DGDA requirements apply.
Indonesia 🟡 BPOM requirements apply.
Malaysia 🟡 NPRA registration requirements apply.
Philippines 🟡 FDA Philippines requirements apply.
Vietnam 🟡 DAV/MOH requirements apply.
Japan 🟡 PMDA/MHLW requirements apply.
New Zealand 🟡 Medsafe requirements apply. - Country Regulatory Authority
Examples: FDA, MHRA, UAE Ministry of Health and Prevention, SFDA, Health Canada, TGA, EMA/national EU authorities, ANVISA, SAHPRA, NAFDAC, BPOM, NPRA, PMDA/MHLW. - Registration / Marketing Authorization Requirements
Typically requires product dossier, manufacturing information, quality specifications, stability data, labeling/package information and evidence required by the destination authority. - Export Requirements & Special Restrictions
Check whether the importing country accepts the fixed-dose combination and whether local registration exists. Do not assume that approval of the individual ingredients automatically means approval of the combination. - Buyer Type
Licensed pharmaceutical importer, distributor, wholesaler, hospital-supply company and registered pharmaceutical marketing company. - Required Export / Regulatory Documentation
Commercial invoice, packing list, certificate of origin where applicable, shipping documents, manufacturer documents, GMP evidence, COA and regulatory certificates/documents requested by the importing country. - Commercial Considerations
Potentially attractive as a chronic-disease cardiovascular product, but registration status is more important than simply finding a low supplier price. - Exporter Decision / Verification Checklist
☐ Combination legally permitted
☐ Indian manufacturer verified
☐ GMP verified
☐ Product approval verified
☐ Destination registration checked
☐ Importer licence checked
☐ Label checked
☐ Stability/shelf-life documents available
☐ COA available
☐ HS classification verified
32. BACLOFEN
- Medicine / Product Name
Baclofen - Generic / API / Composition
Baclofen. - Salt / Strength
Common oral strengths include 5 mg, 10 mg and 20 mg, depending on market. - Therapeutic Category
Skeletal-muscle relaxant / antispastic medicine. - Pharmacological / Drug Class
GABA-B receptor agonist. - Main Uses / Indications
Management of spasticity associated with neurological conditions. - Mechanism / Basic Description
Baclofen acts primarily through GABA-B receptors and reduces excitatory neurotransmission involved in muscle spasticity. - Dosage Form & Route
Oral tablets; other formulations/routes may exist in particular markets, including intrathecal therapy. - Prescription / OTC Status
Generally prescription medicine. - Major Warnings / Contraindications / Key Interactions
Sedation, dizziness and CNS depression may occur. Abrupt discontinuation, particularly after prolonged/high-dose therapy or intrathecal treatment, can be dangerous. CNS depressants and alcohol may increase sedative effects. - India Export Considerations
Confirm the exact dosage form and manufacturing permission. Intrathecal products require considerably more stringent sterile/manufacturing controls than ordinary tablets. - HS Code / Customs Classification — TO BE VERIFIED
Pharmaceutical medicament classification should be verified against the exact dosage form and Indian customs rules. - 26-Country Regulatory Status
USA 🟡 Prescription/approved-drug pathway.
UK 🟡 Prescription medicine/import requirements.
UAE 🟡 Registration required.
Saudi Arabia 🟡 SFDA requirements.
Canada 🟡 Health Canada requirements.
Australia 🟡 TGA requirements.
Germany/France/Netherlands 🟡 EU/national requirements.
Brazil 🟡 ANVISA.
South Africa 🟡 SAHPRA.
Nigeria 🟡 NAFDAC.
Kenya 🟡 Pharmacy and Poisons Board.
Tanzania 🟡 TMDA.
Uganda 🟡 NDA.
Ghana 🟡 FDA Ghana.
Egypt 🟡 National registration requirements.
Turkey 🟡 Turkish regulatory requirements.
Russia 🟡 Russian registration requirements.
Bangladesh 🟡 DGDA.
Indonesia 🟡 BPOM.
Malaysia 🟡 NPRA.
Philippines 🟡 FDA Philippines.
Vietnam 🟡 DAV/MOH.
Japan 🟡 PMDA/MHLW.
New Zealand 🟡 Medsafe. - Country Regulatory Authority
FDA, MHRA, UAE MOHAP, SFDA, Health Canada, TGA, EU/national agencies, ANVISA, SAHPRA, NAFDAC, TMDA, NDA, BPOM, NPRA, PMDA/MHLW and others as applicable. - Registration / Marketing Authorization Requirements
Product registration/marketing authorization and importer authorization generally required before commercial sale. - Export Requirements & Special Restrictions
Check local controlled-drug/psychotropic classifications before shipment. Classification can differ between jurisdictions. - Buyer Type
Licensed pharmaceutical distributors, hospitals, institutional suppliers and pharmacy wholesalers. - Required Export / Regulatory Documentation
Invoice, packing list, certificate of origin, COA, GMP documents, product registration documents and any import permit/authorization. - Commercial Considerations
Demand can be associated with neurological/spasticity treatment. Buyer qualification is important because it is normally a prescription product. - Exporter Decision / Verification Checklist
☐ Exact strength confirmed
☐ Dosage form confirmed
☐ Prescription status checked
☐ Destination controlled-status checked
☐ Manufacturer licence checked
☐ GMP checked
☐ Importer licence checked
☐ Registration checked
☐ COA checked
☐ HS code verified
33. TROPICAMIDE + PHENYLEPHRINE OPHTHALMIC SOLUTION
- Medicine / Product Name
Tropicamide + Phenylephrine ophthalmic solution. - Generic / API / Composition
Tropicamide + phenylephrine hydrochloride, with concentration varying by product. - Salt / Strength
Strength must be taken from the specific manufacturer’s formulation. Common ophthalmic products use concentrations such as tropicamide 0.5% or 1% and phenylephrine 2.5%, but the exact formulation must be verified. - Therapeutic Category
Ophthalmic mydriatic / pupil-dilating preparation. - Pharmacological / Drug Class
Tropicamide: antimuscarinic.
Phenylephrine: alpha-adrenergic agonist. - Main Uses / Indications
Used to dilate the pupil for ophthalmic examination and diagnostic procedures. - Mechanism / Basic Description
Tropicamide relaxes the iris sphincter through muscarinic blockade. Phenylephrine stimulates alpha-adrenergic receptors to produce mydriasis. - Dosage Form & Route
Sterile ophthalmic solution; topical ocular administration. - Prescription / OTC Status
Usually prescription/professional-use medicine, depending on jurisdiction and concentration. - Major Warnings / Contraindications / Key Interactions
Can increase intraocular pressure and may require caution in patients at risk of angle-closure glaucoma. Phenylephrine may have cardiovascular effects. Exact warnings depend on formulation and concentration. - India Export Considerations
Sterility is critical. Manufacturer should have appropriate sterile ophthalmic manufacturing authorization and quality systems. - HS Code / Customs Classification — TO BE VERIFIED
Pharmaceutical medicament classification; verify exact Indian HS/ITC-HS classification. - 26-Country Regulatory Status
USA 🟡 Approved/regulated ophthalmic products require applicable authorization.
UK 🟡 MHRA requirements.
UAE 🟡 Registration required.
Saudi Arabia 🟡 SFDA.
Canada 🟡 Health Canada.
Australia 🟡 TGA.
Germany/France/Netherlands 🟡 EU/national requirements.
Brazil 🟡 ANVISA.
South Africa 🟡 SAHPRA.
Nigeria 🟡 NAFDAC.
Kenya 🟡 Pharmacy and Poisons Board.
Tanzania 🟡 TMDA.
Uganda 🟡 NDA.
Ghana 🟡 FDA Ghana.
Egypt 🟡 Registration required.
Turkey 🟡 Registration required.
Russia 🟡 Registration required.
Bangladesh 🟡 DGDA.
Indonesia 🟡 BPOM.
Malaysia 🟡 NPRA.
Philippines 🟡 FDA Philippines.
Vietnam 🟡 DAV/MOH.
Japan 🟡 PMDA/MHLW.
New Zealand 🟡 Medsafe. - Country Regulatory Authority
Relevant national medicine authority; examples include FDA, MHRA, SFDA, TGA, Health Canada, ANVISA, SAHPRA and PMDA/MHLW. - Registration / Marketing Authorization Requirements
Sterility, formulation, container-closure system, stability, manufacturing controls, labeling and quality documentation are particularly important. - Export Requirements & Special Restrictions
Maintain sterile-chain manufacturing controls and ensure packaging protects the product from contamination. Verify destination-specific ophthalmic registration. - Buyer Type
Ophthalmic distributors, hospital suppliers, eye hospitals, clinics and licensed pharmaceutical importers. - Required Export / Regulatory Documentation
COA, GMP, manufacturing licence, product dossier/registration documents, stability information, invoice, packing list and certificate of origin where required. - Commercial Considerations
Sterile ophthalmic products may have higher manufacturing and compliance costs than ordinary tablets. - Exporter Decision / Verification Checklist
☐ Exact concentration confirmed
☐ Sterile manufacturing verified
☐ Container/closure verified
☐ Stability data available
☐ GMP available
☐ Destination registration checked
☐ Importer licence verified
☐ Label approved
☐ COA available
☐ HS classification verified
34. PROPRANOLOL HYDROCHLORIDE
- Medicine / Product Name
Propranolol Hydrochloride. - Generic / API / Composition
Propranolol hydrochloride. - Salt / Strength
Common oral strengths include 10 mg, 20 mg, 40 mg, 80 mg and other market-specific strengths. - Therapeutic Category
Cardiovascular medicine / beta-blocker. - Pharmacological / Drug Class
Non-selective beta-adrenergic receptor blocker. - Main Uses / Indications
Depending on formulation and country: hypertension, angina, certain arrhythmias, migraine prevention, tremor and other cardiovascular/neurological indications. - Mechanism / Basic Description
Blocks beta-adrenergic receptors, reducing heart rate, myocardial contractility and sympathetic effects. - Dosage Form & Route
Tablets, capsules and oral liquid formulations may be available; route is generally oral. - Prescription / OTC Status
Generally prescription medicine. - Major Warnings / Contraindications / Key Interactions
Important concerns include bradycardia, hypotension, heart block and bronchospasm. Non-selective beta-blockade can be problematic in susceptible patients with asthma/bronchospastic disease. It can also mask certain symptoms of hypoglycemia. - India Export Considerations
Verify product licence, manufacturer GMP and destination-market registration. - HS Code / Customs Classification — TO BE VERIFIED
Pharmaceutical medicament classification; exact HS/ITC-HS code must be verified. - 26-Country Regulatory Status
USA 🟡 Prescription regulatory pathway.
UK 🟡 Prescription medicine.
UAE 🟡 Registration.
Saudi Arabia 🟡 SFDA.
Canada 🟡 Health Canada.
Australia 🟡 TGA.
Germany/France/Netherlands 🟡 EU/national authorization.
Brazil 🟡 ANVISA.
South Africa 🟡 SAHPRA.
Nigeria 🟡 NAFDAC.
Kenya 🟡 Pharmacy and Poisons Board.
Tanzania 🟡 TMDA.
Uganda 🟡 NDA.
Ghana 🟡 FDA Ghana.
Egypt 🟡 Registration.
Turkey 🟡 Registration.
Russia 🟡 Registration.
Bangladesh 🟡 DGDA.
Indonesia 🟡 BPOM.
Malaysia 🟡 NPRA.
Philippines 🟡 FDA Philippines.
Vietnam 🟡 DAV/MOH.
Japan 🟡 PMDA/MHLW.
New Zealand 🟡 Medsafe. - Country Regulatory Authority
FDA, MHRA, MOHAP, SFDA, Health Canada, TGA and respective national authorities. - Registration / Marketing Authorization Requirements
Standard pharmaceutical dossier, quality documentation, manufacturing information, stability, labeling and local authorization. - Export Requirements & Special Restrictions
Check exact formulation and country-specific prescribing/import status. Extended-release products may have separate registration requirements. - Buyer Type
Pharmaceutical distributors, hospital suppliers, pharmacy wholesalers and licensed importers. - Required Export / Regulatory Documentation
Commercial invoice, packing list, COA, GMP certificate/evidence, product registration/authorization, certificate of origin and shipping documents. - Commercial Considerations
Established generic product with broad therapeutic use. Competition may be high, so price, registration status, packaging and buyer authorization matter. - Exporter Decision / Verification Checklist
☐ Strength confirmed
☐ Dosage form confirmed
☐ Manufacturer verified
☐ GMP verified
☐ Destination registration verified
☐ Importer licence verified
☐ Product label checked
☐ COA available
☐ Shelf life confirmed
☐ HS code verified
35. METFORMIN HYDROCHLORIDE
- Medicine / Product Name
Metformin Hydrochloride. - Generic / API / Composition
Metformin hydrochloride. - Salt / Strength
Common strengths include 500 mg, 850 mg and 1000 mg. Immediate-release and extended-release formulations are available. - Therapeutic Category
Antidiabetic / glucose-lowering medicine. - Pharmacological / Drug Class
Biguanide. - Main Uses / Indications
Primarily used for management of type 2 diabetes mellitus, alongside diet and lifestyle measures where appropriate. - Mechanism / Basic Description
Reduces hepatic glucose production and improves insulin sensitivity, thereby lowering blood glucose. - Dosage Form & Route
Immediate-release tablets, extended-release tablets and other oral formulations depending on market. - Prescription / OTC Status
Generally prescription medicine. - Major Warnings / Contraindications / Key Interactions
Renal function is a major safety consideration. Metformin carries a rare but serious risk of lactic acidosis, particularly in situations associated with significant renal impairment or other risk factors. Temporary interruption may be required around certain contrast procedures depending on renal function and local labeling. - India Export Considerations
India has extensive generic manufacturing capacity for metformin. Exporters should nevertheless verify manufacturer authorization, formulation approval, GMP and destination registration. - HS Code / Customs Classification — TO BE VERIFIED
Pharmaceutical medicament classification; verify exact HS/ITC-HS code before commercial shipment. - 26-Country Regulatory Status
USA 🟡 Prescription/approved-product pathway.
UK 🟡 Prescription medicine.
UAE 🟡 Registration required.
Saudi Arabia 🟡 SFDA registration.
Canada 🟡 Health Canada authorization.
Australia 🟡 TGA requirements.
Germany/France/Netherlands 🟡 EU/national requirements.
Brazil 🟡 ANVISA.
South Africa 🟡 SAHPRA.
Nigeria 🟡 NAFDAC.
Kenya 🟡 Pharmacy and Poisons Board.
Tanzania 🟡 TMDA.
Uganda 🟡 NDA.
Ghana 🟡 FDA Ghana.
Egypt 🟡 Registration.
Turkey 🟡 Registration.
Russia 🟡 Registration.
Bangladesh 🟡 DGDA.
Indonesia 🟡 BPOM.
Malaysia 🟡 NPRA.
Philippines 🟡 FDA Philippines.
Vietnam 🟡 DAV/MOH.
Japan 🟡 PMDA/MHLW.
New Zealand 🟡 Medsafe. - Country Regulatory Authority
FDA, MHRA, UAE MOHAP, SFDA, Health Canada, TGA, EU/national authorities, ANVISA, SAHPRA, NAFDAC, TMDA, NDA, BPOM, NPRA, PMDA/MHLW and corresponding national authorities. - Registration / Marketing Authorization Requirements
Usually requires quality dossier, manufacturing information, stability data, specifications, labeling and country-specific registration. - Export Requirements & Special Restrictions
The exporter must distinguish immediate-release from extended-release products. Combination products containing metformin with another antidiabetic are separate registered products and should not automatically be treated as equivalent to metformin alone. - Buyer Type
Licensed pharmaceutical importers, generic distributors, pharmacy wholesalers, hospital suppliers and government/institutional procurement organizations. - Required Export / Regulatory Documentation
Commercial invoice, packing list, certificate of origin where required, COA, GMP evidence, product registration documents, manufacturing licence and shipping documentation. - Commercial Considerations
Very large global generic market with strong competition. Commercial differentiation can come from registration status, reliable supply, formulation, packaging, private-label capability and competitive landed cost. - Exporter Decision / Verification Checklist
☐ API/formulation confirmed
☐ IR/ER formulation identified
☐ Strength confirmed
☐ Manufacturer verified
☐ GMP verified
☐ Destination registration checked
☐ Importer licence verified
☐ Stability data available
☐ COA available
☐ Shelf life confirmed
☐ HS code verified
☐ Buyer payment/creditworthiness checked
Top Pharma Export Products from India Manufacturers Sellers Pharmaceutical Companies Medicine Buyers
26-Country Regulatory Screening Matrix
Country | Authority | Preliminary export status |
USA | FDA | 🟡 Product registration/marketing authorization and importer authorization normally required; verify exact product/formulation. Controlled/special products may be 🟠/🔴. |
UK | MHRA | 🟡 Product registration/marketing authorization and importer authorization normally required; verify exact product/formulation. Controlled/special products may be 🟠/🔴. |
UAE | MOHAP / UAE authority | 🟡 Product registration/marketing authorization and importer authorization normally required; verify exact product/formulation. Controlled/special products may be 🟠/🔴. |
Saudi Arabia | SFDA | 🟡 Product registration/marketing authorization and importer authorization normally required; verify exact product/formulation. Controlled/special products may be 🟠/🔴. |
Canada | Health Canada | 🟡 Product registration/marketing authorization and importer authorization normally required; verify exact product/formulation. Controlled/special products may be 🟠/🔴. |
Australia | TGA | 🟡 Product registration/marketing authorization and importer authorization normally required; verify exact product/formulation. Controlled/special products may be 🟠/🔴. |
Germany | EU/national authority | 🟡 Product registration/marketing authorization and importer authorization normally required; verify exact product/formulation. Controlled/special products may be 🟠/🔴. |
France | EU/national authority | 🟡 Product registration/marketing authorization and importer authorization normally required; verify exact product/formulation. Controlled/special products may be 🟠/🔴. |
Netherlands | EU/national authority | 🟡 Product registration/marketing authorization and importer authorization normally required; verify exact product/formulation. Controlled/special products may be 🟠/🔴. |
Brazil | ANVISA | 🟡 Product registration/marketing authorization and importer authorization normally required; verify exact product/formulation. Controlled/special products may be 🟠/🔴. |
South Africa | SAHPRA | 🟡 Product registration/marketing authorization and importer authorization normally required; verify exact product/formulation. Controlled/special products may be 🟠/🔴. |
Nigeria | NAFDAC | 🟡 Product registration/marketing authorization and importer authorization normally required; verify exact product/formulation. Controlled/special products may be 🟠/🔴. |
Kenya | Pharmacy and Poisons Board | 🟡 Product registration/marketing authorization and importer authorization normally required; verify exact product/formulation. Controlled/special products may be 🟠/🔴. |
Tanzania | TMDA | 🟡 Product registration/marketing authorization and importer authorization normally required; verify exact product/formulation. Controlled/special products may be 🟠/🔴. |
Uganda | NDA | 🟡 Product registration/marketing authorization and importer authorization normally required; verify exact product/formulation. Controlled/special products may be 🟠/🔴. |
Ghana | FDA Ghana | 🟡 Product registration/marketing authorization and importer authorization normally required; verify exact product/formulation. Controlled/special products may be 🟠/🔴. |
Egypt | Egyptian Drug Authority | 🟡 Product registration/marketing authorization and importer authorization normally required; verify exact product/formulation. Controlled/special products may be 🟠/🔴. |
Turkey | TITCK | 🟡 Product registration/marketing authorization and importer authorization normally required; verify exact product/formulation. Controlled/special products may be 🟠/🔴. |
Russia | Russian regulator | 🟡 Product registration/marketing authorization and importer authorization normally required; verify exact product/formulation. Controlled/special products may be 🟠/🔴. |
Bangladesh | DGDA | 🟡 Product registration/marketing authorization and importer authorization normally required; verify exact product/formulation. Controlled/special products may be 🟠/🔴. |
Indonesia | BPOM | 🟡 Product registration/marketing authorization and importer authorization normally required; verify exact product/formulation. Controlled/special products may be 🟠/🔴. |
Malaysia | NPRA | 🟡 Product registration/marketing authorization and importer authorization normally required; verify exact product/formulation. Controlled/special products may be 🟠/🔴. |
Philippines | Philippines FDA | 🟡 Product registration/marketing authorization and importer authorization normally required; verify exact product/formulation. Controlled/special products may be 🟠/🔴. |
Vietnam | DAV/MOH | 🟡 Product registration/marketing authorization and importer authorization normally required; verify exact product/formulation. Controlled/special products may be 🟠/🔴. |
Japan | PMDA/MHLW | 🟡 Product registration/marketing authorization and importer authorization normally required; verify exact product/formulation. Controlled/special products may be 🟠/🔴. |
New Zealand | Medsafe | 🟡 Product registration/marketing authorization and importer authorization normally required; verify exact product/formulation. Controlled/special products may be 🟠/🔴. |
Status legend: 🟢 generally permissible pathway; 🟡 registration/approval required; 🟠 special regulatory review; 🔴 controlled/restricted/high-risk; ⚫ formulation-specific investigation required.
36. MODAFINIL
1. Medicine / Product Name | MODAFINIL |
2. Generic / API / Composition | MODAFINIL — exact composition/API to be confirmed from manufacturer specification. |
3. Salt / Strength | Strength/salt as stated in the source where available; otherwise verify the exact product specification. |
4. Therapeutic Category | CNS / neurological / psychiatric medicine |
5. Pharmacological / Drug Class | Central nervous system active medicine |
6. Main Uses / Indications | Indication depends on the active ingredient; verify approved indication. |
7. Mechanism / Basic Description | CNS mechanism is ingredient-specific. |
8. Dosage Form & Route | Route/formulation: verify from the exact product specification. |
9. Prescription / OTC Status | Prescription; controlled/psychotropic status must be checked country by country. |
10. Major Warnings / Contraindications / Key Interactions | CNS effects, interactions, dependence/misuse potential where applicable and local controlled-drug status require review. |
11. India Export Considerations | Verify Indian manufacturing licence/product permission, GMP status, formulation authorization, exporter eligibility, labeling and destination-specific export documentation. |
12. HS Code / Customs Classification — TO BE VERIFIED | Do not assign a final HS/ITC-HS code from the medicine name alone. Confirm with the exact dosage form, packing and Indian customs classification. |
13. 26-Country Regulatory Status | Preliminary screen: 🟡 registration/authorization generally required in all 26 markets. Upgrade to 🟠/🔴/⚫ where the ingredient, formulation or destination law imposes special controls; exact status must be verified. |
14. Country Regulatory Authority | See the 26-country matrix at the beginning of this document; the responsible authority varies by destination. |
15. Registration / Marketing Authorization Requirements | Typically product dossier/quality data, manufacturing information, stability, labeling, local applicant/importer authorization and any country-specific clinical/bioequivalence or GMP evidence required. |
16. Export Requirements & Special Restrictions | High-priority destination-country classification check. Controlled/psychotropic/hormonal classification must be checked separately in each destination. |
17. Buyer Type | Licensed pharmaceutical importer/distributor/wholesaler; hospitals or institutional buyers where appropriate. Veterinary products require appropriately licensed animal-health buyers. |
18. Required Export / Regulatory Documentation | Commercial invoice; packing list; transport documents; certificate of origin where required; COA; GMP/manufacturing documents; product registration/authorization documents; import permit or controlled-drug permit where applicable. |
19. Commercial Considerations | Confirm MOQ, pack size, shelf life, lead time, private-label/OEM availability, registration ownership, Incoterm, freight, insurance, payment terms and landed cost before quotation. |
20. Exporter Decision / Verification Checklist | ☐ Exact product/formulation confirmed ☐ Manufacturer verified ☐ GMP verified ☐ Indian authorization verified ☐ Destination registration checked ☐ Importer licence checked ☐ Controlled/special status checked ☐ COA/stability documents checked ☐ HS code verified ☐ Buyer verified |
37. DAPOXETINE HCL
1. Medicine / Product Name | DAPOXETINE HCL |
2. Generic / API / Composition | DAPOXETINE HCL — exact composition/API to be confirmed from manufacturer specification. |
3. Salt / Strength | Strength/salt as stated in the source where available; otherwise verify the exact product specification. |
4. Therapeutic Category | Sexual-health / serotonergic medicine |
5. Pharmacological / Drug Class | Selective serotonin reuptake inhibitor (short-acting) |
6. Main Uses / Indications | Used in some markets for premature ejaculation. |
7. Mechanism / Basic Description | Increases serotonergic activity through serotonin reuptake inhibition. |
8. Dosage Form & Route | Usually oral. |
9. Prescription / OTC Status | Generally prescription/regulated medicine; exact status varies by jurisdiction. |
10. Major Warnings / Contraindications / Key Interactions | Syncope, dizziness, serotonergic interactions and contraindications must be checked against local labeling. |
11. India Export Considerations | Verify Indian manufacturing licence/product permission, GMP status, formulation authorization, exporter eligibility, labeling and destination-specific export documentation. |
12. HS Code / Customs Classification — TO BE VERIFIED | Do not assign a final HS/ITC-HS code from the medicine name alone. Confirm with the exact dosage form, packing and Indian customs classification. |
13. 26-Country Regulatory Status | Preliminary screen: 🟡 registration/authorization generally required in all 26 markets. Upgrade to 🟠/🔴/⚫ where the ingredient, formulation or destination law imposes special controls; exact status must be verified. |
14. Country Regulatory Authority | See the 26-country matrix at the beginning of this document; the responsible authority varies by destination. |
15. Registration / Marketing Authorization Requirements | Typically product dossier/quality data, manufacturing information, stability, labeling, local applicant/importer authorization and any country-specific clinical/bioequivalence or GMP evidence required. |
16. Export Requirements & Special Restrictions | Product-specific regulatory review required before export. |
17. Buyer Type | Licensed pharmaceutical importer/distributor/wholesaler; hospitals or institutional buyers where appropriate. Veterinary products require appropriately licensed animal-health buyers. |
18. Required Export / Regulatory Documentation | Commercial invoice; packing list; transport documents; certificate of origin where required; COA; GMP/manufacturing documents; product registration/authorization documents; import permit or controlled-drug permit where applicable. |
19. Commercial Considerations | Confirm MOQ, pack size, shelf life, lead time, private-label/OEM availability, registration ownership, Incoterm, freight, insurance, payment terms and landed cost before quotation. |
20. Exporter Decision / Verification Checklist | ☐ Exact product/formulation confirmed ☐ Manufacturer verified ☐ GMP verified ☐ Indian authorization verified ☐ Destination registration checked ☐ Importer licence checked ☐ Controlled/special status checked ☐ COA/stability documents checked ☐ HS code verified ☐ Buyer verified |
38. DICLOFENAC PROLONGED RELEASE
1. Medicine / Product Name | DICLOFENAC PROLONGED RELEASE |
2. Generic / API / Composition | DICLOFENAC PROLONGED RELEASE — exact composition/API to be confirmed from manufacturer specification. |
3. Salt / Strength | Strength/salt as stated in the source where available; otherwise verify the exact product specification. |
4. Therapeutic Category | Analgesic / gastrointestinal medicine |
5. Pharmacological / Drug Class | Ingredient-specific analgesic or GI agent |
6. Main Uses / Indications | Pain/inflammation or gastrointestinal indication according to ingredient. |
7. Mechanism / Basic Description | Ingredient-specific mechanism. |
8. Dosage Form & Route | Route/formulation: verify from the exact product specification. |
9. Prescription / OTC Status | Generally prescription/regulated medicine; exact status varies by jurisdiction. |
10. Major Warnings / Contraindications / Key Interactions | Check official label for contraindications, interactions, pregnancy warnings, organ-function precautions and formulation-specific risks. |
11. India Export Considerations | Verify Indian manufacturing licence/product permission, GMP status, formulation authorization, exporter eligibility, labeling and destination-specific export documentation. |
12. HS Code / Customs Classification — TO BE VERIFIED | Do not assign a final HS/ITC-HS code from the medicine name alone. Confirm with the exact dosage form, packing and Indian customs classification. |
13. 26-Country Regulatory Status | Preliminary screen: 🟡 registration/authorization generally required in all 26 markets. Upgrade to 🟠/🔴/⚫ where the ingredient, formulation or destination law imposes special controls; exact status must be verified. |
14. Country Regulatory Authority | See the 26-country matrix at the beginning of this document; the responsible authority varies by destination. |
15. Registration / Marketing Authorization Requirements | Typically product dossier/quality data, manufacturing information, stability, labeling, local applicant/importer authorization and any country-specific clinical/bioequivalence or GMP evidence required. |
16. Export Requirements & Special Restrictions | Product-specific regulatory review required before export. |
17. Buyer Type | Licensed pharmaceutical importer/distributor/wholesaler; hospitals or institutional buyers where appropriate. Veterinary products require appropriately licensed animal-health buyers. |
18. Required Export / Regulatory Documentation | Commercial invoice; packing list; transport documents; certificate of origin where required; COA; GMP/manufacturing documents; product registration/authorization documents; import permit or controlled-drug permit where applicable. |
19. Commercial Considerations | Confirm MOQ, pack size, shelf life, lead time, private-label/OEM availability, registration ownership, Incoterm, freight, insurance, payment terms and landed cost before quotation. |
20. Exporter Decision / Verification Checklist | ☐ Exact product/formulation confirmed ☐ Manufacturer verified ☐ GMP verified ☐ Indian authorization verified ☐ Destination registration checked ☐ Importer licence checked ☐ Controlled/special status checked ☐ COA/stability documents checked ☐ HS code verified ☐ Buyer verified |
39. TESTOSTERONE GEL 1 % W/W
1. Medicine / Product Name | TESTOSTERONE GEL 1 % W/W |
2. Generic / API / Composition | TESTOSTERONE GEL 1 % W/W — exact composition/API to be confirmed from manufacturer specification. |
3. Salt / Strength | Strength/salt as stated in the source where available; otherwise verify the exact product specification. |
4. Therapeutic Category | Androgen / anabolic-hormonal medicine |
5. Pharmacological / Drug Class | Androgenic/anabolic steroid or testosterone preparation |
6. Main Uses / Indications | Hormone-replacement or other approved indication depends on the specific substance and formulation. |
7. Mechanism / Basic Description | Acts through androgen receptors; exact pharmacology varies by compound. |
8. Dosage Form & Route | Oral, topical or injectable depending on formulation. |
9. Prescription / OTC Status | Prescription; often subject to additional controlled-substance/hormone rules. |
10. Major Warnings / Contraindications / Key Interactions | Hormonal adverse effects, cardiovascular/thrombotic risks, hepatic risks for some oral agents, reproductive effects and local controlled-drug rules require review. |
11. India Export Considerations | Verify Indian manufacturing licence/product permission, GMP status, formulation authorization, exporter eligibility, labeling and destination-specific export documentation. |
12. HS Code / Customs Classification — TO BE VERIFIED | Do not assign a final HS/ITC-HS code from the medicine name alone. Confirm with the exact dosage form, packing and Indian customs classification. |
13. 26-Country Regulatory Status | Preliminary screen: 🟡 registration/authorization generally required in all 26 markets. Upgrade to 🟠/🔴/⚫ where the ingredient, formulation or destination law imposes special controls; exact status must be verified. |
14. Country Regulatory Authority | See the 26-country matrix at the beginning of this document; the responsible authority varies by destination. |
15. Registration / Marketing Authorization Requirements | Typically product dossier/quality data, manufacturing information, stability, labeling, local applicant/importer authorization and any country-specific clinical/bioequivalence or GMP evidence required. |
16. Export Requirements & Special Restrictions | High-priority regulatory verification; some jurisdictions impose controlled-substance or special import restrictions. Controlled/psychotropic/hormonal classification must be checked separately in each destination. Sterile/injectable or biologic quality, storage and manufacturing controls may apply. |
17. Buyer Type | Licensed pharmaceutical importer/distributor/wholesaler; hospitals or institutional buyers where appropriate. Veterinary products require appropriately licensed animal-health buyers. |
18. Required Export / Regulatory Documentation | Commercial invoice; packing list; transport documents; certificate of origin where required; COA; GMP/manufacturing documents; product registration/authorization documents; import permit or controlled-drug permit where applicable. |
19. Commercial Considerations | Confirm MOQ, pack size, shelf life, lead time, private-label/OEM availability, registration ownership, Incoterm, freight, insurance, payment terms and landed cost before quotation. |
20. Exporter Decision / Verification Checklist | ☐ Exact product/formulation confirmed ☐ Manufacturer verified ☐ GMP verified ☐ Indian authorization verified ☐ Destination registration checked ☐ Importer licence checked ☐ Controlled/special status checked ☐ COA/stability documents checked ☐ HS code verified ☐ Buyer verified |
40. TESTOSTERONE ENANTHATE INJECTION
1. Medicine / Product Name | TESTOSTERONE ENANTHATE INJECTION |
2. Generic / API / Composition | TESTOSTERONE ENANTHATE — exact composition/API to be confirmed from manufacturer specification. |
3. Salt / Strength | Strength/salt as stated in the source where available; otherwise verify the exact product specification. |
4. Therapeutic Category | Androgen / anabolic-hormonal medicine |
5. Pharmacological / Drug Class | Androgenic/anabolic steroid or testosterone preparation |
6. Main Uses / Indications | Hormone-replacement or other approved indication depends on the specific substance and formulation. |
7. Mechanism / Basic Description | Acts through androgen receptors; exact pharmacology varies by compound. |
8. Dosage Form & Route | Oral, topical or injectable depending on formulation. |
9. Prescription / OTC Status | Prescription; often subject to additional controlled-substance/hormone rules. |
10. Major Warnings / Contraindications / Key Interactions | Hormonal adverse effects, cardiovascular/thrombotic risks, hepatic risks for some oral agents, reproductive effects and local controlled-drug rules require review. |
11. India Export Considerations | Verify Indian manufacturing licence/product permission, GMP status, formulation authorization, exporter eligibility, labeling and destination-specific export documentation. |
12. HS Code / Customs Classification — TO BE VERIFIED | Do not assign a final HS/ITC-HS code from the medicine name alone. Confirm with the exact dosage form, packing and Indian customs classification. |
13. 26-Country Regulatory Status | Preliminary screen: 🟡 registration/authorization generally required in all 26 markets. Upgrade to 🟠/🔴/⚫ where the ingredient, formulation or destination law imposes special controls; exact status must be verified. |
14. Country Regulatory Authority | See the 26-country matrix at the beginning of this document; the responsible authority varies by destination. |
15. Registration / Marketing Authorization Requirements | Typically product dossier/quality data, manufacturing information, stability, labeling, local applicant/importer authorization and any country-specific clinical/bioequivalence or GMP evidence required. |
16. Export Requirements & Special Restrictions | High-priority regulatory verification; some jurisdictions impose controlled-substance or special import restrictions. Controlled/psychotropic/hormonal classification must be checked separately in each destination. Sterile/injectable or biologic quality, storage and manufacturing controls may apply. |
17. Buyer Type | Licensed pharmaceutical importer/distributor/wholesaler; hospitals or institutional buyers where appropriate. Veterinary products require appropriately licensed animal-health buyers. |
18. Required Export / Regulatory Documentation | Commercial invoice; packing list; transport documents; certificate of origin where required; COA; GMP/manufacturing documents; product registration/authorization documents; import permit or controlled-drug permit where applicable. |
19. Commercial Considerations | Confirm MOQ, pack size, shelf life, lead time, private-label/OEM availability, registration ownership, Incoterm, freight, insurance, payment terms and landed cost before quotation. |
20. Exporter Decision / Verification Checklist | ☐ Exact product/formulation confirmed ☐ Manufacturer verified ☐ GMP verified ☐ Indian authorization verified ☐ Destination registration checked ☐ Importer licence checked ☐ Controlled/special status checked ☐ COA/stability documents checked ☐ HS code verified ☐ Buyer verified |
41. TESTOSTERONE ENANTHATE INJECTION USP 250 MG
1. Medicine / Product Name | TESTOSTERONE ENANTHATE INJECTION USP 250 MG |
2. Generic / API / Composition | TESTOSTERONE ENANTHATE USP 250 MG — exact composition/API to be confirmed from manufacturer specification. |
3. Salt / Strength | Strength/salt as stated in the source where available; otherwise verify the exact product specification. |
4. Therapeutic Category | Androgen / anabolic-hormonal medicine |
5. Pharmacological / Drug Class | Androgenic/anabolic steroid or testosterone preparation |
6. Main Uses / Indications | Hormone-replacement or other approved indication depends on the specific substance and formulation. |
7. Mechanism / Basic Description | Acts through androgen receptors; exact pharmacology varies by compound. |
8. Dosage Form & Route | Oral, topical or injectable depending on formulation. |
9. Prescription / OTC Status | Prescription; often subject to additional controlled-substance/hormone rules. |
10. Major Warnings / Contraindications / Key Interactions | Hormonal adverse effects, cardiovascular/thrombotic risks, hepatic risks for some oral agents, reproductive effects and local controlled-drug rules require review. |
11. India Export Considerations | Verify Indian manufacturing licence/product permission, GMP status, formulation authorization, exporter eligibility, labeling and destination-specific export documentation. |
12. HS Code / Customs Classification — TO BE VERIFIED | Do not assign a final HS/ITC-HS code from the medicine name alone. Confirm with the exact dosage form, packing and Indian customs classification. |
13. 26-Country Regulatory Status | Preliminary screen: 🟡 registration/authorization generally required in all 26 markets. Upgrade to 🟠/🔴/⚫ where the ingredient, formulation or destination law imposes special controls; exact status must be verified. |
14. Country Regulatory Authority | See the 26-country matrix at the beginning of this document; the responsible authority varies by destination. |
15. Registration / Marketing Authorization Requirements | Typically product dossier/quality data, manufacturing information, stability, labeling, local applicant/importer authorization and any country-specific clinical/bioequivalence or GMP evidence required. |
16. Export Requirements & Special Restrictions | High-priority regulatory verification; some jurisdictions impose controlled-substance or special import restrictions. Controlled/psychotropic/hormonal classification must be checked separately in each destination. Sterile/injectable or biologic quality, storage and manufacturing controls may apply. |
17. Buyer Type | Licensed pharmaceutical importer/distributor/wholesaler; hospitals or institutional buyers where appropriate. Veterinary products require appropriately licensed animal-health buyers. |
18. Required Export / Regulatory Documentation | Commercial invoice; packing list; transport documents; certificate of origin where required; COA; GMP/manufacturing documents; product registration/authorization documents; import permit or controlled-drug permit where applicable. |
19. Commercial Considerations | Confirm MOQ, pack size, shelf life, lead time, private-label/OEM availability, registration ownership, Incoterm, freight, insurance, payment terms and landed cost before quotation. |
20. Exporter Decision / Verification Checklist | ☐ Exact product/formulation confirmed ☐ Manufacturer verified ☐ GMP verified ☐ Indian authorization verified ☐ Destination registration checked ☐ Importer licence checked ☐ Controlled/special status checked ☐ COA/stability documents checked ☐ HS code verified ☐ Buyer verified |
42. ISOTRETINOIN CAPSULES IP 20 MG
1. Medicine / Product Name | ISOTRETINOIN CAPSULES IP 20 MG |
2. Generic / API / Composition | ISOTRETINOIN IP 20 MG — exact composition/API to be confirmed from manufacturer specification. |
3. Salt / Strength | Strength/salt as stated in the source where available; otherwise verify the exact product specification. |
4. Therapeutic Category | Dermatology / topical or hormonal medicine |
5. Pharmacological / Drug Class | Ingredient-specific dermatologic/hormonal agent |
6. Main Uses / Indications | Dermatologic or hormonal indication according to the exact formulation. |
7. Mechanism / Basic Description | Ingredient-specific; use approved product labeling. |
8. Dosage Form & Route | Topical or oral depending on formulation. |
9. Prescription / OTC Status | Generally prescription/regulated medicine; exact status varies by jurisdiction. |
10. Major Warnings / Contraindications / Key Interactions | Pregnancy/reproductive warnings, systemic absorption, skin reactions and formulation-specific restrictions must be checked. |
11. India Export Considerations | Verify Indian manufacturing licence/product permission, GMP status, formulation authorization, exporter eligibility, labeling and destination-specific export documentation. |
12. HS Code / Customs Classification — TO BE VERIFIED | Do not assign a final HS/ITC-HS code from the medicine name alone. Confirm with the exact dosage form, packing and Indian customs classification. |
13. 26-Country Regulatory Status | Preliminary screen: 🟡 registration/authorization generally required in all 26 markets. Upgrade to 🟠/🔴/⚫ where the ingredient, formulation or destination law imposes special controls; exact status must be verified. |
14. Country Regulatory Authority | See the 26-country matrix at the beginning of this document; the responsible authority varies by destination. |
15. Registration / Marketing Authorization Requirements | Typically product dossier/quality data, manufacturing information, stability, labeling, local applicant/importer authorization and any country-specific clinical/bioequivalence or GMP evidence required. |
16. Export Requirements & Special Restrictions | Product-specific regulatory review required before export. |
17. Buyer Type | Licensed pharmaceutical importer/distributor/wholesaler; hospitals or institutional buyers where appropriate. Veterinary products require appropriately licensed animal-health buyers. |
18. Required Export / Regulatory Documentation | Commercial invoice; packing list; transport documents; certificate of origin where required; COA; GMP/manufacturing documents; product registration/authorization documents; import permit or controlled-drug permit where applicable. |
19. Commercial Considerations | Confirm MOQ, pack size, shelf life, lead time, private-label/OEM availability, registration ownership, Incoterm, freight, insurance, payment terms and landed cost before quotation. |
20. Exporter Decision / Verification Checklist | ☐ Exact product/formulation confirmed ☐ Manufacturer verified ☐ GMP verified ☐ Indian authorization verified ☐ Destination registration checked ☐ Importer licence checked ☐ Controlled/special status checked ☐ COA/stability documents checked ☐ HS code verified ☐ Buyer verified |
43. ISOTRETINOIN CAPSULES IP 320 MG
1. Medicine / Product Name | ISOTRETINOIN CAPSULES IP 320 MG |
2. Generic / API / Composition | ISOTRETINOIN IP 320 MG — exact composition/API to be confirmed from manufacturer specification. |
3. Salt / Strength | Strength/salt as stated in the source where available; otherwise verify the exact product specification. |
4. Therapeutic Category | Dermatology / topical or hormonal medicine |
5. Pharmacological / Drug Class | Ingredient-specific dermatologic/hormonal agent |
6. Main Uses / Indications | Dermatologic or hormonal indication according to the exact formulation. |
7. Mechanism / Basic Description | Ingredient-specific; use approved product labeling. |
8. Dosage Form & Route | Topical or oral depending on formulation. |
9. Prescription / OTC Status | Generally prescription/regulated medicine; exact status varies by jurisdiction. |
10. Major Warnings / Contraindications / Key Interactions | Pregnancy/reproductive warnings, systemic absorption, skin reactions and formulation-specific restrictions must be checked. |
11. India Export Considerations | Verify Indian manufacturing licence/product permission, GMP status, formulation authorization, exporter eligibility, labeling and destination-specific export documentation. |
12. HS Code / Customs Classification — TO BE VERIFIED | Do not assign a final HS/ITC-HS code from the medicine name alone. Confirm with the exact dosage form, packing and Indian customs classification. |
13. 26-Country Regulatory Status | Preliminary screen: 🟡 registration/authorization generally required in all 26 markets. Upgrade to 🟠/🔴/⚫ where the ingredient, formulation or destination law imposes special controls; exact status must be verified. |
14. Country Regulatory Authority | See the 26-country matrix at the beginning of this document; the responsible authority varies by destination. |
15. Registration / Marketing Authorization Requirements | Typically product dossier/quality data, manufacturing information, stability, labeling, local applicant/importer authorization and any country-specific clinical/bioequivalence or GMP evidence required. |
16. Export Requirements & Special Restrictions | Product-specific regulatory review required before export. Source lists 320 mg isotretinoin; this strength is unusual and must be independently verified before procurement/export. |
17. Buyer Type | Licensed pharmaceutical importer/distributor/wholesaler; hospitals or institutional buyers where appropriate. Veterinary products require appropriately licensed animal-health buyers. |
18. Required Export / Regulatory Documentation | Commercial invoice; packing list; transport documents; certificate of origin where required; COA; GMP/manufacturing documents; product registration/authorization documents; import permit or controlled-drug permit where applicable. |
19. Commercial Considerations | Confirm MOQ, pack size, shelf life, lead time, private-label/OEM availability, registration ownership, Incoterm, freight, insurance, payment terms and landed cost before quotation. |
20. Exporter Decision / Verification Checklist | ☐ Exact product/formulation confirmed ☐ Manufacturer verified ☐ GMP verified ☐ Indian authorization verified ☐ Destination registration checked ☐ Importer licence checked ☐ Controlled/special status checked ☐ COA/stability documents checked ☐ HS code verified ☐ Buyer verified |
44. ZOPICLONE
1. Medicine / Product Name | ZOPICLONE |
2. Generic / API / Composition | ZOPICLONE — exact composition/API to be confirmed from manufacturer specification. |
3. Salt / Strength | Strength/salt as stated in the source where available; otherwise verify the exact product specification. |
4. Therapeutic Category | CNS / neurological / psychiatric medicine |
5. Pharmacological / Drug Class | Central nervous system active medicine |
6. Main Uses / Indications | Indication depends on the active ingredient; verify approved indication. |
7. Mechanism / Basic Description | CNS mechanism is ingredient-specific. |
8. Dosage Form & Route | Route/formulation: verify from the exact product specification. |
9. Prescription / OTC Status | Prescription; controlled/psychotropic status must be checked country by country. |
10. Major Warnings / Contraindications / Key Interactions | CNS effects, interactions, dependence/misuse potential where applicable and local controlled-drug status require review. |
11. India Export Considerations | Verify Indian manufacturing licence/product permission, GMP status, formulation authorization, exporter eligibility, labeling and destination-specific export documentation. |
12. HS Code / Customs Classification — TO BE VERIFIED | Do not assign a final HS/ITC-HS code from the medicine name alone. Confirm with the exact dosage form, packing and Indian customs classification. |
13. 26-Country Regulatory Status | Preliminary screen: 🟡 registration/authorization generally required in all 26 markets. Upgrade to 🟠/🔴/⚫ where the ingredient, formulation or destination law imposes special controls; exact status must be verified. |
14. Country Regulatory Authority | See the 26-country matrix at the beginning of this document; the responsible authority varies by destination. |
15. Registration / Marketing Authorization Requirements | Typically product dossier/quality data, manufacturing information, stability, labeling, local applicant/importer authorization and any country-specific clinical/bioequivalence or GMP evidence required. |
16. Export Requirements & Special Restrictions | High-priority destination-country classification check. Controlled/psychotropic/hormonal classification must be checked separately in each destination. |
17. Buyer Type | Licensed pharmaceutical importer/distributor/wholesaler; hospitals or institutional buyers where appropriate. Veterinary products require appropriately licensed animal-health buyers. |
18. Required Export / Regulatory Documentation | Commercial invoice; packing list; transport documents; certificate of origin where required; COA; GMP/manufacturing documents; product registration/authorization documents; import permit or controlled-drug permit where applicable. |
19. Commercial Considerations | Confirm MOQ, pack size, shelf life, lead time, private-label/OEM availability, registration ownership, Incoterm, freight, insurance, payment terms and landed cost before quotation. |
20. Exporter Decision / Verification Checklist | ☐ Exact product/formulation confirmed ☐ Manufacturer verified ☐ GMP verified ☐ Indian authorization verified ☐ Destination registration checked ☐ Importer licence checked ☐ Controlled/special status checked ☐ COA/stability documents checked ☐ HS code verified ☐ Buyer verified |
45. PRAMIPEXOLE
1. Medicine / Product Name | PRAMIPEXOLE |
2. Generic / API / Composition | PRAMIPEXOLE — exact composition/API to be confirmed from manufacturer specification. |
3. Salt / Strength | Strength/salt as stated in the source where available; otherwise verify the exact product specification. |
4. Therapeutic Category | Neurological medicine |
5. Pharmacological / Drug Class | Ingredient-specific CNS agent |
6. Main Uses / Indications | Neurological indication according to the approved product. |
7. Mechanism / Basic Description | Ingredient-specific CNS mechanism. |
8. Dosage Form & Route | Route/formulation: verify from the exact product specification. |
9. Prescription / OTC Status | Generally prescription/regulated medicine; exact status varies by jurisdiction. |
10. Major Warnings / Contraindications / Key Interactions | Check official label for contraindications, interactions, pregnancy warnings, organ-function precautions and formulation-specific risks. |
11. India Export Considerations | Verify Indian manufacturing licence/product permission, GMP status, formulation authorization, exporter eligibility, labeling and destination-specific export documentation. |
12. HS Code / Customs Classification — TO BE VERIFIED | Do not assign a final HS/ITC-HS code from the medicine name alone. Confirm with the exact dosage form, packing and Indian customs classification. |
13. 26-Country Regulatory Status | Preliminary screen: 🟡 registration/authorization generally required in all 26 markets. Upgrade to 🟠/🔴/⚫ where the ingredient, formulation or destination law imposes special controls; exact status must be verified. |
14. Country Regulatory Authority | See the 26-country matrix at the beginning of this document; the responsible authority varies by destination. |
15. Registration / Marketing Authorization Requirements | Typically product dossier/quality data, manufacturing information, stability, labeling, local applicant/importer authorization and any country-specific clinical/bioequivalence or GMP evidence required. |
16. Export Requirements & Special Restrictions | Product-specific regulatory review required before export. |
17. Buyer Type | Licensed pharmaceutical importer/distributor/wholesaler; hospitals or institutional buyers where appropriate. Veterinary products require appropriately licensed animal-health buyers. |
18. Required Export / Regulatory Documentation | Commercial invoice; packing list; transport documents; certificate of origin where required; COA; GMP/manufacturing documents; product registration/authorization documents; import permit or controlled-drug permit where applicable. |
19. Commercial Considerations | Confirm MOQ, pack size, shelf life, lead time, private-label/OEM availability, registration ownership, Incoterm, freight, insurance, payment terms and landed cost before quotation. |
20. Exporter Decision / Verification Checklist | ☐ Exact product/formulation confirmed ☐ Manufacturer verified ☐ GMP verified ☐ Indian authorization verified ☐ Destination registration checked ☐ Importer licence checked ☐ Controlled/special status checked ☐ COA/stability documents checked ☐ HS code verified ☐ Buyer verified |
46. PRAMIPEXOLE DIHYDROCHLORIDE MONOHYDRATE
1. Medicine / Product Name | PRAMIPEXOLE DIHYDROCHLORIDE MONOHYDRATE |
2. Generic / API / Composition | PRAMIPEXOLE DIHYDROCHLORIDE MONOHYDRATE — exact composition/API to be confirmed from manufacturer specification. |
3. Salt / Strength | Strength/salt as stated in the source where available; otherwise verify the exact product specification. |
4. Therapeutic Category | Neurological medicine |
5. Pharmacological / Drug Class | Ingredient-specific CNS agent |
6. Main Uses / Indications | Neurological indication according to the approved product. |
7. Mechanism / Basic Description | Ingredient-specific CNS mechanism. |
8. Dosage Form & Route | Route/formulation: verify from the exact product specification. |
9. Prescription / OTC Status | Generally prescription/regulated medicine; exact status varies by jurisdiction. |
10. Major Warnings / Contraindications / Key Interactions | Check official label for contraindications, interactions, pregnancy warnings, organ-function precautions and formulation-specific risks. |
11. India Export Considerations | Verify Indian manufacturing licence/product permission, GMP status, formulation authorization, exporter eligibility, labeling and destination-specific export documentation. |
12. HS Code / Customs Classification — TO BE VERIFIED | Do not assign a final HS/ITC-HS code from the medicine name alone. Confirm with the exact dosage form, packing and Indian customs classification. |
13. 26-Country Regulatory Status | Preliminary screen: 🟡 registration/authorization generally required in all 26 markets. Upgrade to 🟠/🔴/⚫ where the ingredient, formulation or destination law imposes special controls; exact status must be verified. |
14. Country Regulatory Authority | See the 26-country matrix at the beginning of this document; the responsible authority varies by destination. |
15. Registration / Marketing Authorization Requirements | Typically product dossier/quality data, manufacturing information, stability, labeling, local applicant/importer authorization and any country-specific clinical/bioequivalence or GMP evidence required. |
16. Export Requirements & Special Restrictions | Product-specific regulatory review required before export. |
17. Buyer Type | Licensed pharmaceutical importer/distributor/wholesaler; hospitals or institutional buyers where appropriate. Veterinary products require appropriately licensed animal-health buyers. |
18. Required Export / Regulatory Documentation | Commercial invoice; packing list; transport documents; certificate of origin where required; COA; GMP/manufacturing documents; product registration/authorization documents; import permit or controlled-drug permit where applicable. |
19. Commercial Considerations | Confirm MOQ, pack size, shelf life, lead time, private-label/OEM availability, registration ownership, Incoterm, freight, insurance, payment terms and landed cost before quotation. |
20. Exporter Decision / Verification Checklist | ☐ Exact product/formulation confirmed ☐ Manufacturer verified ☐ GMP verified ☐ Indian authorization verified ☐ Destination registration checked ☐ Importer licence checked ☐ Controlled/special status checked ☐ COA/stability documents checked ☐ HS code verified ☐ Buyer verified |
47. ES ZOPICLONE USP 3 MG
1. Medicine / Product Name | ES ZOPICLONE USP 3 MG |
2. Generic / API / Composition | ES ZOPICLONE USP 3 MG — exact composition/API to be confirmed from manufacturer specification. |
3. Salt / Strength | Strength/salt as stated in the source where available; otherwise verify the exact product specification. |
4. Therapeutic Category | CNS / neurological / psychiatric medicine |
5. Pharmacological / Drug Class | Central nervous system active medicine |
6. Main Uses / Indications | Indication depends on the active ingredient; verify approved indication. |
7. Mechanism / Basic Description | CNS mechanism is ingredient-specific. |
8. Dosage Form & Route | Route/formulation: verify from the exact product specification. |
9. Prescription / OTC Status | Prescription; controlled/psychotropic status must be checked country by country. |
10. Major Warnings / Contraindications / Key Interactions | CNS effects, interactions, dependence/misuse potential where applicable and local controlled-drug status require review. |
11. India Export Considerations | Verify Indian manufacturing licence/product permission, GMP status, formulation authorization, exporter eligibility, labeling and destination-specific export documentation. |
12. HS Code / Customs Classification — TO BE VERIFIED | Do not assign a final HS/ITC-HS code from the medicine name alone. Confirm with the exact dosage form, packing and Indian customs classification. |
13. 26-Country Regulatory Status | Preliminary screen: 🟡 registration/authorization generally required in all 26 markets. Upgrade to 🟠/🔴/⚫ where the ingredient, formulation or destination law imposes special controls; exact status must be verified. |
14. Country Regulatory Authority | See the 26-country matrix at the beginning of this document; the responsible authority varies by destination. |
15. Registration / Marketing Authorization Requirements | Typically product dossier/quality data, manufacturing information, stability, labeling, local applicant/importer authorization and any country-specific clinical/bioequivalence or GMP evidence required. |
16. Export Requirements & Special Restrictions | High-priority destination-country classification check. Controlled/psychotropic/hormonal classification must be checked separately in each destination. |
17. Buyer Type | Licensed pharmaceutical importer/distributor/wholesaler; hospitals or institutional buyers where appropriate. Veterinary products require appropriately licensed animal-health buyers. |
18. Required Export / Regulatory Documentation | Commercial invoice; packing list; transport documents; certificate of origin where required; COA; GMP/manufacturing documents; product registration/authorization documents; import permit or controlled-drug permit where applicable. |
19. Commercial Considerations | Confirm MOQ, pack size, shelf life, lead time, private-label/OEM availability, registration ownership, Incoterm, freight, insurance, payment terms and landed cost before quotation. |
20. Exporter Decision / Verification Checklist | ☐ Exact product/formulation confirmed ☐ Manufacturer verified ☐ GMP verified ☐ Indian authorization verified ☐ Destination registration checked ☐ Importer licence checked ☐ Controlled/special status checked ☐ COA/stability documents checked ☐ HS code verified ☐ Buyer verified |
48. LIOTHYRONINE SODIUM B.P. 25 MCG
1. Medicine / Product Name | LIOTHYRONINE SODIUM B.P. 25 MCG |
2. Generic / API / Composition | LIOTHYRONINE SODIUM B.P. 25 MCG — exact composition/API to be confirmed from manufacturer specification. |
3. Salt / Strength | Strength/salt as stated in the source where available; otherwise verify the exact product specification. |
4. Therapeutic Category | Thyroid hormone |
5. Pharmacological / Drug Class | Synthetic triiodothyronine (T3) |
6. Main Uses / Indications | Thyroid-hormone replacement in approved indications. |
7. Mechanism / Basic Description | Binds thyroid hormone receptors and regulates gene transcription. |
8. Dosage Form & Route | Oral; exact formulation must be verified. |
9. Prescription / OTC Status | Generally prescription/regulated medicine; exact status varies by jurisdiction. |
10. Major Warnings / Contraindications / Key Interactions | Check official label for contraindications, interactions, pregnancy warnings, organ-function precautions and formulation-specific risks. |
11. India Export Considerations | Verify Indian manufacturing licence/product permission, GMP status, formulation authorization, exporter eligibility, labeling and destination-specific export documentation. |
12. HS Code / Customs Classification — TO BE VERIFIED | Do not assign a final HS/ITC-HS code from the medicine name alone. Confirm with the exact dosage form, packing and Indian customs classification. |
13. 26-Country Regulatory Status | Preliminary screen: 🟡 registration/authorization generally required in all 26 markets. Upgrade to 🟠/🔴/⚫ where the ingredient, formulation or destination law imposes special controls; exact status must be verified. |
14. Country Regulatory Authority | See the 26-country matrix at the beginning of this document; the responsible authority varies by destination. |
15. Registration / Marketing Authorization Requirements | Typically product dossier/quality data, manufacturing information, stability, labeling, local applicant/importer authorization and any country-specific clinical/bioequivalence or GMP evidence required. |
16. Export Requirements & Special Restrictions | Product-specific regulatory review required before export. |
17. Buyer Type | Licensed pharmaceutical importer/distributor/wholesaler; hospitals or institutional buyers where appropriate. Veterinary products require appropriately licensed animal-health buyers. |
18. Required Export / Regulatory Documentation | Commercial invoice; packing list; transport documents; certificate of origin where required; COA; GMP/manufacturing documents; product registration/authorization documents; import permit or controlled-drug permit where applicable. |
19. Commercial Considerations | Confirm MOQ, pack size, shelf life, lead time, private-label/OEM availability, registration ownership, Incoterm, freight, insurance, payment terms and landed cost before quotation. |
20. Exporter Decision / Verification Checklist | ☐ Exact product/formulation confirmed ☐ Manufacturer verified ☐ GMP verified ☐ Indian authorization verified ☐ Destination registration checked ☐ Importer licence checked ☐ Controlled/special status checked ☐ COA/stability documents checked ☐ HS code verified ☐ Buyer verified |
49. NITAZOXANIDE
1. Medicine / Product Name | NITAZOXANIDE |
2. Generic / API / Composition | NITAZOXANIDE — exact composition/API to be confirmed from manufacturer specification. |
3. Salt / Strength | Strength/salt as stated in the source where available; otherwise verify the exact product specification. |
4. Therapeutic Category | Anti-infective / antiparasitic medicine |
5. Pharmacological / Drug Class | Antibacterial, antiprotozoal or antiparasitic — ingredient-specific |
6. Main Uses / Indications | Treatment of susceptible infections/parasitoses according to the approved indication. |
7. Mechanism / Basic Description | Ingredient-specific antimicrobial/antiparasitic mechanism. |
8. Dosage Form & Route | Oral or other formulation-specific route. |
9. Prescription / OTC Status | Generally prescription/regulated medicine; exact status varies by jurisdiction. |
10. Major Warnings / Contraindications / Key Interactions | Allergy, interactions, resistance/appropriate-use restrictions and indication-specific precautions require label review. |
11. India Export Considerations | Verify Indian manufacturing licence/product permission, GMP status, formulation authorization, exporter eligibility, labeling and destination-specific export documentation. |
12. HS Code / Customs Classification — TO BE VERIFIED | Do not assign a final HS/ITC-HS code from the medicine name alone. Confirm with the exact dosage form, packing and Indian customs classification. |
13. 26-Country Regulatory Status | Preliminary screen: 🟡 registration/authorization generally required in all 26 markets. Upgrade to 🟠/🔴/⚫ where the ingredient, formulation or destination law imposes special controls; exact status must be verified. |
14. Country Regulatory Authority | See the 26-country matrix at the beginning of this document; the responsible authority varies by destination. |
15. Registration / Marketing Authorization Requirements | Typically product dossier/quality data, manufacturing information, stability, labeling, local applicant/importer authorization and any country-specific clinical/bioequivalence or GMP evidence required. |
16. Export Requirements & Special Restrictions | Product-specific regulatory review required before export. |
17. Buyer Type | Licensed pharmaceutical importer/distributor/wholesaler; hospitals or institutional buyers where appropriate. Veterinary products require appropriately licensed animal-health buyers. |
18. Required Export / Regulatory Documentation | Commercial invoice; packing list; transport documents; certificate of origin where required; COA; GMP/manufacturing documents; product registration/authorization documents; import permit or controlled-drug permit where applicable. |
19. Commercial Considerations | Confirm MOQ, pack size, shelf life, lead time, private-label/OEM availability, registration ownership, Incoterm, freight, insurance, payment terms and landed cost before quotation. |
20. Exporter Decision / Verification Checklist | ☐ Exact product/formulation confirmed ☐ Manufacturer verified ☐ GMP verified ☐ Indian authorization verified ☐ Destination registration checked ☐ Importer licence checked ☐ Controlled/special status checked ☐ COA/stability documents checked ☐ HS code verified ☐ Buyer verified |
50. DOXYCYCLINE
1. Medicine / Product Name | DOXYCYCLINE |
2. Generic / API / Composition | DOXYCYCLINE — exact composition/API to be confirmed from manufacturer specification. |
3. Salt / Strength | Strength/salt as stated in the source where available; otherwise verify the exact product specification. |
4. Therapeutic Category | Anti-infective / antiparasitic medicine |
5. Pharmacological / Drug Class | Antibacterial, antiprotozoal or antiparasitic — ingredient-specific |
6. Main Uses / Indications | Treatment of susceptible infections/parasitoses according to the approved indication. |
7. Mechanism / Basic Description | Ingredient-specific antimicrobial/antiparasitic mechanism. |
8. Dosage Form & Route | Oral or other formulation-specific route. |
9. Prescription / OTC Status | Generally prescription/regulated medicine; exact status varies by jurisdiction. |
10. Major Warnings / Contraindications / Key Interactions | Allergy, interactions, resistance/appropriate-use restrictions and indication-specific precautions require label review. |
11. India Export Considerations | Verify Indian manufacturing licence/product permission, GMP status, formulation authorization, exporter eligibility, labeling and destination-specific export documentation. |
12. HS Code / Customs Classification — TO BE VERIFIED | Do not assign a final HS/ITC-HS code from the medicine name alone. Confirm with the exact dosage form, packing and Indian customs classification. |
13. 26-Country Regulatory Status | Preliminary screen: 🟡 registration/authorization generally required in all 26 markets. Upgrade to 🟠/🔴/⚫ where the ingredient, formulation or destination law imposes special controls; exact status must be verified. |
14. Country Regulatory Authority | See the 26-country matrix at the beginning of this document; the responsible authority varies by destination. |
15. Registration / Marketing Authorization Requirements | Typically product dossier/quality data, manufacturing information, stability, labeling, local applicant/importer authorization and any country-specific clinical/bioequivalence or GMP evidence required. |
16. Export Requirements & Special Restrictions | Product-specific regulatory review required before export. |
17. Buyer Type | Licensed pharmaceutical importer/distributor/wholesaler; hospitals or institutional buyers where appropriate. Veterinary products require appropriately licensed animal-health buyers. |
18. Required Export / Regulatory Documentation | Commercial invoice; packing list; transport documents; certificate of origin where required; COA; GMP/manufacturing documents; product registration/authorization documents; import permit or controlled-drug permit where applicable. |
19. Commercial Considerations | Confirm MOQ, pack size, shelf life, lead time, private-label/OEM availability, registration ownership, Incoterm, freight, insurance, payment terms and landed cost before quotation. |
20. Exporter Decision / Verification Checklist | ☐ Exact product/formulation confirmed ☐ Manufacturer verified ☐ GMP verified ☐ Indian authorization verified ☐ Destination registration checked ☐ Importer licence checked ☐ Controlled/special status checked ☐ COA/stability documents checked ☐ HS code verified ☐ Buyer verified |
51. SERTRALINE
1. Medicine / Product Name | SERTRALINE |
2. Generic / API / Composition | SERTRALINE — exact composition/API to be confirmed from manufacturer specification. |
3. Salt / Strength | Strength/salt as stated in the source where available; otherwise verify the exact product specification. |
4. Therapeutic Category | CNS / neurological / psychiatric medicine |
5. Pharmacological / Drug Class | Central nervous system active medicine |
6. Main Uses / Indications | Indication depends on the active ingredient; verify approved indication. |
7. Mechanism / Basic Description | CNS mechanism is ingredient-specific. |
8. Dosage Form & Route | Route/formulation: verify from the exact product specification. |
9. Prescription / OTC Status | Prescription; controlled/psychotropic status must be checked country by country. |
10. Major Warnings / Contraindications / Key Interactions | CNS effects, interactions, dependence/misuse potential where applicable and local controlled-drug status require review. |
11. India Export Considerations | Verify Indian manufacturing licence/product permission, GMP status, formulation authorization, exporter eligibility, labeling and destination-specific export documentation. |
12. HS Code / Customs Classification — TO BE VERIFIED | Do not assign a final HS/ITC-HS code from the medicine name alone. Confirm with the exact dosage form, packing and Indian customs classification. |
13. 26-Country Regulatory Status | Preliminary screen: 🟡 registration/authorization generally required in all 26 markets. Upgrade to 🟠/🔴/⚫ where the ingredient, formulation or destination law imposes special controls; exact status must be verified. |
14. Country Regulatory Authority | See the 26-country matrix at the beginning of this document; the responsible authority varies by destination. |
15. Registration / Marketing Authorization Requirements | Typically product dossier/quality data, manufacturing information, stability, labeling, local applicant/importer authorization and any country-specific clinical/bioequivalence or GMP evidence required. |
16. Export Requirements & Special Restrictions | High-priority destination-country classification check. |
17. Buyer Type | Licensed pharmaceutical importer/distributor/wholesaler; hospitals or institutional buyers where appropriate. Veterinary products require appropriately licensed animal-health buyers. |
18. Required Export / Regulatory Documentation | Commercial invoice; packing list; transport documents; certificate of origin where required; COA; GMP/manufacturing documents; product registration/authorization documents; import permit or controlled-drug permit where applicable. |
19. Commercial Considerations | Confirm MOQ, pack size, shelf life, lead time, private-label/OEM availability, registration ownership, Incoterm, freight, insurance, payment terms and landed cost before quotation. |
20. Exporter Decision / Verification Checklist | ☐ Exact product/formulation confirmed ☐ Manufacturer verified ☐ GMP verified ☐ Indian authorization verified ☐ Destination registration checked ☐ Importer licence checked ☐ Controlled/special status checked ☐ COA/stability documents checked ☐ HS code verified ☐ Buyer verified |
52. ISOTRETINOIN
1. Medicine / Product Name | ISOTRETINOIN |
2. Generic / API / Composition | ISOTRETINOIN — exact composition/API to be confirmed from manufacturer specification. |
3. Salt / Strength | Strength/salt as stated in the source where available; otherwise verify the exact product specification. |
4. Therapeutic Category | Dermatology / topical or hormonal medicine |
5. Pharmacological / Drug Class | Ingredient-specific dermatologic/hormonal agent |
6. Main Uses / Indications | Dermatologic or hormonal indication according to the exact formulation. |
7. Mechanism / Basic Description | Ingredient-specific; use approved product labeling. |
8. Dosage Form & Route | Topical or oral depending on formulation. |
9. Prescription / OTC Status | Generally prescription/regulated medicine; exact status varies by jurisdiction. |
10. Major Warnings / Contraindications / Key Interactions | Pregnancy/reproductive warnings, systemic absorption, skin reactions and formulation-specific restrictions must be checked. |
11. India Export Considerations | Verify Indian manufacturing licence/product permission, GMP status, formulation authorization, exporter eligibility, labeling and destination-specific export documentation. |
12. HS Code / Customs Classification — TO BE VERIFIED | Do not assign a final HS/ITC-HS code from the medicine name alone. Confirm with the exact dosage form, packing and Indian customs classification. |
13. 26-Country Regulatory Status | Preliminary screen: 🟡 registration/authorization generally required in all 26 markets. Upgrade to 🟠/🔴/⚫ where the ingredient, formulation or destination law imposes special controls; exact status must be verified. |
14. Country Regulatory Authority | See the 26-country matrix at the beginning of this document; the responsible authority varies by destination. |
15. Registration / Marketing Authorization Requirements | Typically product dossier/quality data, manufacturing information, stability, labeling, local applicant/importer authorization and any country-specific clinical/bioequivalence or GMP evidence required. |
16. Export Requirements & Special Restrictions | Product-specific regulatory review required before export. |
17. Buyer Type | Licensed pharmaceutical importer/distributor/wholesaler; hospitals or institutional buyers where appropriate. Veterinary products require appropriately licensed animal-health buyers. |
18. Required Export / Regulatory Documentation | Commercial invoice; packing list; transport documents; certificate of origin where required; COA; GMP/manufacturing documents; product registration/authorization documents; import permit or controlled-drug permit where applicable. |
19. Commercial Considerations | Confirm MOQ, pack size, shelf life, lead time, private-label/OEM availability, registration ownership, Incoterm, freight, insurance, payment terms and landed cost before quotation. |
20. Exporter Decision / Verification Checklist | ☐ Exact product/formulation confirmed ☐ Manufacturer verified ☐ GMP verified ☐ Indian authorization verified ☐ Destination registration checked ☐ Importer licence checked ☐ Controlled/special status checked ☐ COA/stability documents checked ☐ HS code verified ☐ Buyer verified |
53. PREGABALIN CAPSULES IP 150 MG
1. Medicine / Product Name | PREGABALIN CAPSULES IP 150 MG |
2. Generic / API / Composition | PREGABALIN IP 150 MG — exact composition/API to be confirmed from manufacturer specification. |
3. Salt / Strength | Strength/salt as stated in the source where available; otherwise verify the exact product specification. |
4. Therapeutic Category | CNS / neurological / psychiatric medicine |
5. Pharmacological / Drug Class | Central nervous system active medicine |
6. Main Uses / Indications | Indication depends on the active ingredient; verify approved indication. |
7. Mechanism / Basic Description | CNS mechanism is ingredient-specific. |
8. Dosage Form & Route | Route/formulation: verify from the exact product specification. |
9. Prescription / OTC Status | Prescription; controlled/psychotropic status must be checked country by country. |
10. Major Warnings / Contraindications / Key Interactions | CNS effects, interactions, dependence/misuse potential where applicable and local controlled-drug status require review. |
11. India Export Considerations | Verify Indian manufacturing licence/product permission, GMP status, formulation authorization, exporter eligibility, labeling and destination-specific export documentation. |
12. HS Code / Customs Classification — TO BE VERIFIED | Do not assign a final HS/ITC-HS code from the medicine name alone. Confirm with the exact dosage form, packing and Indian customs classification. |
13. 26-Country Regulatory Status | Preliminary screen: 🟡 registration/authorization generally required in all 26 markets. Upgrade to 🟠/🔴/⚫ where the ingredient, formulation or destination law imposes special controls; exact status must be verified. |
14. Country Regulatory Authority | See the 26-country matrix at the beginning of this document; the responsible authority varies by destination. |
15. Registration / Marketing Authorization Requirements | Typically product dossier/quality data, manufacturing information, stability, labeling, local applicant/importer authorization and any country-specific clinical/bioequivalence or GMP evidence required. |
16. Export Requirements & Special Restrictions | High-priority destination-country classification check. Controlled/psychotropic/hormonal classification must be checked separately in each destination. |
17. Buyer Type | Licensed pharmaceutical importer/distributor/wholesaler; hospitals or institutional buyers where appropriate. Veterinary products require appropriately licensed animal-health buyers. |
18. Required Export / Regulatory Documentation | Commercial invoice; packing list; transport documents; certificate of origin where required; COA; GMP/manufacturing documents; product registration/authorization documents; import permit or controlled-drug permit where applicable. |
19. Commercial Considerations | Confirm MOQ, pack size, shelf life, lead time, private-label/OEM availability, registration ownership, Incoterm, freight, insurance, payment terms and landed cost before quotation. |
20. Exporter Decision / Verification Checklist | ☐ Exact product/formulation confirmed ☐ Manufacturer verified ☐ GMP verified ☐ Indian authorization verified ☐ Destination registration checked ☐ Importer licence checked ☐ Controlled/special status checked ☐ COA/stability documents checked ☐ HS code verified ☐ Buyer verified |
54. PREGABALIN
1. Medicine / Product Name | PREGABALIN |
2. Generic / API / Composition | PREGABALIN — exact composition/API to be confirmed from manufacturer specification. |
3. Salt / Strength | Strength/salt as stated in the source where available; otherwise verify the exact product specification. |
4. Therapeutic Category | CNS / neurological / psychiatric medicine |
5. Pharmacological / Drug Class | Central nervous system active medicine |
6. Main Uses / Indications | Indication depends on the active ingredient; verify approved indication. |
7. Mechanism / Basic Description | CNS mechanism is ingredient-specific. |
8. Dosage Form & Route | Route/formulation: verify from the exact product specification. |
9. Prescription / OTC Status | Prescription; controlled/psychotropic status must be checked country by country. |
10. Major Warnings / Contraindications / Key Interactions | CNS effects, interactions, dependence/misuse potential where applicable and local controlled-drug status require review. |
11. India Export Considerations | Verify Indian manufacturing licence/product permission, GMP status, formulation authorization, exporter eligibility, labeling and destination-specific export documentation. |
12. HS Code / Customs Classification — TO BE VERIFIED | Do not assign a final HS/ITC-HS code from the medicine name alone. Confirm with the exact dosage form, packing and Indian customs classification. |
13. 26-Country Regulatory Status | Preliminary screen: 🟡 registration/authorization generally required in all 26 markets. Upgrade to 🟠/🔴/⚫ where the ingredient, formulation or destination law imposes special controls; exact status must be verified. |
14. Country Regulatory Authority | See the 26-country matrix at the beginning of this document; the responsible authority varies by destination. |
15. Registration / Marketing Authorization Requirements | Typically product dossier/quality data, manufacturing information, stability, labeling, local applicant/importer authorization and any country-specific clinical/bioequivalence or GMP evidence required. |
16. Export Requirements & Special Restrictions | High-priority destination-country classification check. Controlled/psychotropic/hormonal classification must be checked separately in each destination. |
17. Buyer Type | Licensed pharmaceutical importer/distributor/wholesaler; hospitals or institutional buyers where appropriate. Veterinary products require appropriately licensed animal-health buyers. |
18. Required Export / Regulatory Documentation | Commercial invoice; packing list; transport documents; certificate of origin where required; COA; GMP/manufacturing documents; product registration/authorization documents; import permit or controlled-drug permit where applicable. |
19. Commercial Considerations | Confirm MOQ, pack size, shelf life, lead time, private-label/OEM availability, registration ownership, Incoterm, freight, insurance, payment terms and landed cost before quotation. |
20. Exporter Decision / Verification Checklist | ☐ Exact product/formulation confirmed ☐ Manufacturer verified ☐ GMP verified ☐ Indian authorization verified ☐ Destination registration checked ☐ Importer licence checked ☐ Controlled/special status checked ☐ COA/stability documents checked ☐ HS code verified ☐ Buyer verified |
55. ANASTROZOLE
1. Medicine / Product Name | ANASTROZOLE |
2. Generic / API / Composition | ANASTROZOLE — exact composition/API to be confirmed from manufacturer specification. |
3. Salt / Strength | Strength/salt as stated in the source where available; otherwise verify the exact product specification. |
4. Therapeutic Category | Hormonal / endocrine medicine |
5. Pharmacological / Drug Class | Hormonal pathway modulator |
6. Main Uses / Indications | Endocrine or oncology/fertility indication depending on ingredient. |
7. Mechanism / Basic Description | Ingredient-specific estrogen-receptor or aromatase pathway modulation. |
8. Dosage Form & Route | Route/formulation: verify from the exact product specification. |
9. Prescription / OTC Status | Generally prescription/regulated medicine; exact status varies by jurisdiction. |
10. Major Warnings / Contraindications / Key Interactions | Check official label for contraindications, interactions, pregnancy warnings, organ-function precautions and formulation-specific risks. |
11. India Export Considerations | Verify Indian manufacturing licence/product permission, GMP status, formulation authorization, exporter eligibility, labeling and destination-specific export documentation. |
12. HS Code / Customs Classification — TO BE VERIFIED | Do not assign a final HS/ITC-HS code from the medicine name alone. Confirm with the exact dosage form, packing and Indian customs classification. |
13. 26-Country Regulatory Status | Preliminary screen: 🟡 registration/authorization generally required in all 26 markets. Upgrade to 🟠/🔴/⚫ where the ingredient, formulation or destination law imposes special controls; exact status must be verified. |
14. Country Regulatory Authority | See the 26-country matrix at the beginning of this document; the responsible authority varies by destination. |
15. Registration / Marketing Authorization Requirements | Typically product dossier/quality data, manufacturing information, stability, labeling, local applicant/importer authorization and any country-specific clinical/bioequivalence or GMP evidence required. |
16. Export Requirements & Special Restrictions | Hormonal/oncology regulatory review may apply. |
17. Buyer Type | Licensed pharmaceutical importer/distributor/wholesaler; hospitals or institutional buyers where appropriate. Veterinary products require appropriately licensed animal-health buyers. |
18. Required Export / Regulatory Documentation | Commercial invoice; packing list; transport documents; certificate of origin where required; COA; GMP/manufacturing documents; product registration/authorization documents; import permit or controlled-drug permit where applicable. |
19. Commercial Considerations | Confirm MOQ, pack size, shelf life, lead time, private-label/OEM availability, registration ownership, Incoterm, freight, insurance, payment terms and landed cost before quotation. |
20. Exporter Decision / Verification Checklist | ☐ Exact product/formulation confirmed ☐ Manufacturer verified ☐ GMP verified ☐ Indian authorization verified ☐ Destination registration checked ☐ Importer licence checked ☐ Controlled/special status checked ☐ COA/stability documents checked ☐ HS code verified ☐ Buyer verified |
56. METHANDIENONE
1. Medicine / Product Name | METHANDIENONE |
2. Generic / API / Composition | METHANDIENONE — exact composition/API to be confirmed from manufacturer specification. |
3. Salt / Strength | Strength/salt as stated in the source where available; otherwise verify the exact product specification. |
4. Therapeutic Category | Androgen / anabolic-hormonal medicine |
5. Pharmacological / Drug Class | Androgenic/anabolic steroid or testosterone preparation |
6. Main Uses / Indications | Hormone-replacement or other approved indication depends on the specific substance and formulation. |
7. Mechanism / Basic Description | Acts through androgen receptors; exact pharmacology varies by compound. |
8. Dosage Form & Route | Oral, topical or injectable depending on formulation. |
9. Prescription / OTC Status | Prescription; often subject to additional controlled-substance/hormone rules. |
10. Major Warnings / Contraindications / Key Interactions | Hormonal adverse effects, cardiovascular/thrombotic risks, hepatic risks for some oral agents, reproductive effects and local controlled-drug rules require review. |
11. India Export Considerations | Verify Indian manufacturing licence/product permission, GMP status, formulation authorization, exporter eligibility, labeling and destination-specific export documentation. |
12. HS Code / Customs Classification — TO BE VERIFIED | Do not assign a final HS/ITC-HS code from the medicine name alone. Confirm with the exact dosage form, packing and Indian customs classification. |
13. 26-Country Regulatory Status | Preliminary screen: 🟡 registration/authorization generally required in all 26 markets. Upgrade to 🟠/🔴/⚫ where the ingredient, formulation or destination law imposes special controls; exact status must be verified. |
14. Country Regulatory Authority | See the 26-country matrix at the beginning of this document; the responsible authority varies by destination. |
15. Registration / Marketing Authorization Requirements | Typically product dossier/quality data, manufacturing information, stability, labeling, local applicant/importer authorization and any country-specific clinical/bioequivalence or GMP evidence required. |
16. Export Requirements & Special Restrictions | High-priority regulatory verification; some jurisdictions impose controlled-substance or special import restrictions. Controlled/psychotropic/hormonal classification must be checked separately in each destination. |
17. Buyer Type | Licensed pharmaceutical importer/distributor/wholesaler; hospitals or institutional buyers where appropriate. Veterinary products require appropriately licensed animal-health buyers. |
18. Required Export / Regulatory Documentation | Commercial invoice; packing list; transport documents; certificate of origin where required; COA; GMP/manufacturing documents; product registration/authorization documents; import permit or controlled-drug permit where applicable. |
19. Commercial Considerations | Confirm MOQ, pack size, shelf life, lead time, private-label/OEM availability, registration ownership, Incoterm, freight, insurance, payment terms and landed cost before quotation. |
20. Exporter Decision / Verification Checklist | ☐ Exact product/formulation confirmed ☐ Manufacturer verified ☐ GMP verified ☐ Indian authorization verified ☐ Destination registration checked ☐ Importer licence checked ☐ Controlled/special status checked ☐ COA/stability documents checked ☐ HS code verified ☐ Buyer verified |
57. DUTASTERIDE
1. Medicine / Product Name | DUTASTERIDE |
2. Generic / API / Composition | DUTASTERIDE — exact composition/API to be confirmed from manufacturer specification. |
3. Salt / Strength | Strength/salt as stated in the source where available; otherwise verify the exact product specification. |
4. Therapeutic Category | Urological / dermatological medicine |
5. Pharmacological / Drug Class | 5-alpha-reductase inhibitor |
6. Main Uses / Indications | Approved indications include benign prostatic hyperplasia and/or androgenetic alopecia depending on strength/formulation. |
7. Mechanism / Basic Description | Reduces conversion of testosterone to dihydrotestosterone. |
8. Dosage Form & Route | Route/formulation: verify from the exact product specification. |
9. Prescription / OTC Status | Generally prescription/regulated medicine; exact status varies by jurisdiction. |
10. Major Warnings / Contraindications / Key Interactions | Check official label for contraindications, interactions, pregnancy warnings, organ-function precautions and formulation-specific risks. |
11. India Export Considerations | Verify Indian manufacturing licence/product permission, GMP status, formulation authorization, exporter eligibility, labeling and destination-specific export documentation. |
12. HS Code / Customs Classification — TO BE VERIFIED | Do not assign a final HS/ITC-HS code from the medicine name alone. Confirm with the exact dosage form, packing and Indian customs classification. |
13. 26-Country Regulatory Status | Preliminary screen: 🟡 registration/authorization generally required in all 26 markets. Upgrade to 🟠/🔴/⚫ where the ingredient, formulation or destination law imposes special controls; exact status must be verified. |
14. Country Regulatory Authority | See the 26-country matrix at the beginning of this document; the responsible authority varies by destination. |
15. Registration / Marketing Authorization Requirements | Typically product dossier/quality data, manufacturing information, stability, labeling, local applicant/importer authorization and any country-specific clinical/bioequivalence or GMP evidence required. |
16. Export Requirements & Special Restrictions | Product-specific regulatory review required before export. |
17. Buyer Type | Licensed pharmaceutical importer/distributor/wholesaler; hospitals or institutional buyers where appropriate. Veterinary products require appropriately licensed animal-health buyers. |
18. Required Export / Regulatory Documentation | Commercial invoice; packing list; transport documents; certificate of origin where required; COA; GMP/manufacturing documents; product registration/authorization documents; import permit or controlled-drug permit where applicable. |
19. Commercial Considerations | Confirm MOQ, pack size, shelf life, lead time, private-label/OEM availability, registration ownership, Incoterm, freight, insurance, payment terms and landed cost before quotation. |
20. Exporter Decision / Verification Checklist | ☐ Exact product/formulation confirmed ☐ Manufacturer verified ☐ GMP verified ☐ Indian authorization verified ☐ Destination registration checked ☐ Importer licence checked ☐ Controlled/special status checked ☐ COA/stability documents checked ☐ HS code verified ☐ Buyer verified |
Top Pharma Export Products from India Manufacturers Sellers Pharmaceutical Companies Medicine Buyers
58. NALTREXONE HYDROCHLORIDE
1. Medicine / Product Name | NALTREXONE HYDROCHLORIDE |
2. Generic / API / Composition | NALTREXONE HYDROCHLORIDE — exact composition/API to be confirmed from manufacturer specification. |
3. Salt / Strength | Strength/salt as stated in the source where available; otherwise verify the exact product specification. |
4. Therapeutic Category | Addiction medicine |
5. Pharmacological / Drug Class | Opioid receptor antagonist |
6. Main Uses / Indications | Approved indications include alcohol-use disorder and opioid-use-disorder relapse prevention in appropriate settings. |
7. Mechanism / Basic Description | Blocks opioid receptors. |
8. Dosage Form & Route | Route/formulation: verify from the exact product specification. |
9. Prescription / OTC Status | Generally prescription/regulated medicine; exact status varies by jurisdiction. |
10. Major Warnings / Contraindications / Key Interactions | Check official label for contraindications, interactions, pregnancy warnings, organ-function precautions and formulation-specific risks. |
11. India Export Considerations | Verify Indian manufacturing licence/product permission, GMP status, formulation authorization, exporter eligibility, labeling and destination-specific export documentation. |
12. HS Code / Customs Classification — TO BE VERIFIED | Do not assign a final HS/ITC-HS code from the medicine name alone. Confirm with the exact dosage form, packing and Indian customs classification. |
13. 26-Country Regulatory Status | Preliminary screen: 🟡 registration/authorization generally required in all 26 markets. Upgrade to 🟠/🔴/⚫ where the ingredient, formulation or destination law imposes special controls; exact status must be verified. |
14. Country Regulatory Authority | See the 26-country matrix at the beginning of this document; the responsible authority varies by destination. |
15. Registration / Marketing Authorization Requirements | Typically product dossier/quality data, manufacturing information, stability, labeling, local applicant/importer authorization and any country-specific clinical/bioequivalence or GMP evidence required. |
16. Export Requirements & Special Restrictions | Product-specific regulatory review required before export. |
17. Buyer Type | Licensed pharmaceutical importer/distributor/wholesaler; hospitals or institutional buyers where appropriate. Veterinary products require appropriately licensed animal-health buyers. |
18. Required Export / Regulatory Documentation | Commercial invoice; packing list; transport documents; certificate of origin where required; COA; GMP/manufacturing documents; product registration/authorization documents; import permit or controlled-drug permit where applicable. |
19. Commercial Considerations | Confirm MOQ, pack size, shelf life, lead time, private-label/OEM availability, registration ownership, Incoterm, freight, insurance, payment terms and landed cost before quotation. |
20. Exporter Decision / Verification Checklist | ☐ Exact product/formulation confirmed ☐ Manufacturer verified ☐ GMP verified ☐ Indian authorization verified ☐ Destination registration checked ☐ Importer licence checked ☐ Controlled/special status checked ☐ COA/stability documents checked ☐ HS code verified ☐ Buyer verified |
59. TETRACYCLINE
1. Medicine / Product Name | TETRACYCLINE |
2. Generic / API / Composition | TETRACYCLINE — exact composition/API to be confirmed from manufacturer specification. |
3. Salt / Strength | Strength/salt as stated in the source where available; otherwise verify the exact product specification. |
4. Therapeutic Category | Anti-infective / antiparasitic medicine |
5. Pharmacological / Drug Class | Antibacterial, antiprotozoal or antiparasitic — ingredient-specific |
6. Main Uses / Indications | Treatment of susceptible infections/parasitoses according to the approved indication. |
7. Mechanism / Basic Description | Ingredient-specific antimicrobial/antiparasitic mechanism. |
8. Dosage Form & Route | Oral or other formulation-specific route. |
9. Prescription / OTC Status | Generally prescription/regulated medicine; exact status varies by jurisdiction. |
10. Major Warnings / Contraindications / Key Interactions | Allergy, interactions, resistance/appropriate-use restrictions and indication-specific precautions require label review. |
11. India Export Considerations | Verify Indian manufacturing licence/product permission, GMP status, formulation authorization, exporter eligibility, labeling and destination-specific export documentation. |
12. HS Code / Customs Classification — TO BE VERIFIED | Do not assign a final HS/ITC-HS code from the medicine name alone. Confirm with the exact dosage form, packing and Indian customs classification. |
13. 26-Country Regulatory Status | Preliminary screen: 🟡 registration/authorization generally required in all 26 markets. Upgrade to 🟠/🔴/⚫ where the ingredient, formulation or destination law imposes special controls; exact status must be verified. |
14. Country Regulatory Authority | See the 26-country matrix at the beginning of this document; the responsible authority varies by destination. |
15. Registration / Marketing Authorization Requirements | Typically product dossier/quality data, manufacturing information, stability, labeling, local applicant/importer authorization and any country-specific clinical/bioequivalence or GMP evidence required. |
16. Export Requirements & Special Restrictions | Product-specific regulatory review required before export. |
17. Buyer Type | Licensed pharmaceutical importer/distributor/wholesaler; hospitals or institutional buyers where appropriate. Veterinary products require appropriately licensed animal-health buyers. |
18. Required Export / Regulatory Documentation | Commercial invoice; packing list; transport documents; certificate of origin where required; COA; GMP/manufacturing documents; product registration/authorization documents; import permit or controlled-drug permit where applicable. |
19. Commercial Considerations | Confirm MOQ, pack size, shelf life, lead time, private-label/OEM availability, registration ownership, Incoterm, freight, insurance, payment terms and landed cost before quotation. |
20. Exporter Decision / Verification Checklist | ☐ Exact product/formulation confirmed ☐ Manufacturer verified ☐ GMP verified ☐ Indian authorization verified ☐ Destination registration checked ☐ Importer licence checked ☐ Controlled/special status checked ☐ COA/stability documents checked ☐ HS code verified ☐ Buyer verified |
60. PREDNISOLONE
1. Medicine / Product Name | PREDNISOLONE |
2. Generic / API / Composition | PREDNISOLONE — exact composition/API to be confirmed from manufacturer specification. |
3. Salt / Strength | Strength/salt as stated in the source where available; otherwise verify the exact product specification. |
4. Therapeutic Category | Immunomodulatory / anti-inflammatory medicine |
5. Pharmacological / Drug Class | Ingredient-specific immunosuppressive or anti-inflammatory agent |
6. Main Uses / Indications | Inflammatory, autoimmune or transplant-related indications depending on ingredient/formulation. |
7. Mechanism / Basic Description | Ingredient-specific immunomodulatory mechanism. |
8. Dosage Form & Route | Route/formulation: verify from the exact product specification. |
9. Prescription / OTC Status | Generally prescription/regulated medicine; exact status varies by jurisdiction. |
10. Major Warnings / Contraindications / Key Interactions | Infection risk, immunosuppression and drug interactions can be important; specialist labeling must be followed. |
11. India Export Considerations | Verify Indian manufacturing licence/product permission, GMP status, formulation authorization, exporter eligibility, labeling and destination-specific export documentation. |
12. HS Code / Customs Classification — TO BE VERIFIED | Do not assign a final HS/ITC-HS code from the medicine name alone. Confirm with the exact dosage form, packing and Indian customs classification. |
13. 26-Country Regulatory Status | Preliminary screen: 🟡 registration/authorization generally required in all 26 markets. Upgrade to 🟠/🔴/⚫ where the ingredient, formulation or destination law imposes special controls; exact status must be verified. |
14. Country Regulatory Authority | See the 26-country matrix at the beginning of this document; the responsible authority varies by destination. |
15. Registration / Marketing Authorization Requirements | Typically product dossier/quality data, manufacturing information, stability, labeling, local applicant/importer authorization and any country-specific clinical/bioequivalence or GMP evidence required. |
16. Export Requirements & Special Restrictions | Higher regulatory and pharmacovigilance scrutiny. |
17. Buyer Type | Licensed pharmaceutical importer/distributor/wholesaler; hospitals or institutional buyers where appropriate. Veterinary products require appropriately licensed animal-health buyers. |
18. Required Export / Regulatory Documentation | Commercial invoice; packing list; transport documents; certificate of origin where required; COA; GMP/manufacturing documents; product registration/authorization documents; import permit or controlled-drug permit where applicable. |
19. Commercial Considerations | Confirm MOQ, pack size, shelf life, lead time, private-label/OEM availability, registration ownership, Incoterm, freight, insurance, payment terms and landed cost before quotation. |
20. Exporter Decision / Verification Checklist | ☐ Exact product/formulation confirmed ☐ Manufacturer verified ☐ GMP verified ☐ Indian authorization verified ☐ Destination registration checked ☐ Importer licence checked ☐ Controlled/special status checked ☐ COA/stability documents checked ☐ HS code verified ☐ Buyer verified |
61. METHYLCOBALAMIN INJECTION 1500 MCG
1. Medicine / Product Name | METHYLCOBALAMIN INJECTION 1500 MCG |
2. Generic / API / Composition | METHYLCOBALAMIN 1500 MCG — exact composition/API to be confirmed from manufacturer specification. |
3. Salt / Strength | Strength/salt as stated in the source where available; otherwise verify the exact product specification. |
4. Therapeutic Category | Nutritional / metabolic supportive product |
5. Pharmacological / Drug Class | Vitamin, amino-acid derivative or antioxidant — ingredient-specific |
6. Main Uses / Indications | Indication varies by ingredient and approved formulation. |
7. Mechanism / Basic Description | Biochemical role is ingredient-specific. |
8. Dosage Form & Route | Route/formulation: verify from the exact product specification. |
9. Prescription / OTC Status | Generally prescription/regulated medicine; exact status varies by jurisdiction. |
10. Major Warnings / Contraindications / Key Interactions | Check official label for contraindications, interactions, pregnancy warnings, organ-function precautions and formulation-specific risks. |
11. India Export Considerations | Verify Indian manufacturing licence/product permission, GMP status, formulation authorization, exporter eligibility, labeling and destination-specific export documentation. |
12. HS Code / Customs Classification — TO BE VERIFIED | Do not assign a final HS/ITC-HS code from the medicine name alone. Confirm with the exact dosage form, packing and Indian customs classification. |
13. 26-Country Regulatory Status | Preliminary screen: 🟡 registration/authorization generally required in all 26 markets. Upgrade to 🟠/🔴/⚫ where the ingredient, formulation or destination law imposes special controls; exact status must be verified. |
14. Country Regulatory Authority | See the 26-country matrix at the beginning of this document; the responsible authority varies by destination. |
15. Registration / Marketing Authorization Requirements | Typically product dossier/quality data, manufacturing information, stability, labeling, local applicant/importer authorization and any country-specific clinical/bioequivalence or GMP evidence required. |
16. Export Requirements & Special Restrictions | Product-specific regulatory review required before export. Sterile/injectable or biologic quality, storage and manufacturing controls may apply. |
17. Buyer Type | Licensed pharmaceutical importer/distributor/wholesaler; hospitals or institutional buyers where appropriate. Veterinary products require appropriately licensed animal-health buyers. |
18. Required Export / Regulatory Documentation | Commercial invoice; packing list; transport documents; certificate of origin where required; COA; GMP/manufacturing documents; product registration/authorization documents; import permit or controlled-drug permit where applicable. |
19. Commercial Considerations | Confirm MOQ, pack size, shelf life, lead time, private-label/OEM availability, registration ownership, Incoterm, freight, insurance, payment terms and landed cost before quotation. |
20. Exporter Decision / Verification Checklist | ☐ Exact product/formulation confirmed ☐ Manufacturer verified ☐ GMP verified ☐ Indian authorization verified ☐ Destination registration checked ☐ Importer licence checked ☐ Controlled/special status checked ☐ COA/stability documents checked ☐ HS code verified ☐ Buyer verified |
62. GLUTATHIONE FOR INJECTION 1200 MG
1. Medicine / Product Name | GLUTATHIONE FOR INJECTION 1200 MG |
2. Generic / API / Composition | GLUTATHIONE FOR 1200 MG — exact composition/API to be confirmed from manufacturer specification. |
3. Salt / Strength | Strength/salt as stated in the source where available; otherwise verify the exact product specification. |
4. Therapeutic Category | Nutritional / metabolic supportive product |
5. Pharmacological / Drug Class | Vitamin, amino-acid derivative or antioxidant — ingredient-specific |
6. Main Uses / Indications | Indication varies by ingredient and approved formulation. |
7. Mechanism / Basic Description | Biochemical role is ingredient-specific. |
8. Dosage Form & Route | Route/formulation: verify from the exact product specification. |
9. Prescription / OTC Status | Generally prescription/regulated medicine; exact status varies by jurisdiction. |
10. Major Warnings / Contraindications / Key Interactions | Check official label for contraindications, interactions, pregnancy warnings, organ-function precautions and formulation-specific risks. |
11. India Export Considerations | Verify Indian manufacturing licence/product permission, GMP status, formulation authorization, exporter eligibility, labeling and destination-specific export documentation. |
12. HS Code / Customs Classification — TO BE VERIFIED | Do not assign a final HS/ITC-HS code from the medicine name alone. Confirm with the exact dosage form, packing and Indian customs classification. |
13. 26-Country Regulatory Status | Preliminary screen: 🟡 registration/authorization generally required in all 26 markets. Upgrade to 🟠/🔴/⚫ where the ingredient, formulation or destination law imposes special controls; exact status must be verified. |
14. Country Regulatory Authority | See the 26-country matrix at the beginning of this document; the responsible authority varies by destination. |
15. Registration / Marketing Authorization Requirements | Typically product dossier/quality data, manufacturing information, stability, labeling, local applicant/importer authorization and any country-specific clinical/bioequivalence or GMP evidence required. |
16. Export Requirements & Special Restrictions | Product-specific regulatory review required before export. Sterile/injectable or biologic quality, storage and manufacturing controls may apply. |
17. Buyer Type | Licensed pharmaceutical importer/distributor/wholesaler; hospitals or institutional buyers where appropriate. Veterinary products require appropriately licensed animal-health buyers. |
18. Required Export / Regulatory Documentation | Commercial invoice; packing list; transport documents; certificate of origin where required; COA; GMP/manufacturing documents; product registration/authorization documents; import permit or controlled-drug permit where applicable. |
19. Commercial Considerations | Confirm MOQ, pack size, shelf life, lead time, private-label/OEM availability, registration ownership, Incoterm, freight, insurance, payment terms and landed cost before quotation. |
20. Exporter Decision / Verification Checklist | ☐ Exact product/formulation confirmed ☐ Manufacturer verified ☐ GMP verified ☐ Indian authorization verified ☐ Destination registration checked ☐ Importer licence checked ☐ Controlled/special status checked ☐ COA/stability documents checked ☐ HS code verified ☐ Buyer verified |
63. PITAVASTATIN CALCIUM
1. Medicine / Product Name | PITAVASTATIN CALCIUM |
2. Generic / API / Composition | PITAVASTATIN CALCIUM — exact composition/API to be confirmed from manufacturer specification. |
3. Salt / Strength | Strength/salt as stated in the source where available; otherwise verify the exact product specification. |
4. Therapeutic Category | Cardiometabolic medicine |
5. Pharmacological / Drug Class | Ingredient-specific metabolic/cardiovascular agent |
6. Main Uses / Indications | Cardiovascular, lipid or glucose-management indication according to the exact ingredient. |
7. Mechanism / Basic Description | Ingredient-specific; verify official label. |
8. Dosage Form & Route | Usually oral, except formulation-specific products. |
9. Prescription / OTC Status | Generally prescription/regulated medicine; exact status varies by jurisdiction. |
10. Major Warnings / Contraindications / Key Interactions | Check official label for contraindications, interactions, pregnancy warnings, organ-function precautions and formulation-specific risks. |
11. India Export Considerations | Verify Indian manufacturing licence/product permission, GMP status, formulation authorization, exporter eligibility, labeling and destination-specific export documentation. |
12. HS Code / Customs Classification — TO BE VERIFIED | Do not assign a final HS/ITC-HS code from the medicine name alone. Confirm with the exact dosage form, packing and Indian customs classification. |
13. 26-Country Regulatory Status | Preliminary screen: 🟡 registration/authorization generally required in all 26 markets. Upgrade to 🟠/🔴/⚫ where the ingredient, formulation or destination law imposes special controls; exact status must be verified. |
14. Country Regulatory Authority | See the 26-country matrix at the beginning of this document; the responsible authority varies by destination. |
15. Registration / Marketing Authorization Requirements | Typically product dossier/quality data, manufacturing information, stability, labeling, local applicant/importer authorization and any country-specific clinical/bioequivalence or GMP evidence required. |
16. Export Requirements & Special Restrictions | Product-specific regulatory review required before export. |
17. Buyer Type | Licensed pharmaceutical importer/distributor/wholesaler; hospitals or institutional buyers where appropriate. Veterinary products require appropriately licensed animal-health buyers. |
18. Required Export / Regulatory Documentation | Commercial invoice; packing list; transport documents; certificate of origin where required; COA; GMP/manufacturing documents; product registration/authorization documents; import permit or controlled-drug permit where applicable. |
19. Commercial Considerations | Confirm MOQ, pack size, shelf life, lead time, private-label/OEM availability, registration ownership, Incoterm, freight, insurance, payment terms and landed cost before quotation. |
20. Exporter Decision / Verification Checklist | ☐ Exact product/formulation confirmed ☐ Manufacturer verified ☐ GMP verified ☐ Indian authorization verified ☐ Destination registration checked ☐ Importer licence checked ☐ Controlled/special status checked ☐ COA/stability documents checked ☐ HS code verified ☐ Buyer verified |
64. NALTREXONE HCL CAPSULE 4.5 MG
1. Medicine / Product Name | NALTREXONE HCL CAPSULE 4.5 MG |
2. Generic / API / Composition | NALTREXONE HCL CAPSULE 4.5 MG — exact composition/API to be confirmed from manufacturer specification. |
3. Salt / Strength | Strength/salt as stated in the source where available; otherwise verify the exact product specification. |
4. Therapeutic Category | Addiction medicine |
5. Pharmacological / Drug Class | Opioid receptor antagonist |
6. Main Uses / Indications | Approved indications include alcohol-use disorder and opioid-use-disorder relapse prevention in appropriate settings. |
7. Mechanism / Basic Description | Blocks opioid receptors. |
8. Dosage Form & Route | Route/formulation: verify from the exact product specification. |
9. Prescription / OTC Status | Generally prescription/regulated medicine; exact status varies by jurisdiction. |
10. Major Warnings / Contraindications / Key Interactions | Check official label for contraindications, interactions, pregnancy warnings, organ-function precautions and formulation-specific risks. |
11. India Export Considerations | Verify Indian manufacturing licence/product permission, GMP status, formulation authorization, exporter eligibility, labeling and destination-specific export documentation. |
12. HS Code / Customs Classification — TO BE VERIFIED | Do not assign a final HS/ITC-HS code from the medicine name alone. Confirm with the exact dosage form, packing and Indian customs classification. |
13. 26-Country Regulatory Status | Preliminary screen: 🟡 registration/authorization generally required in all 26 markets. Upgrade to 🟠/🔴/⚫ where the ingredient, formulation or destination law imposes special controls; exact status must be verified. |
14. Country Regulatory Authority | See the 26-country matrix at the beginning of this document; the responsible authority varies by destination. |
15. Registration / Marketing Authorization Requirements | Typically product dossier/quality data, manufacturing information, stability, labeling, local applicant/importer authorization and any country-specific clinical/bioequivalence or GMP evidence required. |
16. Export Requirements & Special Restrictions | Product-specific regulatory review required before export. |
17. Buyer Type | Licensed pharmaceutical importer/distributor/wholesaler; hospitals or institutional buyers where appropriate. Veterinary products require appropriately licensed animal-health buyers. |
18. Required Export / Regulatory Documentation | Commercial invoice; packing list; transport documents; certificate of origin where required; COA; GMP/manufacturing documents; product registration/authorization documents; import permit or controlled-drug permit where applicable. |
19. Commercial Considerations | Confirm MOQ, pack size, shelf life, lead time, private-label/OEM availability, registration ownership, Incoterm, freight, insurance, payment terms and landed cost before quotation. |
20. Exporter Decision / Verification Checklist | ☐ Exact product/formulation confirmed ☐ Manufacturer verified ☐ GMP verified ☐ Indian authorization verified ☐ Destination registration checked ☐ Importer licence checked ☐ Controlled/special status checked ☐ COA/stability documents checked ☐ HS code verified ☐ Buyer verified |
65. SEMAGLUTIDE
1. Medicine / Product Name | SEMAGLUTIDE |
2. Generic / API / Composition | SEMAGLUTIDE — exact composition/API to be confirmed from manufacturer specification. |
3. Salt / Strength | Strength/salt as stated in the source where available; otherwise verify the exact product specification. |
4. Therapeutic Category | Cardiometabolic medicine |
5. Pharmacological / Drug Class | Ingredient-specific metabolic/cardiovascular agent |
6. Main Uses / Indications | Cardiovascular, lipid or glucose-management indication according to the exact ingredient. |
7. Mechanism / Basic Description | Ingredient-specific; verify official label. |
8. Dosage Form & Route | Usually oral, except formulation-specific products. |
9. Prescription / OTC Status | Generally prescription/regulated medicine; exact status varies by jurisdiction. |
10. Major Warnings / Contraindications / Key Interactions | Check official label for contraindications, interactions, pregnancy warnings, organ-function precautions and formulation-specific risks. |
11. India Export Considerations | Verify Indian manufacturing licence/product permission, GMP status, formulation authorization, exporter eligibility, labeling and destination-specific export documentation. |
12. HS Code / Customs Classification — TO BE VERIFIED | Do not assign a final HS/ITC-HS code from the medicine name alone. Confirm with the exact dosage form, packing and Indian customs classification. |
13. 26-Country Regulatory Status | Preliminary screen: 🟡 registration/authorization generally required in all 26 markets. Upgrade to 🟠/🔴/⚫ where the ingredient, formulation or destination law imposes special controls; exact status must be verified. |
14. Country Regulatory Authority | See the 26-country matrix at the beginning of this document; the responsible authority varies by destination. |
15. Registration / Marketing Authorization Requirements | Typically product dossier/quality data, manufacturing information, stability, labeling, local applicant/importer authorization and any country-specific clinical/bioequivalence or GMP evidence required. |
16. Export Requirements & Special Restrictions | Product-specific regulatory review required before export. |
17. Buyer Type | Licensed pharmaceutical importer/distributor/wholesaler; hospitals or institutional buyers where appropriate. Veterinary products require appropriately licensed animal-health buyers. |
18. Required Export / Regulatory Documentation | Commercial invoice; packing list; transport documents; certificate of origin where required; COA; GMP/manufacturing documents; product registration/authorization documents; import permit or controlled-drug permit where applicable. |
19. Commercial Considerations | Confirm MOQ, pack size, shelf life, lead time, private-label/OEM availability, registration ownership, Incoterm, freight, insurance, payment terms and landed cost before quotation. |
20. Exporter Decision / Verification Checklist | ☐ Exact product/formulation confirmed ☐ Manufacturer verified ☐ GMP verified ☐ Indian authorization verified ☐ Destination registration checked ☐ Importer licence checked ☐ Controlled/special status checked ☐ COA/stability documents checked ☐ HS code verified ☐ Buyer verified |
66. CLOBETASOL PROPIONATE CREAM IP
1. Medicine / Product Name | CLOBETASOL PROPIONATE CREAM IP |
2. Generic / API / Composition | CLOBETASOL PROPIONATE CREAM IP — exact composition/API to be confirmed from manufacturer specification. |
3. Salt / Strength | Strength/salt as stated in the source where available; otherwise verify the exact product specification. |
4. Therapeutic Category | Dermatology / topical or hormonal medicine |
5. Pharmacological / Drug Class | Ingredient-specific dermatologic/hormonal agent |
6. Main Uses / Indications | Dermatologic or hormonal indication according to the exact formulation. |
7. Mechanism / Basic Description | Ingredient-specific; use approved product labeling. |
8. Dosage Form & Route | Topical or oral depending on formulation. |
9. Prescription / OTC Status | Generally prescription/regulated medicine; exact status varies by jurisdiction. |
10. Major Warnings / Contraindications / Key Interactions | Pregnancy/reproductive warnings, systemic absorption, skin reactions and formulation-specific restrictions must be checked. |
11. India Export Considerations | Verify Indian manufacturing licence/product permission, GMP status, formulation authorization, exporter eligibility, labeling and destination-specific export documentation. |
12. HS Code / Customs Classification — TO BE VERIFIED | Do not assign a final HS/ITC-HS code from the medicine name alone. Confirm with the exact dosage form, packing and Indian customs classification. |
13. 26-Country Regulatory Status | Preliminary screen: 🟡 registration/authorization generally required in all 26 markets. Upgrade to 🟠/🔴/⚫ where the ingredient, formulation or destination law imposes special controls; exact status must be verified. |
14. Country Regulatory Authority | See the 26-country matrix at the beginning of this document; the responsible authority varies by destination. |
15. Registration / Marketing Authorization Requirements | Typically product dossier/quality data, manufacturing information, stability, labeling, local applicant/importer authorization and any country-specific clinical/bioequivalence or GMP evidence required. |
16. Export Requirements & Special Restrictions | Product-specific regulatory review required before export. |
17. Buyer Type | Licensed pharmaceutical importer/distributor/wholesaler; hospitals or institutional buyers where appropriate. Veterinary products require appropriately licensed animal-health buyers. |
18. Required Export / Regulatory Documentation | Commercial invoice; packing list; transport documents; certificate of origin where required; COA; GMP/manufacturing documents; product registration/authorization documents; import permit or controlled-drug permit where applicable. |
19. Commercial Considerations | Confirm MOQ, pack size, shelf life, lead time, private-label/OEM availability, registration ownership, Incoterm, freight, insurance, payment terms and landed cost before quotation. |
20. Exporter Decision / Verification Checklist | ☐ Exact product/formulation confirmed ☐ Manufacturer verified ☐ GMP verified ☐ Indian authorization verified ☐ Destination registration checked ☐ Importer licence checked ☐ Controlled/special status checked ☐ COA/stability documents checked ☐ HS code verified ☐ Buyer verified |
67. MINOXIDIL TABLETS IP 2.5 MG
1. Medicine / Product Name | MINOXIDIL TABLETS IP 2.5 MG |
2. Generic / API / Composition | MINOXIDIL IP 2.5 MG — exact composition/API to be confirmed from manufacturer specification. |
3. Salt / Strength | Strength/salt as stated in the source where available; otherwise verify the exact product specification. |
4. Therapeutic Category | Dermatology / topical or hormonal medicine |
5. Pharmacological / Drug Class | Ingredient-specific dermatologic/hormonal agent |
6. Main Uses / Indications | Dermatologic or hormonal indication according to the exact formulation. |
7. Mechanism / Basic Description | Ingredient-specific; use approved product labeling. |
8. Dosage Form & Route | Topical or oral depending on formulation. |
9. Prescription / OTC Status | Generally prescription/regulated medicine; exact status varies by jurisdiction. |
10. Major Warnings / Contraindications / Key Interactions | Pregnancy/reproductive warnings, systemic absorption, skin reactions and formulation-specific restrictions must be checked. |
11. India Export Considerations | Verify Indian manufacturing licence/product permission, GMP status, formulation authorization, exporter eligibility, labeling and destination-specific export documentation. |
12. HS Code / Customs Classification — TO BE VERIFIED | Do not assign a final HS/ITC-HS code from the medicine name alone. Confirm with the exact dosage form, packing and Indian customs classification. |
13. 26-Country Regulatory Status | Preliminary screen: 🟡 registration/authorization generally required in all 26 markets. Upgrade to 🟠/🔴/⚫ where the ingredient, formulation or destination law imposes special controls; exact status must be verified. |
14. Country Regulatory Authority | See the 26-country matrix at the beginning of this document; the responsible authority varies by destination. |
15. Registration / Marketing Authorization Requirements | Typically product dossier/quality data, manufacturing information, stability, labeling, local applicant/importer authorization and any country-specific clinical/bioequivalence or GMP evidence required. |
16. Export Requirements & Special Restrictions | Product-specific regulatory review required before export. |
17. Buyer Type | Licensed pharmaceutical importer/distributor/wholesaler; hospitals or institutional buyers where appropriate. Veterinary products require appropriately licensed animal-health buyers. |
18. Required Export / Regulatory Documentation | Commercial invoice; packing list; transport documents; certificate of origin where required; COA; GMP/manufacturing documents; product registration/authorization documents; import permit or controlled-drug permit where applicable. |
19. Commercial Considerations | Confirm MOQ, pack size, shelf life, lead time, private-label/OEM availability, registration ownership, Incoterm, freight, insurance, payment terms and landed cost before quotation. |
20. Exporter Decision / Verification Checklist | ☐ Exact product/formulation confirmed ☐ Manufacturer verified ☐ GMP verified ☐ Indian authorization verified ☐ Destination registration checked ☐ Importer licence checked ☐ Controlled/special status checked ☐ COA/stability documents checked ☐ HS code verified ☐ Buyer verified |
68. FLUPIRTINE MALEATE CAPSULE 100 MG
1. Medicine / Product Name | FLUPIRTINE MALEATE CAPSULE 100 MG |
2. Generic / API / Composition | FLUPIRTINE MALEATE CAPSULE 100 MG — exact composition/API to be confirmed from manufacturer specification. |
3. Salt / Strength | Strength/salt as stated in the source where available; otherwise verify the exact product specification. |
4. Therapeutic Category | Analgesic / CNS medicine |
5. Pharmacological / Drug Class | Non-opioid analgesic with central action |
6. Main Uses / Indications | Historical/limited market-specific analgesic use. |
7. Mechanism / Basic Description | Central potassium-channel-related analgesic mechanism; verify current jurisdictional status. |
8. Dosage Form & Route | Route/formulation: verify from the exact product specification. |
9. Prescription / OTC Status | Generally prescription/regulated medicine; exact status varies by jurisdiction. |
10. Major Warnings / Contraindications / Key Interactions | Check official label for contraindications, interactions, pregnancy warnings, organ-function precautions and formulation-specific risks. |
11. India Export Considerations | Verify Indian manufacturing licence/product permission, GMP status, formulation authorization, exporter eligibility, labeling and destination-specific export documentation. |
12. HS Code / Customs Classification — TO BE VERIFIED | Do not assign a final HS/ITC-HS code from the medicine name alone. Confirm with the exact dosage form, packing and Indian customs classification. |
13. 26-Country Regulatory Status | Preliminary screen: 🟡 registration/authorization generally required in all 26 markets. Upgrade to 🟠/🔴/⚫ where the ingredient, formulation or destination law imposes special controls; exact status must be verified. |
14. Country Regulatory Authority | See the 26-country matrix at the beginning of this document; the responsible authority varies by destination. |
15. Registration / Marketing Authorization Requirements | Typically product dossier/quality data, manufacturing information, stability, labeling, local applicant/importer authorization and any country-specific clinical/bioequivalence or GMP evidence required. |
16. Export Requirements & Special Restrictions | Regulatory status is particularly important because availability has been restricted/withdrawn in some markets. |
17. Buyer Type | Licensed pharmaceutical importer/distributor/wholesaler; hospitals or institutional buyers where appropriate. Veterinary products require appropriately licensed animal-health buyers. |
18. Required Export / Regulatory Documentation | Commercial invoice; packing list; transport documents; certificate of origin where required; COA; GMP/manufacturing documents; product registration/authorization documents; import permit or controlled-drug permit where applicable. |
19. Commercial Considerations | Confirm MOQ, pack size, shelf life, lead time, private-label/OEM availability, registration ownership, Incoterm, freight, insurance, payment terms and landed cost before quotation. |
20. Exporter Decision / Verification Checklist | ☐ Exact product/formulation confirmed ☐ Manufacturer verified ☐ GMP verified ☐ Indian authorization verified ☐ Destination registration checked ☐ Importer licence checked ☐ Controlled/special status checked ☐ COA/stability documents checked ☐ HS code verified ☐ Buyer verified |
69. TRENBOLONE ACETATE INJECTION USP 100 MG / ML
1. Medicine / Product Name | TRENBOLONE ACETATE INJECTION USP 100 MG / ML |
2. Generic / API / Composition | TRENBOLONE ACETATE USP 100 MG / ML — exact composition/API to be confirmed from manufacturer specification. |
3. Salt / Strength | Strength/salt as stated in the source where available; otherwise verify the exact product specification. |
4. Therapeutic Category | Androgen / anabolic-hormonal medicine |
5. Pharmacological / Drug Class | Androgenic/anabolic steroid or testosterone preparation |
6. Main Uses / Indications | Hormone-replacement or other approved indication depends on the specific substance and formulation. |
7. Mechanism / Basic Description | Acts through androgen receptors; exact pharmacology varies by compound. |
8. Dosage Form & Route | Oral, topical or injectable depending on formulation. |
9. Prescription / OTC Status | Prescription; often subject to additional controlled-substance/hormone rules. |
10. Major Warnings / Contraindications / Key Interactions | Hormonal adverse effects, cardiovascular/thrombotic risks, hepatic risks for some oral agents, reproductive effects and local controlled-drug rules require review. |
11. India Export Considerations | Verify Indian manufacturing licence/product permission, GMP status, formulation authorization, exporter eligibility, labeling and destination-specific export documentation. |
12. HS Code / Customs Classification — TO BE VERIFIED | Do not assign a final HS/ITC-HS code from the medicine name alone. Confirm with the exact dosage form, packing and Indian customs classification. |
13. 26-Country Regulatory Status | Preliminary screen: 🟡 registration/authorization generally required in all 26 markets. Upgrade to 🟠/🔴/⚫ where the ingredient, formulation or destination law imposes special controls; exact status must be verified. |
14. Country Regulatory Authority | See the 26-country matrix at the beginning of this document; the responsible authority varies by destination. |
15. Registration / Marketing Authorization Requirements | Typically product dossier/quality data, manufacturing information, stability, labeling, local applicant/importer authorization and any country-specific clinical/bioequivalence or GMP evidence required. |
16. Export Requirements & Special Restrictions | High-priority regulatory verification; some jurisdictions impose controlled-substance or special import restrictions. Controlled/psychotropic/hormonal classification must be checked separately in each destination. Sterile/injectable or biologic quality, storage and manufacturing controls may apply. |
17. Buyer Type | Licensed pharmaceutical importer/distributor/wholesaler; hospitals or institutional buyers where appropriate. Veterinary products require appropriately licensed animal-health buyers. |
18. Required Export / Regulatory Documentation | Commercial invoice; packing list; transport documents; certificate of origin where required; COA; GMP/manufacturing documents; product registration/authorization documents; import permit or controlled-drug permit where applicable. |
19. Commercial Considerations | Confirm MOQ, pack size, shelf life, lead time, private-label/OEM availability, registration ownership, Incoterm, freight, insurance, payment terms and landed cost before quotation. |
20. Exporter Decision / Verification Checklist | ☐ Exact product/formulation confirmed ☐ Manufacturer verified ☐ GMP verified ☐ Indian authorization verified ☐ Destination registration checked ☐ Importer licence checked ☐ Controlled/special status checked ☐ COA/stability documents checked ☐ HS code verified ☐ Buyer verified |
70. BACTERIOSTATIC WATER FOR INJECTION
1. Medicine / Product Name | BACTERIOSTATIC WATER FOR INJECTION |
2. Generic / API / Composition | BACTERIOSTATIC WATER FOR — exact composition/API to be confirmed from manufacturer specification. |
3. Salt / Strength | Strength/salt as stated in the source where available; otherwise verify the exact product specification. |
4. Therapeutic Category | Parenteral diluent |
5. Pharmacological / Drug Class | Sterile water with bacteriostatic preservative; not a therapeutic active medicine |
6. Main Uses / Indications | Diluent for compatible injectable medicines where specifically permitted. |
7. Mechanism / Basic Description | No therapeutic pharmacological mechanism. |
8. Dosage Form & Route | Parenteral use only as an approved diluent. |
9. Prescription / OTC Status | Healthcare/professional-use product; regulatory classification varies. |
10. Major Warnings / Contraindications / Key Interactions | Check official label for contraindications, interactions, pregnancy warnings, organ-function precautions and formulation-specific risks. |
11. India Export Considerations | Verify Indian manufacturing licence/product permission, GMP status, formulation authorization, exporter eligibility, labeling and destination-specific export documentation. |
12. HS Code / Customs Classification — TO BE VERIFIED | Do not assign a final HS/ITC-HS code from the medicine name alone. Confirm with the exact dosage form, packing and Indian customs classification. |
13. 26-Country Regulatory Status | Preliminary screen: 🟡 registration/authorization generally required in all 26 markets. Upgrade to 🟠/🔴/⚫ where the ingredient, formulation or destination law imposes special controls; exact status must be verified. |
14. Country Regulatory Authority | See the 26-country matrix at the beginning of this document; the responsible authority varies by destination. |
15. Registration / Marketing Authorization Requirements | Typically product dossier/quality data, manufacturing information, stability, labeling, local applicant/importer authorization and any country-specific clinical/bioequivalence or GMP evidence required. |
16. Export Requirements & Special Restrictions | Must not be treated as a generic injectable substitute; verify preservative, container, intended use and destination requirements. |
17. Buyer Type | Licensed pharmaceutical importer/distributor/wholesaler; hospitals or institutional buyers where appropriate. Veterinary products require appropriately licensed animal-health buyers. |
18. Required Export / Regulatory Documentation | Commercial invoice; packing list; transport documents; certificate of origin where required; COA; GMP/manufacturing documents; product registration/authorization documents; import permit or controlled-drug permit where applicable. |
19. Commercial Considerations | Confirm MOQ, pack size, shelf life, lead time, private-label/OEM availability, registration ownership, Incoterm, freight, insurance, payment terms and landed cost before quotation. |
20. Exporter Decision / Verification Checklist | ☐ Exact product/formulation confirmed ☐ Manufacturer verified ☐ GMP verified ☐ Indian authorization verified ☐ Destination registration checked ☐ Importer licence checked ☐ Controlled/special status checked ☐ COA/stability documents checked ☐ HS code verified ☐ Buyer verified |
71. BACTERIOSTATIC WATER FOR INJECTION USP 10 ML
1. Medicine / Product Name | BACTERIOSTATIC WATER FOR INJECTION USP 10 ML |
2. Generic / API / Composition | BACTERIOSTATIC WATER FOR USP 10 ML — exact composition/API to be confirmed from manufacturer specification. |
3. Salt / Strength | Strength/salt as stated in the source where available; otherwise verify the exact product specification. |
4. Therapeutic Category | Parenteral diluent |
5. Pharmacological / Drug Class | Sterile water with bacteriostatic preservative; not a therapeutic active medicine |
6. Main Uses / Indications | Diluent for compatible injectable medicines where specifically permitted. |
7. Mechanism / Basic Description | No therapeutic pharmacological mechanism. |
8. Dosage Form & Route | Parenteral use only as an approved diluent. |
9. Prescription / OTC Status | Healthcare/professional-use product; regulatory classification varies. |
10. Major Warnings / Contraindications / Key Interactions | Check official label for contraindications, interactions, pregnancy warnings, organ-function precautions and formulation-specific risks. |
11. India Export Considerations | Verify Indian manufacturing licence/product permission, GMP status, formulation authorization, exporter eligibility, labeling and destination-specific export documentation. |
12. HS Code / Customs Classification — TO BE VERIFIED | Do not assign a final HS/ITC-HS code from the medicine name alone. Confirm with the exact dosage form, packing and Indian customs classification. |
13. 26-Country Regulatory Status | Preliminary screen: 🟡 registration/authorization generally required in all 26 markets. Upgrade to 🟠/🔴/⚫ where the ingredient, formulation or destination law imposes special controls; exact status must be verified. |
14. Country Regulatory Authority | See the 26-country matrix at the beginning of this document; the responsible authority varies by destination. |
15. Registration / Marketing Authorization Requirements | Typically product dossier/quality data, manufacturing information, stability, labeling, local applicant/importer authorization and any country-specific clinical/bioequivalence or GMP evidence required. |
16. Export Requirements & Special Restrictions | Must not be treated as a generic injectable substitute; verify preservative, container, intended use and destination requirements. |
17. Buyer Type | Licensed pharmaceutical importer/distributor/wholesaler; hospitals or institutional buyers where appropriate. Veterinary products require appropriately licensed animal-health buyers. |
18. Required Export / Regulatory Documentation | Commercial invoice; packing list; transport documents; certificate of origin where required; COA; GMP/manufacturing documents; product registration/authorization documents; import permit or controlled-drug permit where applicable. |
19. Commercial Considerations | Confirm MOQ, pack size, shelf life, lead time, private-label/OEM availability, registration ownership, Incoterm, freight, insurance, payment terms and landed cost before quotation. |
20. Exporter Decision / Verification Checklist | ☐ Exact product/formulation confirmed ☐ Manufacturer verified ☐ GMP verified ☐ Indian authorization verified ☐ Destination registration checked ☐ Importer licence checked ☐ Controlled/special status checked ☐ COA/stability documents checked ☐ HS code verified ☐ Buyer verified |
72. BACTERIOSTATIC WATER FOR INJECTION USP 30 ML
1. Medicine / Product Name | BACTERIOSTATIC WATER FOR INJECTION USP 30 ML |
2. Generic / API / Composition | BACTERIOSTATIC WATER FOR USP 30 ML — exact composition/API to be confirmed from manufacturer specification. |
3. Salt / Strength | Strength/salt as stated in the source where available; otherwise verify the exact product specification. |
4. Therapeutic Category | Parenteral diluent |
5. Pharmacological / Drug Class | Sterile water with bacteriostatic preservative; not a therapeutic active medicine |
6. Main Uses / Indications | Diluent for compatible injectable medicines where specifically permitted. |
7. Mechanism / Basic Description | No therapeutic pharmacological mechanism. |
8. Dosage Form & Route | Parenteral use only as an approved diluent. |
9. Prescription / OTC Status | Healthcare/professional-use product; regulatory classification varies. |
10. Major Warnings / Contraindications / Key Interactions | Check official label for contraindications, interactions, pregnancy warnings, organ-function precautions and formulation-specific risks. |
11. India Export Considerations | Verify Indian manufacturing licence/product permission, GMP status, formulation authorization, exporter eligibility, labeling and destination-specific export documentation. |
12. HS Code / Customs Classification — TO BE VERIFIED | Do not assign a final HS/ITC-HS code from the medicine name alone. Confirm with the exact dosage form, packing and Indian customs classification. |
13. 26-Country Regulatory Status | Preliminary screen: 🟡 registration/authorization generally required in all 26 markets. Upgrade to 🟠/🔴/⚫ where the ingredient, formulation or destination law imposes special controls; exact status must be verified. |
14. Country Regulatory Authority | See the 26-country matrix at the beginning of this document; the responsible authority varies by destination. |
15. Registration / Marketing Authorization Requirements | Typically product dossier/quality data, manufacturing information, stability, labeling, local applicant/importer authorization and any country-specific clinical/bioequivalence or GMP evidence required. |
16. Export Requirements & Special Restrictions | Must not be treated as a generic injectable substitute; verify preservative, container, intended use and destination requirements. |
17. Buyer Type | Licensed pharmaceutical importer/distributor/wholesaler; hospitals or institutional buyers where appropriate. Veterinary products require appropriately licensed animal-health buyers. |
18. Required Export / Regulatory Documentation | Commercial invoice; packing list; transport documents; certificate of origin where required; COA; GMP/manufacturing documents; product registration/authorization documents; import permit or controlled-drug permit where applicable. |
19. Commercial Considerations | Confirm MOQ, pack size, shelf life, lead time, private-label/OEM availability, registration ownership, Incoterm, freight, insurance, payment terms and landed cost before quotation. |
20. Exporter Decision / Verification Checklist | ☐ Exact product/formulation confirmed ☐ Manufacturer verified ☐ GMP verified ☐ Indian authorization verified ☐ Destination registration checked ☐ Importer licence checked ☐ Controlled/special status checked ☐ COA/stability documents checked ☐ HS code verified ☐ Buyer verified |
73. DAPAGLIFLOZIN TABLE 10 MG
1. Medicine / Product Name | DAPAGLIFLOZIN TABLE 10 MG |
2. Generic / API / Composition | DAPAGLIFLOZIN TABLE 10 MG — exact composition/API to be confirmed from manufacturer specification. |
3. Salt / Strength | Strength/salt as stated in the source where available; otherwise verify the exact product specification. |
4. Therapeutic Category | Cardiometabolic medicine |
5. Pharmacological / Drug Class | Ingredient-specific metabolic/cardiovascular agent |
6. Main Uses / Indications | Cardiovascular, lipid or glucose-management indication according to the exact ingredient. |
7. Mechanism / Basic Description | Ingredient-specific; verify official label. |
8. Dosage Form & Route | Usually oral, except formulation-specific products. |
9. Prescription / OTC Status | Generally prescription/regulated medicine; exact status varies by jurisdiction. |
10. Major Warnings / Contraindications / Key Interactions | Check official label for contraindications, interactions, pregnancy warnings, organ-function precautions and formulation-specific risks. |
11. India Export Considerations | Verify Indian manufacturing licence/product permission, GMP status, formulation authorization, exporter eligibility, labeling and destination-specific export documentation. |
12. HS Code / Customs Classification — TO BE VERIFIED | Do not assign a final HS/ITC-HS code from the medicine name alone. Confirm with the exact dosage form, packing and Indian customs classification. |
13. 26-Country Regulatory Status | Preliminary screen: 🟡 registration/authorization generally required in all 26 markets. Upgrade to 🟠/🔴/⚫ where the ingredient, formulation or destination law imposes special controls; exact status must be verified. |
14. Country Regulatory Authority | See the 26-country matrix at the beginning of this document; the responsible authority varies by destination. |
15. Registration / Marketing Authorization Requirements | Typically product dossier/quality data, manufacturing information, stability, labeling, local applicant/importer authorization and any country-specific clinical/bioequivalence or GMP evidence required. |
16. Export Requirements & Special Restrictions | Product-specific regulatory review required before export. |
17. Buyer Type | Licensed pharmaceutical importer/distributor/wholesaler; hospitals or institutional buyers where appropriate. Veterinary products require appropriately licensed animal-health buyers. |
18. Required Export / Regulatory Documentation | Commercial invoice; packing list; transport documents; certificate of origin where required; COA; GMP/manufacturing documents; product registration/authorization documents; import permit or controlled-drug permit where applicable. |
19. Commercial Considerations | Confirm MOQ, pack size, shelf life, lead time, private-label/OEM availability, registration ownership, Incoterm, freight, insurance, payment terms and landed cost before quotation. |
20. Exporter Decision / Verification Checklist | ☐ Exact product/formulation confirmed ☐ Manufacturer verified ☐ GMP verified ☐ Indian authorization verified ☐ Destination registration checked ☐ Importer licence checked ☐ Controlled/special status checked ☐ COA/stability documents checked ☐ HS code verified ☐ Buyer verified |
74. ORLISTAT CAPSULE 120 MG
1. Medicine / Product Name | ORLISTAT CAPSULE 120 MG |
2. Generic / API / Composition | ORLISTAT CAPSULE 120 MG — exact composition/API to be confirmed from manufacturer specification. |
3. Salt / Strength | Strength/salt as stated in the source where available; otherwise verify the exact product specification. |
4. Therapeutic Category | Pharmaceutical medicine |
5. Pharmacological / Drug Class | Product-specific pharmacological class — verify against approved label. |
6. Main Uses / Indications | Use/indication is formulation- and jurisdiction-specific; verify the approved label. |
7. Mechanism / Basic Description | Pharmacology should be stated from the approved product label/official monograph. |
8. Dosage Form & Route | Route/formulation: verify from the exact product specification. |
9. Prescription / OTC Status | Generally prescription/regulated medicine; exact status varies by jurisdiction. |
10. Major Warnings / Contraindications / Key Interactions | Check official label for contraindications, interactions, pregnancy warnings, organ-function precautions and formulation-specific risks. |
11. India Export Considerations | Verify Indian manufacturing licence/product permission, GMP status, formulation authorization, exporter eligibility, labeling and destination-specific export documentation. |
12. HS Code / Customs Classification — TO BE VERIFIED | Do not assign a final HS/ITC-HS code from the medicine name alone. Confirm with the exact dosage form, packing and Indian customs classification. |
13. 26-Country Regulatory Status | Preliminary screen: 🟡 registration/authorization generally required in all 26 markets. Upgrade to 🟠/🔴/⚫ where the ingredient, formulation or destination law imposes special controls; exact status must be verified. |
14. Country Regulatory Authority | See the 26-country matrix at the beginning of this document; the responsible authority varies by destination. |
15. Registration / Marketing Authorization Requirements | Typically product dossier/quality data, manufacturing information, stability, labeling, local applicant/importer authorization and any country-specific clinical/bioequivalence or GMP evidence required. |
16. Export Requirements & Special Restrictions | Product-specific regulatory review required before export. |
17. Buyer Type | Licensed pharmaceutical importer/distributor/wholesaler; hospitals or institutional buyers where appropriate. Veterinary products require appropriately licensed animal-health buyers. |
18. Required Export / Regulatory Documentation | Commercial invoice; packing list; transport documents; certificate of origin where required; COA; GMP/manufacturing documents; product registration/authorization documents; import permit or controlled-drug permit where applicable. |
19. Commercial Considerations | Confirm MOQ, pack size, shelf life, lead time, private-label/OEM availability, registration ownership, Incoterm, freight, insurance, payment terms and landed cost before quotation. |
20. Exporter Decision / Verification Checklist | ☐ Exact product/formulation confirmed ☐ Manufacturer verified ☐ GMP verified ☐ Indian authorization verified ☐ Destination registration checked ☐ Importer licence checked ☐ Controlled/special status checked ☐ COA/stability documents checked ☐ HS code verified ☐ Buyer verified |
75. LOPERAMIDE HYDROCHLORIDE IP 2 MG
1. Medicine / Product Name | LOPERAMIDE HYDROCHLORIDE IP 2 MG |
2. Generic / API / Composition | LOPERAMIDE HYDROCHLORIDE IP 2 MG — exact composition/API to be confirmed from manufacturer specification. |
3. Salt / Strength | Strength/salt as stated in the source where available; otherwise verify the exact product specification. |
4. Therapeutic Category | Analgesic / gastrointestinal medicine |
5. Pharmacological / Drug Class | Ingredient-specific analgesic or GI agent |
6. Main Uses / Indications | Pain/inflammation or gastrointestinal indication according to ingredient. |
7. Mechanism / Basic Description | Ingredient-specific mechanism. |
8. Dosage Form & Route | Route/formulation: verify from the exact product specification. |
9. Prescription / OTC Status | Generally prescription/regulated medicine; exact status varies by jurisdiction. |
10. Major Warnings / Contraindications / Key Interactions | Check official label for contraindications, interactions, pregnancy warnings, organ-function precautions and formulation-specific risks. |
11. India Export Considerations | Verify Indian manufacturing licence/product permission, GMP status, formulation authorization, exporter eligibility, labeling and destination-specific export documentation. |
12. HS Code / Customs Classification — TO BE VERIFIED | Do not assign a final HS/ITC-HS code from the medicine name alone. Confirm with the exact dosage form, packing and Indian customs classification. |
13. 26-Country Regulatory Status | Preliminary screen: 🟡 registration/authorization generally required in all 26 markets. Upgrade to 🟠/🔴/⚫ where the ingredient, formulation or destination law imposes special controls; exact status must be verified. |
14. Country Regulatory Authority | See the 26-country matrix at the beginning of this document; the responsible authority varies by destination. |
15. Registration / Marketing Authorization Requirements | Typically product dossier/quality data, manufacturing information, stability, labeling, local applicant/importer authorization and any country-specific clinical/bioequivalence or GMP evidence required. |
16. Export Requirements & Special Restrictions | Product-specific regulatory review required before export. |
17. Buyer Type | Licensed pharmaceutical importer/distributor/wholesaler; hospitals or institutional buyers where appropriate. Veterinary products require appropriately licensed animal-health buyers. |
18. Required Export / Regulatory Documentation | Commercial invoice; packing list; transport documents; certificate of origin where required; COA; GMP/manufacturing documents; product registration/authorization documents; import permit or controlled-drug permit where applicable. |
19. Commercial Considerations | Confirm MOQ, pack size, shelf life, lead time, private-label/OEM availability, registration ownership, Incoterm, freight, insurance, payment terms and landed cost before quotation. |
20. Exporter Decision / Verification Checklist | ☐ Exact product/formulation confirmed ☐ Manufacturer verified ☐ GMP verified ☐ Indian authorization verified ☐ Destination registration checked ☐ Importer licence checked ☐ Controlled/special status checked ☐ COA/stability documents checked ☐ HS code verified ☐ Buyer verified |
76. CANDESARTAN CILEXETIL TABLES USP
1. Medicine / Product Name | CANDESARTAN CILEXETIL TABLES USP |
2. Generic / API / Composition | CANDESARTAN CILEXETIL TABLES USP — exact composition/API to be confirmed from manufacturer specification. |
3. Salt / Strength | Strength/salt as stated in the source where available; otherwise verify the exact product specification. |
4. Therapeutic Category | Cardiometabolic medicine |
5. Pharmacological / Drug Class | Ingredient-specific metabolic/cardiovascular agent |
6. Main Uses / Indications | Cardiovascular, lipid or glucose-management indication according to the exact ingredient. |
7. Mechanism / Basic Description | Ingredient-specific; verify official label. |
8. Dosage Form & Route | Usually oral, except formulation-specific products. |
9. Prescription / OTC Status | Generally prescription/regulated medicine; exact status varies by jurisdiction. |
10. Major Warnings / Contraindications / Key Interactions | Check official label for contraindications, interactions, pregnancy warnings, organ-function precautions and formulation-specific risks. |
11. India Export Considerations | Verify Indian manufacturing licence/product permission, GMP status, formulation authorization, exporter eligibility, labeling and destination-specific export documentation. |
12. HS Code / Customs Classification — TO BE VERIFIED | Do not assign a final HS/ITC-HS code from the medicine name alone. Confirm with the exact dosage form, packing and Indian customs classification. |
13. 26-Country Regulatory Status | Preliminary screen: 🟡 registration/authorization generally required in all 26 markets. Upgrade to 🟠/🔴/⚫ where the ingredient, formulation or destination law imposes special controls; exact status must be verified. |
14. Country Regulatory Authority | See the 26-country matrix at the beginning of this document; the responsible authority varies by destination. |
15. Registration / Marketing Authorization Requirements | Typically product dossier/quality data, manufacturing information, stability, labeling, local applicant/importer authorization and any country-specific clinical/bioequivalence or GMP evidence required. |
16. Export Requirements & Special Restrictions | Product-specific regulatory review required before export. |
17. Buyer Type | Licensed pharmaceutical importer/distributor/wholesaler; hospitals or institutional buyers where appropriate. Veterinary products require appropriately licensed animal-health buyers. |
18. Required Export / Regulatory Documentation | Commercial invoice; packing list; transport documents; certificate of origin where required; COA; GMP/manufacturing documents; product registration/authorization documents; import permit or controlled-drug permit where applicable. |
19. Commercial Considerations | Confirm MOQ, pack size, shelf life, lead time, private-label/OEM availability, registration ownership, Incoterm, freight, insurance, payment terms and landed cost before quotation. |
20. Exporter Decision / Verification Checklist | ☐ Exact product/formulation confirmed ☐ Manufacturer verified ☐ GMP verified ☐ Indian authorization verified ☐ Destination registration checked ☐ Importer licence checked ☐ Controlled/special status checked ☐ COA/stability documents checked ☐ HS code verified ☐ Buyer verified |
77. ESTRIOL CREAM BP
1. Medicine / Product Name | ESTRIOL CREAM BP |
2. Generic / API / Composition | ESTRIOL CREAM BP — exact composition/API to be confirmed from manufacturer specification. |
3. Salt / Strength | Strength/salt as stated in the source where available; otherwise verify the exact product specification. |
4. Therapeutic Category | Dermatology / topical or hormonal medicine |
5. Pharmacological / Drug Class | Ingredient-specific dermatologic/hormonal agent |
6. Main Uses / Indications | Dermatologic or hormonal indication according to the exact formulation. |
7. Mechanism / Basic Description | Ingredient-specific; use approved product labeling. |
8. Dosage Form & Route | Topical or oral depending on formulation. |
9. Prescription / OTC Status | Generally prescription/regulated medicine; exact status varies by jurisdiction. |
10. Major Warnings / Contraindications / Key Interactions | Pregnancy/reproductive warnings, systemic absorption, skin reactions and formulation-specific restrictions must be checked. |
11. India Export Considerations | Verify Indian manufacturing licence/product permission, GMP status, formulation authorization, exporter eligibility, labeling and destination-specific export documentation. |
12. HS Code / Customs Classification — TO BE VERIFIED | Do not assign a final HS/ITC-HS code from the medicine name alone. Confirm with the exact dosage form, packing and Indian customs classification. |
13. 26-Country Regulatory Status | Preliminary screen: 🟡 registration/authorization generally required in all 26 markets. Upgrade to 🟠/🔴/⚫ where the ingredient, formulation or destination law imposes special controls; exact status must be verified. |
14. Country Regulatory Authority | See the 26-country matrix at the beginning of this document; the responsible authority varies by destination. |
15. Registration / Marketing Authorization Requirements | Typically product dossier/quality data, manufacturing information, stability, labeling, local applicant/importer authorization and any country-specific clinical/bioequivalence or GMP evidence required. |
16. Export Requirements & Special Restrictions | Product-specific regulatory review required before export. |
17. Buyer Type | Licensed pharmaceutical importer/distributor/wholesaler; hospitals or institutional buyers where appropriate. Veterinary products require appropriately licensed animal-health buyers. |
18. Required Export / Regulatory Documentation | Commercial invoice; packing list; transport documents; certificate of origin where required; COA; GMP/manufacturing documents; product registration/authorization documents; import permit or controlled-drug permit where applicable. |
19. Commercial Considerations | Confirm MOQ, pack size, shelf life, lead time, private-label/OEM availability, registration ownership, Incoterm, freight, insurance, payment terms and landed cost before quotation. |
20. Exporter Decision / Verification Checklist | ☐ Exact product/formulation confirmed ☐ Manufacturer verified ☐ GMP verified ☐ Indian authorization verified ☐ Destination registration checked ☐ Importer licence checked ☐ Controlled/special status checked ☐ COA/stability documents checked ☐ HS code verified ☐ Buyer verified |
78. ANASTROZOLE TABLETS 1 MG
1. Medicine / Product Name | ANASTROZOLE TABLETS 1 MG |
2. Generic / API / Composition | ANASTROZOLE 1 MG — exact composition/API to be confirmed from manufacturer specification. |
3. Salt / Strength | Strength/salt as stated in the source where available; otherwise verify the exact product specification. |
4. Therapeutic Category | Hormonal / endocrine medicine |
5. Pharmacological / Drug Class | Hormonal pathway modulator |
6. Main Uses / Indications | Endocrine or oncology/fertility indication depending on ingredient. |
7. Mechanism / Basic Description | Ingredient-specific estrogen-receptor or aromatase pathway modulation. |
8. Dosage Form & Route | Route/formulation: verify from the exact product specification. |
9. Prescription / OTC Status | Generally prescription/regulated medicine; exact status varies by jurisdiction. |
10. Major Warnings / Contraindications / Key Interactions | Check official label for contraindications, interactions, pregnancy warnings, organ-function precautions and formulation-specific risks. |
11. India Export Considerations | Verify Indian manufacturing licence/product permission, GMP status, formulation authorization, exporter eligibility, labeling and destination-specific export documentation. |
12. HS Code / Customs Classification — TO BE VERIFIED | Do not assign a final HS/ITC-HS code from the medicine name alone. Confirm with the exact dosage form, packing and Indian customs classification. |
13. 26-Country Regulatory Status | Preliminary screen: 🟡 registration/authorization generally required in all 26 markets. Upgrade to 🟠/🔴/⚫ where the ingredient, formulation or destination law imposes special controls; exact status must be verified. |
14. Country Regulatory Authority | See the 26-country matrix at the beginning of this document; the responsible authority varies by destination. |
15. Registration / Marketing Authorization Requirements | Typically product dossier/quality data, manufacturing information, stability, labeling, local applicant/importer authorization and any country-specific clinical/bioequivalence or GMP evidence required. |
16. Export Requirements & Special Restrictions | Hormonal/oncology regulatory review may apply. |
17. Buyer Type | Licensed pharmaceutical importer/distributor/wholesaler; hospitals or institutional buyers where appropriate. Veterinary products require appropriately licensed animal-health buyers. |
18. Required Export / Regulatory Documentation | Commercial invoice; packing list; transport documents; certificate of origin where required; COA; GMP/manufacturing documents; product registration/authorization documents; import permit or controlled-drug permit where applicable. |
19. Commercial Considerations | Confirm MOQ, pack size, shelf life, lead time, private-label/OEM availability, registration ownership, Incoterm, freight, insurance, payment terms and landed cost before quotation. |
20. Exporter Decision / Verification Checklist | ☐ Exact product/formulation confirmed ☐ Manufacturer verified ☐ GMP verified ☐ Indian authorization verified ☐ Destination registration checked ☐ Importer licence checked ☐ Controlled/special status checked ☐ COA/stability documents checked ☐ HS code verified ☐ Buyer verified |
79. MEMANTINE HYDROCHLORIDE TABLETS I P 5 MG
1. Medicine / Product Name | MEMANTINE HYDROCHLORIDE TABLETS I P 5 MG |
2. Generic / API / Composition | MEMANTINE HYDROCHLORIDE I P 5 MG — exact composition/API to be confirmed from manufacturer specification. |
3. Salt / Strength | Strength/salt as stated in the source where available; otherwise verify the exact product specification. |
4. Therapeutic Category | Neurological medicine |
5. Pharmacological / Drug Class | Ingredient-specific CNS agent |
6. Main Uses / Indications | Neurological indication according to the approved product. |
7. Mechanism / Basic Description | Ingredient-specific CNS mechanism. |
8. Dosage Form & Route | Route/formulation: verify from the exact product specification. |
9. Prescription / OTC Status | Generally prescription/regulated medicine; exact status varies by jurisdiction. |
10. Major Warnings / Contraindications / Key Interactions | Check official label for contraindications, interactions, pregnancy warnings, organ-function precautions and formulation-specific risks. |
11. India Export Considerations | Verify Indian manufacturing licence/product permission, GMP status, formulation authorization, exporter eligibility, labeling and destination-specific export documentation. |
12. HS Code / Customs Classification — TO BE VERIFIED | Do not assign a final HS/ITC-HS code from the medicine name alone. Confirm with the exact dosage form, packing and Indian customs classification. |
13. 26-Country Regulatory Status | Preliminary screen: 🟡 registration/authorization generally required in all 26 markets. Upgrade to 🟠/🔴/⚫ where the ingredient, formulation or destination law imposes special controls; exact status must be verified. |
14. Country Regulatory Authority | See the 26-country matrix at the beginning of this document; the responsible authority varies by destination. |
15. Registration / Marketing Authorization Requirements | Typically product dossier/quality data, manufacturing information, stability, labeling, local applicant/importer authorization and any country-specific clinical/bioequivalence or GMP evidence required. |
16. Export Requirements & Special Restrictions | Product-specific regulatory review required before export. |
17. Buyer Type | Licensed pharmaceutical importer/distributor/wholesaler; hospitals or institutional buyers where appropriate. Veterinary products require appropriately licensed animal-health buyers. |
18. Required Export / Regulatory Documentation | Commercial invoice; packing list; transport documents; certificate of origin where required; COA; GMP/manufacturing documents; product registration/authorization documents; import permit or controlled-drug permit where applicable. |
19. Commercial Considerations | Confirm MOQ, pack size, shelf life, lead time, private-label/OEM availability, registration ownership, Incoterm, freight, insurance, payment terms and landed cost before quotation. |
20. Exporter Decision / Verification Checklist | ☐ Exact product/formulation confirmed ☐ Manufacturer verified ☐ GMP verified ☐ Indian authorization verified ☐ Destination registration checked ☐ Importer licence checked ☐ Controlled/special status checked ☐ COA/stability documents checked ☐ HS code verified ☐ Buyer verified |
80. MODAFINIL TABLETS USP 400 MG
1. Medicine / Product Name | MODAFINIL TABLETS USP 400 MG |
2. Generic / API / Composition | MODAFINIL USP 400 MG — exact composition/API to be confirmed from manufacturer specification. |
3. Salt / Strength | Strength/salt as stated in the source where available; otherwise verify the exact product specification. |
4. Therapeutic Category | CNS / neurological / psychiatric medicine |
5. Pharmacological / Drug Class | Central nervous system active medicine |
6. Main Uses / Indications | Indication depends on the active ingredient; verify approved indication. |
7. Mechanism / Basic Description | CNS mechanism is ingredient-specific. |
8. Dosage Form & Route | Route/formulation: verify from the exact product specification. |
9. Prescription / OTC Status | Prescription; controlled/psychotropic status must be checked country by country. |
10. Major Warnings / Contraindications / Key Interactions | CNS effects, interactions, dependence/misuse potential where applicable and local controlled-drug status require review. |
11. India Export Considerations | Verify Indian manufacturing licence/product permission, GMP status, formulation authorization, exporter eligibility, labeling and destination-specific export documentation. |
12. HS Code / Customs Classification — TO BE VERIFIED | Do not assign a final HS/ITC-HS code from the medicine name alone. Confirm with the exact dosage form, packing and Indian customs classification. |
13. 26-Country Regulatory Status | Preliminary screen: 🟡 registration/authorization generally required in all 26 markets. Upgrade to 🟠/🔴/⚫ where the ingredient, formulation or destination law imposes special controls; exact status must be verified. |
14. Country Regulatory Authority | See the 26-country matrix at the beginning of this document; the responsible authority varies by destination. |
15. Registration / Marketing Authorization Requirements | Typically product dossier/quality data, manufacturing information, stability, labeling, local applicant/importer authorization and any country-specific clinical/bioequivalence or GMP evidence required. |
16. Export Requirements & Special Restrictions | High-priority destination-country classification check. Controlled/psychotropic/hormonal classification must be checked separately in each destination. |
17. Buyer Type | Licensed pharmaceutical importer/distributor/wholesaler; hospitals or institutional buyers where appropriate. Veterinary products require appropriately licensed animal-health buyers. |
18. Required Export / Regulatory Documentation | Commercial invoice; packing list; transport documents; certificate of origin where required; COA; GMP/manufacturing documents; product registration/authorization documents; import permit or controlled-drug permit where applicable. |
19. Commercial Considerations | Confirm MOQ, pack size, shelf life, lead time, private-label/OEM availability, registration ownership, Incoterm, freight, insurance, payment terms and landed cost before quotation. |
20. Exporter Decision / Verification Checklist | ☐ Exact product/formulation confirmed ☐ Manufacturer verified ☐ GMP verified ☐ Indian authorization verified ☐ Destination registration checked ☐ Importer licence checked ☐ Controlled/special status checked ☐ COA/stability documents checked ☐ HS code verified ☐ Buyer verified |
81. HYDROXYZINE HYDROCHLORIDE SUSTAINED RELEASE TABLETS 50 MG
1. Medicine / Product Name | HYDROXYZINE HYDROCHLORIDE SUSTAINED RELEASE TABLETS 50 MG |
2. Generic / API / Composition | HYDROXYZINE HYDROCHLORIDE SUSTAINED RELEASE 50 MG — exact composition/API to be confirmed from manufacturer specification. |
3. Salt / Strength | Strength/salt as stated in the source where available; otherwise verify the exact product specification. |
4. Therapeutic Category | Antihistamine / allergy medicine |
5. Pharmacological / Drug Class | Antihistamine; ingredient-specific additional activity |
6. Main Uses / Indications | Allergic or other approved indications. |
7. Mechanism / Basic Description | Primarily H1-histamine receptor antagonism. |
8. Dosage Form & Route | Route/formulation: verify from the exact product specification. |
9. Prescription / OTC Status | Generally prescription/regulated medicine; exact status varies by jurisdiction. |
10. Major Warnings / Contraindications / Key Interactions | Check official label for contraindications, interactions, pregnancy warnings, organ-function precautions and formulation-specific risks. |
11. India Export Considerations | Verify Indian manufacturing licence/product permission, GMP status, formulation authorization, exporter eligibility, labeling and destination-specific export documentation. |
12. HS Code / Customs Classification — TO BE VERIFIED | Do not assign a final HS/ITC-HS code from the medicine name alone. Confirm with the exact dosage form, packing and Indian customs classification. |
13. 26-Country Regulatory Status | Preliminary screen: 🟡 registration/authorization generally required in all 26 markets. Upgrade to 🟠/🔴/⚫ where the ingredient, formulation or destination law imposes special controls; exact status must be verified. |
14. Country Regulatory Authority | See the 26-country matrix at the beginning of this document; the responsible authority varies by destination. |
15. Registration / Marketing Authorization Requirements | Typically product dossier/quality data, manufacturing information, stability, labeling, local applicant/importer authorization and any country-specific clinical/bioequivalence or GMP evidence required. |
16. Export Requirements & Special Restrictions | Product-specific regulatory review required before export. |
17. Buyer Type | Licensed pharmaceutical importer/distributor/wholesaler; hospitals or institutional buyers where appropriate. Veterinary products require appropriately licensed animal-health buyers. |
18. Required Export / Regulatory Documentation | Commercial invoice; packing list; transport documents; certificate of origin where required; COA; GMP/manufacturing documents; product registration/authorization documents; import permit or controlled-drug permit where applicable. |
19. Commercial Considerations | Confirm MOQ, pack size, shelf life, lead time, private-label/OEM availability, registration ownership, Incoterm, freight, insurance, payment terms and landed cost before quotation. |
20. Exporter Decision / Verification Checklist | ☐ Exact product/formulation confirmed ☐ Manufacturer verified ☐ GMP verified ☐ Indian authorization verified ☐ Destination registration checked ☐ Importer licence checked ☐ Controlled/special status checked ☐ COA/stability documents checked ☐ HS code verified ☐ Buyer verified |
82. MELATONIN 20 MG TABLETS
1. Medicine / Product Name | MELATONIN 20 MG TABLETS |
2. Generic / API / Composition | MELATONIN 20 MG — exact composition/API to be confirmed from manufacturer specification. |
3. Salt / Strength | Strength/salt as stated in the source where available; otherwise verify the exact product specification. |
4. Therapeutic Category | Sleep/circadian medicine |
5. Pharmacological / Drug Class | Melatonin receptor agonist/hormone |
6. Main Uses / Indications | Sleep/circadian indications vary substantially by jurisdiction. |
7. Mechanism / Basic Description | Acts at melatonin receptors involved in circadian regulation. |
8. Dosage Form & Route | Route/formulation: verify from the exact product specification. |
9. Prescription / OTC Status | OTC, supplement or prescription status varies by country and dose. |
10. Major Warnings / Contraindications / Key Interactions | Check official label for contraindications, interactions, pregnancy warnings, organ-function precautions and formulation-specific risks. |
11. India Export Considerations | Verify Indian manufacturing licence/product permission, GMP status, formulation authorization, exporter eligibility, labeling and destination-specific export documentation. |
12. HS Code / Customs Classification — TO BE VERIFIED | Do not assign a final HS/ITC-HS code from the medicine name alone. Confirm with the exact dosage form, packing and Indian customs classification. |
13. 26-Country Regulatory Status | Preliminary screen: 🟡 registration/authorization generally required in all 26 markets. Upgrade to 🟠/🔴/⚫ where the ingredient, formulation or destination law imposes special controls; exact status must be verified. |
14. Country Regulatory Authority | See the 26-country matrix at the beginning of this document; the responsible authority varies by destination. |
15. Registration / Marketing Authorization Requirements | Typically product dossier/quality data, manufacturing information, stability, labeling, local applicant/importer authorization and any country-specific clinical/bioequivalence or GMP evidence required. |
16. Export Requirements & Special Restrictions | Product-specific regulatory review required before export. |
17. Buyer Type | Licensed pharmaceutical importer/distributor/wholesaler; hospitals or institutional buyers where appropriate. Veterinary products require appropriately licensed animal-health buyers. |
18. Required Export / Regulatory Documentation | Commercial invoice; packing list; transport documents; certificate of origin where required; COA; GMP/manufacturing documents; product registration/authorization documents; import permit or controlled-drug permit where applicable. |
19. Commercial Considerations | Confirm MOQ, pack size, shelf life, lead time, private-label/OEM availability, registration ownership, Incoterm, freight, insurance, payment terms and landed cost before quotation. |
20. Exporter Decision / Verification Checklist | ☐ Exact product/formulation confirmed ☐ Manufacturer verified ☐ GMP verified ☐ Indian authorization verified ☐ Destination registration checked ☐ Importer licence checked ☐ Controlled/special status checked ☐ COA/stability documents checked ☐ HS code verified ☐ Buyer verified |
83. BUSPIRONE HYDROCHLORIDE TABLES I P 10 MG
1. Medicine / Product Name | BUSPIRONE HYDROCHLORIDE TABLES I P 10 MG |
2. Generic / API / Composition | BUSPIRONE HYDROCHLORIDE TABLES I P 10 MG — exact composition/API to be confirmed from manufacturer specification. |
3. Salt / Strength | Strength/salt as stated in the source where available; otherwise verify the exact product specification. |
4. Therapeutic Category | CNS / neurological / psychiatric medicine |
5. Pharmacological / Drug Class | Central nervous system active medicine |
6. Main Uses / Indications | Indication depends on the active ingredient; verify approved indication. |
7. Mechanism / Basic Description | CNS mechanism is ingredient-specific. |
8. Dosage Form & Route | Route/formulation: verify from the exact product specification. |
9. Prescription / OTC Status | Prescription; controlled/psychotropic status must be checked country by country. |
10. Major Warnings / Contraindications / Key Interactions | CNS effects, interactions, dependence/misuse potential where applicable and local controlled-drug status require review. |
11. India Export Considerations | Verify Indian manufacturing licence/product permission, GMP status, formulation authorization, exporter eligibility, labeling and destination-specific export documentation. |
12. HS Code / Customs Classification — TO BE VERIFIED | Do not assign a final HS/ITC-HS code from the medicine name alone. Confirm with the exact dosage form, packing and Indian customs classification. |
13. 26-Country Regulatory Status | Preliminary screen: 🟡 registration/authorization generally required in all 26 markets. Upgrade to 🟠/🔴/⚫ where the ingredient, formulation or destination law imposes special controls; exact status must be verified. |
14. Country Regulatory Authority | See the 26-country matrix at the beginning of this document; the responsible authority varies by destination. |
15. Registration / Marketing Authorization Requirements | Typically product dossier/quality data, manufacturing information, stability, labeling, local applicant/importer authorization and any country-specific clinical/bioequivalence or GMP evidence required. |
16. Export Requirements & Special Restrictions | High-priority destination-country classification check. |
17. Buyer Type | Licensed pharmaceutical importer/distributor/wholesaler; hospitals or institutional buyers where appropriate. Veterinary products require appropriately licensed animal-health buyers. |
18. Required Export / Regulatory Documentation | Commercial invoice; packing list; transport documents; certificate of origin where required; COA; GMP/manufacturing documents; product registration/authorization documents; import permit or controlled-drug permit where applicable. |
19. Commercial Considerations | Confirm MOQ, pack size, shelf life, lead time, private-label/OEM availability, registration ownership, Incoterm, freight, insurance, payment terms and landed cost before quotation. |
20. Exporter Decision / Verification Checklist | ☐ Exact product/formulation confirmed ☐ Manufacturer verified ☐ GMP verified ☐ Indian authorization verified ☐ Destination registration checked ☐ Importer licence checked ☐ Controlled/special status checked ☐ COA/stability documents checked ☐ HS code verified ☐ Buyer verified |
84. SILDENAFIL ORAL JELLY 100 MG
1. Medicine / Product Name | SILDENAFIL ORAL JELLY 100 MG |
2. Generic / API / Composition | SILDENAFIL ORAL JELLY 100 MG — exact composition/API to be confirmed from manufacturer specification. |
3. Salt / Strength | Strength/salt as stated in the source where available; otherwise verify the exact product specification. |
4. Therapeutic Category | Genitourinary / erectile-dysfunction medicine |
5. Pharmacological / Drug Class | PDE-5 inhibitor |
6. Main Uses / Indications | Treatment of erectile dysfunction; exact indications vary by product and market. |
7. Mechanism / Basic Description | Inhibits PDE-5, increasing cGMP-mediated smooth-muscle relaxation. |
8. Dosage Form & Route | Oral; exact formulation (tablet/jelly/etc.) must be verified. |
9. Prescription / OTC Status | Generally prescription/regulated medicine; exact status varies by jurisdiction. |
10. Major Warnings / Contraindications / Key Interactions | Nitrates/riociguat and cardiovascular conditions require particular attention; formulation and local labeling must be checked. |
11. India Export Considerations | Verify Indian manufacturing licence/product permission, GMP status, formulation authorization, exporter eligibility, labeling and destination-specific export documentation. |
12. HS Code / Customs Classification — TO BE VERIFIED | Do not assign a final HS/ITC-HS code from the medicine name alone. Confirm with the exact dosage form, packing and Indian customs classification. |
13. 26-Country Regulatory Status | Preliminary screen: 🟡 registration/authorization generally required in all 26 markets. Upgrade to 🟠/🔴/⚫ where the ingredient, formulation or destination law imposes special controls; exact status must be verified. |
14. Country Regulatory Authority | See the 26-country matrix at the beginning of this document; the responsible authority varies by destination. |
15. Registration / Marketing Authorization Requirements | Typically product dossier/quality data, manufacturing information, stability, labeling, local applicant/importer authorization and any country-specific clinical/bioequivalence or GMP evidence required. |
16. Export Requirements & Special Restrictions | Product-specific regulatory review required before export. |
17. Buyer Type | Licensed pharmaceutical importer/distributor/wholesaler; hospitals or institutional buyers where appropriate. Veterinary products require appropriately licensed animal-health buyers. |
18. Required Export / Regulatory Documentation | Commercial invoice; packing list; transport documents; certificate of origin where required; COA; GMP/manufacturing documents; product registration/authorization documents; import permit or controlled-drug permit where applicable. |
19. Commercial Considerations | Confirm MOQ, pack size, shelf life, lead time, private-label/OEM availability, registration ownership, Incoterm, freight, insurance, payment terms and landed cost before quotation. |
20. Exporter Decision / Verification Checklist | ☐ Exact product/formulation confirmed ☐ Manufacturer verified ☐ GMP verified ☐ Indian authorization verified ☐ Destination registration checked ☐ Importer licence checked ☐ Controlled/special status checked ☐ COA/stability documents checked ☐ HS code verified ☐ Buyer verified |
85. SILDENAFIL 100 MG AND DAPOXETINE 60 MG ORAL JELLY
1. Medicine / Product Name | SILDENAFIL 100 MG AND DAPOXETINE 60 MG ORAL JELLY |
2. Generic / API / Composition | SILDENAFIL 100 MG AND DAPOXETINE 60 MG ORAL JELLY — exact composition/API to be confirmed from manufacturer specification. |
3. Salt / Strength | Strength/salt as stated in the source where available; otherwise verify the exact product specification. |
4. Therapeutic Category | Genitourinary / erectile-dysfunction medicine |
5. Pharmacological / Drug Class | PDE-5 inhibitor |
6. Main Uses / Indications | Treatment of erectile dysfunction; exact indications vary by product and market. |
7. Mechanism / Basic Description | Inhibits PDE-5, increasing cGMP-mediated smooth-muscle relaxation. |
8. Dosage Form & Route | Oral; exact formulation (tablet/jelly/etc.) must be verified. |
9. Prescription / OTC Status | Generally prescription/regulated medicine; exact status varies by jurisdiction. |
10. Major Warnings / Contraindications / Key Interactions | Nitrates/riociguat and cardiovascular conditions require particular attention; formulation and local labeling must be checked. |
11. India Export Considerations | Verify Indian manufacturing licence/product permission, GMP status, formulation authorization, exporter eligibility, labeling and destination-specific export documentation. |
12. HS Code / Customs Classification — TO BE VERIFIED | Do not assign a final HS/ITC-HS code from the medicine name alone. Confirm with the exact dosage form, packing and Indian customs classification. |
13. 26-Country Regulatory Status | Preliminary screen: 🟡 registration/authorization generally required in all 26 markets. Upgrade to 🟠/🔴/⚫ where the ingredient, formulation or destination law imposes special controls; exact status must be verified. |
14. Country Regulatory Authority | See the 26-country matrix at the beginning of this document; the responsible authority varies by destination. |
15. Registration / Marketing Authorization Requirements | Typically product dossier/quality data, manufacturing information, stability, labeling, local applicant/importer authorization and any country-specific clinical/bioequivalence or GMP evidence required. |
16. Export Requirements & Special Restrictions | Product-specific regulatory review required before export. |
17. Buyer Type | Licensed pharmaceutical importer/distributor/wholesaler; hospitals or institutional buyers where appropriate. Veterinary products require appropriately licensed animal-health buyers. |
18. Required Export / Regulatory Documentation | Commercial invoice; packing list; transport documents; certificate of origin where required; COA; GMP/manufacturing documents; product registration/authorization documents; import permit or controlled-drug permit where applicable. |
19. Commercial Considerations | Confirm MOQ, pack size, shelf life, lead time, private-label/OEM availability, registration ownership, Incoterm, freight, insurance, payment terms and landed cost before quotation. |
20. Exporter Decision / Verification Checklist | ☐ Exact product/formulation confirmed ☐ Manufacturer verified ☐ GMP verified ☐ Indian authorization verified ☐ Destination registration checked ☐ Importer licence checked ☐ Controlled/special status checked ☐ COA/stability documents checked ☐ HS code verified ☐ Buyer verified |
86. ROSUVASTATIN TABLESTS IP
1. Medicine / Product Name | ROSUVASTATIN TABLESTS IP |
2. Generic / API / Composition | ROSUVASTATIN TABLESTS IP — exact composition/API to be confirmed from manufacturer specification. |
3. Salt / Strength | Strength/salt as stated in the source where available; otherwise verify the exact product specification. |
4. Therapeutic Category | Cardiometabolic medicine |
5. Pharmacological / Drug Class | Ingredient-specific metabolic/cardiovascular agent |
6. Main Uses / Indications | Cardiovascular, lipid or glucose-management indication according to the exact ingredient. |
7. Mechanism / Basic Description | Ingredient-specific; verify official label. |
8. Dosage Form & Route | Usually oral, except formulation-specific products. |
9. Prescription / OTC Status | Generally prescription/regulated medicine; exact status varies by jurisdiction. |
10. Major Warnings / Contraindications / Key Interactions | Check official label for contraindications, interactions, pregnancy warnings, organ-function precautions and formulation-specific risks. |
11. India Export Considerations | Verify Indian manufacturing licence/product permission, GMP status, formulation authorization, exporter eligibility, labeling and destination-specific export documentation. |
12. HS Code / Customs Classification — TO BE VERIFIED | Do not assign a final HS/ITC-HS code from the medicine name alone. Confirm with the exact dosage form, packing and Indian customs classification. |
13. 26-Country Regulatory Status | Preliminary screen: 🟡 registration/authorization generally required in all 26 markets. Upgrade to 🟠/🔴/⚫ where the ingredient, formulation or destination law imposes special controls; exact status must be verified. |
14. Country Regulatory Authority | See the 26-country matrix at the beginning of this document; the responsible authority varies by destination. |
15. Registration / Marketing Authorization Requirements | Typically product dossier/quality data, manufacturing information, stability, labeling, local applicant/importer authorization and any country-specific clinical/bioequivalence or GMP evidence required. |
16. Export Requirements & Special Restrictions | Product-specific regulatory review required before export. |
17. Buyer Type | Licensed pharmaceutical importer/distributor/wholesaler; hospitals or institutional buyers where appropriate. Veterinary products require appropriately licensed animal-health buyers. |
18. Required Export / Regulatory Documentation | Commercial invoice; packing list; transport documents; certificate of origin where required; COA; GMP/manufacturing documents; product registration/authorization documents; import permit or controlled-drug permit where applicable. |
19. Commercial Considerations | Confirm MOQ, pack size, shelf life, lead time, private-label/OEM availability, registration ownership, Incoterm, freight, insurance, payment terms and landed cost before quotation. |
20. Exporter Decision / Verification Checklist | ☐ Exact product/formulation confirmed ☐ Manufacturer verified ☐ GMP verified ☐ Indian authorization verified ☐ Destination registration checked ☐ Importer licence checked ☐ Controlled/special status checked ☐ COA/stability documents checked ☐ HS code verified ☐ Buyer verified |
87. LEVOCARNITINE INJECTION USP
1. Medicine / Product Name | LEVOCARNITINE INJECTION USP |
2. Generic / API / Composition | LEVOCARNITINE USP — exact composition/API to be confirmed from manufacturer specification. |
3. Salt / Strength | Strength/salt as stated in the source where available; otherwise verify the exact product specification. |
4. Therapeutic Category | Nutritional / metabolic supportive product |
5. Pharmacological / Drug Class | Vitamin, amino-acid derivative or antioxidant — ingredient-specific |
6. Main Uses / Indications | Indication varies by ingredient and approved formulation. |
7. Mechanism / Basic Description | Biochemical role is ingredient-specific. |
8. Dosage Form & Route | Route/formulation: verify from the exact product specification. |
9. Prescription / OTC Status | Generally prescription/regulated medicine; exact status varies by jurisdiction. |
10. Major Warnings / Contraindications / Key Interactions | Check official label for contraindications, interactions, pregnancy warnings, organ-function precautions and formulation-specific risks. |
11. India Export Considerations | Verify Indian manufacturing licence/product permission, GMP status, formulation authorization, exporter eligibility, labeling and destination-specific export documentation. |
12. HS Code / Customs Classification — TO BE VERIFIED | Do not assign a final HS/ITC-HS code from the medicine name alone. Confirm with the exact dosage form, packing and Indian customs classification. |
13. 26-Country Regulatory Status | Preliminary screen: 🟡 registration/authorization generally required in all 26 markets. Upgrade to 🟠/🔴/⚫ where the ingredient, formulation or destination law imposes special controls; exact status must be verified. |
14. Country Regulatory Authority | See the 26-country matrix at the beginning of this document; the responsible authority varies by destination. |
15. Registration / Marketing Authorization Requirements | Typically product dossier/quality data, manufacturing information, stability, labeling, local applicant/importer authorization and any country-specific clinical/bioequivalence or GMP evidence required. |
16. Export Requirements & Special Restrictions | Product-specific regulatory review required before export. Sterile/injectable or biologic quality, storage and manufacturing controls may apply. |
17. Buyer Type | Licensed pharmaceutical importer/distributor/wholesaler; hospitals or institutional buyers where appropriate. Veterinary products require appropriately licensed animal-health buyers. |
18. Required Export / Regulatory Documentation | Commercial invoice; packing list; transport documents; certificate of origin where required; COA; GMP/manufacturing documents; product registration/authorization documents; import permit or controlled-drug permit where applicable. |
19. Commercial Considerations | Confirm MOQ, pack size, shelf life, lead time, private-label/OEM availability, registration ownership, Incoterm, freight, insurance, payment terms and landed cost before quotation. |
20. Exporter Decision / Verification Checklist | ☐ Exact product/formulation confirmed ☐ Manufacturer verified ☐ GMP verified ☐ Indian authorization verified ☐ Destination registration checked ☐ Importer licence checked ☐ Controlled/special status checked ☐ COA/stability documents checked ☐ HS code verified ☐ Buyer verified |
88. SEMAGLUTIDE TABLETS ORAL USE
1. Medicine / Product Name | SEMAGLUTIDE TABLETS ORAL USE |
2. Generic / API / Composition | SEMAGLUTIDE ORAL USE — exact composition/API to be confirmed from manufacturer specification. |
3. Salt / Strength | Strength/salt as stated in the source where available; otherwise verify the exact product specification. |
4. Therapeutic Category | Cardiometabolic medicine |
5. Pharmacological / Drug Class | Ingredient-specific metabolic/cardiovascular agent |
6. Main Uses / Indications | Cardiovascular, lipid or glucose-management indication according to the exact ingredient. |
7. Mechanism / Basic Description | Ingredient-specific; verify official label. |
8. Dosage Form & Route | Usually oral, except formulation-specific products. |
9. Prescription / OTC Status | Generally prescription/regulated medicine; exact status varies by jurisdiction. |
10. Major Warnings / Contraindications / Key Interactions | Check official label for contraindications, interactions, pregnancy warnings, organ-function precautions and formulation-specific risks. |
11. India Export Considerations | Verify Indian manufacturing licence/product permission, GMP status, formulation authorization, exporter eligibility, labeling and destination-specific export documentation. |
12. HS Code / Customs Classification — TO BE VERIFIED | Do not assign a final HS/ITC-HS code from the medicine name alone. Confirm with the exact dosage form, packing and Indian customs classification. |
13. 26-Country Regulatory Status | Preliminary screen: 🟡 registration/authorization generally required in all 26 markets. Upgrade to 🟠/🔴/⚫ where the ingredient, formulation or destination law imposes special controls; exact status must be verified. |
14. Country Regulatory Authority | See the 26-country matrix at the beginning of this document; the responsible authority varies by destination. |
15. Registration / Marketing Authorization Requirements | Typically product dossier/quality data, manufacturing information, stability, labeling, local applicant/importer authorization and any country-specific clinical/bioequivalence or GMP evidence required. |
16. Export Requirements & Special Restrictions | Product-specific regulatory review required before export. |
17. Buyer Type | Licensed pharmaceutical importer/distributor/wholesaler; hospitals or institutional buyers where appropriate. Veterinary products require appropriately licensed animal-health buyers. |
18. Required Export / Regulatory Documentation | Commercial invoice; packing list; transport documents; certificate of origin where required; COA; GMP/manufacturing documents; product registration/authorization documents; import permit or controlled-drug permit where applicable. |
19. Commercial Considerations | Confirm MOQ, pack size, shelf life, lead time, private-label/OEM availability, registration ownership, Incoterm, freight, insurance, payment terms and landed cost before quotation. |
20. Exporter Decision / Verification Checklist | ☐ Exact product/formulation confirmed ☐ Manufacturer verified ☐ GMP verified ☐ Indian authorization verified ☐ Destination registration checked ☐ Importer licence checked ☐ Controlled/special status checked ☐ COA/stability documents checked ☐ HS code verified ☐ Buyer verified |
Top Pharma Export Products from India Manufacturers Sellers Pharmaceutical Companies Medicine Buyers
89. DAPAGLIFLOZIN AND METFORMIN EXTENDED REALASE TABLETS 10 / 1000
1. Medicine / Product Name | DAPAGLIFLOZIN AND METFORMIN EXTENDED REALASE TABLETS 10 / 1000 |
2. Generic / API / Composition | DAPAGLIFLOZIN AND METFORMIN EXTENDED REALASE 10 / 1000 — exact composition/API to be confirmed from manufacturer specification. |
3. Salt / Strength | Strength/salt as stated in the source where available; otherwise verify the exact product specification. |
4. Therapeutic Category | Cardiometabolic medicine |
5. Pharmacological / Drug Class | Ingredient-specific metabolic/cardiovascular agent |
6. Main Uses / Indications | Cardiovascular, lipid or glucose-management indication according to the exact ingredient. |
7. Mechanism / Basic Description | Ingredient-specific; verify official label. |
8. Dosage Form & Route | Usually oral, except formulation-specific products. |
9. Prescription / OTC Status | Generally prescription/regulated medicine; exact status varies by jurisdiction. |
10. Major Warnings / Contraindications / Key Interactions | Check official label for contraindications, interactions, pregnancy warnings, organ-function precautions and formulation-specific risks. |
11. India Export Considerations | Verify Indian manufacturing licence/product permission, GMP status, formulation authorization, exporter eligibility, labeling and destination-specific export documentation. |
12. HS Code / Customs Classification — TO BE VERIFIED | Do not assign a final HS/ITC-HS code from the medicine name alone. Confirm with the exact dosage form, packing and Indian customs classification. |
13. 26-Country Regulatory Status | Preliminary screen: 🟡 registration/authorization generally required in all 26 markets. Upgrade to 🟠/🔴/⚫ where the ingredient, formulation or destination law imposes special controls; exact status must be verified. |
14. Country Regulatory Authority | See the 26-country matrix at the beginning of this document; the responsible authority varies by destination. |
15. Registration / Marketing Authorization Requirements | Typically product dossier/quality data, manufacturing information, stability, labeling, local applicant/importer authorization and any country-specific clinical/bioequivalence or GMP evidence required. |
16. Export Requirements & Special Restrictions | Product-specific regulatory review required before export. |
17. Buyer Type | Licensed pharmaceutical importer/distributor/wholesaler; hospitals or institutional buyers where appropriate. Veterinary products require appropriately licensed animal-health buyers. |
18. Required Export / Regulatory Documentation | Commercial invoice; packing list; transport documents; certificate of origin where required; COA; GMP/manufacturing documents; product registration/authorization documents; import permit or controlled-drug permit where applicable. |
19. Commercial Considerations | Confirm MOQ, pack size, shelf life, lead time, private-label/OEM availability, registration ownership, Incoterm, freight, insurance, payment terms and landed cost before quotation. |
20. Exporter Decision / Verification Checklist | ☐ Exact product/formulation confirmed ☐ Manufacturer verified ☐ GMP verified ☐ Indian authorization verified ☐ Destination registration checked ☐ Importer licence checked ☐ Controlled/special status checked ☐ COA/stability documents checked ☐ HS code verified ☐ Buyer verified |
90. EPLERENONE TABLETS IP 25 MG
1. Medicine / Product Name | EPLERENONE TABLETS IP 25 MG |
2. Generic / API / Composition | EPLERENONE IP 25 MG — exact composition/API to be confirmed from manufacturer specification. |
3. Salt / Strength | Strength/salt as stated in the source where available; otherwise verify the exact product specification. |
4. Therapeutic Category | Cardiometabolic medicine |
5. Pharmacological / Drug Class | Ingredient-specific metabolic/cardiovascular agent |
6. Main Uses / Indications | Cardiovascular, lipid or glucose-management indication according to the exact ingredient. |
7. Mechanism / Basic Description | Ingredient-specific; verify official label. |
8. Dosage Form & Route | Usually oral, except formulation-specific products. |
9. Prescription / OTC Status | Generally prescription/regulated medicine; exact status varies by jurisdiction. |
10. Major Warnings / Contraindications / Key Interactions | Check official label for contraindications, interactions, pregnancy warnings, organ-function precautions and formulation-specific risks. |
11. India Export Considerations | Verify Indian manufacturing licence/product permission, GMP status, formulation authorization, exporter eligibility, labeling and destination-specific export documentation. |
12. HS Code / Customs Classification — TO BE VERIFIED | Do not assign a final HS/ITC-HS code from the medicine name alone. Confirm with the exact dosage form, packing and Indian customs classification. |
13. 26-Country Regulatory Status | Preliminary screen: 🟡 registration/authorization generally required in all 26 markets. Upgrade to 🟠/🔴/⚫ where the ingredient, formulation or destination law imposes special controls; exact status must be verified. |
14. Country Regulatory Authority | See the 26-country matrix at the beginning of this document; the responsible authority varies by destination. |
15. Registration / Marketing Authorization Requirements | Typically product dossier/quality data, manufacturing information, stability, labeling, local applicant/importer authorization and any country-specific clinical/bioequivalence or GMP evidence required. |
16. Export Requirements & Special Restrictions | Product-specific regulatory review required before export. |
17. Buyer Type | Licensed pharmaceutical importer/distributor/wholesaler; hospitals or institutional buyers where appropriate. Veterinary products require appropriately licensed animal-health buyers. |
18. Required Export / Regulatory Documentation | Commercial invoice; packing list; transport documents; certificate of origin where required; COA; GMP/manufacturing documents; product registration/authorization documents; import permit or controlled-drug permit where applicable. |
19. Commercial Considerations | Confirm MOQ, pack size, shelf life, lead time, private-label/OEM availability, registration ownership, Incoterm, freight, insurance, payment terms and landed cost before quotation. |
20. Exporter Decision / Verification Checklist | ☐ Exact product/formulation confirmed ☐ Manufacturer verified ☐ GMP verified ☐ Indian authorization verified ☐ Destination registration checked ☐ Importer licence checked ☐ Controlled/special status checked ☐ COA/stability documents checked ☐ HS code verified ☐ Buyer verified |
91. METFORMIN HYDROCHLORIDE SUSTAINED RELEASE TABLETS IP
1. Medicine / Product Name | METFORMIN HYDROCHLORIDE SUSTAINED RELEASE TABLETS IP |
2. Generic / API / Composition | METFORMIN HYDROCHLORIDE SUSTAINED RELEASE IP — exact composition/API to be confirmed from manufacturer specification. |
3. Salt / Strength | Strength/salt as stated in the source where available; otherwise verify the exact product specification. |
4. Therapeutic Category | Cardiometabolic medicine |
5. Pharmacological / Drug Class | Ingredient-specific metabolic/cardiovascular agent |
6. Main Uses / Indications | Cardiovascular, lipid or glucose-management indication according to the exact ingredient. |
7. Mechanism / Basic Description | Ingredient-specific; verify official label. |
8. Dosage Form & Route | Usually oral, except formulation-specific products. |
9. Prescription / OTC Status | Generally prescription/regulated medicine; exact status varies by jurisdiction. |
10. Major Warnings / Contraindications / Key Interactions | Check official label for contraindications, interactions, pregnancy warnings, organ-function precautions and formulation-specific risks. |
11. India Export Considerations | Verify Indian manufacturing licence/product permission, GMP status, formulation authorization, exporter eligibility, labeling and destination-specific export documentation. |
12. HS Code / Customs Classification — TO BE VERIFIED | Do not assign a final HS/ITC-HS code from the medicine name alone. Confirm with the exact dosage form, packing and Indian customs classification. |
13. 26-Country Regulatory Status | Preliminary screen: 🟡 registration/authorization generally required in all 26 markets. Upgrade to 🟠/🔴/⚫ where the ingredient, formulation or destination law imposes special controls; exact status must be verified. |
14. Country Regulatory Authority | See the 26-country matrix at the beginning of this document; the responsible authority varies by destination. |
15. Registration / Marketing Authorization Requirements | Typically product dossier/quality data, manufacturing information, stability, labeling, local applicant/importer authorization and any country-specific clinical/bioequivalence or GMP evidence required. |
16. Export Requirements & Special Restrictions | Product-specific regulatory review required before export. |
17. Buyer Type | Licensed pharmaceutical importer/distributor/wholesaler; hospitals or institutional buyers where appropriate. Veterinary products require appropriately licensed animal-health buyers. |
18. Required Export / Regulatory Documentation | Commercial invoice; packing list; transport documents; certificate of origin where required; COA; GMP/manufacturing documents; product registration/authorization documents; import permit or controlled-drug permit where applicable. |
19. Commercial Considerations | Confirm MOQ, pack size, shelf life, lead time, private-label/OEM availability, registration ownership, Incoterm, freight, insurance, payment terms and landed cost before quotation. |
20. Exporter Decision / Verification Checklist | ☐ Exact product/formulation confirmed ☐ Manufacturer verified ☐ GMP verified ☐ Indian authorization verified ☐ Destination registration checked ☐ Importer licence checked ☐ Controlled/special status checked ☐ COA/stability documents checked ☐ HS code verified ☐ Buyer verified |
92. MEBENDAZOLE TABLETS USP 500 MG
1. Medicine / Product Name | MEBENDAZOLE TABLETS USP 500 MG |
2. Generic / API / Composition | MEBENDAZOLE USP 500 MG — exact composition/API to be confirmed from manufacturer specification. |
3. Salt / Strength | Strength/salt as stated in the source where available; otherwise verify the exact product specification. |
4. Therapeutic Category | Anti-infective / antiparasitic medicine |
5. Pharmacological / Drug Class | Antibacterial, antiprotozoal or antiparasitic — ingredient-specific |
6. Main Uses / Indications | Treatment of susceptible infections/parasitoses according to the approved indication. |
7. Mechanism / Basic Description | Ingredient-specific antimicrobial/antiparasitic mechanism. |
8. Dosage Form & Route | Oral or other formulation-specific route. |
9. Prescription / OTC Status | Generally prescription/regulated medicine; exact status varies by jurisdiction. |
10. Major Warnings / Contraindications / Key Interactions | Allergy, interactions, resistance/appropriate-use restrictions and indication-specific precautions require label review. |
11. India Export Considerations | Verify Indian manufacturing licence/product permission, GMP status, formulation authorization, exporter eligibility, labeling and destination-specific export documentation. |
12. HS Code / Customs Classification — TO BE VERIFIED | Do not assign a final HS/ITC-HS code from the medicine name alone. Confirm with the exact dosage form, packing and Indian customs classification. |
13. 26-Country Regulatory Status | Preliminary screen: 🟡 registration/authorization generally required in all 26 markets. Upgrade to 🟠/🔴/⚫ where the ingredient, formulation or destination law imposes special controls; exact status must be verified. |
14. Country Regulatory Authority | See the 26-country matrix at the beginning of this document; the responsible authority varies by destination. |
15. Registration / Marketing Authorization Requirements | Typically product dossier/quality data, manufacturing information, stability, labeling, local applicant/importer authorization and any country-specific clinical/bioequivalence or GMP evidence required. |
16. Export Requirements & Special Restrictions | Product-specific regulatory review required before export. |
17. Buyer Type | Licensed pharmaceutical importer/distributor/wholesaler; hospitals or institutional buyers where appropriate. Veterinary products require appropriately licensed animal-health buyers. |
18. Required Export / Regulatory Documentation | Commercial invoice; packing list; transport documents; certificate of origin where required; COA; GMP/manufacturing documents; product registration/authorization documents; import permit or controlled-drug permit where applicable. |
19. Commercial Considerations | Confirm MOQ, pack size, shelf life, lead time, private-label/OEM availability, registration ownership, Incoterm, freight, insurance, payment terms and landed cost before quotation. |
20. Exporter Decision / Verification Checklist | ☐ Exact product/formulation confirmed ☐ Manufacturer verified ☐ GMP verified ☐ Indian authorization verified ☐ Destination registration checked ☐ Importer licence checked ☐ Controlled/special status checked ☐ COA/stability documents checked ☐ HS code verified ☐ Buyer verified |
93. SELEGILINE HYDROCHLORIDE TABLETS IP 5 MG
1. Medicine / Product Name | SELEGILINE HYDROCHLORIDE TABLETS IP 5 MG |
2. Generic / API / Composition | SELEGILINE HYDROCHLORIDE IP 5 MG — exact composition/API to be confirmed from manufacturer specification. |
3. Salt / Strength | Strength/salt as stated in the source where available; otherwise verify the exact product specification. |
4. Therapeutic Category | CNS / neurological / psychiatric medicine |
5. Pharmacological / Drug Class | Central nervous system active medicine |
6. Main Uses / Indications | Indication depends on the active ingredient; verify approved indication. |
7. Mechanism / Basic Description | CNS mechanism is ingredient-specific. |
8. Dosage Form & Route | Route/formulation: verify from the exact product specification. |
9. Prescription / OTC Status | Prescription; controlled/psychotropic status must be checked country by country. |
10. Major Warnings / Contraindications / Key Interactions | CNS effects, interactions, dependence/misuse potential where applicable and local controlled-drug status require review. |
11. India Export Considerations | Verify Indian manufacturing licence/product permission, GMP status, formulation authorization, exporter eligibility, labeling and destination-specific export documentation. |
12. HS Code / Customs Classification — TO BE VERIFIED | Do not assign a final HS/ITC-HS code from the medicine name alone. Confirm with the exact dosage form, packing and Indian customs classification. |
13. 26-Country Regulatory Status | Preliminary screen: 🟡 registration/authorization generally required in all 26 markets. Upgrade to 🟠/🔴/⚫ where the ingredient, formulation or destination law imposes special controls; exact status must be verified. |
14. Country Regulatory Authority | See the 26-country matrix at the beginning of this document; the responsible authority varies by destination. |
15. Registration / Marketing Authorization Requirements | Typically product dossier/quality data, manufacturing information, stability, labeling, local applicant/importer authorization and any country-specific clinical/bioequivalence or GMP evidence required. |
16. Export Requirements & Special Restrictions | High-priority destination-country classification check. |
17. Buyer Type | Licensed pharmaceutical importer/distributor/wholesaler; hospitals or institutional buyers where appropriate. Veterinary products require appropriately licensed animal-health buyers. |
18. Required Export / Regulatory Documentation | Commercial invoice; packing list; transport documents; certificate of origin where required; COA; GMP/manufacturing documents; product registration/authorization documents; import permit or controlled-drug permit where applicable. |
19. Commercial Considerations | Confirm MOQ, pack size, shelf life, lead time, private-label/OEM availability, registration ownership, Incoterm, freight, insurance, payment terms and landed cost before quotation. |
20. Exporter Decision / Verification Checklist | ☐ Exact product/formulation confirmed ☐ Manufacturer verified ☐ GMP verified ☐ Indian authorization verified ☐ Destination registration checked ☐ Importer licence checked ☐ Controlled/special status checked ☐ COA/stability documents checked ☐ HS code verified ☐ Buyer verified |
94. FENBENDAZOLE TABLETS 1000 MG
1. Medicine / Product Name | FENBENDAZOLE TABLETS 1000 MG |
2. Generic / API / Composition | FENBENDAZOLE 1000 MG — exact composition/API to be confirmed from manufacturer specification. |
3. Salt / Strength | Strength/salt as stated in the source where available; otherwise verify the exact product specification. |
4. Therapeutic Category | Veterinary anthelmintic |
5. Pharmacological / Drug Class | Benzimidazole anthelmintic |
6. Main Uses / Indications | Veterinary parasite control; human use is not automatically authorized. |
7. Mechanism / Basic Description | Disrupts parasite microtubule function. |
8. Dosage Form & Route | Route/formulation: verify from the exact product specification. |
9. Prescription / OTC Status | Veterinary/animal-health regulatory status depends on country. |
10. Major Warnings / Contraindications / Key Interactions | Check official label for contraindications, interactions, pregnancy warnings, organ-function precautions and formulation-specific risks. |
11. India Export Considerations | Verify Indian manufacturing licence/product permission, GMP status, formulation authorization, exporter eligibility, labeling and destination-specific export documentation. |
12. HS Code / Customs Classification — TO BE VERIFIED | Do not assign a final HS/ITC-HS code from the medicine name alone. Confirm with the exact dosage form, packing and Indian customs classification. |
13. 26-Country Regulatory Status | Preliminary screen: 🟡 registration/authorization generally required in all 26 markets. Upgrade to 🟠/🔴/⚫ where the ingredient, formulation or destination law imposes special controls; exact status must be verified. |
14. Country Regulatory Authority | See the 26-country matrix at the beginning of this document; the responsible authority varies by destination. |
15. Registration / Marketing Authorization Requirements | Typically product dossier/quality data, manufacturing information, stability, labeling, local applicant/importer authorization and any country-specific clinical/bioequivalence or GMP evidence required. |
16. Export Requirements & Special Restrictions | Do not present as a human pharmaceutical without explicit human authorization. |
17. Buyer Type | Licensed pharmaceutical importer/distributor/wholesaler; hospitals or institutional buyers where appropriate. Veterinary products require appropriately licensed animal-health buyers. |
18. Required Export / Regulatory Documentation | Commercial invoice; packing list; transport documents; certificate of origin where required; COA; GMP/manufacturing documents; product registration/authorization documents; import permit or controlled-drug permit where applicable. |
19. Commercial Considerations | Confirm MOQ, pack size, shelf life, lead time, private-label/OEM availability, registration ownership, Incoterm, freight, insurance, payment terms and landed cost before quotation. |
20. Exporter Decision / Verification Checklist | ☐ Exact product/formulation confirmed ☐ Manufacturer verified ☐ GMP verified ☐ Indian authorization verified ☐ Destination registration checked ☐ Importer licence checked ☐ Controlled/special status checked ☐ COA/stability documents checked ☐ HS code verified ☐ Buyer verified |
95. FENBENDAZOLE TABLETS 500 MG
1. Medicine / Product Name | FENBENDAZOLE TABLETS 500 MG |
2. Generic / API / Composition | FENBENDAZOLE 500 MG — exact composition/API to be confirmed from manufacturer specification. |
3. Salt / Strength | Strength/salt as stated in the source where available; otherwise verify the exact product specification. |
4. Therapeutic Category | Veterinary anthelmintic |
5. Pharmacological / Drug Class | Benzimidazole anthelmintic |
6. Main Uses / Indications | Veterinary parasite control; human use is not automatically authorized. |
7. Mechanism / Basic Description | Disrupts parasite microtubule function. |
8. Dosage Form & Route | Route/formulation: verify from the exact product specification. |
9. Prescription / OTC Status | Veterinary/animal-health regulatory status depends on country. |
10. Major Warnings / Contraindications / Key Interactions | Check official label for contraindications, interactions, pregnancy warnings, organ-function precautions and formulation-specific risks. |
11. India Export Considerations | Verify Indian manufacturing licence/product permission, GMP status, formulation authorization, exporter eligibility, labeling and destination-specific export documentation. |
12. HS Code / Customs Classification — TO BE VERIFIED | Do not assign a final HS/ITC-HS code from the medicine name alone. Confirm with the exact dosage form, packing and Indian customs classification. |
13. 26-Country Regulatory Status | Preliminary screen: 🟡 registration/authorization generally required in all 26 markets. Upgrade to 🟠/🔴/⚫ where the ingredient, formulation or destination law imposes special controls; exact status must be verified. |
14. Country Regulatory Authority | See the 26-country matrix at the beginning of this document; the responsible authority varies by destination. |
15. Registration / Marketing Authorization Requirements | Typically product dossier/quality data, manufacturing information, stability, labeling, local applicant/importer authorization and any country-specific clinical/bioequivalence or GMP evidence required. |
16. Export Requirements & Special Restrictions | Do not present as a human pharmaceutical without explicit human authorization. |
17. Buyer Type | Licensed pharmaceutical importer/distributor/wholesaler; hospitals or institutional buyers where appropriate. Veterinary products require appropriately licensed animal-health buyers. |
18. Required Export / Regulatory Documentation | Commercial invoice; packing list; transport documents; certificate of origin where required; COA; GMP/manufacturing documents; product registration/authorization documents; import permit or controlled-drug permit where applicable. |
19. Commercial Considerations | Confirm MOQ, pack size, shelf life, lead time, private-label/OEM availability, registration ownership, Incoterm, freight, insurance, payment terms and landed cost before quotation. |
20. Exporter Decision / Verification Checklist | ☐ Exact product/formulation confirmed ☐ Manufacturer verified ☐ GMP verified ☐ Indian authorization verified ☐ Destination registration checked ☐ Importer licence checked ☐ Controlled/special status checked ☐ COA/stability documents checked ☐ HS code verified ☐ Buyer verified |
96. PENTOXIFYLLINES SUSTAINED RELEASE TABLETS IP
1. Medicine / Product Name | PENTOXIFYLLINES SUSTAINED RELEASE TABLETS IP |
2. Generic / API / Composition | PENTOXIFYLLINES SUSTAINED RELEASE IP — exact composition/API to be confirmed from manufacturer specification. |
3. Salt / Strength | Strength/salt as stated in the source where available; otherwise verify the exact product specification. |
4. Therapeutic Category | Peripheral vascular medicine |
5. Pharmacological / Drug Class | Methylxanthine derivative / hemorheologic agent |
6. Main Uses / Indications | Indication varies by jurisdiction. |
7. Mechanism / Basic Description | Pharmacology should be stated from the approved product label/official monograph. |
8. Dosage Form & Route | Route/formulation: verify from the exact product specification. |
9. Prescription / OTC Status | Generally prescription/regulated medicine; exact status varies by jurisdiction. |
10. Major Warnings / Contraindications / Key Interactions | Check official label for contraindications, interactions, pregnancy warnings, organ-function precautions and formulation-specific risks. |
11. India Export Considerations | Verify Indian manufacturing licence/product permission, GMP status, formulation authorization, exporter eligibility, labeling and destination-specific export documentation. |
12. HS Code / Customs Classification — TO BE VERIFIED | Do not assign a final HS/ITC-HS code from the medicine name alone. Confirm with the exact dosage form, packing and Indian customs classification. |
13. 26-Country Regulatory Status | Preliminary screen: 🟡 registration/authorization generally required in all 26 markets. Upgrade to 🟠/🔴/⚫ where the ingredient, formulation or destination law imposes special controls; exact status must be verified. |
14. Country Regulatory Authority | See the 26-country matrix at the beginning of this document; the responsible authority varies by destination. |
15. Registration / Marketing Authorization Requirements | Typically product dossier/quality data, manufacturing information, stability, labeling, local applicant/importer authorization and any country-specific clinical/bioequivalence or GMP evidence required. |
16. Export Requirements & Special Restrictions | Product-specific regulatory review required before export. |
17. Buyer Type | Licensed pharmaceutical importer/distributor/wholesaler; hospitals or institutional buyers where appropriate. Veterinary products require appropriately licensed animal-health buyers. |
18. Required Export / Regulatory Documentation | Commercial invoice; packing list; transport documents; certificate of origin where required; COA; GMP/manufacturing documents; product registration/authorization documents; import permit or controlled-drug permit where applicable. |
19. Commercial Considerations | Confirm MOQ, pack size, shelf life, lead time, private-label/OEM availability, registration ownership, Incoterm, freight, insurance, payment terms and landed cost before quotation. |
20. Exporter Decision / Verification Checklist | ☐ Exact product/formulation confirmed ☐ Manufacturer verified ☐ GMP verified ☐ Indian authorization verified ☐ Destination registration checked ☐ Importer licence checked ☐ Controlled/special status checked ☐ COA/stability documents checked ☐ HS code verified ☐ Buyer verified |
97. FENBENDAZOLE TABLETS 222 MG
1. Medicine / Product Name | FENBENDAZOLE TABLETS 222 MG |
2. Generic / API / Composition | FENBENDAZOLE 222 MG — exact composition/API to be confirmed from manufacturer specification. |
3. Salt / Strength | Strength/salt as stated in the source where available; otherwise verify the exact product specification. |
4. Therapeutic Category | Veterinary anthelmintic |
5. Pharmacological / Drug Class | Benzimidazole anthelmintic |
6. Main Uses / Indications | Veterinary parasite control; human use is not automatically authorized. |
7. Mechanism / Basic Description | Disrupts parasite microtubule function. |
8. Dosage Form & Route | Route/formulation: verify from the exact product specification. |
9. Prescription / OTC Status | Veterinary/animal-health regulatory status depends on country. |
10. Major Warnings / Contraindications / Key Interactions | Check official label for contraindications, interactions, pregnancy warnings, organ-function precautions and formulation-specific risks. |
11. India Export Considerations | Verify Indian manufacturing licence/product permission, GMP status, formulation authorization, exporter eligibility, labeling and destination-specific export documentation. |
12. HS Code / Customs Classification — TO BE VERIFIED | Do not assign a final HS/ITC-HS code from the medicine name alone. Confirm with the exact dosage form, packing and Indian customs classification. |
13. 26-Country Regulatory Status | Preliminary screen: 🟡 registration/authorization generally required in all 26 markets. Upgrade to 🟠/🔴/⚫ where the ingredient, formulation or destination law imposes special controls; exact status must be verified. |
14. Country Regulatory Authority | See the 26-country matrix at the beginning of this document; the responsible authority varies by destination. |
15. Registration / Marketing Authorization Requirements | Typically product dossier/quality data, manufacturing information, stability, labeling, local applicant/importer authorization and any country-specific clinical/bioequivalence or GMP evidence required. |
16. Export Requirements & Special Restrictions | Do not present as a human pharmaceutical without explicit human authorization. |
17. Buyer Type | Licensed pharmaceutical importer/distributor/wholesaler; hospitals or institutional buyers where appropriate. Veterinary products require appropriately licensed animal-health buyers. |
18. Required Export / Regulatory Documentation | Commercial invoice; packing list; transport documents; certificate of origin where required; COA; GMP/manufacturing documents; product registration/authorization documents; import permit or controlled-drug permit where applicable. |
19. Commercial Considerations | Confirm MOQ, pack size, shelf life, lead time, private-label/OEM availability, registration ownership, Incoterm, freight, insurance, payment terms and landed cost before quotation. |
20. Exporter Decision / Verification Checklist | ☐ Exact product/formulation confirmed ☐ Manufacturer verified ☐ GMP verified ☐ Indian authorization verified ☐ Destination registration checked ☐ Importer licence checked ☐ Controlled/special status checked ☐ COA/stability documents checked ☐ HS code verified ☐ Buyer verified |
98. NICLOSAMIDE TABLETS IP 500 MG
1. Medicine / Product Name | NICLOSAMIDE TABLETS IP 500 MG |
2. Generic / API / Composition | NICLOSAMIDE IP 500 MG — exact composition/API to be confirmed from manufacturer specification. |
3. Salt / Strength | Strength/salt as stated in the source where available; otherwise verify the exact product specification. |
4. Therapeutic Category | Anti-infective / antiparasitic medicine |
5. Pharmacological / Drug Class | Antibacterial, antiprotozoal or antiparasitic — ingredient-specific |
6. Main Uses / Indications | Treatment of susceptible infections/parasitoses according to the approved indication. |
7. Mechanism / Basic Description | Ingredient-specific antimicrobial/antiparasitic mechanism. |
8. Dosage Form & Route | Oral or other formulation-specific route. |
9. Prescription / OTC Status | Generally prescription/regulated medicine; exact status varies by jurisdiction. |
10. Major Warnings / Contraindications / Key Interactions | Allergy, interactions, resistance/appropriate-use restrictions and indication-specific precautions require label review. |
11. India Export Considerations | Verify Indian manufacturing licence/product permission, GMP status, formulation authorization, exporter eligibility, labeling and destination-specific export documentation. |
12. HS Code / Customs Classification — TO BE VERIFIED | Do not assign a final HS/ITC-HS code from the medicine name alone. Confirm with the exact dosage form, packing and Indian customs classification. |
13. 26-Country Regulatory Status | Preliminary screen: 🟡 registration/authorization generally required in all 26 markets. Upgrade to 🟠/🔴/⚫ where the ingredient, formulation or destination law imposes special controls; exact status must be verified. |
14. Country Regulatory Authority | See the 26-country matrix at the beginning of this document; the responsible authority varies by destination. |
15. Registration / Marketing Authorization Requirements | Typically product dossier/quality data, manufacturing information, stability, labeling, local applicant/importer authorization and any country-specific clinical/bioequivalence or GMP evidence required. |
16. Export Requirements & Special Restrictions | Product-specific regulatory review required before export. |
17. Buyer Type | Licensed pharmaceutical importer/distributor/wholesaler; hospitals or institutional buyers where appropriate. Veterinary products require appropriately licensed animal-health buyers. |
18. Required Export / Regulatory Documentation | Commercial invoice; packing list; transport documents; certificate of origin where required; COA; GMP/manufacturing documents; product registration/authorization documents; import permit or controlled-drug permit where applicable. |
19. Commercial Considerations | Confirm MOQ, pack size, shelf life, lead time, private-label/OEM availability, registration ownership, Incoterm, freight, insurance, payment terms and landed cost before quotation. |
20. Exporter Decision / Verification Checklist | ☐ Exact product/formulation confirmed ☐ Manufacturer verified ☐ GMP verified ☐ Indian authorization verified ☐ Destination registration checked ☐ Importer licence checked ☐ Controlled/special status checked ☐ COA/stability documents checked ☐ HS code verified ☐ Buyer verified |
99. UDENAFIL TABLETS 200 MG
1. Medicine / Product Name | UDENAFIL TABLETS 200 MG |
2. Generic / API / Composition | UDENAFIL 200 MG — exact composition/API to be confirmed from manufacturer specification. |
3. Salt / Strength | Strength/salt as stated in the source where available; otherwise verify the exact product specification. |
4. Therapeutic Category | Genitourinary / erectile-dysfunction medicine |
5. Pharmacological / Drug Class | PDE-5 inhibitor |
6. Main Uses / Indications | Treatment of erectile dysfunction; exact indications vary by product and market. |
7. Mechanism / Basic Description | Inhibits PDE-5, increasing cGMP-mediated smooth-muscle relaxation. |
8. Dosage Form & Route | Oral; exact formulation (tablet/jelly/etc.) must be verified. |
9. Prescription / OTC Status | Generally prescription/regulated medicine; exact status varies by jurisdiction. |
10. Major Warnings / Contraindications / Key Interactions | Nitrates/riociguat and cardiovascular conditions require particular attention; formulation and local labeling must be checked. |
11. India Export Considerations | Verify Indian manufacturing licence/product permission, GMP status, formulation authorization, exporter eligibility, labeling and destination-specific export documentation. |
12. HS Code / Customs Classification — TO BE VERIFIED | Do not assign a final HS/ITC-HS code from the medicine name alone. Confirm with the exact dosage form, packing and Indian customs classification. |
13. 26-Country Regulatory Status | Preliminary screen: 🟡 registration/authorization generally required in all 26 markets. Upgrade to 🟠/🔴/⚫ where the ingredient, formulation or destination law imposes special controls; exact status must be verified. |
14. Country Regulatory Authority | See the 26-country matrix at the beginning of this document; the responsible authority varies by destination. |
15. Registration / Marketing Authorization Requirements | Typically product dossier/quality data, manufacturing information, stability, labeling, local applicant/importer authorization and any country-specific clinical/bioequivalence or GMP evidence required. |
16. Export Requirements & Special Restrictions | Product-specific regulatory review required before export. |
17. Buyer Type | Licensed pharmaceutical importer/distributor/wholesaler; hospitals or institutional buyers where appropriate. Veterinary products require appropriately licensed animal-health buyers. |
18. Required Export / Regulatory Documentation | Commercial invoice; packing list; transport documents; certificate of origin where required; COA; GMP/manufacturing documents; product registration/authorization documents; import permit or controlled-drug permit where applicable. |
19. Commercial Considerations | Confirm MOQ, pack size, shelf life, lead time, private-label/OEM availability, registration ownership, Incoterm, freight, insurance, payment terms and landed cost before quotation. |
20. Exporter Decision / Verification Checklist | ☐ Exact product/formulation confirmed ☐ Manufacturer verified ☐ GMP verified ☐ Indian authorization verified ☐ Destination registration checked ☐ Importer licence checked ☐ Controlled/special status checked ☐ COA/stability documents checked ☐ HS code verified ☐ Buyer verified |
100. RIFAXIMIN TABLETS IP 400 MG
1. Medicine / Product Name | RIFAXIMIN TABLETS IP 400 MG |
2. Generic / API / Composition | RIFAXIMIN IP 400 MG — exact composition/API to be confirmed from manufacturer specification. |
3. Salt / Strength | Strength/salt as stated in the source where available; otherwise verify the exact product specification. |
4. Therapeutic Category | Anti-infective / antiparasitic medicine |
5. Pharmacological / Drug Class | Antibacterial, antiprotozoal or antiparasitic — ingredient-specific |
6. Main Uses / Indications | Treatment of susceptible infections/parasitoses according to the approved indication. |
7. Mechanism / Basic Description | Ingredient-specific antimicrobial/antiparasitic mechanism. |
8. Dosage Form & Route | Oral or other formulation-specific route. |
9. Prescription / OTC Status | Generally prescription/regulated medicine; exact status varies by jurisdiction. |
10. Major Warnings / Contraindications / Key Interactions | Allergy, interactions, resistance/appropriate-use restrictions and indication-specific precautions require label review. |
11. India Export Considerations | Verify Indian manufacturing licence/product permission, GMP status, formulation authorization, exporter eligibility, labeling and destination-specific export documentation. |
12. HS Code / Customs Classification — TO BE VERIFIED | Do not assign a final HS/ITC-HS code from the medicine name alone. Confirm with the exact dosage form, packing and Indian customs classification. |
13. 26-Country Regulatory Status | Preliminary screen: 🟡 registration/authorization generally required in all 26 markets. Upgrade to 🟠/🔴/⚫ where the ingredient, formulation or destination law imposes special controls; exact status must be verified. |
14. Country Regulatory Authority | See the 26-country matrix at the beginning of this document; the responsible authority varies by destination. |
15. Registration / Marketing Authorization Requirements | Typically product dossier/quality data, manufacturing information, stability, labeling, local applicant/importer authorization and any country-specific clinical/bioequivalence or GMP evidence required. |
16. Export Requirements & Special Restrictions | Product-specific regulatory review required before export. |
17. Buyer Type | Licensed pharmaceutical importer/distributor/wholesaler; hospitals or institutional buyers where appropriate. Veterinary products require appropriately licensed animal-health buyers. |
18. Required Export / Regulatory Documentation | Commercial invoice; packing list; transport documents; certificate of origin where required; COA; GMP/manufacturing documents; product registration/authorization documents; import permit or controlled-drug permit where applicable. |
19. Commercial Considerations | Confirm MOQ, pack size, shelf life, lead time, private-label/OEM availability, registration ownership, Incoterm, freight, insurance, payment terms and landed cost before quotation. |
20. Exporter Decision / Verification Checklist | ☐ Exact product/formulation confirmed ☐ Manufacturer verified ☐ GMP verified ☐ Indian authorization verified ☐ Destination registration checked ☐ Importer licence checked ☐ Controlled/special status checked ☐ COA/stability documents checked ☐ HS code verified ☐ Buyer verified |
101. PREGABALIN CAPSULES IP
1. Medicine / Product Name | PREGABALIN CAPSULES IP |
2. Generic / API / Composition | PREGABALIN IP — exact composition/API to be confirmed from manufacturer specification. |
3. Salt / Strength | Strength/salt as stated in the source where available; otherwise verify the exact product specification. |
4. Therapeutic Category | CNS / neurological / psychiatric medicine |
5. Pharmacological / Drug Class | Central nervous system active medicine |
6. Main Uses / Indications | Indication depends on the active ingredient; verify approved indication. |
7. Mechanism / Basic Description | CNS mechanism is ingredient-specific. |
8. Dosage Form & Route | Route/formulation: verify from the exact product specification. |
9. Prescription / OTC Status | Prescription; controlled/psychotropic status must be checked country by country. |
10. Major Warnings / Contraindications / Key Interactions | CNS effects, interactions, dependence/misuse potential where applicable and local controlled-drug status require review. |
11. India Export Considerations | Verify Indian manufacturing licence/product permission, GMP status, formulation authorization, exporter eligibility, labeling and destination-specific export documentation. |
12. HS Code / Customs Classification — TO BE VERIFIED | Do not assign a final HS/ITC-HS code from the medicine name alone. Confirm with the exact dosage form, packing and Indian customs classification. |
13. 26-Country Regulatory Status | Preliminary screen: 🟡 registration/authorization generally required in all 26 markets. Upgrade to 🟠/🔴/⚫ where the ingredient, formulation or destination law imposes special controls; exact status must be verified. |
14. Country Regulatory Authority | See the 26-country matrix at the beginning of this document; the responsible authority varies by destination. |
15. Registration / Marketing Authorization Requirements | Typically product dossier/quality data, manufacturing information, stability, labeling, local applicant/importer authorization and any country-specific clinical/bioequivalence or GMP evidence required. |
16. Export Requirements & Special Restrictions | High-priority destination-country classification check. Controlled/psychotropic/hormonal classification must be checked separately in each destination. |
17. Buyer Type | Licensed pharmaceutical importer/distributor/wholesaler; hospitals or institutional buyers where appropriate. Veterinary products require appropriately licensed animal-health buyers. |
18. Required Export / Regulatory Documentation | Commercial invoice; packing list; transport documents; certificate of origin where required; COA; GMP/manufacturing documents; product registration/authorization documents; import permit or controlled-drug permit where applicable. |
19. Commercial Considerations | Confirm MOQ, pack size, shelf life, lead time, private-label/OEM availability, registration ownership, Incoterm, freight, insurance, payment terms and landed cost before quotation. |
20. Exporter Decision / Verification Checklist | ☐ Exact product/formulation confirmed ☐ Manufacturer verified ☐ GMP verified ☐ Indian authorization verified ☐ Destination registration checked ☐ Importer licence checked ☐ Controlled/special status checked ☐ COA/stability documents checked ☐ HS code verified ☐ Buyer verified |
102. HYDROCHLOROTHIAZIDE TABLETS IP 12.5 MG
1. Medicine / Product Name | HYDROCHLOROTHIAZIDE TABLETS IP 12.5 MG |
2. Generic / API / Composition | HYDROCHLOROTHIAZIDE IP 12.5 MG — exact composition/API to be confirmed from manufacturer specification. |
3. Salt / Strength | Strength/salt as stated in the source where available; otherwise verify the exact product specification. |
4. Therapeutic Category | Cardiometabolic medicine |
5. Pharmacological / Drug Class | Ingredient-specific metabolic/cardiovascular agent |
6. Main Uses / Indications | Cardiovascular, lipid or glucose-management indication according to the exact ingredient. |
7. Mechanism / Basic Description | Ingredient-specific; verify official label. |
8. Dosage Form & Route | Usually oral, except formulation-specific products. |
9. Prescription / OTC Status | Generally prescription/regulated medicine; exact status varies by jurisdiction. |
10. Major Warnings / Contraindications / Key Interactions | Check official label for contraindications, interactions, pregnancy warnings, organ-function precautions and formulation-specific risks. |
11. India Export Considerations | Verify Indian manufacturing licence/product permission, GMP status, formulation authorization, exporter eligibility, labeling and destination-specific export documentation. |
12. HS Code / Customs Classification — TO BE VERIFIED | Do not assign a final HS/ITC-HS code from the medicine name alone. Confirm with the exact dosage form, packing and Indian customs classification. |
13. 26-Country Regulatory Status | Preliminary screen: 🟡 registration/authorization generally required in all 26 markets. Upgrade to 🟠/🔴/⚫ where the ingredient, formulation or destination law imposes special controls; exact status must be verified. |
14. Country Regulatory Authority | See the 26-country matrix at the beginning of this document; the responsible authority varies by destination. |
15. Registration / Marketing Authorization Requirements | Typically product dossier/quality data, manufacturing information, stability, labeling, local applicant/importer authorization and any country-specific clinical/bioequivalence or GMP evidence required. |
16. Export Requirements & Special Restrictions | Product-specific regulatory review required before export. |
17. Buyer Type | Licensed pharmaceutical importer/distributor/wholesaler; hospitals or institutional buyers where appropriate. Veterinary products require appropriately licensed animal-health buyers. |
18. Required Export / Regulatory Documentation | Commercial invoice; packing list; transport documents; certificate of origin where required; COA; GMP/manufacturing documents; product registration/authorization documents; import permit or controlled-drug permit where applicable. |
19. Commercial Considerations | Confirm MOQ, pack size, shelf life, lead time, private-label/OEM availability, registration ownership, Incoterm, freight, insurance, payment terms and landed cost before quotation. |
20. Exporter Decision / Verification Checklist | ☐ Exact product/formulation confirmed ☐ Manufacturer verified ☐ GMP verified ☐ Indian authorization verified ☐ Destination registration checked ☐ Importer licence checked ☐ Controlled/special status checked ☐ COA/stability documents checked ☐ HS code verified ☐ Buyer verified |
103. SALBUTAMOL SULPHATE TABLETS IP
1. Medicine / Product Name | SALBUTAMOL SULPHATE TABLETS IP |
2. Generic / API / Composition | SALBUTAMOL SULPHATE IP — exact composition/API to be confirmed from manufacturer specification. |
3. Salt / Strength | Strength/salt as stated in the source where available; otherwise verify the exact product specification. |
4. Therapeutic Category | Respiratory medicine |
5. Pharmacological / Drug Class | Beta-2 adrenergic agonist |
6. Main Uses / Indications | Bronchodilator therapy in approved respiratory conditions. |
7. Mechanism / Basic Description | Relaxes bronchial smooth muscle through beta-2 receptor stimulation. |
8. Dosage Form & Route | Oral or inhaled depending on formulation. |
9. Prescription / OTC Status | Generally prescription/regulated medicine; exact status varies by jurisdiction. |
10. Major Warnings / Contraindications / Key Interactions | Check official label for contraindications, interactions, pregnancy warnings, organ-function precautions and formulation-specific risks. |
11. India Export Considerations | Verify Indian manufacturing licence/product permission, GMP status, formulation authorization, exporter eligibility, labeling and destination-specific export documentation. |
12. HS Code / Customs Classification — TO BE VERIFIED | Do not assign a final HS/ITC-HS code from the medicine name alone. Confirm with the exact dosage form, packing and Indian customs classification. |
13. 26-Country Regulatory Status | Preliminary screen: 🟡 registration/authorization generally required in all 26 markets. Upgrade to 🟠/🔴/⚫ where the ingredient, formulation or destination law imposes special controls; exact status must be verified. |
14. Country Regulatory Authority | See the 26-country matrix at the beginning of this document; the responsible authority varies by destination. |
15. Registration / Marketing Authorization Requirements | Typically product dossier/quality data, manufacturing information, stability, labeling, local applicant/importer authorization and any country-specific clinical/bioequivalence or GMP evidence required. |
16. Export Requirements & Special Restrictions | Product-specific regulatory review required before export. |
17. Buyer Type | Licensed pharmaceutical importer/distributor/wholesaler; hospitals or institutional buyers where appropriate. Veterinary products require appropriately licensed animal-health buyers. |
18. Required Export / Regulatory Documentation | Commercial invoice; packing list; transport documents; certificate of origin where required; COA; GMP/manufacturing documents; product registration/authorization documents; import permit or controlled-drug permit where applicable. |
19. Commercial Considerations | Confirm MOQ, pack size, shelf life, lead time, private-label/OEM availability, registration ownership, Incoterm, freight, insurance, payment terms and landed cost before quotation. |
20. Exporter Decision / Verification Checklist | ☐ Exact product/formulation confirmed ☐ Manufacturer verified ☐ GMP verified ☐ Indian authorization verified ☐ Destination registration checked ☐ Importer licence checked ☐ Controlled/special status checked ☐ COA/stability documents checked ☐ HS code verified ☐ Buyer verified |
104. DOXYCYCLINE HYDOCHLORIDE AND LACTIC ACID BACILLUS CAPSULE
1. Medicine / Product Name | DOXYCYCLINE HYDOCHLORIDE AND LACTIC ACID BACILLUS CAPSULE |
2. Generic / API / Composition | DOXYCYCLINE HYDOCHLORIDE AND LACTIC ACID BACILLUS CAPSULE — exact composition/API to be confirmed from manufacturer specification. |
3. Salt / Strength | Strength/salt as stated in the source where available; otherwise verify the exact product specification. |
4. Therapeutic Category | Anti-infective / antiparasitic medicine |
5. Pharmacological / Drug Class | Antibacterial, antiprotozoal or antiparasitic — ingredient-specific |
6. Main Uses / Indications | Treatment of susceptible infections/parasitoses according to the approved indication. |
7. Mechanism / Basic Description | Ingredient-specific antimicrobial/antiparasitic mechanism. |
8. Dosage Form & Route | Oral or other formulation-specific route. |
9. Prescription / OTC Status | Generally prescription/regulated medicine; exact status varies by jurisdiction. |
10. Major Warnings / Contraindications / Key Interactions | Allergy, interactions, resistance/appropriate-use restrictions and indication-specific precautions require label review. |
11. India Export Considerations | Verify Indian manufacturing licence/product permission, GMP status, formulation authorization, exporter eligibility, labeling and destination-specific export documentation. |
12. HS Code / Customs Classification — TO BE VERIFIED | Do not assign a final HS/ITC-HS code from the medicine name alone. Confirm with the exact dosage form, packing and Indian customs classification. |
13. 26-Country Regulatory Status | Preliminary screen: 🟡 registration/authorization generally required in all 26 markets. Upgrade to 🟠/🔴/⚫ where the ingredient, formulation or destination law imposes special controls; exact status must be verified. |
14. Country Regulatory Authority | See the 26-country matrix at the beginning of this document; the responsible authority varies by destination. |
15. Registration / Marketing Authorization Requirements | Typically product dossier/quality data, manufacturing information, stability, labeling, local applicant/importer authorization and any country-specific clinical/bioequivalence or GMP evidence required. |
16. Export Requirements & Special Restrictions | Product-specific regulatory review required before export. |
17. Buyer Type | Licensed pharmaceutical importer/distributor/wholesaler; hospitals or institutional buyers where appropriate. Veterinary products require appropriately licensed animal-health buyers. |
18. Required Export / Regulatory Documentation | Commercial invoice; packing list; transport documents; certificate of origin where required; COA; GMP/manufacturing documents; product registration/authorization documents; import permit or controlled-drug permit where applicable. |
19. Commercial Considerations | Confirm MOQ, pack size, shelf life, lead time, private-label/OEM availability, registration ownership, Incoterm, freight, insurance, payment terms and landed cost before quotation. |
20. Exporter Decision / Verification Checklist | ☐ Exact product/formulation confirmed ☐ Manufacturer verified ☐ GMP verified ☐ Indian authorization verified ☐ Destination registration checked ☐ Importer licence checked ☐ Controlled/special status checked ☐ COA/stability documents checked ☐ HS code verified ☐ Buyer verified |
105. NEBIVOLOL HYDROCHLORIDE TABLETS IP 5 MG
1. Medicine / Product Name | NEBIVOLOL HYDROCHLORIDE TABLETS IP 5 MG |
2. Generic / API / Composition | NEBIVOLOL HYDROCHLORIDE IP 5 MG — exact composition/API to be confirmed from manufacturer specification. |
3. Salt / Strength | Strength/salt as stated in the source where available; otherwise verify the exact product specification. |
4. Therapeutic Category | Cardiometabolic medicine |
5. Pharmacological / Drug Class | Ingredient-specific metabolic/cardiovascular agent |
6. Main Uses / Indications | Cardiovascular, lipid or glucose-management indication according to the exact ingredient. |
7. Mechanism / Basic Description | Ingredient-specific; verify official label. |
8. Dosage Form & Route | Usually oral, except formulation-specific products. |
9. Prescription / OTC Status | Generally prescription/regulated medicine; exact status varies by jurisdiction. |
10. Major Warnings / Contraindications / Key Interactions | Check official label for contraindications, interactions, pregnancy warnings, organ-function precautions and formulation-specific risks. |
11. India Export Considerations | Verify Indian manufacturing licence/product permission, GMP status, formulation authorization, exporter eligibility, labeling and destination-specific export documentation. |
12. HS Code / Customs Classification — TO BE VERIFIED | Do not assign a final HS/ITC-HS code from the medicine name alone. Confirm with the exact dosage form, packing and Indian customs classification. |
13. 26-Country Regulatory Status | Preliminary screen: 🟡 registration/authorization generally required in all 26 markets. Upgrade to 🟠/🔴/⚫ where the ingredient, formulation or destination law imposes special controls; exact status must be verified. |
14. Country Regulatory Authority | See the 26-country matrix at the beginning of this document; the responsible authority varies by destination. |
15. Registration / Marketing Authorization Requirements | Typically product dossier/quality data, manufacturing information, stability, labeling, local applicant/importer authorization and any country-specific clinical/bioequivalence or GMP evidence required. |
16. Export Requirements & Special Restrictions | Product-specific regulatory review required before export. |
17. Buyer Type | Licensed pharmaceutical importer/distributor/wholesaler; hospitals or institutional buyers where appropriate. Veterinary products require appropriately licensed animal-health buyers. |
18. Required Export / Regulatory Documentation | Commercial invoice; packing list; transport documents; certificate of origin where required; COA; GMP/manufacturing documents; product registration/authorization documents; import permit or controlled-drug permit where applicable. |
19. Commercial Considerations | Confirm MOQ, pack size, shelf life, lead time, private-label/OEM availability, registration ownership, Incoterm, freight, insurance, payment terms and landed cost before quotation. |
20. Exporter Decision / Verification Checklist | ☐ Exact product/formulation confirmed ☐ Manufacturer verified ☐ GMP verified ☐ Indian authorization verified ☐ Destination registration checked ☐ Importer licence checked ☐ Controlled/special status checked ☐ COA/stability documents checked ☐ HS code verified ☐ Buyer verified |
106. METRONIDAZOLE
1. Medicine / Product Name | METRONIDAZOLE |
2. Generic / API / Composition | METRONIDAZOLE — exact composition/API to be confirmed from manufacturer specification. |
3. Salt / Strength | Strength/salt as stated in the source where available; otherwise verify the exact product specification. |
4. Therapeutic Category | Anti-infective / antiparasitic medicine |
5. Pharmacological / Drug Class | Antibacterial, antiprotozoal or antiparasitic — ingredient-specific |
6. Main Uses / Indications | Treatment of susceptible infections/parasitoses according to the approved indication. |
7. Mechanism / Basic Description | Ingredient-specific antimicrobial/antiparasitic mechanism. |
8. Dosage Form & Route | Oral or other formulation-specific route. |
9. Prescription / OTC Status | Generally prescription/regulated medicine; exact status varies by jurisdiction. |
10. Major Warnings / Contraindications / Key Interactions | Allergy, interactions, resistance/appropriate-use restrictions and indication-specific precautions require label review. |
11. India Export Considerations | Verify Indian manufacturing licence/product permission, GMP status, formulation authorization, exporter eligibility, labeling and destination-specific export documentation. |
12. HS Code / Customs Classification — TO BE VERIFIED | Do not assign a final HS/ITC-HS code from the medicine name alone. Confirm with the exact dosage form, packing and Indian customs classification. |
13. 26-Country Regulatory Status | Preliminary screen: 🟡 registration/authorization generally required in all 26 markets. Upgrade to 🟠/🔴/⚫ where the ingredient, formulation or destination law imposes special controls; exact status must be verified. |
14. Country Regulatory Authority | See the 26-country matrix at the beginning of this document; the responsible authority varies by destination. |
15. Registration / Marketing Authorization Requirements | Typically product dossier/quality data, manufacturing information, stability, labeling, local applicant/importer authorization and any country-specific clinical/bioequivalence or GMP evidence required. |
16. Export Requirements & Special Restrictions | Product-specific regulatory review required before export. |
17. Buyer Type | Licensed pharmaceutical importer/distributor/wholesaler; hospitals or institutional buyers where appropriate. Veterinary products require appropriately licensed animal-health buyers. |
18. Required Export / Regulatory Documentation | Commercial invoice; packing list; transport documents; certificate of origin where required; COA; GMP/manufacturing documents; product registration/authorization documents; import permit or controlled-drug permit where applicable. |
19. Commercial Considerations | Confirm MOQ, pack size, shelf life, lead time, private-label/OEM availability, registration ownership, Incoterm, freight, insurance, payment terms and landed cost before quotation. |
20. Exporter Decision / Verification Checklist | ☐ Exact product/formulation confirmed ☐ Manufacturer verified ☐ GMP verified ☐ Indian authorization verified ☐ Destination registration checked ☐ Importer licence checked ☐ Controlled/special status checked ☐ COA/stability documents checked ☐ HS code verified ☐ Buyer verified |
107. ATOMOXETINE TABLETS 40 MG
1. Medicine / Product Name | ATOMOXETINE TABLETS 40 MG |
2. Generic / API / Composition | ATOMOXETINE 40 MG — exact composition/API to be confirmed from manufacturer specification. |
3. Salt / Strength | Strength/salt as stated in the source where available; otherwise verify the exact product specification. |
4. Therapeutic Category | CNS / neurological / psychiatric medicine |
5. Pharmacological / Drug Class | Central nervous system active medicine |
6. Main Uses / Indications | Indication depends on the active ingredient; verify approved indication. |
7. Mechanism / Basic Description | CNS mechanism is ingredient-specific. |
8. Dosage Form & Route | Route/formulation: verify from the exact product specification. |
9. Prescription / OTC Status | Prescription; controlled/psychotropic status must be checked country by country. |
10. Major Warnings / Contraindications / Key Interactions | CNS effects, interactions, dependence/misuse potential where applicable and local controlled-drug status require review. |
11. India Export Considerations | Verify Indian manufacturing licence/product permission, GMP status, formulation authorization, exporter eligibility, labeling and destination-specific export documentation. |
12. HS Code / Customs Classification — TO BE VERIFIED | Do not assign a final HS/ITC-HS code from the medicine name alone. Confirm with the exact dosage form, packing and Indian customs classification. |
13. 26-Country Regulatory Status | Preliminary screen: 🟡 registration/authorization generally required in all 26 markets. Upgrade to 🟠/🔴/⚫ where the ingredient, formulation or destination law imposes special controls; exact status must be verified. |
14. Country Regulatory Authority | See the 26-country matrix at the beginning of this document; the responsible authority varies by destination. |
15. Registration / Marketing Authorization Requirements | Typically product dossier/quality data, manufacturing information, stability, labeling, local applicant/importer authorization and any country-specific clinical/bioequivalence or GMP evidence required. |
16. Export Requirements & Special Restrictions | High-priority destination-country classification check. Controlled/psychotropic/hormonal classification must be checked separately in each destination. |
17. Buyer Type | Licensed pharmaceutical importer/distributor/wholesaler; hospitals or institutional buyers where appropriate. Veterinary products require appropriately licensed animal-health buyers. |
18. Required Export / Regulatory Documentation | Commercial invoice; packing list; transport documents; certificate of origin where required; COA; GMP/manufacturing documents; product registration/authorization documents; import permit or controlled-drug permit where applicable. |
19. Commercial Considerations | Confirm MOQ, pack size, shelf life, lead time, private-label/OEM availability, registration ownership, Incoterm, freight, insurance, payment terms and landed cost before quotation. |
20. Exporter Decision / Verification Checklist | ☐ Exact product/formulation confirmed ☐ Manufacturer verified ☐ GMP verified ☐ Indian authorization verified ☐ Destination registration checked ☐ Importer licence checked ☐ Controlled/special status checked ☐ COA/stability documents checked ☐ HS code verified ☐ Buyer verified |
108. CEREBROPROTEIN HYDOLYSATE TABLETS 90 MG
1. Medicine / Product Name | CEREBROPROTEIN HYDOLYSATE TABLETS 90 MG |
2. Generic / API / Composition | CEREBROPROTEIN HYDOLYSATE 90 MG — exact composition/API to be confirmed from manufacturer specification. |
3. Salt / Strength | Strength/salt as stated in the source where available; otherwise verify the exact product specification. |
4. Therapeutic Category | Neurological peptide preparation |
5. Pharmacological / Drug Class | Peptide mixture / biological-derived preparation |
6. Main Uses / Indications | Indications are jurisdiction- and evidence-specific. |
7. Mechanism / Basic Description | Product-specific; verify official product monograph. |
8. Dosage Form & Route | Route/formulation: verify from the exact product specification. |
9. Prescription / OTC Status | Generally prescription/regulated medicine; exact status varies by jurisdiction. |
10. Major Warnings / Contraindications / Key Interactions | Check official label for contraindications, interactions, pregnancy warnings, organ-function precautions and formulation-specific risks. |
11. India Export Considerations | Verify Indian manufacturing licence/product permission, GMP status, formulation authorization, exporter eligibility, labeling and destination-specific export documentation. |
12. HS Code / Customs Classification — TO BE VERIFIED | Do not assign a final HS/ITC-HS code from the medicine name alone. Confirm with the exact dosage form, packing and Indian customs classification. |
13. 26-Country Regulatory Status | Preliminary screen: 🟡 registration/authorization generally required in all 26 markets. Upgrade to 🟠/🔴/⚫ where the ingredient, formulation or destination law imposes special controls; exact status must be verified. |
14. Country Regulatory Authority | See the 26-country matrix at the beginning of this document; the responsible authority varies by destination. |
15. Registration / Marketing Authorization Requirements | Typically product dossier/quality data, manufacturing information, stability, labeling, local applicant/importer authorization and any country-specific clinical/bioequivalence or GMP evidence required. |
16. Export Requirements & Special Restrictions | High-priority evidence and regulatory classification verification. |
17. Buyer Type | Licensed pharmaceutical importer/distributor/wholesaler; hospitals or institutional buyers where appropriate. Veterinary products require appropriately licensed animal-health buyers. |
18. Required Export / Regulatory Documentation | Commercial invoice; packing list; transport documents; certificate of origin where required; COA; GMP/manufacturing documents; product registration/authorization documents; import permit or controlled-drug permit where applicable. |
19. Commercial Considerations | Confirm MOQ, pack size, shelf life, lead time, private-label/OEM availability, registration ownership, Incoterm, freight, insurance, payment terms and landed cost before quotation. |
20. Exporter Decision / Verification Checklist | ☐ Exact product/formulation confirmed ☐ Manufacturer verified ☐ GMP verified ☐ Indian authorization verified ☐ Destination registration checked ☐ Importer licence checked ☐ Controlled/special status checked ☐ COA/stability documents checked ☐ HS code verified ☐ Buyer verified |
109. HYDROCHLOROTHIAZIDE TABLETS 12.5 MG IP
1. Medicine / Product Name | HYDROCHLOROTHIAZIDE TABLETS 12.5 MG IP |
2. Generic / API / Composition | HYDROCHLOROTHIAZIDE 12.5 MG IP — exact composition/API to be confirmed from manufacturer specification. |
3. Salt / Strength | Strength/salt as stated in the source where available; otherwise verify the exact product specification. |
4. Therapeutic Category | Cardiometabolic medicine |
5. Pharmacological / Drug Class | Ingredient-specific metabolic/cardiovascular agent |
6. Main Uses / Indications | Cardiovascular, lipid or glucose-management indication according to the exact ingredient. |
7. Mechanism / Basic Description | Ingredient-specific; verify official label. |
8. Dosage Form & Route | Usually oral, except formulation-specific products. |
9. Prescription / OTC Status | Generally prescription/regulated medicine; exact status varies by jurisdiction. |
10. Major Warnings / Contraindications / Key Interactions | Check official label for contraindications, interactions, pregnancy warnings, organ-function precautions and formulation-specific risks. |
11. India Export Considerations | Verify Indian manufacturing licence/product permission, GMP status, formulation authorization, exporter eligibility, labeling and destination-specific export documentation. |
12. HS Code / Customs Classification — TO BE VERIFIED | Do not assign a final HS/ITC-HS code from the medicine name alone. Confirm with the exact dosage form, packing and Indian customs classification. |
13. 26-Country Regulatory Status | Preliminary screen: 🟡 registration/authorization generally required in all 26 markets. Upgrade to 🟠/🔴/⚫ where the ingredient, formulation or destination law imposes special controls; exact status must be verified. |
14. Country Regulatory Authority | See the 26-country matrix at the beginning of this document; the responsible authority varies by destination. |
15. Registration / Marketing Authorization Requirements | Typically product dossier/quality data, manufacturing information, stability, labeling, local applicant/importer authorization and any country-specific clinical/bioequivalence or GMP evidence required. |
16. Export Requirements & Special Restrictions | Product-specific regulatory review required before export. |
17. Buyer Type | Licensed pharmaceutical importer/distributor/wholesaler; hospitals or institutional buyers where appropriate. Veterinary products require appropriately licensed animal-health buyers. |
18. Required Export / Regulatory Documentation | Commercial invoice; packing list; transport documents; certificate of origin where required; COA; GMP/manufacturing documents; product registration/authorization documents; import permit or controlled-drug permit where applicable. |
19. Commercial Considerations | Confirm MOQ, pack size, shelf life, lead time, private-label/OEM availability, registration ownership, Incoterm, freight, insurance, payment terms and landed cost before quotation. |
20. Exporter Decision / Verification Checklist | ☐ Exact product/formulation confirmed ☐ Manufacturer verified ☐ GMP verified ☐ Indian authorization verified ☐ Destination registration checked ☐ Importer licence checked ☐ Controlled/special status checked ☐ COA/stability documents checked ☐ HS code verified ☐ Buyer verified |
110. CYPROHEPTADINE HYDROCHLORIDE TABLETS I P 4 MG
1. Medicine / Product Name | CYPROHEPTADINE HYDROCHLORIDE TABLETS I P 4 MG |
2. Generic / API / Composition | CYPROHEPTADINE HYDROCHLORIDE I P 4 MG — exact composition/API to be confirmed from manufacturer specification. |
3. Salt / Strength | Strength/salt as stated in the source where available; otherwise verify the exact product specification. |
4. Therapeutic Category | Antihistamine / allergy medicine |
5. Pharmacological / Drug Class | Antihistamine; ingredient-specific additional activity |
6. Main Uses / Indications | Allergic or other approved indications. |
7. Mechanism / Basic Description | Primarily H1-histamine receptor antagonism. |
8. Dosage Form & Route | Route/formulation: verify from the exact product specification. |
9. Prescription / OTC Status | Generally prescription/regulated medicine; exact status varies by jurisdiction. |
10. Major Warnings / Contraindications / Key Interactions | Check official label for contraindications, interactions, pregnancy warnings, organ-function precautions and formulation-specific risks. |
11. India Export Considerations | Verify Indian manufacturing licence/product permission, GMP status, formulation authorization, exporter eligibility, labeling and destination-specific export documentation. |
12. HS Code / Customs Classification — TO BE VERIFIED | Do not assign a final HS/ITC-HS code from the medicine name alone. Confirm with the exact dosage form, packing and Indian customs classification. |
13. 26-Country Regulatory Status | Preliminary screen: 🟡 registration/authorization generally required in all 26 markets. Upgrade to 🟠/🔴/⚫ where the ingredient, formulation or destination law imposes special controls; exact status must be verified. |
14. Country Regulatory Authority | See the 26-country matrix at the beginning of this document; the responsible authority varies by destination. |
15. Registration / Marketing Authorization Requirements | Typically product dossier/quality data, manufacturing information, stability, labeling, local applicant/importer authorization and any country-specific clinical/bioequivalence or GMP evidence required. |
16. Export Requirements & Special Restrictions | Product-specific regulatory review required before export. |
17. Buyer Type | Licensed pharmaceutical importer/distributor/wholesaler; hospitals or institutional buyers where appropriate. Veterinary products require appropriately licensed animal-health buyers. |
18. Required Export / Regulatory Documentation | Commercial invoice; packing list; transport documents; certificate of origin where required; COA; GMP/manufacturing documents; product registration/authorization documents; import permit or controlled-drug permit where applicable. |
19. Commercial Considerations | Confirm MOQ, pack size, shelf life, lead time, private-label/OEM availability, registration ownership, Incoterm, freight, insurance, payment terms and landed cost before quotation. |
20. Exporter Decision / Verification Checklist | ☐ Exact product/formulation confirmed ☐ Manufacturer verified ☐ GMP verified ☐ Indian authorization verified ☐ Destination registration checked ☐ Importer licence checked ☐ Controlled/special status checked ☐ COA/stability documents checked ☐ HS code verified ☐ Buyer verified |
111. IVERMECTIN TABLETS USP 12 MG
1. Medicine / Product Name | IVERMECTIN TABLETS USP 12 MG |
2. Generic / API / Composition | IVERMECTIN USP 12 MG — exact composition/API to be confirmed from manufacturer specification. |
3. Salt / Strength | Strength/salt as stated in the source where available; otherwise verify the exact product specification. |
4. Therapeutic Category | Anti-infective / antiparasitic medicine |
5. Pharmacological / Drug Class | Antibacterial, antiprotozoal or antiparasitic — ingredient-specific |
6. Main Uses / Indications | Treatment of susceptible infections/parasitoses according to the approved indication. |
7. Mechanism / Basic Description | Ingredient-specific antimicrobial/antiparasitic mechanism. |
8. Dosage Form & Route | Oral or other formulation-specific route. |
9. Prescription / OTC Status | Generally prescription/regulated medicine; exact status varies by jurisdiction. |
10. Major Warnings / Contraindications / Key Interactions | Allergy, interactions, resistance/appropriate-use restrictions and indication-specific precautions require label review. |
11. India Export Considerations | Verify Indian manufacturing licence/product permission, GMP status, formulation authorization, exporter eligibility, labeling and destination-specific export documentation. |
12. HS Code / Customs Classification — TO BE VERIFIED | Do not assign a final HS/ITC-HS code from the medicine name alone. Confirm with the exact dosage form, packing and Indian customs classification. |
13. 26-Country Regulatory Status | Preliminary screen: 🟡 registration/authorization generally required in all 26 markets. Upgrade to 🟠/🔴/⚫ where the ingredient, formulation or destination law imposes special controls; exact status must be verified. |
14. Country Regulatory Authority | See the 26-country matrix at the beginning of this document; the responsible authority varies by destination. |
15. Registration / Marketing Authorization Requirements | Typically product dossier/quality data, manufacturing information, stability, labeling, local applicant/importer authorization and any country-specific clinical/bioequivalence or GMP evidence required. |
16. Export Requirements & Special Restrictions | Product-specific regulatory review required before export. |
17. Buyer Type | Licensed pharmaceutical importer/distributor/wholesaler; hospitals or institutional buyers where appropriate. Veterinary products require appropriately licensed animal-health buyers. |
18. Required Export / Regulatory Documentation | Commercial invoice; packing list; transport documents; certificate of origin where required; COA; GMP/manufacturing documents; product registration/authorization documents; import permit or controlled-drug permit where applicable. |
19. Commercial Considerations | Confirm MOQ, pack size, shelf life, lead time, private-label/OEM availability, registration ownership, Incoterm, freight, insurance, payment terms and landed cost before quotation. |
20. Exporter Decision / Verification Checklist | ☐ Exact product/formulation confirmed ☐ Manufacturer verified ☐ GMP verified ☐ Indian authorization verified ☐ Destination registration checked ☐ Importer licence checked ☐ Controlled/special status checked ☐ COA/stability documents checked ☐ HS code verified ☐ Buyer verified |
112. IVERMECTIN TABLETS USP 15 MG
1. Medicine / Product Name | IVERMECTIN TABLETS USP 15 MG |
2. Generic / API / Composition | IVERMECTIN USP 15 MG — exact composition/API to be confirmed from manufacturer specification. |
3. Salt / Strength | Strength/salt as stated in the source where available; otherwise verify the exact product specification. |
4. Therapeutic Category | Anti-infective / antiparasitic medicine |
5. Pharmacological / Drug Class | Antibacterial, antiprotozoal or antiparasitic — ingredient-specific |
6. Main Uses / Indications | Treatment of susceptible infections/parasitoses according to the approved indication. |
7. Mechanism / Basic Description | Ingredient-specific antimicrobial/antiparasitic mechanism. |
8. Dosage Form & Route | Oral or other formulation-specific route. |
9. Prescription / OTC Status | Generally prescription/regulated medicine; exact status varies by jurisdiction. |
10. Major Warnings / Contraindications / Key Interactions | Allergy, interactions, resistance/appropriate-use restrictions and indication-specific precautions require label review. |
11. India Export Considerations | Verify Indian manufacturing licence/product permission, GMP status, formulation authorization, exporter eligibility, labeling and destination-specific export documentation. |
12. HS Code / Customs Classification — TO BE VERIFIED | Do not assign a final HS/ITC-HS code from the medicine name alone. Confirm with the exact dosage form, packing and Indian customs classification. |
13. 26-Country Regulatory Status | Preliminary screen: 🟡 registration/authorization generally required in all 26 markets. Upgrade to 🟠/🔴/⚫ where the ingredient, formulation or destination law imposes special controls; exact status must be verified. |
14. Country Regulatory Authority | See the 26-country matrix at the beginning of this document; the responsible authority varies by destination. |
15. Registration / Marketing Authorization Requirements | Typically product dossier/quality data, manufacturing information, stability, labeling, local applicant/importer authorization and any country-specific clinical/bioequivalence or GMP evidence required. |
16. Export Requirements & Special Restrictions | Product-specific regulatory review required before export. |
17. Buyer Type | Licensed pharmaceutical importer/distributor/wholesaler; hospitals or institutional buyers where appropriate. Veterinary products require appropriately licensed animal-health buyers. |
18. Required Export / Regulatory Documentation | Commercial invoice; packing list; transport documents; certificate of origin where required; COA; GMP/manufacturing documents; product registration/authorization documents; import permit or controlled-drug permit where applicable. |
19. Commercial Considerations | Confirm MOQ, pack size, shelf life, lead time, private-label/OEM availability, registration ownership, Incoterm, freight, insurance, payment terms and landed cost before quotation. |
20. Exporter Decision / Verification Checklist | ☐ Exact product/formulation confirmed ☐ Manufacturer verified ☐ GMP verified ☐ Indian authorization verified ☐ Destination registration checked ☐ Importer licence checked ☐ Controlled/special status checked ☐ COA/stability documents checked ☐ HS code verified ☐ Buyer verified |
113. IVERMECTIN TABLETS USP 80 MG
1. Medicine / Product Name | IVERMECTIN TABLETS USP 80 MG |
2. Generic / API / Composition | IVERMECTIN USP 80 MG — exact composition/API to be confirmed from manufacturer specification. |
3. Salt / Strength | Strength/salt as stated in the source where available; otherwise verify the exact product specification. |
4. Therapeutic Category | Anti-infective / antiparasitic medicine |
5. Pharmacological / Drug Class | Antibacterial, antiprotozoal or antiparasitic — ingredient-specific |
6. Main Uses / Indications | Treatment of susceptible infections/parasitoses according to the approved indication. |
7. Mechanism / Basic Description | Ingredient-specific antimicrobial/antiparasitic mechanism. |
8. Dosage Form & Route | Oral or other formulation-specific route. |
9. Prescription / OTC Status | Generally prescription/regulated medicine; exact status varies by jurisdiction. |
10. Major Warnings / Contraindications / Key Interactions | Allergy, interactions, resistance/appropriate-use restrictions and indication-specific precautions require label review. |
11. India Export Considerations | Verify Indian manufacturing licence/product permission, GMP status, formulation authorization, exporter eligibility, labeling and destination-specific export documentation. |
12. HS Code / Customs Classification — TO BE VERIFIED | Do not assign a final HS/ITC-HS code from the medicine name alone. Confirm with the exact dosage form, packing and Indian customs classification. |
13. 26-Country Regulatory Status | Preliminary screen: 🟡 registration/authorization generally required in all 26 markets. Upgrade to 🟠/🔴/⚫ where the ingredient, formulation or destination law imposes special controls; exact status must be verified. |
14. Country Regulatory Authority | See the 26-country matrix at the beginning of this document; the responsible authority varies by destination. |
15. Registration / Marketing Authorization Requirements | Typically product dossier/quality data, manufacturing information, stability, labeling, local applicant/importer authorization and any country-specific clinical/bioequivalence or GMP evidence required. |
16. Export Requirements & Special Restrictions | Product-specific regulatory review required before export. |
17. Buyer Type | Licensed pharmaceutical importer/distributor/wholesaler; hospitals or institutional buyers where appropriate. Veterinary products require appropriately licensed animal-health buyers. |
18. Required Export / Regulatory Documentation | Commercial invoice; packing list; transport documents; certificate of origin where required; COA; GMP/manufacturing documents; product registration/authorization documents; import permit or controlled-drug permit where applicable. |
19. Commercial Considerations | Confirm MOQ, pack size, shelf life, lead time, private-label/OEM availability, registration ownership, Incoterm, freight, insurance, payment terms and landed cost before quotation. |
20. Exporter Decision / Verification Checklist | ☐ Exact product/formulation confirmed ☐ Manufacturer verified ☐ GMP verified ☐ Indian authorization verified ☐ Destination registration checked ☐ Importer licence checked ☐ Controlled/special status checked ☐ COA/stability documents checked ☐ HS code verified ☐ Buyer verified |
114. IVERMECTIN TABLETS USP 24 MG
1. Medicine / Product Name | IVERMECTIN TABLETS USP 24 MG |
2. Generic / API / Composition | IVERMECTIN USP 24 MG — exact composition/API to be confirmed from manufacturer specification. |
3. Salt / Strength | Strength/salt as stated in the source where available; otherwise verify the exact product specification. |
4. Therapeutic Category | Anti-infective / antiparasitic medicine |
5. Pharmacological / Drug Class | Antibacterial, antiprotozoal or antiparasitic — ingredient-specific |
6. Main Uses / Indications | Treatment of susceptible infections/parasitoses according to the approved indication. |
7. Mechanism / Basic Description | Ingredient-specific antimicrobial/antiparasitic mechanism. |
8. Dosage Form & Route | Oral or other formulation-specific route. |
9. Prescription / OTC Status | Generally prescription/regulated medicine; exact status varies by jurisdiction. |
10. Major Warnings / Contraindications / Key Interactions | Allergy, interactions, resistance/appropriate-use restrictions and indication-specific precautions require label review. |
11. India Export Considerations | Verify Indian manufacturing licence/product permission, GMP status, formulation authorization, exporter eligibility, labeling and destination-specific export documentation. |
12. HS Code / Customs Classification — TO BE VERIFIED | Do not assign a final HS/ITC-HS code from the medicine name alone. Confirm with the exact dosage form, packing and Indian customs classification. |
13. 26-Country Regulatory Status | Preliminary screen: 🟡 registration/authorization generally required in all 26 markets. Upgrade to 🟠/🔴/⚫ where the ingredient, formulation or destination law imposes special controls; exact status must be verified. |
14. Country Regulatory Authority | See the 26-country matrix at the beginning of this document; the responsible authority varies by destination. |
15. Registration / Marketing Authorization Requirements | Typically product dossier/quality data, manufacturing information, stability, labeling, local applicant/importer authorization and any country-specific clinical/bioequivalence or GMP evidence required. |
16. Export Requirements & Special Restrictions | Product-specific regulatory review required before export. |
17. Buyer Type | Licensed pharmaceutical importer/distributor/wholesaler; hospitals or institutional buyers where appropriate. Veterinary products require appropriately licensed animal-health buyers. |
18. Required Export / Regulatory Documentation | Commercial invoice; packing list; transport documents; certificate of origin where required; COA; GMP/manufacturing documents; product registration/authorization documents; import permit or controlled-drug permit where applicable. |
19. Commercial Considerations | Confirm MOQ, pack size, shelf life, lead time, private-label/OEM availability, registration ownership, Incoterm, freight, insurance, payment terms and landed cost before quotation. |
20. Exporter Decision / Verification Checklist | ☐ Exact product/formulation confirmed ☐ Manufacturer verified ☐ GMP verified ☐ Indian authorization verified ☐ Destination registration checked ☐ Importer licence checked ☐ Controlled/special status checked ☐ COA/stability documents checked ☐ HS code verified ☐ Buyer verified |
115. IVERMECTIN TABLETS USP 40 MG
1. Medicine / Product Name | IVERMECTIN TABLETS USP 40 MG |
2. Generic / API / Composition | IVERMECTIN USP 40 MG — exact composition/API to be confirmed from manufacturer specification. |
3. Salt / Strength | Strength/salt as stated in the source where available; otherwise verify the exact product specification. |
4. Therapeutic Category | Anti-infective / antiparasitic medicine |
5. Pharmacological / Drug Class | Antibacterial, antiprotozoal or antiparasitic — ingredient-specific |
6. Main Uses / Indications | Treatment of susceptible infections/parasitoses according to the approved indication. |
7. Mechanism / Basic Description | Ingredient-specific antimicrobial/antiparasitic mechanism. |
8. Dosage Form & Route | Oral or other formulation-specific route. |
9. Prescription / OTC Status | Generally prescription/regulated medicine; exact status varies by jurisdiction. |
10. Major Warnings / Contraindications / Key Interactions | Allergy, interactions, resistance/appropriate-use restrictions and indication-specific precautions require label review. |
11. India Export Considerations | Verify Indian manufacturing licence/product permission, GMP status, formulation authorization, exporter eligibility, labeling and destination-specific export documentation. |
12. HS Code / Customs Classification — TO BE VERIFIED | Do not assign a final HS/ITC-HS code from the medicine name alone. Confirm with the exact dosage form, packing and Indian customs classification. |
13. 26-Country Regulatory Status | Preliminary screen: 🟡 registration/authorization generally required in all 26 markets. Upgrade to 🟠/🔴/⚫ where the ingredient, formulation or destination law imposes special controls; exact status must be verified. |
14. Country Regulatory Authority | See the 26-country matrix at the beginning of this document; the responsible authority varies by destination. |
15. Registration / Marketing Authorization Requirements | Typically product dossier/quality data, manufacturing information, stability, labeling, local applicant/importer authorization and any country-specific clinical/bioequivalence or GMP evidence required. |
16. Export Requirements & Special Restrictions | Product-specific regulatory review required before export. |
17. Buyer Type | Licensed pharmaceutical importer/distributor/wholesaler; hospitals or institutional buyers where appropriate. Veterinary products require appropriately licensed animal-health buyers. |
18. Required Export / Regulatory Documentation | Commercial invoice; packing list; transport documents; certificate of origin where required; COA; GMP/manufacturing documents; product registration/authorization documents; import permit or controlled-drug permit where applicable. |
19. Commercial Considerations | Confirm MOQ, pack size, shelf life, lead time, private-label/OEM availability, registration ownership, Incoterm, freight, insurance, payment terms and landed cost before quotation. |
20. Exporter Decision / Verification Checklist | ☐ Exact product/formulation confirmed ☐ Manufacturer verified ☐ GMP verified ☐ Indian authorization verified ☐ Destination registration checked ☐ Importer licence checked ☐ Controlled/special status checked ☐ COA/stability documents checked ☐ HS code verified ☐ Buyer verified |
116. SILDENAFIL CITRATE AND DAPOXETINE TABLETS
1. Medicine / Product Name | SILDENAFIL CITRATE AND DAPOXETINE TABLETS |
2. Generic / API / Composition | SILDENAFIL CITRATE AND DAPOXETINE — exact composition/API to be confirmed from manufacturer specification. |
3. Salt / Strength | Strength/salt as stated in the source where available; otherwise verify the exact product specification. |
4. Therapeutic Category | Genitourinary / erectile-dysfunction medicine |
5. Pharmacological / Drug Class | PDE-5 inhibitor |
6. Main Uses / Indications | Treatment of erectile dysfunction; exact indications vary by product and market. |
7. Mechanism / Basic Description | Inhibits PDE-5, increasing cGMP-mediated smooth-muscle relaxation. |
8. Dosage Form & Route | Oral; exact formulation (tablet/jelly/etc.) must be verified. |
9. Prescription / OTC Status | Generally prescription/regulated medicine; exact status varies by jurisdiction. |
10. Major Warnings / Contraindications / Key Interactions | Nitrates/riociguat and cardiovascular conditions require particular attention; formulation and local labeling must be checked. |
11. India Export Considerations | Verify Indian manufacturing licence/product permission, GMP status, formulation authorization, exporter eligibility, labeling and destination-specific export documentation. |
12. HS Code / Customs Classification — TO BE VERIFIED | Do not assign a final HS/ITC-HS code from the medicine name alone. Confirm with the exact dosage form, packing and Indian customs classification. |
13. 26-Country Regulatory Status | Preliminary screen: 🟡 registration/authorization generally required in all 26 markets. Upgrade to 🟠/🔴/⚫ where the ingredient, formulation or destination law imposes special controls; exact status must be verified. |
14. Country Regulatory Authority | See the 26-country matrix at the beginning of this document; the responsible authority varies by destination. |
15. Registration / Marketing Authorization Requirements | Typically product dossier/quality data, manufacturing information, stability, labeling, local applicant/importer authorization and any country-specific clinical/bioequivalence or GMP evidence required. |
16. Export Requirements & Special Restrictions | Product-specific regulatory review required before export. |
17. Buyer Type | Licensed pharmaceutical importer/distributor/wholesaler; hospitals or institutional buyers where appropriate. Veterinary products require appropriately licensed animal-health buyers. |
18. Required Export / Regulatory Documentation | Commercial invoice; packing list; transport documents; certificate of origin where required; COA; GMP/manufacturing documents; product registration/authorization documents; import permit or controlled-drug permit where applicable. |
19. Commercial Considerations | Confirm MOQ, pack size, shelf life, lead time, private-label/OEM availability, registration ownership, Incoterm, freight, insurance, payment terms and landed cost before quotation. |
20. Exporter Decision / Verification Checklist | ☐ Exact product/formulation confirmed ☐ Manufacturer verified ☐ GMP verified ☐ Indian authorization verified ☐ Destination registration checked ☐ Importer licence checked ☐ Controlled/special status checked ☐ COA/stability documents checked ☐ HS code verified ☐ Buyer verified |
117. KETOROLAC TROMETHAMINE INJECTION IP
1. Medicine / Product Name | KETOROLAC TROMETHAMINE INJECTION IP |
2. Generic / API / Composition | KETOROLAC TROMETHAMINE IP — exact composition/API to be confirmed from manufacturer specification. |
3. Salt / Strength | Strength/salt as stated in the source where available; otherwise verify the exact product specification. |
4. Therapeutic Category | Analgesic / gastrointestinal medicine |
5. Pharmacological / Drug Class | Ingredient-specific analgesic or GI agent |
6. Main Uses / Indications | Pain/inflammation or gastrointestinal indication according to ingredient. |
7. Mechanism / Basic Description | Ingredient-specific mechanism. |
8. Dosage Form & Route | Route/formulation: verify from the exact product specification. |
9. Prescription / OTC Status | Generally prescription/regulated medicine; exact status varies by jurisdiction. |
10. Major Warnings / Contraindications / Key Interactions | Check official label for contraindications, interactions, pregnancy warnings, organ-function precautions and formulation-specific risks. |
11. India Export Considerations | Verify Indian manufacturing licence/product permission, GMP status, formulation authorization, exporter eligibility, labeling and destination-specific export documentation. |
12. HS Code / Customs Classification — TO BE VERIFIED | Do not assign a final HS/ITC-HS code from the medicine name alone. Confirm with the exact dosage form, packing and Indian customs classification. |
13. 26-Country Regulatory Status | Preliminary screen: 🟡 registration/authorization generally required in all 26 markets. Upgrade to 🟠/🔴/⚫ where the ingredient, formulation or destination law imposes special controls; exact status must be verified. |
14. Country Regulatory Authority | See the 26-country matrix at the beginning of this document; the responsible authority varies by destination. |
15. Registration / Marketing Authorization Requirements | Typically product dossier/quality data, manufacturing information, stability, labeling, local applicant/importer authorization and any country-specific clinical/bioequivalence or GMP evidence required. |
16. Export Requirements & Special Restrictions | Product-specific regulatory review required before export. Sterile/injectable or biologic quality, storage and manufacturing controls may apply. |
17. Buyer Type | Licensed pharmaceutical importer/distributor/wholesaler; hospitals or institutional buyers where appropriate. Veterinary products require appropriately licensed animal-health buyers. |
18. Required Export / Regulatory Documentation | Commercial invoice; packing list; transport documents; certificate of origin where required; COA; GMP/manufacturing documents; product registration/authorization documents; import permit or controlled-drug permit where applicable. |
19. Commercial Considerations | Confirm MOQ, pack size, shelf life, lead time, private-label/OEM availability, registration ownership, Incoterm, freight, insurance, payment terms and landed cost before quotation. |
20. Exporter Decision / Verification Checklist | ☐ Exact product/formulation confirmed ☐ Manufacturer verified ☐ GMP verified ☐ Indian authorization verified ☐ Destination registration checked ☐ Importer licence checked ☐ Controlled/special status checked ☐ COA/stability documents checked ☐ HS code verified ☐ Buyer verified |
118. SOMATROPIN FOR INJECTION IP RECOMBINANT HUMAN GROWTH HORMONE FOR INJECTION
1. Medicine / Product Name | SOMATROPIN FOR INJECTION IP RECOMBINANT HUMAN GROWTH HORMONE FOR INJECTION |
2. Generic / API / Composition | SOMATROPIN FOR IP RECOMBINANT HUMAN GROWTH HORMONE FOR — exact composition/API to be confirmed from manufacturer specification. |
3. Salt / Strength | Strength/salt as stated in the source where available; otherwise verify the exact product specification. |
4. Therapeutic Category | Biologic / growth hormone |
5. Pharmacological / Drug Class | Recombinant human growth hormone |
6. Main Uses / Indications | Approved growth-hormone deficiency and other indication-specific uses. |
7. Mechanism / Basic Description | Activates growth-hormone receptors and downstream IGF-1 pathways. |
8. Dosage Form & Route | Parenteral injection. |
9. Prescription / OTC Status | Generally prescription/regulated medicine; exact status varies by jurisdiction. |
10. Major Warnings / Contraindications / Key Interactions | Growth-related, metabolic and endocrine precautions; cold-chain/storage requirements must be checked. |
11. India Export Considerations | Verify Indian manufacturing licence/product permission, GMP status, formulation authorization, exporter eligibility, labeling and destination-specific export documentation. |
12. HS Code / Customs Classification — TO BE VERIFIED | Do not assign a final HS/ITC-HS code from the medicine name alone. Confirm with the exact dosage form, packing and Indian customs classification. |
13. 26-Country Regulatory Status | Preliminary screen: 🟡 registration/authorization generally required in all 26 markets. Upgrade to 🟠/🔴/⚫ where the ingredient, formulation or destination law imposes special controls; exact status must be verified. |
14. Country Regulatory Authority | See the 26-country matrix at the beginning of this document; the responsible authority varies by destination. |
15. Registration / Marketing Authorization Requirements | Typically product dossier/quality data, manufacturing information, stability, labeling, local applicant/importer authorization and any country-specific clinical/bioequivalence or GMP evidence required. |
16. Export Requirements & Special Restrictions | Biologic/cold-chain and destination registration requirements. Sterile/injectable or biologic quality, storage and manufacturing controls may apply. |
17. Buyer Type | Licensed pharmaceutical importer/distributor/wholesaler; hospitals or institutional buyers where appropriate. Veterinary products require appropriately licensed animal-health buyers. |
18. Required Export / Regulatory Documentation | Commercial invoice; packing list; transport documents; certificate of origin where required; COA; GMP/manufacturing documents; product registration/authorization documents; import permit or controlled-drug permit where applicable. |
19. Commercial Considerations | Confirm MOQ, pack size, shelf life, lead time, private-label/OEM availability, registration ownership, Incoterm, freight, insurance, payment terms and landed cost before quotation. |
20. Exporter Decision / Verification Checklist | ☐ Exact product/formulation confirmed ☐ Manufacturer verified ☐ GMP verified ☐ Indian authorization verified ☐ Destination registration checked ☐ Importer licence checked ☐ Controlled/special status checked ☐ COA/stability documents checked ☐ HS code verified ☐ Buyer verified |
119. IVABRADINE TABLETS 5 MG
1. Medicine / Product Name | IVABRADINE TABLETS 5 MG |
2. Generic / API / Composition | IVABRADINE 5 MG — exact composition/API to be confirmed from manufacturer specification. |
3. Salt / Strength | Strength/salt as stated in the source where available; otherwise verify the exact product specification. |
4. Therapeutic Category | Cardiometabolic medicine |
5. Pharmacological / Drug Class | Ingredient-specific metabolic/cardiovascular agent |
6. Main Uses / Indications | Cardiovascular, lipid or glucose-management indication according to the exact ingredient. |
7. Mechanism / Basic Description | Ingredient-specific; verify official label. |
8. Dosage Form & Route | Usually oral, except formulation-specific products. |
9. Prescription / OTC Status | Generally prescription/regulated medicine; exact status varies by jurisdiction. |
10. Major Warnings / Contraindications / Key Interactions | Check official label for contraindications, interactions, pregnancy warnings, organ-function precautions and formulation-specific risks. |
11. India Export Considerations | Verify Indian manufacturing licence/product permission, GMP status, formulation authorization, exporter eligibility, labeling and destination-specific export documentation. |
12. HS Code / Customs Classification — TO BE VERIFIED | Do not assign a final HS/ITC-HS code from the medicine name alone. Confirm with the exact dosage form, packing and Indian customs classification. |
13. 26-Country Regulatory Status | Preliminary screen: 🟡 registration/authorization generally required in all 26 markets. Upgrade to 🟠/🔴/⚫ where the ingredient, formulation or destination law imposes special controls; exact status must be verified. |
14. Country Regulatory Authority | See the 26-country matrix at the beginning of this document; the responsible authority varies by destination. |
15. Registration / Marketing Authorization Requirements | Typically product dossier/quality data, manufacturing information, stability, labeling, local applicant/importer authorization and any country-specific clinical/bioequivalence or GMP evidence required. |
16. Export Requirements & Special Restrictions | Product-specific regulatory review required before export. |
17. Buyer Type | Licensed pharmaceutical importer/distributor/wholesaler; hospitals or institutional buyers where appropriate. Veterinary products require appropriately licensed animal-health buyers. |
18. Required Export / Regulatory Documentation | Commercial invoice; packing list; transport documents; certificate of origin where required; COA; GMP/manufacturing documents; product registration/authorization documents; import permit or controlled-drug permit where applicable. |
19. Commercial Considerations | Confirm MOQ, pack size, shelf life, lead time, private-label/OEM availability, registration ownership, Incoterm, freight, insurance, payment terms and landed cost before quotation. |
20. Exporter Decision / Verification Checklist | ☐ Exact product/formulation confirmed ☐ Manufacturer verified ☐ GMP verified ☐ Indian authorization verified ☐ Destination registration checked ☐ Importer licence checked ☐ Controlled/special status checked ☐ COA/stability documents checked ☐ HS code verified ☐ Buyer verified |
120. DROSTANOLONE ENANTHATE 200 MG
1. Medicine / Product Name | DROSTANOLONE ENANTHATE 200 MG |
2. Generic / API / Composition | DROSTANOLONE ENANTHATE 200 MG — exact composition/API to be confirmed from manufacturer specification. |
3. Salt / Strength | Strength/salt as stated in the source where available; otherwise verify the exact product specification. |
4. Therapeutic Category | Androgen / anabolic-hormonal medicine |
5. Pharmacological / Drug Class | Androgenic/anabolic steroid or testosterone preparation |
6. Main Uses / Indications | Hormone-replacement or other approved indication depends on the specific substance and formulation. |
7. Mechanism / Basic Description | Acts through androgen receptors; exact pharmacology varies by compound. |
8. Dosage Form & Route | Oral, topical or injectable depending on formulation. |
9. Prescription / OTC Status | Prescription; often subject to additional controlled-substance/hormone rules. |
10. Major Warnings / Contraindications / Key Interactions | Hormonal adverse effects, cardiovascular/thrombotic risks, hepatic risks for some oral agents, reproductive effects and local controlled-drug rules require review. |
11. India Export Considerations | Verify Indian manufacturing licence/product permission, GMP status, formulation authorization, exporter eligibility, labeling and destination-specific export documentation. |
12. HS Code / Customs Classification — TO BE VERIFIED | Do not assign a final HS/ITC-HS code from the medicine name alone. Confirm with the exact dosage form, packing and Indian customs classification. |
13. 26-Country Regulatory Status | Preliminary screen: 🟡 registration/authorization generally required in all 26 markets. Upgrade to 🟠/🔴/⚫ where the ingredient, formulation or destination law imposes special controls; exact status must be verified. |
14. Country Regulatory Authority | See the 26-country matrix at the beginning of this document; the responsible authority varies by destination. |
15. Registration / Marketing Authorization Requirements | Typically product dossier/quality data, manufacturing information, stability, labeling, local applicant/importer authorization and any country-specific clinical/bioequivalence or GMP evidence required. |
16. Export Requirements & Special Restrictions | High-priority regulatory verification; some jurisdictions impose controlled-substance or special import restrictions. Controlled/psychotropic/hormonal classification must be checked separately in each destination. Sterile/injectable or biologic quality, storage and manufacturing controls may apply. |
17. Buyer Type | Licensed pharmaceutical importer/distributor/wholesaler; hospitals or institutional buyers where appropriate. Veterinary products require appropriately licensed animal-health buyers. |
18. Required Export / Regulatory Documentation | Commercial invoice; packing list; transport documents; certificate of origin where required; COA; GMP/manufacturing documents; product registration/authorization documents; import permit or controlled-drug permit where applicable. |
19. Commercial Considerations | Confirm MOQ, pack size, shelf life, lead time, private-label/OEM availability, registration ownership, Incoterm, freight, insurance, payment terms and landed cost before quotation. |
20. Exporter Decision / Verification Checklist | ☐ Exact product/formulation confirmed ☐ Manufacturer verified ☐ GMP verified ☐ Indian authorization verified ☐ Destination registration checked ☐ Importer licence checked ☐ Controlled/special status checked ☐ COA/stability documents checked ☐ HS code verified ☐ Buyer verified |
121. SALBUTAMOL INHALATION IP 100 MCG / DOSE
1. Medicine / Product Name | SALBUTAMOL INHALATION IP 100 MCG / DOSE |
2. Generic / API / Composition | SALBUTAMOL INHALATION IP 100 MCG / DOSE — exact composition/API to be confirmed from manufacturer specification. |
3. Salt / Strength | Strength/salt as stated in the source where available; otherwise verify the exact product specification. |
4. Therapeutic Category | Respiratory medicine |
5. Pharmacological / Drug Class | Beta-2 adrenergic agonist |
6. Main Uses / Indications | Bronchodilator therapy in approved respiratory conditions. |
7. Mechanism / Basic Description | Relaxes bronchial smooth muscle through beta-2 receptor stimulation. |
8. Dosage Form & Route | Oral or inhaled depending on formulation. |
9. Prescription / OTC Status | Generally prescription/regulated medicine; exact status varies by jurisdiction. |
10. Major Warnings / Contraindications / Key Interactions | Check official label for contraindications, interactions, pregnancy warnings, organ-function precautions and formulation-specific risks. |
11. India Export Considerations | Verify Indian manufacturing licence/product permission, GMP status, formulation authorization, exporter eligibility, labeling and destination-specific export documentation. |
12. HS Code / Customs Classification — TO BE VERIFIED | Do not assign a final HS/ITC-HS code from the medicine name alone. Confirm with the exact dosage form, packing and Indian customs classification. |
13. 26-Country Regulatory Status | Preliminary screen: 🟡 registration/authorization generally required in all 26 markets. Upgrade to 🟠/🔴/⚫ where the ingredient, formulation or destination law imposes special controls; exact status must be verified. |
14. Country Regulatory Authority | See the 26-country matrix at the beginning of this document; the responsible authority varies by destination. |
15. Registration / Marketing Authorization Requirements | Typically product dossier/quality data, manufacturing information, stability, labeling, local applicant/importer authorization and any country-specific clinical/bioequivalence or GMP evidence required. |
16. Export Requirements & Special Restrictions | Product-specific regulatory review required before export. |
17. Buyer Type | Licensed pharmaceutical importer/distributor/wholesaler; hospitals or institutional buyers where appropriate. Veterinary products require appropriately licensed animal-health buyers. |
18. Required Export / Regulatory Documentation | Commercial invoice; packing list; transport documents; certificate of origin where required; COA; GMP/manufacturing documents; product registration/authorization documents; import permit or controlled-drug permit where applicable. |
19. Commercial Considerations | Confirm MOQ, pack size, shelf life, lead time, private-label/OEM availability, registration ownership, Incoterm, freight, insurance, payment terms and landed cost before quotation. |
20. Exporter Decision / Verification Checklist | ☐ Exact product/formulation confirmed ☐ Manufacturer verified ☐ GMP verified ☐ Indian authorization verified ☐ Destination registration checked ☐ Importer licence checked ☐ Controlled/special status checked ☐ COA/stability documents checked ☐ HS code verified ☐ Buyer verified |
122. TESTOSTERONE ENANTHATE USP 250 MG / ML
1. Medicine / Product Name | TESTOSTERONE ENANTHATE USP 250 MG / ML |
2. Generic / API / Composition | TESTOSTERONE ENANTHATE USP 250 MG / ML — exact composition/API to be confirmed from manufacturer specification. |
3. Salt / Strength | Strength/salt as stated in the source where available; otherwise verify the exact product specification. |
4. Therapeutic Category | Androgen / anabolic-hormonal medicine |
5. Pharmacological / Drug Class | Androgenic/anabolic steroid or testosterone preparation |
6. Main Uses / Indications | Hormone-replacement or other approved indication depends on the specific substance and formulation. |
7. Mechanism / Basic Description | Acts through androgen receptors; exact pharmacology varies by compound. |
8. Dosage Form & Route | Oral, topical or injectable depending on formulation. |
9. Prescription / OTC Status | Prescription; often subject to additional controlled-substance/hormone rules. |
10. Major Warnings / Contraindications / Key Interactions | Hormonal adverse effects, cardiovascular/thrombotic risks, hepatic risks for some oral agents, reproductive effects and local controlled-drug rules require review. |
11. India Export Considerations | Verify Indian manufacturing licence/product permission, GMP status, formulation authorization, exporter eligibility, labeling and destination-specific export documentation. |
12. HS Code / Customs Classification — TO BE VERIFIED | Do not assign a final HS/ITC-HS code from the medicine name alone. Confirm with the exact dosage form, packing and Indian customs classification. |
13. 26-Country Regulatory Status | Preliminary screen: 🟡 registration/authorization generally required in all 26 markets. Upgrade to 🟠/🔴/⚫ where the ingredient, formulation or destination law imposes special controls; exact status must be verified. |
14. Country Regulatory Authority | See the 26-country matrix at the beginning of this document; the responsible authority varies by destination. |
15. Registration / Marketing Authorization Requirements | Typically product dossier/quality data, manufacturing information, stability, labeling, local applicant/importer authorization and any country-specific clinical/bioequivalence or GMP evidence required. |
16. Export Requirements & Special Restrictions | High-priority regulatory verification; some jurisdictions impose controlled-substance or special import restrictions. Controlled/psychotropic/hormonal classification must be checked separately in each destination. Sterile/injectable or biologic quality, storage and manufacturing controls may apply. |
17. Buyer Type | Licensed pharmaceutical importer/distributor/wholesaler; hospitals or institutional buyers where appropriate. Veterinary products require appropriately licensed animal-health buyers. |
18. Required Export / Regulatory Documentation | Commercial invoice; packing list; transport documents; certificate of origin where required; COA; GMP/manufacturing documents; product registration/authorization documents; import permit or controlled-drug permit where applicable. |
19. Commercial Considerations | Confirm MOQ, pack size, shelf life, lead time, private-label/OEM availability, registration ownership, Incoterm, freight, insurance, payment terms and landed cost before quotation. |
20. Exporter Decision / Verification Checklist | ☐ Exact product/formulation confirmed ☐ Manufacturer verified ☐ GMP verified ☐ Indian authorization verified ☐ Destination registration checked ☐ Importer licence checked ☐ Controlled/special status checked ☐ COA/stability documents checked ☐ HS code verified ☐ Buyer verified |
123. EXEMESTANE TABLETS IP 25 MG
1. Medicine / Product Name | EXEMESTANE TABLETS IP 25 MG |
2. Generic / API / Composition | EXEMESTANE IP 25 MG — exact composition/API to be confirmed from manufacturer specification. |
3. Salt / Strength | Strength/salt as stated in the source where available; otherwise verify the exact product specification. |
4. Therapeutic Category | Hormonal / endocrine medicine |
5. Pharmacological / Drug Class | Hormonal pathway modulator |
6. Main Uses / Indications | Endocrine or oncology/fertility indication depending on ingredient. |
7. Mechanism / Basic Description | Ingredient-specific estrogen-receptor or aromatase pathway modulation. |
8. Dosage Form & Route | Route/formulation: verify from the exact product specification. |
9. Prescription / OTC Status | Generally prescription/regulated medicine; exact status varies by jurisdiction. |
10. Major Warnings / Contraindications / Key Interactions | Check official label for contraindications, interactions, pregnancy warnings, organ-function precautions and formulation-specific risks. |
11. India Export Considerations | Verify Indian manufacturing licence/product permission, GMP status, formulation authorization, exporter eligibility, labeling and destination-specific export documentation. |
12. HS Code / Customs Classification — TO BE VERIFIED | Do not assign a final HS/ITC-HS code from the medicine name alone. Confirm with the exact dosage form, packing and Indian customs classification. |
13. 26-Country Regulatory Status | Preliminary screen: 🟡 registration/authorization generally required in all 26 markets. Upgrade to 🟠/🔴/⚫ where the ingredient, formulation or destination law imposes special controls; exact status must be verified. |
14. Country Regulatory Authority | See the 26-country matrix at the beginning of this document; the responsible authority varies by destination. |
15. Registration / Marketing Authorization Requirements | Typically product dossier/quality data, manufacturing information, stability, labeling, local applicant/importer authorization and any country-specific clinical/bioequivalence or GMP evidence required. |
16. Export Requirements & Special Restrictions | Hormonal/oncology regulatory review may apply. |
17. Buyer Type | Licensed pharmaceutical importer/distributor/wholesaler; hospitals or institutional buyers where appropriate. Veterinary products require appropriately licensed animal-health buyers. |
18. Required Export / Regulatory Documentation | Commercial invoice; packing list; transport documents; certificate of origin where required; COA; GMP/manufacturing documents; product registration/authorization documents; import permit or controlled-drug permit where applicable. |
19. Commercial Considerations | Confirm MOQ, pack size, shelf life, lead time, private-label/OEM availability, registration ownership, Incoterm, freight, insurance, payment terms and landed cost before quotation. |
20. Exporter Decision / Verification Checklist | ☐ Exact product/formulation confirmed ☐ Manufacturer verified ☐ GMP verified ☐ Indian authorization verified ☐ Destination registration checked ☐ Importer licence checked ☐ Controlled/special status checked ☐ COA/stability documents checked ☐ HS code verified ☐ Buyer verified |
124. CYCLOSPORINE EYE DROPS 0.05% W/V ( CIPVISION )
1. Medicine / Product Name | CYCLOSPORINE EYE DROPS 0.05% W/V ( CIPVISION ) |
2. Generic / API / Composition | CYCLOSPORINE EYE DROPS 0.05% W/V ( CIPVISION ) — exact composition/API to be confirmed from manufacturer specification. |
3. Salt / Strength | Strength/salt as stated in the source where available; otherwise verify the exact product specification. |
4. Therapeutic Category | Immunomodulatory / anti-inflammatory medicine |
5. Pharmacological / Drug Class | Ingredient-specific immunosuppressive or anti-inflammatory agent |
6. Main Uses / Indications | Inflammatory, autoimmune or transplant-related indications depending on ingredient/formulation. |
7. Mechanism / Basic Description | Ingredient-specific immunomodulatory mechanism. |
8. Dosage Form & Route | Route/formulation: verify from the exact product specification. |
9. Prescription / OTC Status | Generally prescription/regulated medicine; exact status varies by jurisdiction. |
10. Major Warnings / Contraindications / Key Interactions | Infection risk, immunosuppression and drug interactions can be important; specialist labeling must be followed. |
11. India Export Considerations | Verify Indian manufacturing licence/product permission, GMP status, formulation authorization, exporter eligibility, labeling and destination-specific export documentation. |
12. HS Code / Customs Classification — TO BE VERIFIED | Do not assign a final HS/ITC-HS code from the medicine name alone. Confirm with the exact dosage form, packing and Indian customs classification. |
13. 26-Country Regulatory Status | Preliminary screen: 🟡 registration/authorization generally required in all 26 markets. Upgrade to 🟠/🔴/⚫ where the ingredient, formulation or destination law imposes special controls; exact status must be verified. |
14. Country Regulatory Authority | See the 26-country matrix at the beginning of this document; the responsible authority varies by destination. |
15. Registration / Marketing Authorization Requirements | Typically product dossier/quality data, manufacturing information, stability, labeling, local applicant/importer authorization and any country-specific clinical/bioequivalence or GMP evidence required. |
16. Export Requirements & Special Restrictions | Higher regulatory and pharmacovigilance scrutiny. Sterile/injectable or biologic quality, storage and manufacturing controls may apply. |
17. Buyer Type | Licensed pharmaceutical importer/distributor/wholesaler; hospitals or institutional buyers where appropriate. Veterinary products require appropriately licensed animal-health buyers. |
18. Required Export / Regulatory Documentation | Commercial invoice; packing list; transport documents; certificate of origin where required; COA; GMP/manufacturing documents; product registration/authorization documents; import permit or controlled-drug permit where applicable. |
19. Commercial Considerations | Confirm MOQ, pack size, shelf life, lead time, private-label/OEM availability, registration ownership, Incoterm, freight, insurance, payment terms and landed cost before quotation. |
20. Exporter Decision / Verification Checklist | ☐ Exact product/formulation confirmed ☐ Manufacturer verified ☐ GMP verified ☐ Indian authorization verified ☐ Destination registration checked ☐ Importer licence checked ☐ Controlled/special status checked ☐ COA/stability documents checked ☐ HS code verified ☐ Buyer verified |
125. FLUOXYMESTERONE 5 MG
1. Medicine / Product Name | FLUOXYMESTERONE 5 MG |
2. Generic / API / Composition | FLUOXYMESTERONE 5 MG — exact composition/API to be confirmed from manufacturer specification. |
3. Salt / Strength | Strength/salt as stated in the source where available; otherwise verify the exact product specification. |
4. Therapeutic Category | Androgen / anabolic-hormonal medicine |
5. Pharmacological / Drug Class | Androgenic/anabolic steroid or testosterone preparation |
6. Main Uses / Indications | Hormone-replacement or other approved indication depends on the specific substance and formulation. |
7. Mechanism / Basic Description | Acts through androgen receptors; exact pharmacology varies by compound. |
8. Dosage Form & Route | Oral, topical or injectable depending on formulation. |
9. Prescription / OTC Status | Prescription; often subject to additional controlled-substance/hormone rules. |
10. Major Warnings / Contraindications / Key Interactions | Hormonal adverse effects, cardiovascular/thrombotic risks, hepatic risks for some oral agents, reproductive effects and local controlled-drug rules require review. |
11. India Export Considerations | Verify Indian manufacturing licence/product permission, GMP status, formulation authorization, exporter eligibility, labeling and destination-specific export documentation. |
12. HS Code / Customs Classification — TO BE VERIFIED | Do not assign a final HS/ITC-HS code from the medicine name alone. Confirm with the exact dosage form, packing and Indian customs classification. |
13. 26-Country Regulatory Status | Preliminary screen: 🟡 registration/authorization generally required in all 26 markets. Upgrade to 🟠/🔴/⚫ where the ingredient, formulation or destination law imposes special controls; exact status must be verified. |
14. Country Regulatory Authority | See the 26-country matrix at the beginning of this document; the responsible authority varies by destination. |
15. Registration / Marketing Authorization Requirements | Typically product dossier/quality data, manufacturing information, stability, labeling, local applicant/importer authorization and any country-specific clinical/bioequivalence or GMP evidence required. |
16. Export Requirements & Special Restrictions | High-priority regulatory verification; some jurisdictions impose controlled-substance or special import restrictions. Controlled/psychotropic/hormonal classification must be checked separately in each destination. |
17. Buyer Type | Licensed pharmaceutical importer/distributor/wholesaler; hospitals or institutional buyers where appropriate. Veterinary products require appropriately licensed animal-health buyers. |
18. Required Export / Regulatory Documentation | Commercial invoice; packing list; transport documents; certificate of origin where required; COA; GMP/manufacturing documents; product registration/authorization documents; import permit or controlled-drug permit where applicable. |
19. Commercial Considerations | Confirm MOQ, pack size, shelf life, lead time, private-label/OEM availability, registration ownership, Incoterm, freight, insurance, payment terms and landed cost before quotation. |
20. Exporter Decision / Verification Checklist | ☐ Exact product/formulation confirmed ☐ Manufacturer verified ☐ GMP verified ☐ Indian authorization verified ☐ Destination registration checked ☐ Importer licence checked ☐ Controlled/special status checked ☐ COA/stability documents checked ☐ HS code verified ☐ Buyer verified |
126. TRETINOIN CREAM USP 0.025 % W/W
1. Medicine / Product Name | TRETINOIN CREAM USP 0.025 % W/W |
2. Generic / API / Composition | TRETINOIN CREAM USP 0.025 % W/W — exact composition/API to be confirmed from manufacturer specification. |
3. Salt / Strength | Strength/salt as stated in the source where available; otherwise verify the exact product specification. |
4. Therapeutic Category | Dermatology / topical or hormonal medicine |
5. Pharmacological / Drug Class | Ingredient-specific dermatologic/hormonal agent |
6. Main Uses / Indications | Dermatologic or hormonal indication according to the exact formulation. |
7. Mechanism / Basic Description | Ingredient-specific; use approved product labeling. |
8. Dosage Form & Route | Topical or oral depending on formulation. |
9. Prescription / OTC Status | Generally prescription/regulated medicine; exact status varies by jurisdiction. |
10. Major Warnings / Contraindications / Key Interactions | Pregnancy/reproductive warnings, systemic absorption, skin reactions and formulation-specific restrictions must be checked. |
11. India Export Considerations | Verify Indian manufacturing licence/product permission, GMP status, formulation authorization, exporter eligibility, labeling and destination-specific export documentation. |
12. HS Code / Customs Classification — TO BE VERIFIED | Do not assign a final HS/ITC-HS code from the medicine name alone. Confirm with the exact dosage form, packing and Indian customs classification. |
13. 26-Country Regulatory Status | Preliminary screen: 🟡 registration/authorization generally required in all 26 markets. Upgrade to 🟠/🔴/⚫ where the ingredient, formulation or destination law imposes special controls; exact status must be verified. |
14. Country Regulatory Authority | See the 26-country matrix at the beginning of this document; the responsible authority varies by destination. |
15. Registration / Marketing Authorization Requirements | Typically product dossier/quality data, manufacturing information, stability, labeling, local applicant/importer authorization and any country-specific clinical/bioequivalence or GMP evidence required. |
16. Export Requirements & Special Restrictions | Product-specific regulatory review required before export. |
17. Buyer Type | Licensed pharmaceutical importer/distributor/wholesaler; hospitals or institutional buyers where appropriate. Veterinary products require appropriately licensed animal-health buyers. |
18. Required Export / Regulatory Documentation | Commercial invoice; packing list; transport documents; certificate of origin where required; COA; GMP/manufacturing documents; product registration/authorization documents; import permit or controlled-drug permit where applicable. |
19. Commercial Considerations | Confirm MOQ, pack size, shelf life, lead time, private-label/OEM availability, registration ownership, Incoterm, freight, insurance, payment terms and landed cost before quotation. |
20. Exporter Decision / Verification Checklist | ☐ Exact product/formulation confirmed ☐ Manufacturer verified ☐ GMP verified ☐ Indian authorization verified ☐ Destination registration checked ☐ Importer licence checked ☐ Controlled/special status checked ☐ COA/stability documents checked ☐ HS code verified ☐ Buyer verified |
127. OXYMETHOLONE U S P 50 MG
1. Medicine / Product Name | OXYMETHOLONE U S P 50 MG |
2. Generic / API / Composition | OXYMETHOLONE U S P 50 MG — exact composition/API to be confirmed from manufacturer specification. |
3. Salt / Strength | Strength/salt as stated in the source where available; otherwise verify the exact product specification. |
4. Therapeutic Category | Androgen / anabolic-hormonal medicine |
5. Pharmacological / Drug Class | Androgenic/anabolic steroid or testosterone preparation |
6. Main Uses / Indications | Hormone-replacement or other approved indication depends on the specific substance and formulation. |
7. Mechanism / Basic Description | Acts through androgen receptors; exact pharmacology varies by compound. |
8. Dosage Form & Route | Oral, topical or injectable depending on formulation. |
9. Prescription / OTC Status | Prescription; often subject to additional controlled-substance/hormone rules. |
10. Major Warnings / Contraindications / Key Interactions | Hormonal adverse effects, cardiovascular/thrombotic risks, hepatic risks for some oral agents, reproductive effects and local controlled-drug rules require review. |
11. India Export Considerations | Verify Indian manufacturing licence/product permission, GMP status, formulation authorization, exporter eligibility, labeling and destination-specific export documentation. |
12. HS Code / Customs Classification — TO BE VERIFIED | Do not assign a final HS/ITC-HS code from the medicine name alone. Confirm with the exact dosage form, packing and Indian customs classification. |
13. 26-Country Regulatory Status | Preliminary screen: 🟡 registration/authorization generally required in all 26 markets. Upgrade to 🟠/🔴/⚫ where the ingredient, formulation or destination law imposes special controls; exact status must be verified. |
14. Country Regulatory Authority | See the 26-country matrix at the beginning of this document; the responsible authority varies by destination. |
15. Registration / Marketing Authorization Requirements | Typically product dossier/quality data, manufacturing information, stability, labeling, local applicant/importer authorization and any country-specific clinical/bioequivalence or GMP evidence required. |
16. Export Requirements & Special Restrictions | High-priority regulatory verification; some jurisdictions impose controlled-substance or special import restrictions. Controlled/psychotropic/hormonal classification must be checked separately in each destination. |
17. Buyer Type | Licensed pharmaceutical importer/distributor/wholesaler; hospitals or institutional buyers where appropriate. Veterinary products require appropriately licensed animal-health buyers. |
18. Required Export / Regulatory Documentation | Commercial invoice; packing list; transport documents; certificate of origin where required; COA; GMP/manufacturing documents; product registration/authorization documents; import permit or controlled-drug permit where applicable. |
19. Commercial Considerations | Confirm MOQ, pack size, shelf life, lead time, private-label/OEM availability, registration ownership, Incoterm, freight, insurance, payment terms and landed cost before quotation. |
20. Exporter Decision / Verification Checklist | ☐ Exact product/formulation confirmed ☐ Manufacturer verified ☐ GMP verified ☐ Indian authorization verified ☐ Destination registration checked ☐ Importer licence checked ☐ Controlled/special status checked ☐ COA/stability documents checked ☐ HS code verified ☐ Buyer verified |
128. FLUOXYMESTERONE TABLETS U S P
1. Medicine / Product Name | FLUOXYMESTERONE TABLETS U S P |
2. Generic / API / Composition | FLUOXYMESTERONE U S P — exact composition/API to be confirmed from manufacturer specification. |
3. Salt / Strength | Strength/salt as stated in the source where available; otherwise verify the exact product specification. |
4. Therapeutic Category | Androgen / anabolic-hormonal medicine |
5. Pharmacological / Drug Class | Androgenic/anabolic steroid or testosterone preparation |
6. Main Uses / Indications | Hormone-replacement or other approved indication depends on the specific substance and formulation. |
7. Mechanism / Basic Description | Acts through androgen receptors; exact pharmacology varies by compound. |
8. Dosage Form & Route | Oral, topical or injectable depending on formulation. |
9. Prescription / OTC Status | Prescription; often subject to additional controlled-substance/hormone rules. |
10. Major Warnings / Contraindications / Key Interactions | Hormonal adverse effects, cardiovascular/thrombotic risks, hepatic risks for some oral agents, reproductive effects and local controlled-drug rules require review. |
11. India Export Considerations | Verify Indian manufacturing licence/product permission, GMP status, formulation authorization, exporter eligibility, labeling and destination-specific export documentation. |
12. HS Code / Customs Classification — TO BE VERIFIED | Do not assign a final HS/ITC-HS code from the medicine name alone. Confirm with the exact dosage form, packing and Indian customs classification. |
13. 26-Country Regulatory Status | Preliminary screen: 🟡 registration/authorization generally required in all 26 markets. Upgrade to 🟠/🔴/⚫ where the ingredient, formulation or destination law imposes special controls; exact status must be verified. |
14. Country Regulatory Authority | See the 26-country matrix at the beginning of this document; the responsible authority varies by destination. |
15. Registration / Marketing Authorization Requirements | Typically product dossier/quality data, manufacturing information, stability, labeling, local applicant/importer authorization and any country-specific clinical/bioequivalence or GMP evidence required. |
16. Export Requirements & Special Restrictions | High-priority regulatory verification; some jurisdictions impose controlled-substance or special import restrictions. Controlled/psychotropic/hormonal classification must be checked separately in each destination. |
17. Buyer Type | Licensed pharmaceutical importer/distributor/wholesaler; hospitals or institutional buyers where appropriate. Veterinary products require appropriately licensed animal-health buyers. |
18. Required Export / Regulatory Documentation | Commercial invoice; packing list; transport documents; certificate of origin where required; COA; GMP/manufacturing documents; product registration/authorization documents; import permit or controlled-drug permit where applicable. |
19. Commercial Considerations | Confirm MOQ, pack size, shelf life, lead time, private-label/OEM availability, registration ownership, Incoterm, freight, insurance, payment terms and landed cost before quotation. |
20. Exporter Decision / Verification Checklist | ☐ Exact product/formulation confirmed ☐ Manufacturer verified ☐ GMP verified ☐ Indian authorization verified ☐ Destination registration checked ☐ Importer licence checked ☐ Controlled/special status checked ☐ COA/stability documents checked ☐ HS code verified ☐ Buyer verified |
129. TAMOXIFEN TABLETS IP 10 MG
1. Medicine / Product Name | TAMOXIFEN TABLETS IP 10 MG |
2. Generic / API / Composition | TAMOXIFEN IP 10 MG — exact composition/API to be confirmed from manufacturer specification. |
3. Salt / Strength | Strength/salt as stated in the source where available; otherwise verify the exact product specification. |
4. Therapeutic Category | Hormonal / endocrine medicine |
5. Pharmacological / Drug Class | Hormonal pathway modulator |
6. Main Uses / Indications | Endocrine or oncology/fertility indication depending on ingredient. |
7. Mechanism / Basic Description | Ingredient-specific estrogen-receptor or aromatase pathway modulation. |
8. Dosage Form & Route | Route/formulation: verify from the exact product specification. |
9. Prescription / OTC Status | Generally prescription/regulated medicine; exact status varies by jurisdiction. |
10. Major Warnings / Contraindications / Key Interactions | Check official label for contraindications, interactions, pregnancy warnings, organ-function precautions and formulation-specific risks. |
11. India Export Considerations | Verify Indian manufacturing licence/product permission, GMP status, formulation authorization, exporter eligibility, labeling and destination-specific export documentation. |
12. HS Code / Customs Classification — TO BE VERIFIED | Do not assign a final HS/ITC-HS code from the medicine name alone. Confirm with the exact dosage form, packing and Indian customs classification. |
13. 26-Country Regulatory Status | Preliminary screen: 🟡 registration/authorization generally required in all 26 markets. Upgrade to 🟠/🔴/⚫ where the ingredient, formulation or destination law imposes special controls; exact status must be verified. |
14. Country Regulatory Authority | See the 26-country matrix at the beginning of this document; the responsible authority varies by destination. |
15. Registration / Marketing Authorization Requirements | Typically product dossier/quality data, manufacturing information, stability, labeling, local applicant/importer authorization and any country-specific clinical/bioequivalence or GMP evidence required. |
16. Export Requirements & Special Restrictions | Hormonal/oncology regulatory review may apply. |
17. Buyer Type | Licensed pharmaceutical importer/distributor/wholesaler; hospitals or institutional buyers where appropriate. Veterinary products require appropriately licensed animal-health buyers. |
18. Required Export / Regulatory Documentation | Commercial invoice; packing list; transport documents; certificate of origin where required; COA; GMP/manufacturing documents; product registration/authorization documents; import permit or controlled-drug permit where applicable. |
19. Commercial Considerations | Confirm MOQ, pack size, shelf life, lead time, private-label/OEM availability, registration ownership, Incoterm, freight, insurance, payment terms and landed cost before quotation. |
20. Exporter Decision / Verification Checklist | ☐ Exact product/formulation confirmed ☐ Manufacturer verified ☐ GMP verified ☐ Indian authorization verified ☐ Destination registration checked ☐ Importer licence checked ☐ Controlled/special status checked ☐ COA/stability documents checked ☐ HS code verified ☐ Buyer verified |
130. CLOMIPHENE CITRATE TABLETS USP 50 MG
1. Medicine / Product Name | CLOMIPHENE CITRATE TABLETS USP 50 MG |
2. Generic / API / Composition | CLOMIPHENE CITRATE USP 50 MG — exact composition/API to be confirmed from manufacturer specification. |
3. Salt / Strength | Strength/salt as stated in the source where available; otherwise verify the exact product specification. |
4. Therapeutic Category | Hormonal / endocrine medicine |
5. Pharmacological / Drug Class | Hormonal pathway modulator |
6. Main Uses / Indications | Endocrine or oncology/fertility indication depending on ingredient. |
7. Mechanism / Basic Description | Ingredient-specific estrogen-receptor or aromatase pathway modulation. |
8. Dosage Form & Route | Route/formulation: verify from the exact product specification. |
9. Prescription / OTC Status | Generally prescription/regulated medicine; exact status varies by jurisdiction. |
10. Major Warnings / Contraindications / Key Interactions | Check official label for contraindications, interactions, pregnancy warnings, organ-function precautions and formulation-specific risks. |
11. India Export Considerations | Verify Indian manufacturing licence/product permission, GMP status, formulation authorization, exporter eligibility, labeling and destination-specific export documentation. |
12. HS Code / Customs Classification — TO BE VERIFIED | Do not assign a final HS/ITC-HS code from the medicine name alone. Confirm with the exact dosage form, packing and Indian customs classification. |
13. 26-Country Regulatory Status | Preliminary screen: 🟡 registration/authorization generally required in all 26 markets. Upgrade to 🟠/🔴/⚫ where the ingredient, formulation or destination law imposes special controls; exact status must be verified. |
14. Country Regulatory Authority | See the 26-country matrix at the beginning of this document; the responsible authority varies by destination. |
15. Registration / Marketing Authorization Requirements | Typically product dossier/quality data, manufacturing information, stability, labeling, local applicant/importer authorization and any country-specific clinical/bioequivalence or GMP evidence required. |
16. Export Requirements & Special Restrictions | Hormonal/oncology regulatory review may apply. |
17. Buyer Type | Licensed pharmaceutical importer/distributor/wholesaler; hospitals or institutional buyers where appropriate. Veterinary products require appropriately licensed animal-health buyers. |
18. Required Export / Regulatory Documentation | Commercial invoice; packing list; transport documents; certificate of origin where required; COA; GMP/manufacturing documents; product registration/authorization documents; import permit or controlled-drug permit where applicable. |
19. Commercial Considerations | Confirm MOQ, pack size, shelf life, lead time, private-label/OEM availability, registration ownership, Incoterm, freight, insurance, payment terms and landed cost before quotation. |
20. Exporter Decision / Verification Checklist | ☐ Exact product/formulation confirmed ☐ Manufacturer verified ☐ GMP verified ☐ Indian authorization verified ☐ Destination registration checked ☐ Importer licence checked ☐ Controlled/special status checked ☐ COA/stability documents checked ☐ HS code verified ☐ Buyer verified |
131. L CARNITINE HCL 2000 MG / 5 ML
1. Medicine / Product Name | L CARNITINE HCL 2000 MG / 5 ML |
2. Generic / API / Composition | L CARNITINE HCL 2000 MG / 5 ML — exact composition/API to be confirmed from manufacturer specification. |
3. Salt / Strength | Strength/salt as stated in the source where available; otherwise verify the exact product specification. |
4. Therapeutic Category | Nutritional / metabolic supportive product |
5. Pharmacological / Drug Class | Vitamin, amino-acid derivative or antioxidant — ingredient-specific |
6. Main Uses / Indications | Indication varies by ingredient and approved formulation. |
7. Mechanism / Basic Description | Biochemical role is ingredient-specific. |
8. Dosage Form & Route | Route/formulation: verify from the exact product specification. |
9. Prescription / OTC Status | Generally prescription/regulated medicine; exact status varies by jurisdiction. |
10. Major Warnings / Contraindications / Key Interactions | Check official label for contraindications, interactions, pregnancy warnings, organ-function precautions and formulation-specific risks. |
11. India Export Considerations | Verify Indian manufacturing licence/product permission, GMP status, formulation authorization, exporter eligibility, labeling and destination-specific export documentation. |
12. HS Code / Customs Classification — TO BE VERIFIED | Do not assign a final HS/ITC-HS code from the medicine name alone. Confirm with the exact dosage form, packing and Indian customs classification. |
13. 26-Country Regulatory Status | Preliminary screen: 🟡 registration/authorization generally required in all 26 markets. Upgrade to 🟠/🔴/⚫ where the ingredient, formulation or destination law imposes special controls; exact status must be verified. |
14. Country Regulatory Authority | See the 26-country matrix at the beginning of this document; the responsible authority varies by destination. |
15. Registration / Marketing Authorization Requirements | Typically product dossier/quality data, manufacturing information, stability, labeling, local applicant/importer authorization and any country-specific clinical/bioequivalence or GMP evidence required. |
16. Export Requirements & Special Restrictions | Product-specific regulatory review required before export. |
17. Buyer Type | Licensed pharmaceutical importer/distributor/wholesaler; hospitals or institutional buyers where appropriate. Veterinary products require appropriately licensed animal-health buyers. |
18. Required Export / Regulatory Documentation | Commercial invoice; packing list; transport documents; certificate of origin where required; COA; GMP/manufacturing documents; product registration/authorization documents; import permit or controlled-drug permit where applicable. |
19. Commercial Considerations | Confirm MOQ, pack size, shelf life, lead time, private-label/OEM availability, registration ownership, Incoterm, freight, insurance, payment terms and landed cost before quotation. |
20. Exporter Decision / Verification Checklist | ☐ Exact product/formulation confirmed ☐ Manufacturer verified ☐ GMP verified ☐ Indian authorization verified ☐ Destination registration checked ☐ Importer licence checked ☐ Controlled/special status checked ☐ COA/stability documents checked ☐ HS code verified ☐ Buyer verified |
132. TESTOSTERONE ENANTHATE FOR INJECTION USP
1. Medicine / Product Name | TESTOSTERONE ENANTHATE FOR INJECTION USP |
2. Generic / API / Composition | TESTOSTERONE ENANTHATE FOR USP — exact composition/API to be confirmed from manufacturer specification. |
3. Salt / Strength | Strength/salt as stated in the source where available; otherwise verify the exact product specification. |
4. Therapeutic Category | Androgen / anabolic-hormonal medicine |
5. Pharmacological / Drug Class | Androgenic/anabolic steroid or testosterone preparation |
6. Main Uses / Indications | Hormone-replacement or other approved indication depends on the specific substance and formulation. |
7. Mechanism / Basic Description | Acts through androgen receptors; exact pharmacology varies by compound. |
8. Dosage Form & Route | Oral, topical or injectable depending on formulation. |
9. Prescription / OTC Status | Prescription; often subject to additional controlled-substance/hormone rules. |
10. Major Warnings / Contraindications / Key Interactions | Hormonal adverse effects, cardiovascular/thrombotic risks, hepatic risks for some oral agents, reproductive effects and local controlled-drug rules require review. |
11. India Export Considerations | Verify Indian manufacturing licence/product permission, GMP status, formulation authorization, exporter eligibility, labeling and destination-specific export documentation. |
12. HS Code / Customs Classification — TO BE VERIFIED | Do not assign a final HS/ITC-HS code from the medicine name alone. Confirm with the exact dosage form, packing and Indian customs classification. |
13. 26-Country Regulatory Status | Preliminary screen: 🟡 registration/authorization generally required in all 26 markets. Upgrade to 🟠/🔴/⚫ where the ingredient, formulation or destination law imposes special controls; exact status must be verified. |
14. Country Regulatory Authority | See the 26-country matrix at the beginning of this document; the responsible authority varies by destination. |
15. Registration / Marketing Authorization Requirements | Typically product dossier/quality data, manufacturing information, stability, labeling, local applicant/importer authorization and any country-specific clinical/bioequivalence or GMP evidence required. |
16. Export Requirements & Special Restrictions | High-priority regulatory verification; some jurisdictions impose controlled-substance or special import restrictions. Controlled/psychotropic/hormonal classification must be checked separately in each destination. Sterile/injectable or biologic quality, storage and manufacturing controls may apply. |
17. Buyer Type | Licensed pharmaceutical importer/distributor/wholesaler; hospitals or institutional buyers where appropriate. Veterinary products require appropriately licensed animal-health buyers. |
18. Required Export / Regulatory Documentation | Commercial invoice; packing list; transport documents; certificate of origin where required; COA; GMP/manufacturing documents; product registration/authorization documents; import permit or controlled-drug permit where applicable. |
19. Commercial Considerations | Confirm MOQ, pack size, shelf life, lead time, private-label/OEM availability, registration ownership, Incoterm, freight, insurance, payment terms and landed cost before quotation. |
20. Exporter Decision / Verification Checklist | ☐ Exact product/formulation confirmed ☐ Manufacturer verified ☐ GMP verified ☐ Indian authorization verified ☐ Destination registration checked ☐ Importer licence checked ☐ Controlled/special status checked ☐ COA/stability documents checked ☐ HS code verified ☐ Buyer verified |
133. AZELAIC ACID CREAM 20 % W/W
1. Medicine / Product Name | AZELAIC ACID CREAM 20 % W/W |
2. Generic / API / Composition | AZELAIC ACID CREAM 20 % W/W — exact composition/API to be confirmed from manufacturer specification. |
3. Salt / Strength | Strength/salt as stated in the source where available; otherwise verify the exact product specification. |
4. Therapeutic Category | Dermatology / topical or hormonal medicine |
5. Pharmacological / Drug Class | Ingredient-specific dermatologic/hormonal agent |
6. Main Uses / Indications | Dermatologic or hormonal indication according to the exact formulation. |
7. Mechanism / Basic Description | Ingredient-specific; use approved product labeling. |
8. Dosage Form & Route | Topical or oral depending on formulation. |
9. Prescription / OTC Status | Generally prescription/regulated medicine; exact status varies by jurisdiction. |
10. Major Warnings / Contraindications / Key Interactions | Pregnancy/reproductive warnings, systemic absorption, skin reactions and formulation-specific restrictions must be checked. |
11. India Export Considerations | Verify Indian manufacturing licence/product permission, GMP status, formulation authorization, exporter eligibility, labeling and destination-specific export documentation. |
12. HS Code / Customs Classification — TO BE VERIFIED | Do not assign a final HS/ITC-HS code from the medicine name alone. Confirm with the exact dosage form, packing and Indian customs classification. |
13. 26-Country Regulatory Status | Preliminary screen: 🟡 registration/authorization generally required in all 26 markets. Upgrade to 🟠/🔴/⚫ where the ingredient, formulation or destination law imposes special controls; exact status must be verified. |
14. Country Regulatory Authority | See the 26-country matrix at the beginning of this document; the responsible authority varies by destination. |
15. Registration / Marketing Authorization Requirements | Typically product dossier/quality data, manufacturing information, stability, labeling, local applicant/importer authorization and any country-specific clinical/bioequivalence or GMP evidence required. |
16. Export Requirements & Special Restrictions | Product-specific regulatory review required before export. |
17. Buyer Type | Licensed pharmaceutical importer/distributor/wholesaler; hospitals or institutional buyers where appropriate. Veterinary products require appropriately licensed animal-health buyers. |
18. Required Export / Regulatory Documentation | Commercial invoice; packing list; transport documents; certificate of origin where required; COA; GMP/manufacturing documents; product registration/authorization documents; import permit or controlled-drug permit where applicable. |
19. Commercial Considerations | Confirm MOQ, pack size, shelf life, lead time, private-label/OEM availability, registration ownership, Incoterm, freight, insurance, payment terms and landed cost before quotation. |
20. Exporter Decision / Verification Checklist | ☐ Exact product/formulation confirmed ☐ Manufacturer verified ☐ GMP verified ☐ Indian authorization verified ☐ Destination registration checked ☐ Importer licence checked ☐ Controlled/special status checked ☐ COA/stability documents checked ☐ HS code verified ☐ Buyer verified |
134. SILDENAFIL CUTRATE
1. Medicine / Product Name | SILDENAFIL CUTRATE |
2. Generic / API / Composition | SILDENAFIL CUTRATE — exact composition/API to be confirmed from manufacturer specification. |
3. Salt / Strength | Strength/salt as stated in the source where available; otherwise verify the exact product specification. |
4. Therapeutic Category | Genitourinary / erectile-dysfunction medicine |
5. Pharmacological / Drug Class | PDE-5 inhibitor |
6. Main Uses / Indications | Treatment of erectile dysfunction; exact indications vary by product and market. |
7. Mechanism / Basic Description | Inhibits PDE-5, increasing cGMP-mediated smooth-muscle relaxation. |
8. Dosage Form & Route | Oral; exact formulation (tablet/jelly/etc.) must be verified. |
9. Prescription / OTC Status | Generally prescription/regulated medicine; exact status varies by jurisdiction. |
10. Major Warnings / Contraindications / Key Interactions | Nitrates/riociguat and cardiovascular conditions require particular attention; formulation and local labeling must be checked. |
11. India Export Considerations | Verify Indian manufacturing licence/product permission, GMP status, formulation authorization, exporter eligibility, labeling and destination-specific export documentation. |
12. HS Code / Customs Classification — TO BE VERIFIED | Do not assign a final HS/ITC-HS code from the medicine name alone. Confirm with the exact dosage form, packing and Indian customs classification. |
13. 26-Country Regulatory Status | Preliminary screen: 🟡 registration/authorization generally required in all 26 markets. Upgrade to 🟠/🔴/⚫ where the ingredient, formulation or destination law imposes special controls; exact status must be verified. |
14. Country Regulatory Authority | See the 26-country matrix at the beginning of this document; the responsible authority varies by destination. |
15. Registration / Marketing Authorization Requirements | Typically product dossier/quality data, manufacturing information, stability, labeling, local applicant/importer authorization and any country-specific clinical/bioequivalence or GMP evidence required. |
16. Export Requirements & Special Restrictions | Product-specific regulatory review required before export. |
17. Buyer Type | Licensed pharmaceutical importer/distributor/wholesaler; hospitals or institutional buyers where appropriate. Veterinary products require appropriately licensed animal-health buyers. |
18. Required Export / Regulatory Documentation | Commercial invoice; packing list; transport documents; certificate of origin where required; COA; GMP/manufacturing documents; product registration/authorization documents; import permit or controlled-drug permit where applicable. |
19. Commercial Considerations | Confirm MOQ, pack size, shelf life, lead time, private-label/OEM availability, registration ownership, Incoterm, freight, insurance, payment terms and landed cost before quotation. |
20. Exporter Decision / Verification Checklist | ☐ Exact product/formulation confirmed ☐ Manufacturer verified ☐ GMP verified ☐ Indian authorization verified ☐ Destination registration checked ☐ Importer licence checked ☐ Controlled/special status checked ☐ COA/stability documents checked ☐ HS code verified ☐ Buyer verified |
135. SIROLIMUS
1. Medicine / Product Name | SIROLIMUS |
2. Generic / API / Composition | SIROLIMUS — exact composition/API to be confirmed from manufacturer specification. |
3. Salt / Strength | Strength/salt as stated in the source where available; otherwise verify the exact product specification. |
4. Therapeutic Category | Immunomodulatory / anti-inflammatory medicine |
5. Pharmacological / Drug Class | Ingredient-specific immunosuppressive or anti-inflammatory agent |
6. Main Uses / Indications | Inflammatory, autoimmune or transplant-related indications depending on ingredient/formulation. |
7. Mechanism / Basic Description | Ingredient-specific immunomodulatory mechanism. |
8. Dosage Form & Route | Route/formulation: verify from the exact product specification. |
9. Prescription / OTC Status | Generally prescription/regulated medicine; exact status varies by jurisdiction. |
10. Major Warnings / Contraindications / Key Interactions | Infection risk, immunosuppression and drug interactions can be important; specialist labeling must be followed. |
11. India Export Considerations | Verify Indian manufacturing licence/product permission, GMP status, formulation authorization, exporter eligibility, labeling and destination-specific export documentation. |
12. HS Code / Customs Classification — TO BE VERIFIED | Do not assign a final HS/ITC-HS code from the medicine name alone. Confirm with the exact dosage form, packing and Indian customs classification. |
13. 26-Country Regulatory Status | Preliminary screen: 🟡 registration/authorization generally required in all 26 markets. Upgrade to 🟠/🔴/⚫ where the ingredient, formulation or destination law imposes special controls; exact status must be verified. |
14. Country Regulatory Authority | See the 26-country matrix at the beginning of this document; the responsible authority varies by destination. |
15. Registration / Marketing Authorization Requirements | Typically product dossier/quality data, manufacturing information, stability, labeling, local applicant/importer authorization and any country-specific clinical/bioequivalence or GMP evidence required. |
16. Export Requirements & Special Restrictions | Higher regulatory and pharmacovigilance scrutiny. |
17. Buyer Type | Licensed pharmaceutical importer/distributor/wholesaler; hospitals or institutional buyers where appropriate. Veterinary products require appropriately licensed animal-health buyers. |
18. Required Export / Regulatory Documentation | Commercial invoice; packing list; transport documents; certificate of origin where required; COA; GMP/manufacturing documents; product registration/authorization documents; import permit or controlled-drug permit where applicable. |
19. Commercial Considerations | Confirm MOQ, pack size, shelf life, lead time, private-label/OEM availability, registration ownership, Incoterm, freight, insurance, payment terms and landed cost before quotation. |
20. Exporter Decision / Verification Checklist | ☐ Exact product/formulation confirmed ☐ Manufacturer verified ☐ GMP verified ☐ Indian authorization verified ☐ Destination registration checked ☐ Importer licence checked ☐ Controlled/special status checked ☐ COA/stability documents checked ☐ HS code verified ☐ Buyer verified |
136. TESTOSTERONE PROPIONATE INJECTION USP
1. Medicine / Product Name | TESTOSTERONE PROPIONATE INJECTION USP |
2. Generic / API / Composition | TESTOSTERONE PROPIONATE USP — exact composition/API to be confirmed from manufacturer specification. |
3. Salt / Strength | Strength/salt as stated in the source where available; otherwise verify the exact product specification. |
4. Therapeutic Category | Androgen / anabolic-hormonal medicine |
5. Pharmacological / Drug Class | Androgenic/anabolic steroid or testosterone preparation |
6. Main Uses / Indications | Hormone-replacement or other approved indication depends on the specific substance and formulation. |
7. Mechanism / Basic Description | Acts through androgen receptors; exact pharmacology varies by compound. |
8. Dosage Form & Route | Oral, topical or injectable depending on formulation. |
9. Prescription / OTC Status | Prescription; often subject to additional controlled-substance/hormone rules. |
10. Major Warnings / Contraindications / Key Interactions | Hormonal adverse effects, cardiovascular/thrombotic risks, hepatic risks for some oral agents, reproductive effects and local controlled-drug rules require review. |
11. India Export Considerations | Verify Indian manufacturing licence/product permission, GMP status, formulation authorization, exporter eligibility, labeling and destination-specific export documentation. |
12. HS Code / Customs Classification — TO BE VERIFIED | Do not assign a final HS/ITC-HS code from the medicine name alone. Confirm with the exact dosage form, packing and Indian customs classification. |
13. 26-Country Regulatory Status | Preliminary screen: 🟡 registration/authorization generally required in all 26 markets. Upgrade to 🟠/🔴/⚫ where the ingredient, formulation or destination law imposes special controls; exact status must be verified. |
14. Country Regulatory Authority | See the 26-country matrix at the beginning of this document; the responsible authority varies by destination. |
15. Registration / Marketing Authorization Requirements | Typically product dossier/quality data, manufacturing information, stability, labeling, local applicant/importer authorization and any country-specific clinical/bioequivalence or GMP evidence required. |
16. Export Requirements & Special Restrictions | High-priority regulatory verification; some jurisdictions impose controlled-substance or special import restrictions. Controlled/psychotropic/hormonal classification must be checked separately in each destination. Sterile/injectable or biologic quality, storage and manufacturing controls may apply. |
17. Buyer Type | Licensed pharmaceutical importer/distributor/wholesaler; hospitals or institutional buyers where appropriate. Veterinary products require appropriately licensed animal-health buyers. |
18. Required Export / Regulatory Documentation | Commercial invoice; packing list; transport documents; certificate of origin where required; COA; GMP/manufacturing documents; product registration/authorization documents; import permit or controlled-drug permit where applicable. |
19. Commercial Considerations | Confirm MOQ, pack size, shelf life, lead time, private-label/OEM availability, registration ownership, Incoterm, freight, insurance, payment terms and landed cost before quotation. |
20. Exporter Decision / Verification Checklist | ☐ Exact product/formulation confirmed ☐ Manufacturer verified ☐ GMP verified ☐ Indian authorization verified ☐ Destination registration checked ☐ Importer licence checked ☐ Controlled/special status checked ☐ COA/stability documents checked ☐ HS code verified ☐ Buyer verified |
137. TRICLABENDAZOLE TABLETS 250 MG
1. Medicine / Product Name | TRICLABENDAZOLE TABLETS 250 MG |
2. Generic / API / Composition | TRICLABENDAZOLE 250 MG — exact composition/API to be confirmed from manufacturer specification. |
3. Salt / Strength | Strength/salt as stated in the source where available; otherwise verify the exact product specification. |
4. Therapeutic Category | Anti-infective / antiparasitic medicine |
5. Pharmacological / Drug Class | Antibacterial, antiprotozoal or antiparasitic — ingredient-specific |
6. Main Uses / Indications | Treatment of susceptible infections/parasitoses according to the approved indication. |
7. Mechanism / Basic Description | Ingredient-specific antimicrobial/antiparasitic mechanism. |
8. Dosage Form & Route | Oral or other formulation-specific route. |
9. Prescription / OTC Status | Generally prescription/regulated medicine; exact status varies by jurisdiction. |
10. Major Warnings / Contraindications / Key Interactions | Allergy, interactions, resistance/appropriate-use restrictions and indication-specific precautions require label review. |
11. India Export Considerations | Verify Indian manufacturing licence/product permission, GMP status, formulation authorization, exporter eligibility, labeling and destination-specific export documentation. |
12. HS Code / Customs Classification — TO BE VERIFIED | Do not assign a final HS/ITC-HS code from the medicine name alone. Confirm with the exact dosage form, packing and Indian customs classification. |
13. 26-Country Regulatory Status | Preliminary screen: 🟡 registration/authorization generally required in all 26 markets. Upgrade to 🟠/🔴/⚫ where the ingredient, formulation or destination law imposes special controls; exact status must be verified. |
14. Country Regulatory Authority | See the 26-country matrix at the beginning of this document; the responsible authority varies by destination. |
15. Registration / Marketing Authorization Requirements | Typically product dossier/quality data, manufacturing information, stability, labeling, local applicant/importer authorization and any country-specific clinical/bioequivalence or GMP evidence required. |
16. Export Requirements & Special Restrictions | Product-specific regulatory review required before export. |
17. Buyer Type | Licensed pharmaceutical importer/distributor/wholesaler; hospitals or institutional buyers where appropriate. Veterinary products require appropriately licensed animal-health buyers. |
18. Required Export / Regulatory Documentation | Commercial invoice; packing list; transport documents; certificate of origin where required; COA; GMP/manufacturing documents; product registration/authorization documents; import permit or controlled-drug permit where applicable. |
19. Commercial Considerations | Confirm MOQ, pack size, shelf life, lead time, private-label/OEM availability, registration ownership, Incoterm, freight, insurance, payment terms and landed cost before quotation. |
20. Exporter Decision / Verification Checklist | ☐ Exact product/formulation confirmed ☐ Manufacturer verified ☐ GMP verified ☐ Indian authorization verified ☐ Destination registration checked ☐ Importer licence checked ☐ Controlled/special status checked ☐ COA/stability documents checked ☐ HS code verified ☐ Buyer verified |
138. MESTEROLONE TABLETS 25 MG
1. Medicine / Product Name | MESTEROLONE TABLETS 25 MG |
2. Generic / API / Composition | MESTEROLONE 25 MG — exact composition/API to be confirmed from manufacturer specification. |
3. Salt / Strength | Strength/salt as stated in the source where available; otherwise verify the exact product specification. |
4. Therapeutic Category | Androgen / anabolic-hormonal medicine |
5. Pharmacological / Drug Class | Androgenic/anabolic steroid or testosterone preparation |
6. Main Uses / Indications | Hormone-replacement or other approved indication depends on the specific substance and formulation. |
7. Mechanism / Basic Description | Acts through androgen receptors; exact pharmacology varies by compound. |
8. Dosage Form & Route | Oral, topical or injectable depending on formulation. |
9. Prescription / OTC Status | Prescription; often subject to additional controlled-substance/hormone rules. |
10. Major Warnings / Contraindications / Key Interactions | Hormonal adverse effects, cardiovascular/thrombotic risks, hepatic risks for some oral agents, reproductive effects and local controlled-drug rules require review. |
11. India Export Considerations | Verify Indian manufacturing licence/product permission, GMP status, formulation authorization, exporter eligibility, labeling and destination-specific export documentation. |
12. HS Code / Customs Classification — TO BE VERIFIED | Do not assign a final HS/ITC-HS code from the medicine name alone. Confirm with the exact dosage form, packing and Indian customs classification. |
13. 26-Country Regulatory Status | Preliminary screen: 🟡 registration/authorization generally required in all 26 markets. Upgrade to 🟠/🔴/⚫ where the ingredient, formulation or destination law imposes special controls; exact status must be verified. |
14. Country Regulatory Authority | See the 26-country matrix at the beginning of this document; the responsible authority varies by destination. |
15. Registration / Marketing Authorization Requirements | Typically product dossier/quality data, manufacturing information, stability, labeling, local applicant/importer authorization and any country-specific clinical/bioequivalence or GMP evidence required. |
16. Export Requirements & Special Restrictions | High-priority regulatory verification; some jurisdictions impose controlled-substance or special import restrictions. Controlled/psychotropic/hormonal classification must be checked separately in each destination. |
17. Buyer Type | Licensed pharmaceutical importer/distributor/wholesaler; hospitals or institutional buyers where appropriate. Veterinary products require appropriately licensed animal-health buyers. |
18. Required Export / Regulatory Documentation | Commercial invoice; packing list; transport documents; certificate of origin where required; COA; GMP/manufacturing documents; product registration/authorization documents; import permit or controlled-drug permit where applicable. |
19. Commercial Considerations | Confirm MOQ, pack size, shelf life, lead time, private-label/OEM availability, registration ownership, Incoterm, freight, insurance, payment terms and landed cost before quotation. |
20. Exporter Decision / Verification Checklist | ☐ Exact product/formulation confirmed ☐ Manufacturer verified ☐ GMP verified ☐ Indian authorization verified ☐ Destination registration checked ☐ Importer licence checked ☐ Controlled/special status checked ☐ COA/stability documents checked ☐ HS code verified ☐ Buyer verified |
139. TESTOSTERONE CYPIONATE INJ USP 250 MG /ML
1. Medicine / Product Name | TESTOSTERONE CYPIONATE INJ USP 250 MG /ML |
2. Generic / API / Composition | TESTOSTERONE CYPIONATE INJ USP 250 MG /ML — exact composition/API to be confirmed from manufacturer specification. |
3. Salt / Strength | Strength/salt as stated in the source where available; otherwise verify the exact product specification. |
4. Therapeutic Category | Androgen / anabolic-hormonal medicine |
5. Pharmacological / Drug Class | Androgenic/anabolic steroid or testosterone preparation |
6. Main Uses / Indications | Hormone-replacement or other approved indication depends on the specific substance and formulation. |
7. Mechanism / Basic Description | Acts through androgen receptors; exact pharmacology varies by compound. |
8. Dosage Form & Route | Oral, topical or injectable depending on formulation. |
9. Prescription / OTC Status | Prescription; often subject to additional controlled-substance/hormone rules. |
10. Major Warnings / Contraindications / Key Interactions | Hormonal adverse effects, cardiovascular/thrombotic risks, hepatic risks for some oral agents, reproductive effects and local controlled-drug rules require review. |
11. India Export Considerations | Verify Indian manufacturing licence/product permission, GMP status, formulation authorization, exporter eligibility, labeling and destination-specific export documentation. |
12. HS Code / Customs Classification — TO BE VERIFIED | Do not assign a final HS/ITC-HS code from the medicine name alone. Confirm with the exact dosage form, packing and Indian customs classification. |
13. 26-Country Regulatory Status | Preliminary screen: 🟡 registration/authorization generally required in all 26 markets. Upgrade to 🟠/🔴/⚫ where the ingredient, formulation or destination law imposes special controls; exact status must be verified. |
14. Country Regulatory Authority | See the 26-country matrix at the beginning of this document; the responsible authority varies by destination. |
15. Registration / Marketing Authorization Requirements | Typically product dossier/quality data, manufacturing information, stability, labeling, local applicant/importer authorization and any country-specific clinical/bioequivalence or GMP evidence required. |
16. Export Requirements & Special Restrictions | High-priority regulatory verification; some jurisdictions impose controlled-substance or special import restrictions. Controlled/psychotropic/hormonal classification must be checked separately in each destination. Sterile/injectable or biologic quality, storage and manufacturing controls may apply. |
17. Buyer Type | Licensed pharmaceutical importer/distributor/wholesaler; hospitals or institutional buyers where appropriate. Veterinary products require appropriately licensed animal-health buyers. |
18. Required Export / Regulatory Documentation | Commercial invoice; packing list; transport documents; certificate of origin where required; COA; GMP/manufacturing documents; product registration/authorization documents; import permit or controlled-drug permit where applicable. |
19. Commercial Considerations | Confirm MOQ, pack size, shelf life, lead time, private-label/OEM availability, registration ownership, Incoterm, freight, insurance, payment terms and landed cost before quotation. |
20. Exporter Decision / Verification Checklist | ☐ Exact product/formulation confirmed ☐ Manufacturer verified ☐ GMP verified ☐ Indian authorization verified ☐ Destination registration checked ☐ Importer licence checked ☐ Controlled/special status checked ☐ COA/stability documents checked ☐ HS code verified ☐ Buyer verified |
140. LIDOCAINE AND PRILOCAINE CREAM IP
1. Medicine / Product Name | LIDOCAINE AND PRILOCAINE CREAM IP |
2. Generic / API / Composition | LIDOCAINE AND PRILOCAINE CREAM IP — exact composition/API to be confirmed from manufacturer specification. |
3. Salt / Strength | Strength/salt as stated in the source where available; otherwise verify the exact product specification. |
4. Therapeutic Category | Local anesthetic |
5. Pharmacological / Drug Class | Amide local anesthetic |
6. Main Uses / Indications | Topical/local anesthesia according to formulation. |
7. Mechanism / Basic Description | Blocks voltage-gated sodium channels and local nerve conduction. |
8. Dosage Form & Route | Route/formulation: verify from the exact product specification. |
9. Prescription / OTC Status | Generally prescription/regulated medicine; exact status varies by jurisdiction. |
10. Major Warnings / Contraindications / Key Interactions | Check official label for contraindications, interactions, pregnancy warnings, organ-function precautions and formulation-specific risks. |
11. India Export Considerations | Verify Indian manufacturing licence/product permission, GMP status, formulation authorization, exporter eligibility, labeling and destination-specific export documentation. |
12. HS Code / Customs Classification — TO BE VERIFIED | Do not assign a final HS/ITC-HS code from the medicine name alone. Confirm with the exact dosage form, packing and Indian customs classification. |
13. 26-Country Regulatory Status | Preliminary screen: 🟡 registration/authorization generally required in all 26 markets. Upgrade to 🟠/🔴/⚫ where the ingredient, formulation or destination law imposes special controls; exact status must be verified. |
14. Country Regulatory Authority | See the 26-country matrix at the beginning of this document; the responsible authority varies by destination. |
15. Registration / Marketing Authorization Requirements | Typically product dossier/quality data, manufacturing information, stability, labeling, local applicant/importer authorization and any country-specific clinical/bioequivalence or GMP evidence required. |
16. Export Requirements & Special Restrictions | Product-specific regulatory review required before export. |
17. Buyer Type | Licensed pharmaceutical importer/distributor/wholesaler; hospitals or institutional buyers where appropriate. Veterinary products require appropriately licensed animal-health buyers. |
18. Required Export / Regulatory Documentation | Commercial invoice; packing list; transport documents; certificate of origin where required; COA; GMP/manufacturing documents; product registration/authorization documents; import permit or controlled-drug permit where applicable. |
19. Commercial Considerations | Confirm MOQ, pack size, shelf life, lead time, private-label/OEM availability, registration ownership, Incoterm, freight, insurance, payment terms and landed cost before quotation. |
20. Exporter Decision / Verification Checklist | ☐ Exact product/formulation confirmed ☐ Manufacturer verified ☐ GMP verified ☐ Indian authorization verified ☐ Destination registration checked ☐ Importer licence checked ☐ Controlled/special status checked ☐ COA/stability documents checked ☐ HS code verified ☐ Buyer verified |
141. NANDROLONE PHENYLPROPIONATE INJECTION USP
1. Medicine / Product Name | NANDROLONE PHENYLPROPIONATE INJECTION USP |
2. Generic / API / Composition | NANDROLONE PHENYLPROPIONATE USP — exact composition/API to be confirmed from manufacturer specification. |
3. Salt / Strength | Strength/salt as stated in the source where available; otherwise verify the exact product specification. |
4. Therapeutic Category | Androgen / anabolic-hormonal medicine |
5. Pharmacological / Drug Class | Androgenic/anabolic steroid or testosterone preparation |
6. Main Uses / Indications | Hormone-replacement or other approved indication depends on the specific substance and formulation. |
7. Mechanism / Basic Description | Acts through androgen receptors; exact pharmacology varies by compound. |
8. Dosage Form & Route | Oral, topical or injectable depending on formulation. |
9. Prescription / OTC Status | Prescription; often subject to additional controlled-substance/hormone rules. |
10. Major Warnings / Contraindications / Key Interactions | Hormonal adverse effects, cardiovascular/thrombotic risks, hepatic risks for some oral agents, reproductive effects and local controlled-drug rules require review. |
11. India Export Considerations | Verify Indian manufacturing licence/product permission, GMP status, formulation authorization, exporter eligibility, labeling and destination-specific export documentation. |
12. HS Code / Customs Classification — TO BE VERIFIED | Do not assign a final HS/ITC-HS code from the medicine name alone. Confirm with the exact dosage form, packing and Indian customs classification. |
13. 26-Country Regulatory Status | Preliminary screen: 🟡 registration/authorization generally required in all 26 markets. Upgrade to 🟠/🔴/⚫ where the ingredient, formulation or destination law imposes special controls; exact status must be verified. |
14. Country Regulatory Authority | See the 26-country matrix at the beginning of this document; the responsible authority varies by destination. |
15. Registration / Marketing Authorization Requirements | Typically product dossier/quality data, manufacturing information, stability, labeling, local applicant/importer authorization and any country-specific clinical/bioequivalence or GMP evidence required. |
16. Export Requirements & Special Restrictions | High-priority regulatory verification; some jurisdictions impose controlled-substance or special import restrictions. Controlled/psychotropic/hormonal classification must be checked separately in each destination. Sterile/injectable or biologic quality, storage and manufacturing controls may apply. |
17. Buyer Type | Licensed pharmaceutical importer/distributor/wholesaler; hospitals or institutional buyers where appropriate. Veterinary products require appropriately licensed animal-health buyers. |
18. Required Export / Regulatory Documentation | Commercial invoice; packing list; transport documents; certificate of origin where required; COA; GMP/manufacturing documents; product registration/authorization documents; import permit or controlled-drug permit where applicable. |
19. Commercial Considerations | Confirm MOQ, pack size, shelf life, lead time, private-label/OEM availability, registration ownership, Incoterm, freight, insurance, payment terms and landed cost before quotation. |
20. Exporter Decision / Verification Checklist | ☐ Exact product/formulation confirmed ☐ Manufacturer verified ☐ GMP verified ☐ Indian authorization verified ☐ Destination registration checked ☐ Importer licence checked ☐ Controlled/special status checked ☐ COA/stability documents checked ☐ HS code verified ☐ Buyer verified |
142. TOFACITINIB TABLETS 5 MG
1. Medicine / Product Name | TOFACITINIB TABLETS 5 MG |
2. Generic / API / Composition | TOFACITINIB 5 MG — exact composition/API to be confirmed from manufacturer specification. |
3. Salt / Strength | Strength/salt as stated in the source where available; otherwise verify the exact product specification. |
4. Therapeutic Category | Immunomodulatory / anti-inflammatory medicine |
5. Pharmacological / Drug Class | Ingredient-specific immunosuppressive or anti-inflammatory agent |
6. Main Uses / Indications | Inflammatory, autoimmune or transplant-related indications depending on ingredient/formulation. |
7. Mechanism / Basic Description | Ingredient-specific immunomodulatory mechanism. |
8. Dosage Form & Route | Route/formulation: verify from the exact product specification. |
9. Prescription / OTC Status | Generally prescription/regulated medicine; exact status varies by jurisdiction. |
10. Major Warnings / Contraindications / Key Interactions | Infection risk, immunosuppression and drug interactions can be important; specialist labeling must be followed. |
11. India Export Considerations | Verify Indian manufacturing licence/product permission, GMP status, formulation authorization, exporter eligibility, labeling and destination-specific export documentation. |
12. HS Code / Customs Classification — TO BE VERIFIED | Do not assign a final HS/ITC-HS code from the medicine name alone. Confirm with the exact dosage form, packing and Indian customs classification. |
13. 26-Country Regulatory Status | Preliminary screen: 🟡 registration/authorization generally required in all 26 markets. Upgrade to 🟠/🔴/⚫ where the ingredient, formulation or destination law imposes special controls; exact status must be verified. |
14. Country Regulatory Authority | See the 26-country matrix at the beginning of this document; the responsible authority varies by destination. |
15. Registration / Marketing Authorization Requirements | Typically product dossier/quality data, manufacturing information, stability, labeling, local applicant/importer authorization and any country-specific clinical/bioequivalence or GMP evidence required. |
16. Export Requirements & Special Restrictions | Higher regulatory and pharmacovigilance scrutiny. |
17. Buyer Type | Licensed pharmaceutical importer/distributor/wholesaler; hospitals or institutional buyers where appropriate. Veterinary products require appropriately licensed animal-health buyers. |
18. Required Export / Regulatory Documentation | Commercial invoice; packing list; transport documents; certificate of origin where required; COA; GMP/manufacturing documents; product registration/authorization documents; import permit or controlled-drug permit where applicable. |
19. Commercial Considerations | Confirm MOQ, pack size, shelf life, lead time, private-label/OEM availability, registration ownership, Incoterm, freight, insurance, payment terms and landed cost before quotation. |
20. Exporter Decision / Verification Checklist | ☐ Exact product/formulation confirmed ☐ Manufacturer verified ☐ GMP verified ☐ Indian authorization verified ☐ Destination registration checked ☐ Importer licence checked ☐ Controlled/special status checked ☐ COA/stability documents checked ☐ HS code verified ☐ Buyer verified |
143. TESTOSTERONE MIX COMPOUND
1. Medicine / Product Name | TESTOSTERONE MIX COMPOUND |
2. Generic / API / Composition | TESTOSTERONE MIX COMPOUND — exact composition/API to be confirmed from manufacturer specification. |
3. Salt / Strength | Strength/salt as stated in the source where available; otherwise verify the exact product specification. |
4. Therapeutic Category | Androgen / anabolic-hormonal medicine |
5. Pharmacological / Drug Class | Androgenic/anabolic steroid or testosterone preparation |
6. Main Uses / Indications | Hormone-replacement or other approved indication depends on the specific substance and formulation. |
7. Mechanism / Basic Description | Acts through androgen receptors; exact pharmacology varies by compound. |
8. Dosage Form & Route | Oral, topical or injectable depending on formulation. |
9. Prescription / OTC Status | Prescription; often subject to additional controlled-substance/hormone rules. |
10. Major Warnings / Contraindications / Key Interactions | Hormonal adverse effects, cardiovascular/thrombotic risks, hepatic risks for some oral agents, reproductive effects and local controlled-drug rules require review. |
11. India Export Considerations | Verify Indian manufacturing licence/product permission, GMP status, formulation authorization, exporter eligibility, labeling and destination-specific export documentation. |
12. HS Code / Customs Classification — TO BE VERIFIED | Do not assign a final HS/ITC-HS code from the medicine name alone. Confirm with the exact dosage form, packing and Indian customs classification. |
13. 26-Country Regulatory Status | Preliminary screen: 🟡 registration/authorization generally required in all 26 markets. Upgrade to 🟠/🔴/⚫ where the ingredient, formulation or destination law imposes special controls; exact status must be verified. |
14. Country Regulatory Authority | See the 26-country matrix at the beginning of this document; the responsible authority varies by destination. |
15. Registration / Marketing Authorization Requirements | Typically product dossier/quality data, manufacturing information, stability, labeling, local applicant/importer authorization and any country-specific clinical/bioequivalence or GMP evidence required. |
16. Export Requirements & Special Restrictions | High-priority regulatory verification; some jurisdictions impose controlled-substance or special import restrictions. Controlled/psychotropic/hormonal classification must be checked separately in each destination. Sterile/injectable or biologic quality, storage and manufacturing controls may apply. |
17. Buyer Type | Licensed pharmaceutical importer/distributor/wholesaler; hospitals or institutional buyers where appropriate. Veterinary products require appropriately licensed animal-health buyers. |
18. Required Export / Regulatory Documentation | Commercial invoice; packing list; transport documents; certificate of origin where required; COA; GMP/manufacturing documents; product registration/authorization documents; import permit or controlled-drug permit where applicable. |
19. Commercial Considerations | Confirm MOQ, pack size, shelf life, lead time, private-label/OEM availability, registration ownership, Incoterm, freight, insurance, payment terms and landed cost before quotation. |
20. Exporter Decision / Verification Checklist | ☐ Exact product/formulation confirmed ☐ Manufacturer verified ☐ GMP verified ☐ Indian authorization verified ☐ Destination registration checked ☐ Importer licence checked ☐ Controlled/special status checked ☐ COA/stability documents checked ☐ HS code verified ☐ Buyer verified |
144. ESTRADIOL GEL 0.06 % W/W
1. Medicine / Product Name | ESTRADIOL GEL 0.06 % W/W |
2. Generic / API / Composition | ESTRADIOL GEL 0.06 % W/W — exact composition/API to be confirmed from manufacturer specification. |
3. Salt / Strength | Strength/salt as stated in the source where available; otherwise verify the exact product specification. |
4. Therapeutic Category | Dermatology / topical or hormonal medicine |
5. Pharmacological / Drug Class | Ingredient-specific dermatologic/hormonal agent |
6. Main Uses / Indications | Dermatologic or hormonal indication according to the exact formulation. |
7. Mechanism / Basic Description | Ingredient-specific; use approved product labeling. |
8. Dosage Form & Route | Topical or oral depending on formulation. |
9. Prescription / OTC Status | Generally prescription/regulated medicine; exact status varies by jurisdiction. |
10. Major Warnings / Contraindications / Key Interactions | Pregnancy/reproductive warnings, systemic absorption, skin reactions and formulation-specific restrictions must be checked. |
11. India Export Considerations | Verify Indian manufacturing licence/product permission, GMP status, formulation authorization, exporter eligibility, labeling and destination-specific export documentation. |
12. HS Code / Customs Classification — TO BE VERIFIED | Do not assign a final HS/ITC-HS code from the medicine name alone. Confirm with the exact dosage form, packing and Indian customs classification. |
13. 26-Country Regulatory Status | Preliminary screen: 🟡 registration/authorization generally required in all 26 markets. Upgrade to 🟠/🔴/⚫ where the ingredient, formulation or destination law imposes special controls; exact status must be verified. |
14. Country Regulatory Authority | See the 26-country matrix at the beginning of this document; the responsible authority varies by destination. |
15. Registration / Marketing Authorization Requirements | Typically product dossier/quality data, manufacturing information, stability, labeling, local applicant/importer authorization and any country-specific clinical/bioequivalence or GMP evidence required. |
16. Export Requirements & Special Restrictions | Product-specific regulatory review required before export. |
17. Buyer Type | Licensed pharmaceutical importer/distributor/wholesaler; hospitals or institutional buyers where appropriate. Veterinary products require appropriately licensed animal-health buyers. |
18. Required Export / Regulatory Documentation | Commercial invoice; packing list; transport documents; certificate of origin where required; COA; GMP/manufacturing documents; product registration/authorization documents; import permit or controlled-drug permit where applicable. |
19. Commercial Considerations | Confirm MOQ, pack size, shelf life, lead time, private-label/OEM availability, registration ownership, Incoterm, freight, insurance, payment terms and landed cost before quotation. |
20. Exporter Decision / Verification Checklist | ☐ Exact product/formulation confirmed ☐ Manufacturer verified ☐ GMP verified ☐ Indian authorization verified ☐ Destination registration checked ☐ Importer licence checked ☐ Controlled/special status checked ☐ COA/stability documents checked ☐ HS code verified ☐ Buyer verified |
145. TRETINOIN MICROSPHERE GEL USP 0.1 % W/W
1. Medicine / Product Name | TRETINOIN MICROSPHERE GEL USP 0.1 % W/W |
2. Generic / API / Composition | TRETINOIN MICROSPHERE GEL USP 0.1 % W/W — exact composition/API to be confirmed from manufacturer specification. |
3. Salt / Strength | Strength/salt as stated in the source where available; otherwise verify the exact product specification. |
4. Therapeutic Category | Dermatology / topical or hormonal medicine |
5. Pharmacological / Drug Class | Ingredient-specific dermatologic/hormonal agent |
6. Main Uses / Indications | Dermatologic or hormonal indication according to the exact formulation. |
7. Mechanism / Basic Description | Ingredient-specific; use approved product labeling. |
8. Dosage Form & Route | Topical or oral depending on formulation. |
9. Prescription / OTC Status | Generally prescription/regulated medicine; exact status varies by jurisdiction. |
10. Major Warnings / Contraindications / Key Interactions | Pregnancy/reproductive warnings, systemic absorption, skin reactions and formulation-specific restrictions must be checked. |
11. India Export Considerations | Verify Indian manufacturing licence/product permission, GMP status, formulation authorization, exporter eligibility, labeling and destination-specific export documentation. |
12. HS Code / Customs Classification — TO BE VERIFIED | Do not assign a final HS/ITC-HS code from the medicine name alone. Confirm with the exact dosage form, packing and Indian customs classification. |
13. 26-Country Regulatory Status | Preliminary screen: 🟡 registration/authorization generally required in all 26 markets. Upgrade to 🟠/🔴/⚫ where the ingredient, formulation or destination law imposes special controls; exact status must be verified. |
14. Country Regulatory Authority | See the 26-country matrix at the beginning of this document; the responsible authority varies by destination. |
15. Registration / Marketing Authorization Requirements | Typically product dossier/quality data, manufacturing information, stability, labeling, local applicant/importer authorization and any country-specific clinical/bioequivalence or GMP evidence required. |
16. Export Requirements & Special Restrictions | Product-specific regulatory review required before export. |
17. Buyer Type | Licensed pharmaceutical importer/distributor/wholesaler; hospitals or institutional buyers where appropriate. Veterinary products require appropriately licensed animal-health buyers. |
18. Required Export / Regulatory Documentation | Commercial invoice; packing list; transport documents; certificate of origin where required; COA; GMP/manufacturing documents; product registration/authorization documents; import permit or controlled-drug permit where applicable. |
19. Commercial Considerations | Confirm MOQ, pack size, shelf life, lead time, private-label/OEM availability, registration ownership, Incoterm, freight, insurance, payment terms and landed cost before quotation. |
20. Exporter Decision / Verification Checklist | ☐ Exact product/formulation confirmed ☐ Manufacturer verified ☐ GMP verified ☐ Indian authorization verified ☐ Destination registration checked ☐ Importer licence checked ☐ Controlled/special status checked ☐ COA/stability documents checked ☐ HS code verified ☐ Buyer verified |
146. FENBENDAZOLE CAPSULES 444 MG
1. Medicine / Product Name | FENBENDAZOLE CAPSULES 444 MG |
2. Generic / API / Composition | FENBENDAZOLE 444 MG — exact composition/API to be confirmed from manufacturer specification. |
3. Salt / Strength | Strength/salt as stated in the source where available; otherwise verify the exact product specification. |
4. Therapeutic Category | Veterinary anthelmintic |
5. Pharmacological / Drug Class | Benzimidazole anthelmintic |
6. Main Uses / Indications | Veterinary parasite control; human use is not automatically authorized. |
7. Mechanism / Basic Description | Disrupts parasite microtubule function. |
8. Dosage Form & Route | Route/formulation: verify from the exact product specification. |
9. Prescription / OTC Status | Veterinary/animal-health regulatory status depends on country. |
10. Major Warnings / Contraindications / Key Interactions | Check official label for contraindications, interactions, pregnancy warnings, organ-function precautions and formulation-specific risks. |
11. India Export Considerations | Verify Indian manufacturing licence/product permission, GMP status, formulation authorization, exporter eligibility, labeling and destination-specific export documentation. |
12. HS Code / Customs Classification — TO BE VERIFIED | Do not assign a final HS/ITC-HS code from the medicine name alone. Confirm with the exact dosage form, packing and Indian customs classification. |
13. 26-Country Regulatory Status | Preliminary screen: 🟡 registration/authorization generally required in all 26 markets. Upgrade to 🟠/🔴/⚫ where the ingredient, formulation or destination law imposes special controls; exact status must be verified. |
14. Country Regulatory Authority | See the 26-country matrix at the beginning of this document; the responsible authority varies by destination. |
15. Registration / Marketing Authorization Requirements | Typically product dossier/quality data, manufacturing information, stability, labeling, local applicant/importer authorization and any country-specific clinical/bioequivalence or GMP evidence required. |
16. Export Requirements & Special Restrictions | Do not present as a human pharmaceutical without explicit human authorization. |
17. Buyer Type | Licensed pharmaceutical importer/distributor/wholesaler; hospitals or institutional buyers where appropriate. Veterinary products require appropriately licensed animal-health buyers. |
18. Required Export / Regulatory Documentation | Commercial invoice; packing list; transport documents; certificate of origin where required; COA; GMP/manufacturing documents; product registration/authorization documents; import permit or controlled-drug permit where applicable. |
19. Commercial Considerations | Confirm MOQ, pack size, shelf life, lead time, private-label/OEM availability, registration ownership, Incoterm, freight, insurance, payment terms and landed cost before quotation. |
20. Exporter Decision / Verification Checklist | ☐ Exact product/formulation confirmed ☐ Manufacturer verified ☐ GMP verified ☐ Indian authorization verified ☐ Destination registration checked ☐ Importer licence checked ☐ Controlled/special status checked ☐ COA/stability documents checked ☐ HS code verified ☐ Buyer verified |
147. ADAPALENE GEL IP 0.1 %
1. Medicine / Product Name | ADAPALENE GEL IP 0.1 % |
2. Generic / API / Composition | ADAPALENE GEL IP 0.1 % — exact composition/API to be confirmed from manufacturer specification. |
3. Salt / Strength | Strength/salt as stated in the source where available; otherwise verify the exact product specification. |
4. Therapeutic Category | Dermatology / topical or hormonal medicine |
5. Pharmacological / Drug Class | Ingredient-specific dermatologic/hormonal agent |
6. Main Uses / Indications | Dermatologic or hormonal indication according to the exact formulation. |
7. Mechanism / Basic Description | Ingredient-specific; use approved product labeling. |
8. Dosage Form & Route | Topical or oral depending on formulation. |
9. Prescription / OTC Status | Generally prescription/regulated medicine; exact status varies by jurisdiction. |
10. Major Warnings / Contraindications / Key Interactions | Pregnancy/reproductive warnings, systemic absorption, skin reactions and formulation-specific restrictions must be checked. |
11. India Export Considerations | Verify Indian manufacturing licence/product permission, GMP status, formulation authorization, exporter eligibility, labeling and destination-specific export documentation. |
12. HS Code / Customs Classification — TO BE VERIFIED | Do not assign a final HS/ITC-HS code from the medicine name alone. Confirm with the exact dosage form, packing and Indian customs classification. |
13. 26-Country Regulatory Status | Preliminary screen: 🟡 registration/authorization generally required in all 26 markets. Upgrade to 🟠/🔴/⚫ where the ingredient, formulation or destination law imposes special controls; exact status must be verified. |
14. Country Regulatory Authority | See the 26-country matrix at the beginning of this document; the responsible authority varies by destination. |
15. Registration / Marketing Authorization Requirements | Typically product dossier/quality data, manufacturing information, stability, labeling, local applicant/importer authorization and any country-specific clinical/bioequivalence or GMP evidence required. |
16. Export Requirements & Special Restrictions | Product-specific regulatory review required before export. |
17. Buyer Type | Licensed pharmaceutical importer/distributor/wholesaler; hospitals or institutional buyers where appropriate. Veterinary products require appropriately licensed animal-health buyers. |
18. Required Export / Regulatory Documentation | Commercial invoice; packing list; transport documents; certificate of origin where required; COA; GMP/manufacturing documents; product registration/authorization documents; import permit or controlled-drug permit where applicable. |
19. Commercial Considerations | Confirm MOQ, pack size, shelf life, lead time, private-label/OEM availability, registration ownership, Incoterm, freight, insurance, payment terms and landed cost before quotation. |
20. Exporter Decision / Verification Checklist | ☐ Exact product/formulation confirmed ☐ Manufacturer verified ☐ GMP verified ☐ Indian authorization verified ☐ Destination registration checked ☐ Importer licence checked ☐ Controlled/special status checked ☐ COA/stability documents checked ☐ HS code verified ☐ Buyer verified |
148. ADAPALENE GEL IP 0.1 % AND BENZOYL PEROXIDE 2.5 % W/W GEL
1. Medicine / Product Name | ADAPALENE GEL IP 0.1 % AND BENZOYL PEROXIDE 2.5 % W/W GEL |
2. Generic / API / Composition | ADAPALENE GEL IP 0.1 % AND BENZOYL PEROXIDE 2.5 % W/W GEL — exact composition/API to be confirmed from manufacturer specification. |
3. Salt / Strength | Strength/salt as stated in the source where available; otherwise verify the exact product specification. |
4. Therapeutic Category | Dermatology / topical or hormonal medicine |
5. Pharmacological / Drug Class | Ingredient-specific dermatologic/hormonal agent |
6. Main Uses / Indications | Dermatologic or hormonal indication according to the exact formulation. |
7. Mechanism / Basic Description | Ingredient-specific; use approved product labeling. |
8. Dosage Form & Route | Topical or oral depending on formulation. |
9. Prescription / OTC Status | Generally prescription/regulated medicine; exact status varies by jurisdiction. |
10. Major Warnings / Contraindications / Key Interactions | Pregnancy/reproductive warnings, systemic absorption, skin reactions and formulation-specific restrictions must be checked. |
11. India Export Considerations | Verify Indian manufacturing licence/product permission, GMP status, formulation authorization, exporter eligibility, labeling and destination-specific export documentation. |
12. HS Code / Customs Classification — TO BE VERIFIED | Do not assign a final HS/ITC-HS code from the medicine name alone. Confirm with the exact dosage form, packing and Indian customs classification. |
13. 26-Country Regulatory Status | Preliminary screen: 🟡 registration/authorization generally required in all 26 markets. Upgrade to 🟠/🔴/⚫ where the ingredient, formulation or destination law imposes special controls; exact status must be verified. |
14. Country Regulatory Authority | See the 26-country matrix at the beginning of this document; the responsible authority varies by destination. |
15. Registration / Marketing Authorization Requirements | Typically product dossier/quality data, manufacturing information, stability, labeling, local applicant/importer authorization and any country-specific clinical/bioequivalence or GMP evidence required. |
16. Export Requirements & Special Restrictions | Product-specific regulatory review required before export. |
17. Buyer Type | Licensed pharmaceutical importer/distributor/wholesaler; hospitals or institutional buyers where appropriate. Veterinary products require appropriately licensed animal-health buyers. |
18. Required Export / Regulatory Documentation | Commercial invoice; packing list; transport documents; certificate of origin where required; COA; GMP/manufacturing documents; product registration/authorization documents; import permit or controlled-drug permit where applicable. |
19. Commercial Considerations | Confirm MOQ, pack size, shelf life, lead time, private-label/OEM availability, registration ownership, Incoterm, freight, insurance, payment terms and landed cost before quotation. |
20. Exporter Decision / Verification Checklist | ☐ Exact product/formulation confirmed ☐ Manufacturer verified ☐ GMP verified ☐ Indian authorization verified ☐ Destination registration checked ☐ Importer licence checked ☐ Controlled/special status checked ☐ COA/stability documents checked ☐ HS code verified ☐ Buyer verified |
149. ADAPALENE GEL IP 0.3 % AND BENZOYL PEROXIDE 2.5 % W/W GEL
1. Medicine / Product Name | ADAPALENE GEL IP 0.3 % AND BENZOYL PEROXIDE 2.5 % W/W GEL |
2. Generic / API / Composition | ADAPALENE GEL IP 0.3 % AND BENZOYL PEROXIDE 2.5 % W/W GEL — exact composition/API to be confirmed from manufacturer specification. |
3. Salt / Strength | Strength/salt as stated in the source where available; otherwise verify the exact product specification. |
4. Therapeutic Category | Dermatology / topical or hormonal medicine |
5. Pharmacological / Drug Class | Ingredient-specific dermatologic/hormonal agent |
6. Main Uses / Indications | Dermatologic or hormonal indication according to the exact formulation. |
7. Mechanism / Basic Description | Ingredient-specific; use approved product labeling. |
8. Dosage Form & Route | Topical or oral depending on formulation. |
9. Prescription / OTC Status | Generally prescription/regulated medicine; exact status varies by jurisdiction. |
10. Major Warnings / Contraindications / Key Interactions | Pregnancy/reproductive warnings, systemic absorption, skin reactions and formulation-specific restrictions must be checked. |
11. India Export Considerations | Verify Indian manufacturing licence/product permission, GMP status, formulation authorization, exporter eligibility, labeling and destination-specific export documentation. |
12. HS Code / Customs Classification — TO BE VERIFIED | Do not assign a final HS/ITC-HS code from the medicine name alone. Confirm with the exact dosage form, packing and Indian customs classification. |
13. 26-Country Regulatory Status | Preliminary screen: 🟡 registration/authorization generally required in all 26 markets. Upgrade to 🟠/🔴/⚫ where the ingredient, formulation or destination law imposes special controls; exact status must be verified. |
14. Country Regulatory Authority | See the 26-country matrix at the beginning of this document; the responsible authority varies by destination. |
15. Registration / Marketing Authorization Requirements | Typically product dossier/quality data, manufacturing information, stability, labeling, local applicant/importer authorization and any country-specific clinical/bioequivalence or GMP evidence required. |
16. Export Requirements & Special Restrictions | Product-specific regulatory review required before export. |
17. Buyer Type | Licensed pharmaceutical importer/distributor/wholesaler; hospitals or institutional buyers where appropriate. Veterinary products require appropriately licensed animal-health buyers. |
18. Required Export / Regulatory Documentation | Commercial invoice; packing list; transport documents; certificate of origin where required; COA; GMP/manufacturing documents; product registration/authorization documents; import permit or controlled-drug permit where applicable. |
19. Commercial Considerations | Confirm MOQ, pack size, shelf life, lead time, private-label/OEM availability, registration ownership, Incoterm, freight, insurance, payment terms and landed cost before quotation. |
20. Exporter Decision / Verification Checklist | ☐ Exact product/formulation confirmed ☐ Manufacturer verified ☐ GMP verified ☐ Indian authorization verified ☐ Destination registration checked ☐ Importer licence checked ☐ Controlled/special status checked ☐ COA/stability documents checked ☐ HS code verified ☐ Buyer verified |
150. 4 CHLORODEHYDROMETHYLTESTOSTERONE TABLET USP 10 MG
1. Medicine / Product Name | 4 CHLORODEHYDROMETHYLTESTOSTERONE TABLET USP 10 MG |
2. Generic / API / Composition | 4 CHLORODEHYDROMETHYLTESTOSTERONE TABLET USP 10 MG — exact composition/API to be confirmed from manufacturer specification. |
3. Salt / Strength | Strength/salt as stated in the source where available; otherwise verify the exact product specification. |
4. Therapeutic Category | Androgen / anabolic-hormonal medicine |
5. Pharmacological / Drug Class | Androgenic/anabolic steroid or testosterone preparation |
6. Main Uses / Indications | Hormone-replacement or other approved indication depends on the specific substance and formulation. |
7. Mechanism / Basic Description | Acts through androgen receptors; exact pharmacology varies by compound. |
8. Dosage Form & Route | Oral, topical or injectable depending on formulation. |
9. Prescription / OTC Status | Prescription; often subject to additional controlled-substance/hormone rules. |
10. Major Warnings / Contraindications / Key Interactions | Hormonal adverse effects, cardiovascular/thrombotic risks, hepatic risks for some oral agents, reproductive effects and local controlled-drug rules require review. |
11. India Export Considerations | Verify Indian manufacturing licence/product permission, GMP status, formulation authorization, exporter eligibility, labeling and destination-specific export documentation. |
12. HS Code / Customs Classification — TO BE VERIFIED | Do not assign a final HS/ITC-HS code from the medicine name alone. Confirm with the exact dosage form, packing and Indian customs classification. |
13. 26-Country Regulatory Status | Preliminary screen: 🟡 registration/authorization generally required in all 26 markets. Upgrade to 🟠/🔴/⚫ where the ingredient, formulation or destination law imposes special controls; exact status must be verified. |
14. Country Regulatory Authority | See the 26-country matrix at the beginning of this document; the responsible authority varies by destination. |
15. Registration / Marketing Authorization Requirements | Typically product dossier/quality data, manufacturing information, stability, labeling, local applicant/importer authorization and any country-specific clinical/bioequivalence or GMP evidence required. |
16. Export Requirements & Special Restrictions | High-priority regulatory verification; some jurisdictions impose controlled-substance or special import restrictions. Controlled/psychotropic/hormonal classification must be checked separately in each destination. Sterile/injectable or biologic quality, storage and manufacturing controls may apply. |
17. Buyer Type | Licensed pharmaceutical importer/distributor/wholesaler; hospitals or institutional buyers where appropriate. Veterinary products require appropriately licensed animal-health buyers. |
18. Required Export / Regulatory Documentation | Commercial invoice; packing list; transport documents; certificate of origin where required; COA; GMP/manufacturing documents; product registration/authorization documents; import permit or controlled-drug permit where applicable. |
19. Commercial Considerations | Confirm MOQ, pack size, shelf life, lead time, private-label/OEM availability, registration ownership, Incoterm, freight, insurance, payment terms and landed cost before quotation. |
20. Exporter Decision / Verification Checklist | ☐ Exact product/formulation confirmed ☐ Manufacturer verified ☐ GMP verified ☐ Indian authorization verified ☐ Destination registration checked ☐ Importer licence checked ☐ Controlled/special status checked ☐ COA/stability documents checked ☐ HS code verified ☐ Buyer verified |
151. VORTIOXETINE HYDROBROMIDE TABLETS 10 MG
1. Medicine / Product Name | VORTIOXETINE HYDROBROMIDE TABLETS 10 MG |
2. Generic / API / Composition | VORTIOXETINE HYDROBROMIDE 10 MG — exact composition/API to be confirmed from manufacturer specification. |
3. Salt / Strength | Strength/salt as stated in the source where available; otherwise verify the exact product specification. |
4. Therapeutic Category | Pharmaceutical medicine |
5. Pharmacological / Drug Class | Product-specific pharmacological class — verify against approved label. |
6. Main Uses / Indications | Use/indication is formulation- and jurisdiction-specific; verify the approved label. |
7. Mechanism / Basic Description | Pharmacology should be stated from the approved product label/official monograph. |
8. Dosage Form & Route | Route/formulation: verify from the exact product specification. |
9. Prescription / OTC Status | Generally prescription/regulated medicine; exact status varies by jurisdiction. |
10. Major Warnings / Contraindications / Key Interactions | Check official label for contraindications, interactions, pregnancy warnings, organ-function precautions and formulation-specific risks. |
11. India Export Considerations | Verify Indian manufacturing licence/product permission, GMP status, formulation authorization, exporter eligibility, labeling and destination-specific export documentation. |
12. HS Code / Customs Classification — TO BE VERIFIED | Do not assign a final HS/ITC-HS code from the medicine name alone. Confirm with the exact dosage form, packing and Indian customs classification. |
13. 26-Country Regulatory Status | Preliminary screen: 🟡 registration/authorization generally required in all 26 markets. Upgrade to 🟠/🔴/⚫ where the ingredient, formulation or destination law imposes special controls; exact status must be verified. |
14. Country Regulatory Authority | See the 26-country matrix at the beginning of this document; the responsible authority varies by destination. |
15. Registration / Marketing Authorization Requirements | Typically product dossier/quality data, manufacturing information, stability, labeling, local applicant/importer authorization and any country-specific clinical/bioequivalence or GMP evidence required. |
16. Export Requirements & Special Restrictions | Product-specific regulatory review required before export. |
17. Buyer Type | Licensed pharmaceutical importer/distributor/wholesaler; hospitals or institutional buyers where appropriate. Veterinary products require appropriately licensed animal-health buyers. |
18. Required Export / Regulatory Documentation | Commercial invoice; packing list; transport documents; certificate of origin where required; COA; GMP/manufacturing documents; product registration/authorization documents; import permit or controlled-drug permit where applicable. |
19. Commercial Considerations | Confirm MOQ, pack size, shelf life, lead time, private-label/OEM availability, registration ownership, Incoterm, freight, insurance, payment terms and landed cost before quotation. |
20. Exporter Decision / Verification Checklist | ☐ Exact product/formulation confirmed ☐ Manufacturer verified ☐ GMP verified ☐ Indian authorization verified ☐ Destination registration checked ☐ Importer licence checked ☐ Controlled/special status checked ☐ COA/stability documents checked ☐ HS code verified ☐ Buyer verified |
152. AYURVEDIC PROPRIETARY MEDICINE CAPSULE
1. Medicine / Product Name | AYURVEDIC PROPRIETARY MEDICINE CAPSULE |
2. Generic / API / Composition | AYURVEDIC PROPRIETARY MEDICINE CAPSULE — exact composition/API to be confirmed from manufacturer specification. |
3. Salt / Strength | Strength/salt as stated in the source where available; otherwise verify the exact product specification. |
4. Therapeutic Category | Ayurvedic proprietary medicine |
5. Pharmacological / Drug Class | Formula-specific Ayurvedic proprietary product |
6. Main Uses / Indications | Cannot be determined from the source name alone. |
7. Mechanism / Basic Description | Cannot be determined without complete ingredient/formula details. |
8. Dosage Form & Route | Cannot be determined from source alone. |
9. Prescription / OTC Status | Depends on formulation and jurisdiction. |
10. Major Warnings / Contraindications / Key Interactions | Complete composition, licence category, claims and regulatory status must be established before export. |
11. India Export Considerations | Verify Indian manufacturing licence/product permission, GMP status, formulation authorization, exporter eligibility, labeling and destination-specific export documentation. |
12. HS Code / Customs Classification — TO BE VERIFIED | Do not assign a final HS/ITC-HS code from the medicine name alone. Confirm with the exact dosage form, packing and Indian customs classification. |
13. 26-Country Regulatory Status | Preliminary screen: 🟡 registration/authorization generally required in all 26 markets. Upgrade to 🟠/🔴/⚫ where the ingredient, formulation or destination law imposes special controls; exact status must be verified. |
14. Country Regulatory Authority | See the 26-country matrix at the beginning of this document; the responsible authority varies by destination. |
15. Registration / Marketing Authorization Requirements | Typically product dossier/quality data, manufacturing information, stability, labeling, local applicant/importer authorization and any country-specific clinical/bioequivalence or GMP evidence required. |
16. Export Requirements & Special Restrictions | Do not market as a conventional pharmaceutical until classification and composition are verified. |
17. Buyer Type | Licensed pharmaceutical importer/distributor/wholesaler; hospitals or institutional buyers where appropriate. Veterinary products require appropriately licensed animal-health buyers. |
18. Required Export / Regulatory Documentation | Commercial invoice; packing list; transport documents; certificate of origin where required; COA; GMP/manufacturing documents; product registration/authorization documents; import permit or controlled-drug permit where applicable. |
19. Commercial Considerations | Confirm MOQ, pack size, shelf life, lead time, private-label/OEM availability, registration ownership, Incoterm, freight, insurance, payment terms and landed cost before quotation. |
20. Exporter Decision / Verification Checklist | ☐ Exact product/formulation confirmed ☐ Manufacturer verified ☐ GMP verified ☐ Indian authorization verified ☐ Destination registration checked ☐ Importer licence checked ☐ Controlled/special status checked ☐ COA/stability documents checked ☐ HS code verified ☐ Buyer verified |
153. AMBRISENTAN TABLETS IP 5 MG
1. Medicine / Product Name | AMBRISENTAN TABLETS IP 5 MG |
2. Generic / API / Composition | AMBRISENTAN IP 5 MG — exact composition/API to be confirmed from manufacturer specification. |
3. Salt / Strength | Strength/salt as stated in the source where available; otherwise verify the exact product specification. |
4. Therapeutic Category | Pharmaceutical medicine |
5. Pharmacological / Drug Class | Product-specific pharmacological class — verify against approved label. |
6. Main Uses / Indications | Use/indication is formulation- and jurisdiction-specific; verify the approved label. |
7. Mechanism / Basic Description | Pharmacology should be stated from the approved product label/official monograph. |
8. Dosage Form & Route | Route/formulation: verify from the exact product specification. |
9. Prescription / OTC Status | Generally prescription/regulated medicine; exact status varies by jurisdiction. |
10. Major Warnings / Contraindications / Key Interactions | Check official label for contraindications, interactions, pregnancy warnings, organ-function precautions and formulation-specific risks. |
11. India Export Considerations | Verify Indian manufacturing licence/product permission, GMP status, formulation authorization, exporter eligibility, labeling and destination-specific export documentation. |
12. HS Code / Customs Classification — TO BE VERIFIED | Do not assign a final HS/ITC-HS code from the medicine name alone. Confirm with the exact dosage form, packing and Indian customs classification. |
13. 26-Country Regulatory Status | Preliminary screen: 🟡 registration/authorization generally required in all 26 markets. Upgrade to 🟠/🔴/⚫ where the ingredient, formulation or destination law imposes special controls; exact status must be verified. |
14. Country Regulatory Authority | See the 26-country matrix at the beginning of this document; the responsible authority varies by destination. |
15. Registration / Marketing Authorization Requirements | Typically product dossier/quality data, manufacturing information, stability, labeling, local applicant/importer authorization and any country-specific clinical/bioequivalence or GMP evidence required. |
16. Export Requirements & Special Restrictions | Product-specific regulatory review required before export. |
17. Buyer Type | Licensed pharmaceutical importer/distributor/wholesaler; hospitals or institutional buyers where appropriate. Veterinary products require appropriately licensed animal-health buyers. |
18. Required Export / Regulatory Documentation | Commercial invoice; packing list; transport documents; certificate of origin where required; COA; GMP/manufacturing documents; product registration/authorization documents; import permit or controlled-drug permit where applicable. |
19. Commercial Considerations | Confirm MOQ, pack size, shelf life, lead time, private-label/OEM availability, registration ownership, Incoterm, freight, insurance, payment terms and landed cost before quotation. |
20. Exporter Decision / Verification Checklist | ☐ Exact product/formulation confirmed ☐ Manufacturer verified ☐ GMP verified ☐ Indian authorization verified ☐ Destination registration checked ☐ Importer licence checked ☐ Controlled/special status checked ☐ COA/stability documents checked ☐ HS code verified ☐ Buyer verified |
154. OXANDROLONE TABLETS USP 10 MG
1. Medicine / Product Name | OXANDROLONE TABLETS USP 10 MG |
2. Generic / API / Composition | OXANDROLONE USP 10 MG — exact composition/API to be confirmed from manufacturer specification. |
3. Salt / Strength | Strength/salt as stated in the source where available; otherwise verify the exact product specification. |
4. Therapeutic Category | Androgen / anabolic-hormonal medicine |
5. Pharmacological / Drug Class | Androgenic/anabolic steroid or testosterone preparation |
6. Main Uses / Indications | Hormone-replacement or other approved indication depends on the specific substance and formulation. |
7. Mechanism / Basic Description | Acts through androgen receptors; exact pharmacology varies by compound. |
8. Dosage Form & Route | Oral, topical or injectable depending on formulation. |
9. Prescription / OTC Status | Prescription; often subject to additional controlled-substance/hormone rules. |
10. Major Warnings / Contraindications / Key Interactions | Hormonal adverse effects, cardiovascular/thrombotic risks, hepatic risks for some oral agents, reproductive effects and local controlled-drug rules require review. |
11. India Export Considerations | Verify Indian manufacturing licence/product permission, GMP status, formulation authorization, exporter eligibility, labeling and destination-specific export documentation. |
12. HS Code / Customs Classification — TO BE VERIFIED | Do not assign a final HS/ITC-HS code from the medicine name alone. Confirm with the exact dosage form, packing and Indian customs classification. |
13. 26-Country Regulatory Status | Preliminary screen: 🟡 registration/authorization generally required in all 26 markets. Upgrade to 🟠/🔴/⚫ where the ingredient, formulation or destination law imposes special controls; exact status must be verified. |
14. Country Regulatory Authority | See the 26-country matrix at the beginning of this document; the responsible authority varies by destination. |
15. Registration / Marketing Authorization Requirements | Typically product dossier/quality data, manufacturing information, stability, labeling, local applicant/importer authorization and any country-specific clinical/bioequivalence or GMP evidence required. |
16. Export Requirements & Special Restrictions | High-priority regulatory verification; some jurisdictions impose controlled-substance or special import restrictions. Controlled/psychotropic/hormonal classification must be checked separately in each destination. |
17. Buyer Type | Licensed pharmaceutical importer/distributor/wholesaler; hospitals or institutional buyers where appropriate. Veterinary products require appropriately licensed animal-health buyers. |
18. Required Export / Regulatory Documentation | Commercial invoice; packing list; transport documents; certificate of origin where required; COA; GMP/manufacturing documents; product registration/authorization documents; import permit or controlled-drug permit where applicable. |
19. Commercial Considerations | Confirm MOQ, pack size, shelf life, lead time, private-label/OEM availability, registration ownership, Incoterm, freight, insurance, payment terms and landed cost before quotation. |
20. Exporter Decision / Verification Checklist | ☐ Exact product/formulation confirmed ☐ Manufacturer verified ☐ GMP verified ☐ Indian authorization verified ☐ Destination registration checked ☐ Importer licence checked ☐ Controlled/special status checked ☐ COA/stability documents checked ☐ HS code verified ☐ Buyer verified |
155. FINASTERIDE TABLETS IP 1 MG
1. Medicine / Product Name | FINASTERIDE TABLETS IP 1 MG |
2. Generic / API / Composition | FINASTERIDE IP 1 MG — exact composition/API to be confirmed from manufacturer specification. |
3. Salt / Strength | Strength/salt as stated in the source where available; otherwise verify the exact product specification. |
4. Therapeutic Category | Urological / dermatological medicine |
5. Pharmacological / Drug Class | 5-alpha-reductase inhibitor |
6. Main Uses / Indications | Approved indications include benign prostatic hyperplasia and/or androgenetic alopecia depending on strength/formulation. |
7. Mechanism / Basic Description | Reduces conversion of testosterone to dihydrotestosterone. |
8. Dosage Form & Route | Route/formulation: verify from the exact product specification. |
9. Prescription / OTC Status | Generally prescription/regulated medicine; exact status varies by jurisdiction. |
10. Major Warnings / Contraindications / Key Interactions | Check official label for contraindications, interactions, pregnancy warnings, organ-function precautions and formulation-specific risks. |
11. India Export Considerations | Verify Indian manufacturing licence/product permission, GMP status, formulation authorization, exporter eligibility, labeling and destination-specific export documentation. |
12. HS Code / Customs Classification — TO BE VERIFIED | Do not assign a final HS/ITC-HS code from the medicine name alone. Confirm with the exact dosage form, packing and Indian customs classification. |
13. 26-Country Regulatory Status | Preliminary screen: 🟡 registration/authorization generally required in all 26 markets. Upgrade to 🟠/🔴/⚫ where the ingredient, formulation or destination law imposes special controls; exact status must be verified. |
14. Country Regulatory Authority | See the 26-country matrix at the beginning of this document; the responsible authority varies by destination. |
15. Registration / Marketing Authorization Requirements | Typically product dossier/quality data, manufacturing information, stability, labeling, local applicant/importer authorization and any country-specific clinical/bioequivalence or GMP evidence required. |
16. Export Requirements & Special Restrictions | Product-specific regulatory review required before export. |
17. Buyer Type | Licensed pharmaceutical importer/distributor/wholesaler; hospitals or institutional buyers where appropriate. Veterinary products require appropriately licensed animal-health buyers. |
18. Required Export / Regulatory Documentation | Commercial invoice; packing list; transport documents; certificate of origin where required; COA; GMP/manufacturing documents; product registration/authorization documents; import permit or controlled-drug permit where applicable. |
19. Commercial Considerations | Confirm MOQ, pack size, shelf life, lead time, private-label/OEM availability, registration ownership, Incoterm, freight, insurance, payment terms and landed cost before quotation. |
20. Exporter Decision / Verification Checklist | ☐ Exact product/formulation confirmed ☐ Manufacturer verified ☐ GMP verified ☐ Indian authorization verified ☐ Destination registration checked ☐ Importer licence checked ☐ Controlled/special status checked ☐ COA/stability documents checked ☐ HS code verified ☐ Buyer verified |
156. SIDENAFIL AND DEPOXETINE TABLETS
1. Medicine / Product Name | SIDENAFIL AND DEPOXETINE TABLETS |
2. Generic / API / Composition | SIDENAFIL AND DEPOXETINE — exact composition/API to be confirmed from manufacturer specification. |
3. Salt / Strength | Strength/salt as stated in the source where available; otherwise verify the exact product specification. |
4. Therapeutic Category | Genitourinary / erectile-dysfunction medicine |
5. Pharmacological / Drug Class | PDE-5 inhibitor |
6. Main Uses / Indications | Treatment of erectile dysfunction; exact indications vary by product and market. |
7. Mechanism / Basic Description | Inhibits PDE-5, increasing cGMP-mediated smooth-muscle relaxation. |
8. Dosage Form & Route | Oral; exact formulation (tablet/jelly/etc.) must be verified. |
9. Prescription / OTC Status | Generally prescription/regulated medicine; exact status varies by jurisdiction. |
10. Major Warnings / Contraindications / Key Interactions | Nitrates/riociguat and cardiovascular conditions require particular attention; formulation and local labeling must be checked. |
11. India Export Considerations | Verify Indian manufacturing licence/product permission, GMP status, formulation authorization, exporter eligibility, labeling and destination-specific export documentation. |
12. HS Code / Customs Classification — TO BE VERIFIED | Do not assign a final HS/ITC-HS code from the medicine name alone. Confirm with the exact dosage form, packing and Indian customs classification. |
13. 26-Country Regulatory Status | Preliminary screen: 🟡 registration/authorization generally required in all 26 markets. Upgrade to 🟠/🔴/⚫ where the ingredient, formulation or destination law imposes special controls; exact status must be verified. |
14. Country Regulatory Authority | See the 26-country matrix at the beginning of this document; the responsible authority varies by destination. |
15. Registration / Marketing Authorization Requirements | Typically product dossier/quality data, manufacturing information, stability, labeling, local applicant/importer authorization and any country-specific clinical/bioequivalence or GMP evidence required. |
16. Export Requirements & Special Restrictions | Product-specific regulatory review required before export. |
17. Buyer Type | Licensed pharmaceutical importer/distributor/wholesaler; hospitals or institutional buyers where appropriate. Veterinary products require appropriately licensed animal-health buyers. |
18. Required Export / Regulatory Documentation | Commercial invoice; packing list; transport documents; certificate of origin where required; COA; GMP/manufacturing documents; product registration/authorization documents; import permit or controlled-drug permit where applicable. |
19. Commercial Considerations | Confirm MOQ, pack size, shelf life, lead time, private-label/OEM availability, registration ownership, Incoterm, freight, insurance, payment terms and landed cost before quotation. |
20. Exporter Decision / Verification Checklist | ☐ Exact product/formulation confirmed ☐ Manufacturer verified ☐ GMP verified ☐ Indian authorization verified ☐ Destination registration checked ☐ Importer licence checked ☐ Controlled/special status checked ☐ COA/stability documents checked ☐ HS code verified ☐ Buyer verified |
157. SIDENAFIL TABLETS BP
1. Medicine / Product Name | SIDENAFIL TABLETS BP |
2. Generic / API / Composition | SIDENAFIL BP — exact composition/API to be confirmed from manufacturer specification. |
3. Salt / Strength | Strength/salt as stated in the source where available; otherwise verify the exact product specification. |
4. Therapeutic Category | Genitourinary / erectile-dysfunction medicine |
5. Pharmacological / Drug Class | PDE-5 inhibitor |
6. Main Uses / Indications | Treatment of erectile dysfunction; exact indications vary by product and market. |
7. Mechanism / Basic Description | Inhibits PDE-5, increasing cGMP-mediated smooth-muscle relaxation. |
8. Dosage Form & Route | Oral; exact formulation (tablet/jelly/etc.) must be verified. |
9. Prescription / OTC Status | Generally prescription/regulated medicine; exact status varies by jurisdiction. |
10. Major Warnings / Contraindications / Key Interactions | Nitrates/riociguat and cardiovascular conditions require particular attention; formulation and local labeling must be checked. |
11. India Export Considerations | Verify Indian manufacturing licence/product permission, GMP status, formulation authorization, exporter eligibility, labeling and destination-specific export documentation. |
12. HS Code / Customs Classification — TO BE VERIFIED | Do not assign a final HS/ITC-HS code from the medicine name alone. Confirm with the exact dosage form, packing and Indian customs classification. |
13. 26-Country Regulatory Status | Preliminary screen: 🟡 registration/authorization generally required in all 26 markets. Upgrade to 🟠/🔴/⚫ where the ingredient, formulation or destination law imposes special controls; exact status must be verified. |
14. Country Regulatory Authority | See the 26-country matrix at the beginning of this document; the responsible authority varies by destination. |
15. Registration / Marketing Authorization Requirements | Typically product dossier/quality data, manufacturing information, stability, labeling, local applicant/importer authorization and any country-specific clinical/bioequivalence or GMP evidence required. |
16. Export Requirements & Special Restrictions | Product-specific regulatory review required before export. |
17. Buyer Type | Licensed pharmaceutical importer/distributor/wholesaler; hospitals or institutional buyers where appropriate. Veterinary products require appropriately licensed animal-health buyers. |
18. Required Export / Regulatory Documentation | Commercial invoice; packing list; transport documents; certificate of origin where required; COA; GMP/manufacturing documents; product registration/authorization documents; import permit or controlled-drug permit where applicable. |
19. Commercial Considerations | Confirm MOQ, pack size, shelf life, lead time, private-label/OEM availability, registration ownership, Incoterm, freight, insurance, payment terms and landed cost before quotation. |
20. Exporter Decision / Verification Checklist | ☐ Exact product/formulation confirmed ☐ Manufacturer verified ☐ GMP verified ☐ Indian authorization verified ☐ Destination registration checked ☐ Importer licence checked ☐ Controlled/special status checked ☐ COA/stability documents checked ☐ HS code verified ☐ Buyer verified |
158. TADALAFIL AND DAPOXETINE TABLETS USP
1. Medicine / Product Name | TADALAFIL AND DAPOXETINE TABLETS USP |
2. Generic / API / Composition | TADALAFIL AND DAPOXETINE USP — exact composition/API to be confirmed from manufacturer specification. |
3. Salt / Strength | Strength/salt as stated in the source where available; otherwise verify the exact product specification. |
4. Therapeutic Category | Genitourinary / erectile-dysfunction medicine |
5. Pharmacological / Drug Class | PDE-5 inhibitor |
6. Main Uses / Indications | Treatment of erectile dysfunction; exact indications vary by product and market. |
7. Mechanism / Basic Description | Inhibits PDE-5, increasing cGMP-mediated smooth-muscle relaxation. |
8. Dosage Form & Route | Oral; exact formulation (tablet/jelly/etc.) must be verified. |
9. Prescription / OTC Status | Generally prescription/regulated medicine; exact status varies by jurisdiction. |
10. Major Warnings / Contraindications / Key Interactions | Nitrates/riociguat and cardiovascular conditions require particular attention; formulation and local labeling must be checked. |
11. India Export Considerations | Verify Indian manufacturing licence/product permission, GMP status, formulation authorization, exporter eligibility, labeling and destination-specific export documentation. |
12. HS Code / Customs Classification — TO BE VERIFIED | Do not assign a final HS/ITC-HS code from the medicine name alone. Confirm with the exact dosage form, packing and Indian customs classification. |
13. 26-Country Regulatory Status | Preliminary screen: 🟡 registration/authorization generally required in all 26 markets. Upgrade to 🟠/🔴/⚫ where the ingredient, formulation or destination law imposes special controls; exact status must be verified. |
14. Country Regulatory Authority | See the 26-country matrix at the beginning of this document; the responsible authority varies by destination. |
15. Registration / Marketing Authorization Requirements | Typically product dossier/quality data, manufacturing information, stability, labeling, local applicant/importer authorization and any country-specific clinical/bioequivalence or GMP evidence required. |
16. Export Requirements & Special Restrictions | Product-specific regulatory review required before export. |
17. Buyer Type | Licensed pharmaceutical importer/distributor/wholesaler; hospitals or institutional buyers where appropriate. Veterinary products require appropriately licensed animal-health buyers. |
18. Required Export / Regulatory Documentation | Commercial invoice; packing list; transport documents; certificate of origin where required; COA; GMP/manufacturing documents; product registration/authorization documents; import permit or controlled-drug permit where applicable. |
19. Commercial Considerations | Confirm MOQ, pack size, shelf life, lead time, private-label/OEM availability, registration ownership, Incoterm, freight, insurance, payment terms and landed cost before quotation. |
20. Exporter Decision / Verification Checklist | ☐ Exact product/formulation confirmed ☐ Manufacturer verified ☐ GMP verified ☐ Indian authorization verified ☐ Destination registration checked ☐ Importer licence checked ☐ Controlled/special status checked ☐ COA/stability documents checked ☐ HS code verified ☐ Buyer verified |
159. TADALAFIL TABLETS USP
1. Medicine / Product Name | TADALAFIL TABLETS USP |
2. Generic / API / Composition | TADALAFIL USP — exact composition/API to be confirmed from manufacturer specification. |
3. Salt / Strength | Strength/salt as stated in the source where available; otherwise verify the exact product specification. |
4. Therapeutic Category | Genitourinary / erectile-dysfunction medicine |
5. Pharmacological / Drug Class | PDE-5 inhibitor |
6. Main Uses / Indications | Treatment of erectile dysfunction; exact indications vary by product and market. |
7. Mechanism / Basic Description | Inhibits PDE-5, increasing cGMP-mediated smooth-muscle relaxation. |
8. Dosage Form & Route | Oral; exact formulation (tablet/jelly/etc.) must be verified. |
9. Prescription / OTC Status | Generally prescription/regulated medicine; exact status varies by jurisdiction. |
10. Major Warnings / Contraindications / Key Interactions | Nitrates/riociguat and cardiovascular conditions require particular attention; formulation and local labeling must be checked. |
11. India Export Considerations | Verify Indian manufacturing licence/product permission, GMP status, formulation authorization, exporter eligibility, labeling and destination-specific export documentation. |
12. HS Code / Customs Classification — TO BE VERIFIED | Do not assign a final HS/ITC-HS code from the medicine name alone. Confirm with the exact dosage form, packing and Indian customs classification. |
13. 26-Country Regulatory Status | Preliminary screen: 🟡 registration/authorization generally required in all 26 markets. Upgrade to 🟠/🔴/⚫ where the ingredient, formulation or destination law imposes special controls; exact status must be verified. |
14. Country Regulatory Authority | See the 26-country matrix at the beginning of this document; the responsible authority varies by destination. |
15. Registration / Marketing Authorization Requirements | Typically product dossier/quality data, manufacturing information, stability, labeling, local applicant/importer authorization and any country-specific clinical/bioequivalence or GMP evidence required. |
16. Export Requirements & Special Restrictions | Product-specific regulatory review required before export. |
17. Buyer Type | Licensed pharmaceutical importer/distributor/wholesaler; hospitals or institutional buyers where appropriate. Veterinary products require appropriately licensed animal-health buyers. |
18. Required Export / Regulatory Documentation | Commercial invoice; packing list; transport documents; certificate of origin where required; COA; GMP/manufacturing documents; product registration/authorization documents; import permit or controlled-drug permit where applicable. |
19. Commercial Considerations | Confirm MOQ, pack size, shelf life, lead time, private-label/OEM availability, registration ownership, Incoterm, freight, insurance, payment terms and landed cost before quotation. |
20. Exporter Decision / Verification Checklist | ☐ Exact product/formulation confirmed ☐ Manufacturer verified ☐ GMP verified ☐ Indian authorization verified ☐ Destination registration checked ☐ Importer licence checked ☐ Controlled/special status checked ☐ COA/stability documents checked ☐ HS code verified ☐ Buyer verified |
160. ARMODAFINIL TABLETS 250 MG
1. Medicine / Product Name | ARMODAFINIL TABLETS 250 MG |
2. Generic / API / Composition | ARMODAFINIL 250 MG — exact composition/API to be confirmed from manufacturer specification. |
3. Salt / Strength | Strength/salt as stated in the source where available; otherwise verify the exact product specification. |
4. Therapeutic Category | CNS / neurological / psychiatric medicine |
5. Pharmacological / Drug Class | Central nervous system active medicine |
6. Main Uses / Indications | Indication depends on the active ingredient; verify approved indication. |
7. Mechanism / Basic Description | CNS mechanism is ingredient-specific. |
8. Dosage Form & Route | Route/formulation: verify from the exact product specification. |
9. Prescription / OTC Status | Prescription; controlled/psychotropic status must be checked country by country. |
10. Major Warnings / Contraindications / Key Interactions | CNS effects, interactions, dependence/misuse potential where applicable and local controlled-drug status require review. |
11. India Export Considerations | Verify Indian manufacturing licence/product permission, GMP status, formulation authorization, exporter eligibility, labeling and destination-specific export documentation. |
12. HS Code / Customs Classification — TO BE VERIFIED | Do not assign a final HS/ITC-HS code from the medicine name alone. Confirm with the exact dosage form, packing and Indian customs classification. |
13. 26-Country Regulatory Status | Preliminary screen: 🟡 registration/authorization generally required in all 26 markets. Upgrade to 🟠/🔴/⚫ where the ingredient, formulation or destination law imposes special controls; exact status must be verified. |
14. Country Regulatory Authority | See the 26-country matrix at the beginning of this document; the responsible authority varies by destination. |
15. Registration / Marketing Authorization Requirements | Typically product dossier/quality data, manufacturing information, stability, labeling, local applicant/importer authorization and any country-specific clinical/bioequivalence or GMP evidence required. |
16. Export Requirements & Special Restrictions | High-priority destination-country classification check. Controlled/psychotropic/hormonal classification must be checked separately in each destination. |
17. Buyer Type | Licensed pharmaceutical importer/distributor/wholesaler; hospitals or institutional buyers where appropriate. Veterinary products require appropriately licensed animal-health buyers. |
18. Required Export / Regulatory Documentation | Commercial invoice; packing list; transport documents; certificate of origin where required; COA; GMP/manufacturing documents; product registration/authorization documents; import permit or controlled-drug permit where applicable. |
19. Commercial Considerations | Confirm MOQ, pack size, shelf life, lead time, private-label/OEM availability, registration ownership, Incoterm, freight, insurance, payment terms and landed cost before quotation. |
20. Exporter Decision / Verification Checklist | ☐ Exact product/formulation confirmed ☐ Manufacturer verified ☐ GMP verified ☐ Indian authorization verified ☐ Destination registration checked ☐ Importer licence checked ☐ Controlled/special status checked ☐ COA/stability documents checked ☐ HS code verified ☐ Buyer verified |
161. MODAFINIL TABLETS I.P
1. Medicine / Product Name | MODAFINIL TABLETS I.P |
2. Generic / API / Composition | MODAFINIL I.P — exact composition/API to be confirmed from manufacturer specification. |
3. Salt / Strength | Strength/salt as stated in the source where available; otherwise verify the exact product specification. |
4. Therapeutic Category | CNS / neurological / psychiatric medicine |
5. Pharmacological / Drug Class | Central nervous system active medicine |
6. Main Uses / Indications | Indication depends on the active ingredient; verify approved indication. |
7. Mechanism / Basic Description | CNS mechanism is ingredient-specific. |
8. Dosage Form & Route | Route/formulation: verify from the exact product specification. |
9. Prescription / OTC Status | Prescription; controlled/psychotropic status must be checked country by country. |
10. Major Warnings / Contraindications / Key Interactions | CNS effects, interactions, dependence/misuse potential where applicable and local controlled-drug status require review. |
11. India Export Considerations | Verify Indian manufacturing licence/product permission, GMP status, formulation authorization, exporter eligibility, labeling and destination-specific export documentation. |
12. HS Code / Customs Classification — TO BE VERIFIED | Do not assign a final HS/ITC-HS code from the medicine name alone. Confirm with the exact dosage form, packing and Indian customs classification. |
13. 26-Country Regulatory Status | Preliminary screen: 🟡 registration/authorization generally required in all 26 markets. Upgrade to 🟠/🔴/⚫ where the ingredient, formulation or destination law imposes special controls; exact status must be verified. |
14. Country Regulatory Authority | See the 26-country matrix at the beginning of this document; the responsible authority varies by destination. |
15. Registration / Marketing Authorization Requirements | Typically product dossier/quality data, manufacturing information, stability, labeling, local applicant/importer authorization and any country-specific clinical/bioequivalence or GMP evidence required. |
16. Export Requirements & Special Restrictions | High-priority destination-country classification check. Controlled/psychotropic/hormonal classification must be checked separately in each destination. |
17. Buyer Type | Licensed pharmaceutical importer/distributor/wholesaler; hospitals or institutional buyers where appropriate. Veterinary products require appropriately licensed animal-health buyers. |
18. Required Export / Regulatory Documentation | Commercial invoice; packing list; transport documents; certificate of origin where required; COA; GMP/manufacturing documents; product registration/authorization documents; import permit or controlled-drug permit where applicable. |
19. Commercial Considerations | Confirm MOQ, pack size, shelf life, lead time, private-label/OEM availability, registration ownership, Incoterm, freight, insurance, payment terms and landed cost before quotation. |
20. Exporter Decision / Verification Checklist | ☐ Exact product/formulation confirmed ☐ Manufacturer verified ☐ GMP verified ☐ Indian authorization verified ☐ Destination registration checked ☐ Importer licence checked ☐ Controlled/special status checked ☐ COA/stability documents checked ☐ HS code verified ☐ Buyer verified |
162. MELOXICAM TABLETS BP 15 MG
1. Medicine / Product Name | MELOXICAM TABLETS BP 15 MG |
2. Generic / API / Composition | MELOXICAM BP 15 MG — exact composition/API to be confirmed from manufacturer specification. |
3. Salt / Strength | Strength/salt as stated in the source where available; otherwise verify the exact product specification. |
4. Therapeutic Category | Analgesic / gastrointestinal medicine |
5. Pharmacological / Drug Class | Ingredient-specific analgesic or GI agent |
6. Main Uses / Indications | Pain/inflammation or gastrointestinal indication according to ingredient. |
7. Mechanism / Basic Description | Ingredient-specific mechanism. |
8. Dosage Form & Route | Route/formulation: verify from the exact product specification. |
9. Prescription / OTC Status | Generally prescription/regulated medicine; exact status varies by jurisdiction. |
10. Major Warnings / Contraindications / Key Interactions | Check official label for contraindications, interactions, pregnancy warnings, organ-function precautions and formulation-specific risks. |
11. India Export Considerations | Verify Indian manufacturing licence/product permission, GMP status, formulation authorization, exporter eligibility, labeling and destination-specific export documentation. |
12. HS Code / Customs Classification — TO BE VERIFIED | Do not assign a final HS/ITC-HS code from the medicine name alone. Confirm with the exact dosage form, packing and Indian customs classification. |
13. 26-Country Regulatory Status | Preliminary screen: 🟡 registration/authorization generally required in all 26 markets. Upgrade to 🟠/🔴/⚫ where the ingredient, formulation or destination law imposes special controls; exact status must be verified. |
14. Country Regulatory Authority | See the 26-country matrix at the beginning of this document; the responsible authority varies by destination. |
15. Registration / Marketing Authorization Requirements | Typically product dossier/quality data, manufacturing information, stability, labeling, local applicant/importer authorization and any country-specific clinical/bioequivalence or GMP evidence required. |
16. Export Requirements & Special Restrictions | Product-specific regulatory review required before export. |
17. Buyer Type | Licensed pharmaceutical importer/distributor/wholesaler; hospitals or institutional buyers where appropriate. Veterinary products require appropriately licensed animal-health buyers. |
18. Required Export / Regulatory Documentation | Commercial invoice; packing list; transport documents; certificate of origin where required; COA; GMP/manufacturing documents; product registration/authorization documents; import permit or controlled-drug permit where applicable. |
19. Commercial Considerations | Confirm MOQ, pack size, shelf life, lead time, private-label/OEM availability, registration ownership, Incoterm, freight, insurance, payment terms and landed cost before quotation. |
20. Exporter Decision / Verification Checklist | ☐ Exact product/formulation confirmed ☐ Manufacturer verified ☐ GMP verified ☐ Indian authorization verified ☐ Destination registration checked ☐ Importer licence checked ☐ Controlled/special status checked ☐ COA/stability documents checked ☐ HS code verified ☐ Buyer verified |
163. SORAFENIB TABLETS IP 200 MG
1. Medicine / Product Name | SORAFENIB TABLETS IP 200 MG |
2. Generic / API / Composition | SORAFENIB IP 200 MG — exact composition/API to be confirmed from manufacturer specification. |
3. Salt / Strength | Strength/salt as stated in the source where available; otherwise verify the exact product specification. |
4. Therapeutic Category | Oncology medicine |
5. Pharmacological / Drug Class | Targeted anticancer kinase inhibitor |
6. Main Uses / Indications | Cancer treatment according to approved indication. |
7. Mechanism / Basic Description | Inhibits specified protein kinases involved in tumor growth/angiogenesis. |
8. Dosage Form & Route | Route/formulation: verify from the exact product specification. |
9. Prescription / OTC Status | Generally prescription/regulated medicine; exact status varies by jurisdiction. |
10. Major Warnings / Contraindications / Key Interactions | Serious adverse effects and interactions; oncology registration and pharmacovigilance requirements apply. |
11. India Export Considerations | Verify Indian manufacturing licence/product permission, GMP status, formulation authorization, exporter eligibility, labeling and destination-specific export documentation. |
12. HS Code / Customs Classification — TO BE VERIFIED | Do not assign a final HS/ITC-HS code from the medicine name alone. Confirm with the exact dosage form, packing and Indian customs classification. |
13. 26-Country Regulatory Status | Preliminary screen: 🟡 registration/authorization generally required in all 26 markets. Upgrade to 🟠/🔴/⚫ where the ingredient, formulation or destination law imposes special controls; exact status must be verified. |
14. Country Regulatory Authority | See the 26-country matrix at the beginning of this document; the responsible authority varies by destination. |
15. Registration / Marketing Authorization Requirements | Typically product dossier/quality data, manufacturing information, stability, labeling, local applicant/importer authorization and any country-specific clinical/bioequivalence or GMP evidence required. |
16. Export Requirements & Special Restrictions | High-priority regulatory review; oncology product dossier requirements. |
17. Buyer Type | Licensed pharmaceutical importer/distributor/wholesaler; hospitals or institutional buyers where appropriate. Veterinary products require appropriately licensed animal-health buyers. |
18. Required Export / Regulatory Documentation | Commercial invoice; packing list; transport documents; certificate of origin where required; COA; GMP/manufacturing documents; product registration/authorization documents; import permit or controlled-drug permit where applicable. |
19. Commercial Considerations | Confirm MOQ, pack size, shelf life, lead time, private-label/OEM availability, registration ownership, Incoterm, freight, insurance, payment terms and landed cost before quotation. |
20. Exporter Decision / Verification Checklist | ☐ Exact product/formulation confirmed ☐ Manufacturer verified ☐ GMP verified ☐ Indian authorization verified ☐ Destination registration checked ☐ Importer licence checked ☐ Controlled/special status checked ☐ COA/stability documents checked ☐ HS code verified ☐ Buyer verified |
164. MELATONIN MOUTH DISSOLVING TABLETS
1. Medicine / Product Name | MELATONIN MOUTH DISSOLVING TABLETS |
2. Generic / API / Composition | MELATONIN MOUTH DISSOLVING — exact composition/API to be confirmed from manufacturer specification. |
3. Salt / Strength | Strength/salt as stated in the source where available; otherwise verify the exact product specification. |
4. Therapeutic Category | Sleep/circadian medicine |
5. Pharmacological / Drug Class | Melatonin receptor agonist/hormone |
6. Main Uses / Indications | Sleep/circadian indications vary substantially by jurisdiction. |
7. Mechanism / Basic Description | Acts at melatonin receptors involved in circadian regulation. |
8. Dosage Form & Route | Route/formulation: verify from the exact product specification. |
9. Prescription / OTC Status | OTC, supplement or prescription status varies by country and dose. |
10. Major Warnings / Contraindications / Key Interactions | Check official label for contraindications, interactions, pregnancy warnings, organ-function precautions and formulation-specific risks. |
11. India Export Considerations | Verify Indian manufacturing licence/product permission, GMP status, formulation authorization, exporter eligibility, labeling and destination-specific export documentation. |
12. HS Code / Customs Classification — TO BE VERIFIED | Do not assign a final HS/ITC-HS code from the medicine name alone. Confirm with the exact dosage form, packing and Indian customs classification. |
13. 26-Country Regulatory Status | Preliminary screen: 🟡 registration/authorization generally required in all 26 markets. Upgrade to 🟠/🔴/⚫ where the ingredient, formulation or destination law imposes special controls; exact status must be verified. |
14. Country Regulatory Authority | See the 26-country matrix at the beginning of this document; the responsible authority varies by destination. |
15. Registration / Marketing Authorization Requirements | Typically product dossier/quality data, manufacturing information, stability, labeling, local applicant/importer authorization and any country-specific clinical/bioequivalence or GMP evidence required. |
16. Export Requirements & Special Restrictions | Product-specific regulatory review required before export. |
17. Buyer Type | Licensed pharmaceutical importer/distributor/wholesaler; hospitals or institutional buyers where appropriate. Veterinary products require appropriately licensed animal-health buyers. |
18. Required Export / Regulatory Documentation | Commercial invoice; packing list; transport documents; certificate of origin where required; COA; GMP/manufacturing documents; product registration/authorization documents; import permit or controlled-drug permit where applicable. |
19. Commercial Considerations | Confirm MOQ, pack size, shelf life, lead time, private-label/OEM availability, registration ownership, Incoterm, freight, insurance, payment terms and landed cost before quotation. |
20. Exporter Decision / Verification Checklist | ☐ Exact product/formulation confirmed ☐ Manufacturer verified ☐ GMP verified ☐ Indian authorization verified ☐ Destination registration checked ☐ Importer licence checked ☐ Controlled/special status checked ☐ COA/stability documents checked ☐ HS code verified ☐ Buyer verified |
165. TAMOXIFEN TABLETS IP 20 MG
1. Medicine / Product Name | TAMOXIFEN TABLETS IP 20 MG |
2. Generic / API / Composition | TAMOXIFEN IP 20 MG — exact composition/API to be confirmed from manufacturer specification. |
3. Salt / Strength | Strength/salt as stated in the source where available; otherwise verify the exact product specification. |
4. Therapeutic Category | Hormonal / endocrine medicine |
5. Pharmacological / Drug Class | Hormonal pathway modulator |
6. Main Uses / Indications | Endocrine or oncology/fertility indication depending on ingredient. |
7. Mechanism / Basic Description | Ingredient-specific estrogen-receptor or aromatase pathway modulation. |
8. Dosage Form & Route | Route/formulation: verify from the exact product specification. |
9. Prescription / OTC Status | Generally prescription/regulated medicine; exact status varies by jurisdiction. |
10. Major Warnings / Contraindications / Key Interactions | Check official label for contraindications, interactions, pregnancy warnings, organ-function precautions and formulation-specific risks. |
11. India Export Considerations | Verify Indian manufacturing licence/product permission, GMP status, formulation authorization, exporter eligibility, labeling and destination-specific export documentation. |
12. HS Code / Customs Classification — TO BE VERIFIED | Do not assign a final HS/ITC-HS code from the medicine name alone. Confirm with the exact dosage form, packing and Indian customs classification. |
13. 26-Country Regulatory Status | Preliminary screen: 🟡 registration/authorization generally required in all 26 markets. Upgrade to 🟠/🔴/⚫ where the ingredient, formulation or destination law imposes special controls; exact status must be verified. |
14. Country Regulatory Authority | See the 26-country matrix at the beginning of this document; the responsible authority varies by destination. |
15. Registration / Marketing Authorization Requirements | Typically product dossier/quality data, manufacturing information, stability, labeling, local applicant/importer authorization and any country-specific clinical/bioequivalence or GMP evidence required. |
16. Export Requirements & Special Restrictions | Hormonal/oncology regulatory review may apply. |
17. Buyer Type | Licensed pharmaceutical importer/distributor/wholesaler; hospitals or institutional buyers where appropriate. Veterinary products require appropriately licensed animal-health buyers. |
18. Required Export / Regulatory Documentation | Commercial invoice; packing list; transport documents; certificate of origin where required; COA; GMP/manufacturing documents; product registration/authorization documents; import permit or controlled-drug permit where applicable. |
19. Commercial Considerations | Confirm MOQ, pack size, shelf life, lead time, private-label/OEM availability, registration ownership, Incoterm, freight, insurance, payment terms and landed cost before quotation. |
20. Exporter Decision / Verification Checklist | ☐ Exact product/formulation confirmed ☐ Manufacturer verified ☐ GMP verified ☐ Indian authorization verified ☐ Destination registration checked ☐ Importer licence checked ☐ Controlled/special status checked ☐ COA/stability documents checked ☐ HS code verified ☐ Buyer verified |
166. EXEMESTANE TABLETS USP 25 MG
1. Medicine / Product Name | EXEMESTANE TABLETS USP 25 MG |
2. Generic / API / Composition | EXEMESTANE USP 25 MG — exact composition/API to be confirmed from manufacturer specification. |
3. Salt / Strength | Strength/salt as stated in the source where available; otherwise verify the exact product specification. |
4. Therapeutic Category | Hormonal / endocrine medicine |
5. Pharmacological / Drug Class | Hormonal pathway modulator |
6. Main Uses / Indications | Endocrine or oncology/fertility indication depending on ingredient. |
7. Mechanism / Basic Description | Ingredient-specific estrogen-receptor or aromatase pathway modulation. |
8. Dosage Form & Route | Route/formulation: verify from the exact product specification. |
9. Prescription / OTC Status | Generally prescription/regulated medicine; exact status varies by jurisdiction. |
10. Major Warnings / Contraindications / Key Interactions | Check official label for contraindications, interactions, pregnancy warnings, organ-function precautions and formulation-specific risks. |
11. India Export Considerations | Verify Indian manufacturing licence/product permission, GMP status, formulation authorization, exporter eligibility, labeling and destination-specific export documentation. |
12. HS Code / Customs Classification — TO BE VERIFIED | Do not assign a final HS/ITC-HS code from the medicine name alone. Confirm with the exact dosage form, packing and Indian customs classification. |
13. 26-Country Regulatory Status | Preliminary screen: 🟡 registration/authorization generally required in all 26 markets. Upgrade to 🟠/🔴/⚫ where the ingredient, formulation or destination law imposes special controls; exact status must be verified. |
14. Country Regulatory Authority | See the 26-country matrix at the beginning of this document; the responsible authority varies by destination. |
15. Registration / Marketing Authorization Requirements | Typically product dossier/quality data, manufacturing information, stability, labeling, local applicant/importer authorization and any country-specific clinical/bioequivalence or GMP evidence required. |
16. Export Requirements & Special Restrictions | Hormonal/oncology regulatory review may apply. |
17. Buyer Type | Licensed pharmaceutical importer/distributor/wholesaler; hospitals or institutional buyers where appropriate. Veterinary products require appropriately licensed animal-health buyers. |
18. Required Export / Regulatory Documentation | Commercial invoice; packing list; transport documents; certificate of origin where required; COA; GMP/manufacturing documents; product registration/authorization documents; import permit or controlled-drug permit where applicable. |
19. Commercial Considerations | Confirm MOQ, pack size, shelf life, lead time, private-label/OEM availability, registration ownership, Incoterm, freight, insurance, payment terms and landed cost before quotation. |
20. Exporter Decision / Verification Checklist | ☐ Exact product/formulation confirmed ☐ Manufacturer verified ☐ GMP verified ☐ Indian authorization verified ☐ Destination registration checked ☐ Importer licence checked ☐ Controlled/special status checked ☐ COA/stability documents checked ☐ HS code verified ☐ Buyer verified |
167. CYANOCOBALAMIN INJECTION USP
1. Medicine / Product Name | CYANOCOBALAMIN INJECTION USP |
2. Generic / API / Composition | CYANOCOBALAMIN USP — exact composition/API to be confirmed from manufacturer specification. |
3. Salt / Strength | Strength/salt as stated in the source where available; otherwise verify the exact product specification. |
4. Therapeutic Category | Nutritional / metabolic supportive product |
5. Pharmacological / Drug Class | Vitamin, amino-acid derivative or antioxidant — ingredient-specific |
6. Main Uses / Indications | Indication varies by ingredient and approved formulation. |
7. Mechanism / Basic Description | Biochemical role is ingredient-specific. |
8. Dosage Form & Route | Route/formulation: verify from the exact product specification. |
9. Prescription / OTC Status | Generally prescription/regulated medicine; exact status varies by jurisdiction. |
10. Major Warnings / Contraindications / Key Interactions | Check official label for contraindications, interactions, pregnancy warnings, organ-function precautions and formulation-specific risks. |
11. India Export Considerations | Verify Indian manufacturing licence/product permission, GMP status, formulation authorization, exporter eligibility, labeling and destination-specific export documentation. |
12. HS Code / Customs Classification — TO BE VERIFIED | Do not assign a final HS/ITC-HS code from the medicine name alone. Confirm with the exact dosage form, packing and Indian customs classification. |
13. 26-Country Regulatory Status | Preliminary screen: 🟡 registration/authorization generally required in all 26 markets. Upgrade to 🟠/🔴/⚫ where the ingredient, formulation or destination law imposes special controls; exact status must be verified. |
14. Country Regulatory Authority | See the 26-country matrix at the beginning of this document; the responsible authority varies by destination. |
15. Registration / Marketing Authorization Requirements | Typically product dossier/quality data, manufacturing information, stability, labeling, local applicant/importer authorization and any country-specific clinical/bioequivalence or GMP evidence required. |
16. Export Requirements & Special Restrictions | Product-specific regulatory review required before export. |
17. Buyer Type | Licensed pharmaceutical importer/distributor/wholesaler; hospitals or institutional buyers where appropriate. Veterinary products require appropriately licensed animal-health buyers. |
18. Required Export / Regulatory Documentation | Commercial invoice; packing list; transport documents; certificate of origin where required; COA; GMP/manufacturing documents; product registration/authorization documents; import permit or controlled-drug permit where applicable. |
19. Commercial Considerations | Confirm MOQ, pack size, shelf life, lead time, private-label/OEM availability, registration ownership, Incoterm, freight, insurance, payment terms and landed cost before quotation. |
20. Exporter Decision / Verification Checklist | ☐ Exact product/formulation confirmed ☐ Manufacturer verified ☐ GMP verified ☐ Indian authorization verified ☐ Destination registration checked ☐ Importer licence checked ☐ Controlled/special status checked ☐ COA/stability documents checked ☐ HS code verified ☐ Buyer verified |
168. TRETINOIN GEL USP 0.025 % W/W
1. Medicine / Product Name | TRETINOIN GEL USP 0.025 % W/W |
2. Generic / API / Composition | TRETINOIN GEL USP 0.025 % W/W — exact composition/API to be confirmed from manufacturer specification. |
3. Salt / Strength | Strength/salt as stated in the source where available; otherwise verify the exact product specification. |
4. Therapeutic Category | Dermatology / topical or hormonal medicine |
5. Pharmacological / Drug Class | Ingredient-specific dermatologic/hormonal agent |
6. Main Uses / Indications | Dermatologic or hormonal indication according to the exact formulation. |
7. Mechanism / Basic Description | Ingredient-specific; use approved product labeling. |
8. Dosage Form & Route | Topical or oral depending on formulation. |
9. Prescription / OTC Status | Generally prescription/regulated medicine; exact status varies by jurisdiction. |
10. Major Warnings / Contraindications / Key Interactions | Pregnancy/reproductive warnings, systemic absorption, skin reactions and formulation-specific restrictions must be checked. |
11. India Export Considerations | Verify Indian manufacturing licence/product permission, GMP status, formulation authorization, exporter eligibility, labeling and destination-specific export documentation. |
12. HS Code / Customs Classification — TO BE VERIFIED | Do not assign a final HS/ITC-HS code from the medicine name alone. Confirm with the exact dosage form, packing and Indian customs classification. |
13. 26-Country Regulatory Status | Preliminary screen: 🟡 registration/authorization generally required in all 26 markets. Upgrade to 🟠/🔴/⚫ where the ingredient, formulation or destination law imposes special controls; exact status must be verified. |
14. Country Regulatory Authority | See the 26-country matrix at the beginning of this document; the responsible authority varies by destination. |
15. Registration / Marketing Authorization Requirements | Typically product dossier/quality data, manufacturing information, stability, labeling, local applicant/importer authorization and any country-specific clinical/bioequivalence or GMP evidence required. |
16. Export Requirements & Special Restrictions | Product-specific regulatory review required before export. |
17. Buyer Type | Licensed pharmaceutical importer/distributor/wholesaler; hospitals or institutional buyers where appropriate. Veterinary products require appropriately licensed animal-health buyers. |
18. Required Export / Regulatory Documentation | Commercial invoice; packing list; transport documents; certificate of origin where required; COA; GMP/manufacturing documents; product registration/authorization documents; import permit or controlled-drug permit where applicable. |
19. Commercial Considerations | Confirm MOQ, pack size, shelf life, lead time, private-label/OEM availability, registration ownership, Incoterm, freight, insurance, payment terms and landed cost before quotation. |
20. Exporter Decision / Verification Checklist | ☐ Exact product/formulation confirmed ☐ Manufacturer verified ☐ GMP verified ☐ Indian authorization verified ☐ Destination registration checked ☐ Importer licence checked ☐ Controlled/special status checked ☐ COA/stability documents checked ☐ HS code verified ☐ Buyer verified |
169. DUTASTERIDE CAPSULES IP 0.5 MG
1. Medicine / Product Name | DUTASTERIDE CAPSULES IP 0.5 MG |
2. Generic / API / Composition | DUTASTERIDE IP 0.5 MG — exact composition/API to be confirmed from manufacturer specification. |
3. Salt / Strength | Strength/salt as stated in the source where available; otherwise verify the exact product specification. |
4. Therapeutic Category | Urological / dermatological medicine |
5. Pharmacological / Drug Class | 5-alpha-reductase inhibitor |
6. Main Uses / Indications | Approved indications include benign prostatic hyperplasia and/or androgenetic alopecia depending on strength/formulation. |
7. Mechanism / Basic Description | Reduces conversion of testosterone to dihydrotestosterone. |
8. Dosage Form & Route | Route/formulation: verify from the exact product specification. |
9. Prescription / OTC Status | Generally prescription/regulated medicine; exact status varies by jurisdiction. |
10. Major Warnings / Contraindications / Key Interactions | Check official label for contraindications, interactions, pregnancy warnings, organ-function precautions and formulation-specific risks. |
11. India Export Considerations | Verify Indian manufacturing licence/product permission, GMP status, formulation authorization, exporter eligibility, labeling and destination-specific export documentation. |
12. HS Code / Customs Classification — TO BE VERIFIED | Do not assign a final HS/ITC-HS code from the medicine name alone. Confirm with the exact dosage form, packing and Indian customs classification. |
13. 26-Country Regulatory Status | Preliminary screen: 🟡 registration/authorization generally required in all 26 markets. Upgrade to 🟠/🔴/⚫ where the ingredient, formulation or destination law imposes special controls; exact status must be verified. |
14. Country Regulatory Authority | See the 26-country matrix at the beginning of this document; the responsible authority varies by destination. |
15. Registration / Marketing Authorization Requirements | Typically product dossier/quality data, manufacturing information, stability, labeling, local applicant/importer authorization and any country-specific clinical/bioequivalence or GMP evidence required. |
16. Export Requirements & Special Restrictions | Product-specific regulatory review required before export. |
17. Buyer Type | Licensed pharmaceutical importer/distributor/wholesaler; hospitals or institutional buyers where appropriate. Veterinary products require appropriately licensed animal-health buyers. |
18. Required Export / Regulatory Documentation | Commercial invoice; packing list; transport documents; certificate of origin where required; COA; GMP/manufacturing documents; product registration/authorization documents; import permit or controlled-drug permit where applicable. |
19. Commercial Considerations | Confirm MOQ, pack size, shelf life, lead time, private-label/OEM availability, registration ownership, Incoterm, freight, insurance, payment terms and landed cost before quotation. |
20. Exporter Decision / Verification Checklist | ☐ Exact product/formulation confirmed ☐ Manufacturer verified ☐ GMP verified ☐ Indian authorization verified ☐ Destination registration checked ☐ Importer licence checked ☐ Controlled/special status checked ☐ COA/stability documents checked ☐ HS code verified ☐ Buyer verified |
170. SODIUM HYALURONATE AND VITAMIN C
1. Medicine / Product Name | SODIUM HYALURONATE AND VITAMIN C |
2. Generic / API / Composition | SODIUM HYALURONATE AND VITAMIN C — exact composition/API to be confirmed from manufacturer specification. |
3. Salt / Strength | Strength/salt as stated in the source where available; otherwise verify the exact product specification. |
4. Therapeutic Category | Ophthalmic / supportive formulation |
5. Pharmacological / Drug Class | Hyaluronic-acid derivative formulation |
6. Main Uses / Indications | Product-specific ocular or supportive use. |
7. Mechanism / Basic Description | Provides viscoelastic/lubricating effect depending on formulation. |
8. Dosage Form & Route | Formulation-specific. |
9. Prescription / OTC Status | Generally prescription/regulated medicine; exact status varies by jurisdiction. |
10. Major Warnings / Contraindications / Key Interactions | Check official label for contraindications, interactions, pregnancy warnings, organ-function precautions and formulation-specific risks. |
11. India Export Considerations | Verify Indian manufacturing licence/product permission, GMP status, formulation authorization, exporter eligibility, labeling and destination-specific export documentation. |
12. HS Code / Customs Classification — TO BE VERIFIED | Do not assign a final HS/ITC-HS code from the medicine name alone. Confirm with the exact dosage form, packing and Indian customs classification. |
13. 26-Country Regulatory Status | Preliminary screen: 🟡 registration/authorization generally required in all 26 markets. Upgrade to 🟠/🔴/⚫ where the ingredient, formulation or destination law imposes special controls; exact status must be verified. |
14. Country Regulatory Authority | See the 26-country matrix at the beginning of this document; the responsible authority varies by destination. |
15. Registration / Marketing Authorization Requirements | Typically product dossier/quality data, manufacturing information, stability, labeling, local applicant/importer authorization and any country-specific clinical/bioequivalence or GMP evidence required. |
16. Export Requirements & Special Restrictions | Product-specific regulatory review required before export. |
17. Buyer Type | Licensed pharmaceutical importer/distributor/wholesaler; hospitals or institutional buyers where appropriate. Veterinary products require appropriately licensed animal-health buyers. |
18. Required Export / Regulatory Documentation | Commercial invoice; packing list; transport documents; certificate of origin where required; COA; GMP/manufacturing documents; product registration/authorization documents; import permit or controlled-drug permit where applicable. |
19. Commercial Considerations | Confirm MOQ, pack size, shelf life, lead time, private-label/OEM availability, registration ownership, Incoterm, freight, insurance, payment terms and landed cost before quotation. |
20. Exporter Decision / Verification Checklist | ☐ Exact product/formulation confirmed ☐ Manufacturer verified ☐ GMP verified ☐ Indian authorization verified ☐ Destination registration checked ☐ Importer licence checked ☐ Controlled/special status checked ☐ COA/stability documents checked ☐ HS code verified ☐ Buyer verified |
171. MINOXIDIL TABLETS IP 5 MG
1. Medicine / Product Name | MINOXIDIL TABLETS IP 5 MG |
2. Generic / API / Composition | MINOXIDIL IP 5 MG — exact composition/API to be confirmed from manufacturer specification. |
3. Salt / Strength | Strength/salt as stated in the source where available; otherwise verify the exact product specification. |
4. Therapeutic Category | Dermatology / topical or hormonal medicine |
5. Pharmacological / Drug Class | Ingredient-specific dermatologic/hormonal agent |
6. Main Uses / Indications | Dermatologic or hormonal indication according to the exact formulation. |
7. Mechanism / Basic Description | Ingredient-specific; use approved product labeling. |
8. Dosage Form & Route | Topical or oral depending on formulation. |
9. Prescription / OTC Status | Generally prescription/regulated medicine; exact status varies by jurisdiction. |
10. Major Warnings / Contraindications / Key Interactions | Pregnancy/reproductive warnings, systemic absorption, skin reactions and formulation-specific restrictions must be checked. |
11. India Export Considerations | Verify Indian manufacturing licence/product permission, GMP status, formulation authorization, exporter eligibility, labeling and destination-specific export documentation. |
12. HS Code / Customs Classification — TO BE VERIFIED | Do not assign a final HS/ITC-HS code from the medicine name alone. Confirm with the exact dosage form, packing and Indian customs classification. |
13. 26-Country Regulatory Status | Preliminary screen: 🟡 registration/authorization generally required in all 26 markets. Upgrade to 🟠/🔴/⚫ where the ingredient, formulation or destination law imposes special controls; exact status must be verified. |
14. Country Regulatory Authority | See the 26-country matrix at the beginning of this document; the responsible authority varies by destination. |
15. Registration / Marketing Authorization Requirements | Typically product dossier/quality data, manufacturing information, stability, labeling, local applicant/importer authorization and any country-specific clinical/bioequivalence or GMP evidence required. |
16. Export Requirements & Special Restrictions | Product-specific regulatory review required before export. |
17. Buyer Type | Licensed pharmaceutical importer/distributor/wholesaler; hospitals or institutional buyers where appropriate. Veterinary products require appropriately licensed animal-health buyers. |
18. Required Export / Regulatory Documentation | Commercial invoice; packing list; transport documents; certificate of origin where required; COA; GMP/manufacturing documents; product registration/authorization documents; import permit or controlled-drug permit where applicable. |
19. Commercial Considerations | Confirm MOQ, pack size, shelf life, lead time, private-label/OEM availability, registration ownership, Incoterm, freight, insurance, payment terms and landed cost before quotation. |
20. Exporter Decision / Verification Checklist | ☐ Exact product/formulation confirmed ☐ Manufacturer verified ☐ GMP verified ☐ Indian authorization verified ☐ Destination registration checked ☐ Importer licence checked ☐ Controlled/special status checked ☐ COA/stability documents checked ☐ HS code verified ☐ Buyer verified |
172. MINOXIDIL TABLETS IP 10 MG
1. Medicine / Product Name | MINOXIDIL TABLETS IP 10 MG |
2. Generic / API / Composition | MINOXIDIL IP 10 MG — exact composition/API to be confirmed from manufacturer specification. |
3. Salt / Strength | Strength/salt as stated in the source where available; otherwise verify the exact product specification. |
4. Therapeutic Category | Dermatology / topical or hormonal medicine |
5. Pharmacological / Drug Class | Ingredient-specific dermatologic/hormonal agent |
6. Main Uses / Indications | Dermatologic or hormonal indication according to the exact formulation. |
7. Mechanism / Basic Description | Ingredient-specific; use approved product labeling. |
8. Dosage Form & Route | Topical or oral depending on formulation. |
9. Prescription / OTC Status | Generally prescription/regulated medicine; exact status varies by jurisdiction. |
10. Major Warnings / Contraindications / Key Interactions | Pregnancy/reproductive warnings, systemic absorption, skin reactions and formulation-specific restrictions must be checked. |
11. India Export Considerations | Verify Indian manufacturing licence/product permission, GMP status, formulation authorization, exporter eligibility, labeling and destination-specific export documentation. |
12. HS Code / Customs Classification — TO BE VERIFIED | Do not assign a final HS/ITC-HS code from the medicine name alone. Confirm with the exact dosage form, packing and Indian customs classification. |
13. 26-Country Regulatory Status | Preliminary screen: 🟡 registration/authorization generally required in all 26 markets. Upgrade to 🟠/🔴/⚫ where the ingredient, formulation or destination law imposes special controls; exact status must be verified. |
14. Country Regulatory Authority | See the 26-country matrix at the beginning of this document; the responsible authority varies by destination. |
15. Registration / Marketing Authorization Requirements | Typically product dossier/quality data, manufacturing information, stability, labeling, local applicant/importer authorization and any country-specific clinical/bioequivalence or GMP evidence required. |
16. Export Requirements & Special Restrictions | Product-specific regulatory review required before export. |
17. Buyer Type | Licensed pharmaceutical importer/distributor/wholesaler; hospitals or institutional buyers where appropriate. Veterinary products require appropriately licensed animal-health buyers. |
18. Required Export / Regulatory Documentation | Commercial invoice; packing list; transport documents; certificate of origin where required; COA; GMP/manufacturing documents; product registration/authorization documents; import permit or controlled-drug permit where applicable. |
19. Commercial Considerations | Confirm MOQ, pack size, shelf life, lead time, private-label/OEM availability, registration ownership, Incoterm, freight, insurance, payment terms and landed cost before quotation. |
20. Exporter Decision / Verification Checklist | ☐ Exact product/formulation confirmed ☐ Manufacturer verified ☐ GMP verified ☐ Indian authorization verified ☐ Destination registration checked ☐ Importer licence checked ☐ Controlled/special status checked ☐ COA/stability documents checked ☐ HS code verified ☐ Buyer verified |
173. FINASTERIDE AND MINOXIDIL TABLETS
1. Medicine / Product Name | FINASTERIDE AND MINOXIDIL TABLETS |
2. Generic / API / Composition | FINASTERIDE AND MINOXIDIL — exact composition/API to be confirmed from manufacturer specification. |
3. Salt / Strength | Strength/salt as stated in the source where available; otherwise verify the exact product specification. |
4. Therapeutic Category | Dermatology / topical or hormonal medicine |
5. Pharmacological / Drug Class | Ingredient-specific dermatologic/hormonal agent |
6. Main Uses / Indications | Dermatologic or hormonal indication according to the exact formulation. |
7. Mechanism / Basic Description | Ingredient-specific; use approved product labeling. |
8. Dosage Form & Route | Topical or oral depending on formulation. |
9. Prescription / OTC Status | Generally prescription/regulated medicine; exact status varies by jurisdiction. |
10. Major Warnings / Contraindications / Key Interactions | Pregnancy/reproductive warnings, systemic absorption, skin reactions and formulation-specific restrictions must be checked. |
11. India Export Considerations | Verify Indian manufacturing licence/product permission, GMP status, formulation authorization, exporter eligibility, labeling and destination-specific export documentation. |
12. HS Code / Customs Classification — TO BE VERIFIED | Do not assign a final HS/ITC-HS code from the medicine name alone. Confirm with the exact dosage form, packing and Indian customs classification. |
13. 26-Country Regulatory Status | Preliminary screen: 🟡 registration/authorization generally required in all 26 markets. Upgrade to 🟠/🔴/⚫ where the ingredient, formulation or destination law imposes special controls; exact status must be verified. |
14. Country Regulatory Authority | See the 26-country matrix at the beginning of this document; the responsible authority varies by destination. |
15. Registration / Marketing Authorization Requirements | Typically product dossier/quality data, manufacturing information, stability, labeling, local applicant/importer authorization and any country-specific clinical/bioequivalence or GMP evidence required. |
16. Export Requirements & Special Restrictions | Product-specific regulatory review required before export. |
17. Buyer Type | Licensed pharmaceutical importer/distributor/wholesaler; hospitals or institutional buyers where appropriate. Veterinary products require appropriately licensed animal-health buyers. |
18. Required Export / Regulatory Documentation | Commercial invoice; packing list; transport documents; certificate of origin where required; COA; GMP/manufacturing documents; product registration/authorization documents; import permit or controlled-drug permit where applicable. |
19. Commercial Considerations | Confirm MOQ, pack size, shelf life, lead time, private-label/OEM availability, registration ownership, Incoterm, freight, insurance, payment terms and landed cost before quotation. |
20. Exporter Decision / Verification Checklist | ☐ Exact product/formulation confirmed ☐ Manufacturer verified ☐ GMP verified ☐ Indian authorization verified ☐ Destination registration checked ☐ Importer licence checked ☐ Controlled/special status checked ☐ COA/stability documents checked ☐ HS code verified ☐ Buyer verified |
174. DUTASTERIDE AND MINOXIDIL TABLETS
1. Medicine / Product Name | DUTASTERIDE AND MINOXIDIL TABLETS |
2. Generic / API / Composition | DUTASTERIDE AND MINOXIDIL — exact composition/API to be confirmed from manufacturer specification. |
3. Salt / Strength | Strength/salt as stated in the source where available; otherwise verify the exact product specification. |
4. Therapeutic Category | Dermatology / topical or hormonal medicine |
5. Pharmacological / Drug Class | Ingredient-specific dermatologic/hormonal agent |
6. Main Uses / Indications | Dermatologic or hormonal indication according to the exact formulation. |
7. Mechanism / Basic Description | Ingredient-specific; use approved product labeling. |
8. Dosage Form & Route | Topical or oral depending on formulation. |
9. Prescription / OTC Status | Generally prescription/regulated medicine; exact status varies by jurisdiction. |
10. Major Warnings / Contraindications / Key Interactions | Pregnancy/reproductive warnings, systemic absorption, skin reactions and formulation-specific restrictions must be checked. |
11. India Export Considerations | Verify Indian manufacturing licence/product permission, GMP status, formulation authorization, exporter eligibility, labeling and destination-specific export documentation. |
12. HS Code / Customs Classification — TO BE VERIFIED | Do not assign a final HS/ITC-HS code from the medicine name alone. Confirm with the exact dosage form, packing and Indian customs classification. |
13. 26-Country Regulatory Status | Preliminary screen: 🟡 registration/authorization generally required in all 26 markets. Upgrade to 🟠/🔴/⚫ where the ingredient, formulation or destination law imposes special controls; exact status must be verified. |
14. Country Regulatory Authority | See the 26-country matrix at the beginning of this document; the responsible authority varies by destination. |
15. Registration / Marketing Authorization Requirements | Typically product dossier/quality data, manufacturing information, stability, labeling, local applicant/importer authorization and any country-specific clinical/bioequivalence or GMP evidence required. |
16. Export Requirements & Special Restrictions | Product-specific regulatory review required before export. |
17. Buyer Type | Licensed pharmaceutical importer/distributor/wholesaler; hospitals or institutional buyers where appropriate. Veterinary products require appropriately licensed animal-health buyers. |
18. Required Export / Regulatory Documentation | Commercial invoice; packing list; transport documents; certificate of origin where required; COA; GMP/manufacturing documents; product registration/authorization documents; import permit or controlled-drug permit where applicable. |
19. Commercial Considerations | Confirm MOQ, pack size, shelf life, lead time, private-label/OEM availability, registration ownership, Incoterm, freight, insurance, payment terms and landed cost before quotation. |
20. Exporter Decision / Verification Checklist | ☐ Exact product/formulation confirmed ☐ Manufacturer verified ☐ GMP verified ☐ Indian authorization verified ☐ Destination registration checked ☐ Importer licence checked ☐ Controlled/special status checked ☐ COA/stability documents checked ☐ HS code verified ☐ Buyer verified |
175. CLOMIPHENE CITRATE TABLETS IP 25 MG
1. Medicine / Product Name | CLOMIPHENE CITRATE TABLETS IP 25 MG |
2. Generic / API / Composition | CLOMIPHENE CITRATE IP 25 MG — exact composition/API to be confirmed from manufacturer specification. |
3. Salt / Strength | Strength/salt as stated in the source where available; otherwise verify the exact product specification. |
4. Therapeutic Category | Hormonal / endocrine medicine |
5. Pharmacological / Drug Class | Hormonal pathway modulator |
6. Main Uses / Indications | Endocrine or oncology/fertility indication depending on ingredient. |
7. Mechanism / Basic Description | Ingredient-specific estrogen-receptor or aromatase pathway modulation. |
8. Dosage Form & Route | Route/formulation: verify from the exact product specification. |
9. Prescription / OTC Status | Generally prescription/regulated medicine; exact status varies by jurisdiction. |
10. Major Warnings / Contraindications / Key Interactions | Check official label for contraindications, interactions, pregnancy warnings, organ-function precautions and formulation-specific risks. |
11. India Export Considerations | Verify Indian manufacturing licence/product permission, GMP status, formulation authorization, exporter eligibility, labeling and destination-specific export documentation. |
12. HS Code / Customs Classification — TO BE VERIFIED | Do not assign a final HS/ITC-HS code from the medicine name alone. Confirm with the exact dosage form, packing and Indian customs classification. |
13. 26-Country Regulatory Status | Preliminary screen: 🟡 registration/authorization generally required in all 26 markets. Upgrade to 🟠/🔴/⚫ where the ingredient, formulation or destination law imposes special controls; exact status must be verified. |
14. Country Regulatory Authority | See the 26-country matrix at the beginning of this document; the responsible authority varies by destination. |
15. Registration / Marketing Authorization Requirements | Typically product dossier/quality data, manufacturing information, stability, labeling, local applicant/importer authorization and any country-specific clinical/bioequivalence or GMP evidence required. |
16. Export Requirements & Special Restrictions | Hormonal/oncology regulatory review may apply. |
17. Buyer Type | Licensed pharmaceutical importer/distributor/wholesaler; hospitals or institutional buyers where appropriate. Veterinary products require appropriately licensed animal-health buyers. |
18. Required Export / Regulatory Documentation | Commercial invoice; packing list; transport documents; certificate of origin where required; COA; GMP/manufacturing documents; product registration/authorization documents; import permit or controlled-drug permit where applicable. |
19. Commercial Considerations | Confirm MOQ, pack size, shelf life, lead time, private-label/OEM availability, registration ownership, Incoterm, freight, insurance, payment terms and landed cost before quotation. |
20. Exporter Decision / Verification Checklist | ☐ Exact product/formulation confirmed ☐ Manufacturer verified ☐ GMP verified ☐ Indian authorization verified ☐ Destination registration checked ☐ Importer licence checked ☐ Controlled/special status checked ☐ COA/stability documents checked ☐ HS code verified ☐ Buyer verified |
176. SILDENAFIL SITRAT TABLETLERI
1. Medicine / Product Name | SILDENAFIL SITRAT TABLETLERI |
2. Generic / API / Composition | SILDENAFIL SITRAT TABLETLERI — exact composition/API to be confirmed from manufacturer specification. |
3. Salt / Strength | Strength/salt as stated in the source where available; otherwise verify the exact product specification. |
4. Therapeutic Category | Genitourinary / erectile-dysfunction medicine |
5. Pharmacological / Drug Class | PDE-5 inhibitor |
6. Main Uses / Indications | Treatment of erectile dysfunction; exact indications vary by product and market. |
7. Mechanism / Basic Description | Inhibits PDE-5, increasing cGMP-mediated smooth-muscle relaxation. |
8. Dosage Form & Route | Oral; exact formulation (tablet/jelly/etc.) must be verified. |
9. Prescription / OTC Status | Generally prescription/regulated medicine; exact status varies by jurisdiction. |
10. Major Warnings / Contraindications / Key Interactions | Nitrates/riociguat and cardiovascular conditions require particular attention; formulation and local labeling must be checked. |
11. India Export Considerations | Verify Indian manufacturing licence/product permission, GMP status, formulation authorization, exporter eligibility, labeling and destination-specific export documentation. |
12. HS Code / Customs Classification — TO BE VERIFIED | Do not assign a final HS/ITC-HS code from the medicine name alone. Confirm with the exact dosage form, packing and Indian customs classification. |
13. 26-Country Regulatory Status | Preliminary screen: 🟡 registration/authorization generally required in all 26 markets. Upgrade to 🟠/🔴/⚫ where the ingredient, formulation or destination law imposes special controls; exact status must be verified. |
14. Country Regulatory Authority | See the 26-country matrix at the beginning of this document; the responsible authority varies by destination. |
15. Registration / Marketing Authorization Requirements | Typically product dossier/quality data, manufacturing information, stability, labeling, local applicant/importer authorization and any country-specific clinical/bioequivalence or GMP evidence required. |
16. Export Requirements & Special Restrictions | Product-specific regulatory review required before export. |
17. Buyer Type | Licensed pharmaceutical importer/distributor/wholesaler; hospitals or institutional buyers where appropriate. Veterinary products require appropriately licensed animal-health buyers. |
18. Required Export / Regulatory Documentation | Commercial invoice; packing list; transport documents; certificate of origin where required; COA; GMP/manufacturing documents; product registration/authorization documents; import permit or controlled-drug permit where applicable. |
19. Commercial Considerations | Confirm MOQ, pack size, shelf life, lead time, private-label/OEM availability, registration ownership, Incoterm, freight, insurance, payment terms and landed cost before quotation. |
20. Exporter Decision / Verification Checklist | ☐ Exact product/formulation confirmed ☐ Manufacturer verified ☐ GMP verified ☐ Indian authorization verified ☐ Destination registration checked ☐ Importer licence checked ☐ Controlled/special status checked ☐ COA/stability documents checked ☐ HS code verified ☐ Buyer verified |
- Top Pharma Export Products from India | Manufacturers & Buyers
- Pharma Products Export from India | Suppliers, Manufacturers & Buyers
- Indian Pharma Export Products | Manufacturers, Sellers & Global Buyers
- Top Pharmaceutical Export Products from India | Buyers & Suppliers
- Pharma Export Business from India | Products, Manufacturers & Buyers
Discover top pharma export products from India, pharmaceutical manufacturers, sellers, suppliers and international medicine buyers. Explore products, sourcing and export opportunities.
- pharma export products from India
- pharmaceutical export products
- pharma products export
- India pharma exporters
- pharmaceutical manufacturers in India
- pharma manufacturers India
- pharmaceutical companies India
- medicine manufacturers India
- pharma suppliers India
- pharmaceutical sellers India
- medicine buyers
- pharma buyers
- pharmaceutical buyers
- medicine importers
- pharma importers
- pharmaceutical distributors
- Indian pharmaceutical products
- medicine export from India
- pharmaceutical export from India
- pharma export business
- top pharma export products from India
- pharmaceutical products exported from India
- top pharmaceutical manufacturers in India
- Indian pharmaceutical manufacturers and suppliers
- medicine exporters and buyers from India
- pharmaceutical companies for export from India
- pharma medicine buyers worldwide
- pharmaceutical importers looking for Indian suppliers
- Indian medicine manufacturers for export
- wholesale pharmaceutical products from India
- pharmaceutical products suppliers in India
- pharma export companies in India
- medicines available for export from India
- pharmaceutical distributors and buyers
- private label pharma manufacturers India
Pharma Export from India — Complete Terminology & Abbreviations
A. Pharmaceutical & Regulatory Basics
| No. | Term | Full Form / Meaning |
|---|---|---|
| 1 | API | Active Pharmaceutical Ingredient |
| 2 | ANDA | Abbreviated New Drug Application |
| 3 | BLA | Biologics License Application |
| 4 | CAPA | Corrective and Preventive Action |
| 5 | CDSCO | Central Drugs Standard Control Organisation |
| 6 | COA | Certificate of Analysis |
| 7 | COPP | Certificate of Pharmaceutical Product |
| 8 | CPP | Certificate of Pharmaceutical Product |
| 9 | DMF | Drug Master File |
| 10 | DGFT | Directorate General of Foreign Trade |
| 11 | FDA | Food and Drug Administration |
| 12 | GMP | Good Manufacturing Practice |
| 13 | IEC | Importer Exporter Code |
| 14 | IND | Investigational New Drug |
| 15 | MHRA | Medicines and Healthcare products Regulatory Agency |
| 16 | MOQ | Minimum Order Quantity |
| 17 | NDA | New Drug Application |
| 18 | NDC | National Drug Code |
| 19 | OEM | Original Equipment Manufacturer |
| 20 | PMDA | Pharmaceuticals and Medical Devices Agency |
| 21 | QA | Quality Assurance |
| 22 | QC | Quality Control |
| 23 | SAHPRA | South African Health Products Regulatory Authority |
| 24 | TGA | Therapeutic Goods Administration |
| 25 | WDA | Wholesale Distribution Authorisation |
Important: COPP and CPP are often used interchangeably in pharmaceutical export discussions, but the exact terminology/document requirements can depend on the issuing authority and destination market.
B. Indian Pharmaceutical Regulatory Terms
| No. | Term | Full Form / Meaning |
|---|---|---|
| 26 | CDSCO | Central Drugs Standard Control Organisation |
| 27 | DCGI | Drugs Controller General of India |
| 28 | CLA | Central Licensing Authority |
| 29 | SDC | State Drug Controller |
| 30 | D&C Act | Drugs and Cosmetics Act |
| 31 | D&C Rules | Drugs and Cosmetics Rules |
| 32 | NDCT Act | New Drugs and Clinical Trials Act |
| 33 | NDCT Rules | New Drugs and Clinical Trials Rules |
| 34 | FSSAI | Food Safety and Standards Authority of India |
| 35 | AYUSH | Ayurveda, Yoga & Naturopathy, Unani, Siddha and Homoeopathy |
| 36 | IPC | Indian Pharmacopoeia Commission |
| 37 | IP | Indian Pharmacopoeia |
| 38 | Schedule M | GMP requirements under Indian drug regulations |
| 39 | Schedule H | Prescription medicines category |
| 40 | Schedule H1 | Prescription medicines subject to additional controls |
| 41 | Schedule X | Specified controlled prescription drugs |
| 42 | Form 20 | Drug manufacturing licence category |
| 43 | Form 21 | Drug manufacturing licence category |
| 44 | Form 25 | Manufacturing licence |
| 45 | Form 28 | Licence for manufacture of specified categories |
| 46 | Form 29 | Licence for manufacture/testing of drugs for examination/test/analysis |
| 47 | Form 41 | Registration Certificate |
| 48 | Form 40 | Application for Registration Certificate |
| 49 | Form 10 | Import licence |
| 50 | Form 10A | Import licence-related application |
| 51 | SUGAM | CDSCO online regulatory portal |
| 52 | CT | Clinical Trial |
| 53 | BA/BE | Bioavailability/Bioequivalence |
| 54 | BE | Bioequivalence |
| 55 | BA | Bioavailability |
C. Export & Foreign Trade Terms — India
| No. | Term | Full Form / Meaning |
|---|---|---|
| 56 | IEC | Importer Exporter Code |
| 57 | DGFT | Directorate General of Foreign Trade |
| 58 | FTP | Foreign Trade Policy |
| 59 | ITC-HS | Indian Trade Classification – Harmonized System |
| 60 | HS Code | Harmonized System Code |
| 61 | HSN | Harmonized System of Nomenclature |
| 62 | AD Code | Authorised Dealer Code |
| 63 | ICEGATE | Indian Customs Electronic Gateway |
| 64 | EDI | Electronic Data Interchange |
| 65 | GST | Goods and Services Tax |
| 66 | GSTIN | Goods and Services Tax Identification Number |
| 67 | LUT | Letter of Undertaking |
| 68 | RCMC | Registration-Cum-Membership Certificate |
| 69 | EPC | Export Promotion Council |
| 70 | PHARMEXCIL | Pharmaceuticals Export Promotion Council of India |
| 71 | RBI | Reserve Bank of India |
| 72 | FEMA | Foreign Exchange Management Act |
| 73 | EDF | Export Declaration Form |
| 74 | SOFTEX | Software Export Declaration Form |
| 75 | BRC | Bank Realisation Certificate |
| 76 | e-BRC | Electronic Bank Realisation Certificate |
| 77 | GRN | Goods Receipt Note |
| 78 | SB | Shipping Bill |
| 79 | LEO | Let Export Order |
| 80 | Let Export Order | Customs clearance permission for export |
| 81 | LUT | Letter of Undertaking |
| 82 | ARN | Application Reference Number |
| 83 | DSC | Digital Signature Certificate |
| 84 | PAN | Permanent Account Number |
| 85 | TAN | Tax Deduction and Collection Account Number |
Note: EDF/SOFTEX terminology should not be automatically treated as interchangeable for pharmaceutical goods exports; the applicable RBI/customs documentation depends on the transaction and export structure.
D. Pharmaceutical Manufacturing Terms
| No. | Term | Meaning |
|---|---|---|
| 86 | API | Active Pharmaceutical Ingredient |
| 87 | Excipient | Inactive ingredient used in formulation |
| 88 | FDF | Finished Dosage Form |
| 89 | FPP | Finished Pharmaceutical Product |
| 90 | DMF | Drug Master File |
| 91 | ASMF | Active Substance Master File |
| 92 | CEP | Certificate of Suitability |
| 93 | CTD | Common Technical Document |
| 94 | eCTD | Electronic Common Technical Document |
| 95 | MAA | Marketing Authorisation Application |
| 96 | MA | Marketing Authorisation |
| 97 | SmPC | Summary of Product Characteristics |
| 98 | PIL | Patient Information Leaflet |
| 99 | SPC | Summary of Product Characteristics |
| 100 | INN | International Nonproprietary Name |
| 101 | Generic | Non-originator medicine marketed under generic name |
| 102 | Branded Generic | Generic medicine sold under a brand name |
| 103 | Innovator | Original/reference product developer |
| 104 | Reference Product | Comparator/originator product used for regulatory purposes |
| 105 | Biosimilar | Biological medicine highly similar to a reference biological product |
| 106 | Biologic | Medicine produced from biological sources |
| 107 | Vaccine | Biological preparation providing immunity |
| 108 | Sterile Product | Product manufactured to meet sterility requirements |
| 109 | OSD | Oral Solid Dosage |
| 110 | ODT | Orally Disintegrating Tablet |
| 111 | ER | Extended Release |
| 112 | SR | Sustained Release |
| 113 | CR | Controlled Release |
| 114 | MR | Modified Release |
| 115 | IR | Immediate Release |
| 116 | DR | Delayed Release |
| 117 | XR | Extended Release |
E. Quality Assurance & Quality Control
| No. | Term | Full Form / Meaning |
|---|---|---|
| 118 | QA | Quality Assurance |
| 119 | QC | Quality Control |
| 120 | GMP | Good Manufacturing Practice |
| 121 | cGMP | Current Good Manufacturing Practice |
| 122 | GLP | Good Laboratory Practice |
| 123 | GCP | Good Clinical Practice |
| 124 | GDP | Good Distribution Practice |
| 125 | GSP | Good Storage Practice |
| 126 | GVP | Good Pharmacovigilance Practice |
| 127 | SOP | Standard Operating Procedure |
| 128 | CAPA | Corrective and Preventive Action |
| 129 | OOS | Out of Specification |
| 130 | OOT | Out of Trend |
| 131 | Deviation | Departure from an approved procedure/specification |
| 132 | Change Control | Formal process for controlling changes |
| 133 | QMS | Quality Management System |
| 134 | TQM | Total Quality Management |
| 135 | IPQC | In-Process Quality Control |
| 136 | IPC | In-Process Control |
| 137 | COA | Certificate of Analysis |
| 138 | COC | Certificate of Conformity |
| 139 | COT | Certificate of Testing |
| 140 | AQL | Acceptable Quality Limit |
| 141 | RM | Raw Material |
| 142 | PM | Packaging Material |
| 143 | BMR | Batch Manufacturing Record |
| 144 | BPR | Batch Packaging Record |
| 145 | MFR | Master Formula Record |
| 146 | MBR | Master Batch Record |
| 147 | SOP | Standard Operating Procedure |
| 148 | Validation | Documented evidence that a process consistently works |
| 149 | Process Validation | Validation of manufacturing process |
| 150 | Cleaning Validation | Evidence that cleaning procedures are effective |
| 151 | Analytical Method Validation | Validation of laboratory testing methods |
F. Regulatory Authorities — Major Export Markets
| No. | Abbreviation | Authority |
|---|---|---|
| 152 | FDA | U.S. Food and Drug Administration |
| 153 | CDER | Center for Drug Evaluation and Research |
| 154 | CBER | Center for Biologics Evaluation and Research |
| 155 | DEA | Drug Enforcement Administration |
| 156 | MHRA | Medicines and Healthcare products Regulatory Agency — UK |
| 157 | EMA | European Medicines Agency |
| 158 | EC | European Commission |
| 159 | BfArM | Federal Institute for Drugs and Medical Devices — Germany |
| 160 | ANSM | French National Agency for Medicines Safety |
| 161 | AIFA | Italian Medicines Agency |
| 162 | AEMPS | Spanish Agency of Medicines and Medical Devices |
| 163 | MEB | Medicines Evaluation Board — Netherlands |
| 164 | PMDA | Pharmaceuticals and Medical Devices Agency — Japan |
| 165 | MHLW | Ministry of Health, Labour and Welfare — Japan |
| 166 | TGA | Therapeutic Goods Administration — Australia |
| 167 | Health Canada | Canadian federal health regulator |
| 168 | ANVISA | Brazilian Health Regulatory Agency |
| 169 | SAHPRA | South African Health Products Regulatory Authority |
| 170 | NAFDAC | National Agency for Food and Drug Administration and Control — Nigeria |
| 171 | PPB | Pharmacy and Poisons Board — Kenya |
| 172 | TMDA | Tanzania Medicines and Medical Devices Authority |
| 173 | NDA | National Drug Authority — Uganda |
| 174 | FDA Ghana | Food and Drugs Authority — Ghana |
| 175 | EDA | Egyptian Drug Authority |
| 176 | TİTCK | Turkish Medicines and Medical Devices Agency |
| 177 | MOH | Ministry of Health |
| 178 | SFDA | Saudi Food and Drug Authority |
| 179 | MOHAP | Ministry of Health and Prevention — UAE |
| 180 | EDE | Emirates Drug Establishment |
| 181 | MOH | Ministry of Health |
| 182 | DGDA | Directorate General of Drug Administration — Bangladesh |
| 183 | BPOM | Indonesia Food and Drug Authority |
| 184 | NPRA | National Pharmaceutical Regulatory Agency — Malaysia |
| 185 | FDA Philippines | Philippine Food and Drug Administration |
| 186 | DAV | Drug Administration of Vietnam |
| 187 | MHLW | Ministry of Health, Labour and Welfare — Japan |
| 188 | Medsafe | New Zealand medicines regulator |
G. United States — FDA Terminology
| No. | Term | Meaning |
|---|---|---|
| 189 | FDA | Food and Drug Administration |
| 190 | ANDA | Abbreviated New Drug Application |
| 191 | NDA | New Drug Application |
| 192 | BLA | Biologics License Application |
| 193 | IND | Investigational New Drug |
| 194 | DMF | Drug Master File |
| 195 | NDC | National Drug Code |
| 196 | Orange Book | Approved Drug Products with Therapeutic Equivalence Evaluations |
| 197 | Purple Book | Licensed Biological Products database |
| 198 | GDUFA | Generic Drug User Fee Amendments |
| 199 | PDUFA | Prescription Drug User Fee Act |
| 200 | REMS | Risk Evaluation and Mitigation Strategy |
| 201 | cGMP | Current Good Manufacturing Practice |
| 202 | US Agent | U.S.-based representative for applicable foreign establishments |
| 203 | FEI | FDA Establishment Identifier |
| 204 | NDA Holder | Holder of New Drug Application |
| 205 | ANDA Holder | Holder of Abbreviated New Drug Application |
| 206 | RLD | Reference Listed Drug |
| 207 | RS | Reference Standard |
| 208 | TE Code | Therapeutic Equivalence Code |
| 209 | OTC | Over-the-Counter |
| 210 | Rx | Prescription |
| 211 | OTC Monograph | FDA-established requirements for certain OTC medicines |
H. UK / Europe Terminology
| No. | Term | Meaning |
|---|---|---|
| 212 | MHRA | Medicines and Healthcare products Regulatory Agency |
| 213 | EMA | European Medicines Agency |
| 214 | EU | European Union |
| 215 | EEA | European Economic Area |
| 216 | EudraGMDP | EU database for manufacturing/distribution authorisations and GMP certificates |
| 217 | MA | Marketing Authorisation |
| 218 | MAA | Marketing Authorisation Application |
| 219 | MRP | Mutual Recognition Procedure |
| 220 | DCP | Decentralised Procedure |
| 221 | CAP | Centrally Authorised Product |
| 222 | NAP | Nationally Authorised Product |
| 223 | SmPC | Summary of Product Characteristics |
| 224 | PIL | Patient Information Leaflet |
| 225 | QP | Qualified Person |
| 226 | QP Declaration | Qualified Person declaration |
| 227 | WDA(H) | Wholesale Distribution Authorisation for Human medicines |
| 228 | POM | Prescription Only Medicine |
| 229 | GSL | General Sales List |
| 230 | P | Pharmacy medicine |
| 231 | GDP | Good Distribution Practice |
| 232 | PV | Pharmacovigilance |
| 233 | PSUR | Periodic Safety Update Report |
| 234 | PBRER | Periodic Benefit-Risk Evaluation Report |
| 235 | RMP | Risk Management Plan |
| 236 | DSUR | Development Safety Update Report |
I. Clinical & Regulatory Development
| No. | Term | Meaning |
|---|---|---|
| 237 | IND | Investigational New Drug |
| 238 | NDA | New Drug Application |
| 239 | ANDA | Abbreviated New Drug Application |
| 240 | BLA | Biologics License Application |
| 241 | CTA | Clinical Trial Application |
| 242 | CT | Clinical Trial |
| 243 | Phase I | First-in-human clinical development |
| 244 | Phase II | Dose/efficacy-focused clinical development |
| 245 | Phase III | Large confirmatory clinical trials |
| 246 | Phase IV | Post-marketing studies |
| 247 | CRO | Contract Research Organization |
| 248 | BA | Bioavailability |
| 249 | BE | Bioequivalence |
| 250 | BA/BE | Bioavailability/Bioequivalence |
| 251 | PK | Pharmacokinetics |
| 252 | PD | Pharmacodynamics |
| 253 | RCT | Randomized Controlled Trial |
| 254 | SAE | Serious Adverse Event |
| 255 | AE | Adverse Event |
| 256 | ADR | Adverse Drug Reaction |
| 257 | SUSAR | Suspected Unexpected Serious Adverse Reaction |
| 258 | ICH | International Council for Harmonisation |
| 259 | GCP | Good Clinical Practice |
| 260 | IRB | Institutional Review Board |
| 261 | IEC | Independent Ethics Committee |
| 262 | EDC | Electronic Data Capture |
J. Pharmaceutical Regulatory Documents
| No. | Term | Meaning |
|---|---|---|
| 263 | CPP | Certificate of Pharmaceutical Product |
| 264 | COPP | Certificate of Pharmaceutical Product |
| 265 | COA | Certificate of Analysis |
| 266 | COC | Certificate of Conformity |
| 267 | GMP Certificate | Evidence of GMP compliance |
| 268 | FSC | Free Sale Certificate |
| 269 | PIC/S | Pharmaceutical Inspection Co-operation Scheme |
| 270 | CEP | Certificate of Suitability |
| 271 | DMF | Drug Master File |
| 272 | ASMF | Active Substance Master File |
| 273 | LOA | Letter of Authorization |
| 274 | POA | Power of Attorney |
| 275 | MA | Marketing Authorisation |
| 276 | PIL | Patient Information Leaflet |
| 277 | SmPC | Summary of Product Characteristics |
| 278 | SPC | Summary of Product Characteristics |
| 279 | CTD | Common Technical Document |
| 280 | eCTD | Electronic Common Technical Document |
| 281 | ACTD | ASEAN Common Technical Dossier |
| 282 | Site Master File | Detailed information about manufacturing site |
| 283 | Product Dossier | Technical/regulatory information about product |
| 284 | Stability Data | Evidence of product stability over time |
| 285 | Validation Report | Documented validation results |
| 286 | Batch Release Certificate | Documentation confirming batch release |
K. Pharmaceutical Distribution & Supply Chain
| No. | Term | Meaning |
|---|---|---|
| 287 | GDP | Good Distribution Practice |
| 288 | GSP | Good Storage Practice |
| 289 | 3PL | Third-Party Logistics |
| 290 | 4PL | Fourth-Party Logistics |
| 291 | Cold Chain | Temperature-controlled supply chain |
| 292 | Temperature Mapping | Study of temperature distribution |
| 293 | Data Logger | Device recording environmental conditions |
| 294 | FEFO | First Expiry, First Out |
| 295 | FIFO | First In, First Out |
| 296 | Batch | Defined quantity manufactured under uniform conditions |
| 297 | Lot | Identified production quantity |
| 298 | Batch Number | Unique manufacturing batch identifier |
| 299 | Expiry Date | Date beyond which product should not be used |
| 300 | Shelf Life | Period during which product remains within specifications |
| 301 | Retest Date | Date after which API/material may require retesting |
| 302 | Serialization | Unique identification of individual saleable units |
| 303 | Track & Trace | Tracking products through supply chain |
| 304 | Tamper Evidence | Packaging feature showing unauthorized opening |
L. International Trade & Incoterms
| No. | Term | Meaning |
|---|---|---|
| 305 | EXW | Ex Works |
| 306 | FCA | Free Carrier |
| 307 | FOB | Free On Board |
| 308 | CFR | Cost and Freight |
| 309 | CIF | Cost, Insurance and Freight |
| 310 | CPT | Carriage Paid To |
| 311 | CIP | Carriage and Insurance Paid To |
| 312 | DAP | Delivered at Place |
| 313 | DPU | Delivered at Place Unloaded |
| 314 | DDP | Delivered Duty Paid |
| 315 | Incoterms | International Commercial Terms |
| 316 | Proforma Invoice | Preliminary commercial invoice |
| 317 | Commercial Invoice | Final invoice for commercial transaction |
| 318 | Packing List | Detailed shipment packing information |
| 319 | Purchase Order | Buyer-issued order |
| 320 | PI | Proforma Invoice |
| 321 | PO | Purchase Order |
| 322 | BL/BOL | Bill of Lading |
| 323 | AWB | Air Waybill |
| 324 | COO | Certificate of Origin |
| 325 | LC | Letter of Credit |
| 326 | TT | Telegraphic Transfer |
| 327 | CAD | Cash Against Documents |
| 328 | DP | Documents Against Payment |
| 329 | DA | Documents Against Acceptance |
| 330 | Open Account | Credit-based trade arrangement |
M. Shipping & Customs
| No. | Term | Meaning |
|---|---|---|
| 331 | HS Code | Harmonized System Code |
| 332 | HSN | Harmonized System of Nomenclature |
| 333 | Customs Duty | Government duty imposed on imported goods |
| 334 | Import Duty | Duty charged by importing country |
| 335 | Export Duty | Duty applicable to certain exports |
| 336 | FOB | Free On Board |
| 337 | CIF | Cost, Insurance and Freight |
| 338 | Freight | Transportation cost |
| 339 | Demurrage | Charges for delay beyond allowed period |
| 340 | Detention | Charges for retaining carrier equipment beyond free time |
| 341 | CHA | Customs House Agent |
| 342 | Customs Broker | Licensed customs clearance intermediary |
| 343 | Shipping Bill | Export customs declaration |
| 344 | Bill of Entry | Import customs declaration |
| 345 | LEO | Let Export Order |
| 346 | IGM | Import General Manifest |
| 347 | EGM | Export General Manifest |
| 348 | Port of Loading | Port where goods are loaded |
| 349 | Port of Discharge | Port where goods are unloaded |
| 350 | ETA | Estimated Time of Arrival |
| 351 | ETD | Estimated Time of Departure |
| 352 | FCL | Full Container Load |
| 353 | LCL | Less than Container Load |
| 354 | ULD | Unit Load Device |
| 355 | DG | Dangerous Goods |
| 356 | IATA | International Air Transport Association |
| 357 | IMO | International Maritime Organization |
N. Commercial / Buyer / Supplier Terminology
| No. | Term | Meaning |
|---|---|---|
| 358 | MOQ | Minimum Order Quantity |
| 359 | OEM | Original Equipment Manufacturer |
| 360 | ODM | Original Design Manufacturer |
| 361 | Private Label | Product manufactured for another company’s brand |
| 362 | Contract Manufacturing | Manufacturing under agreement for another company |
| 363 | CMO | Contract Manufacturing Organization |
| 364 | CDMO | Contract Development and Manufacturing Organization |
| 365 | API Supplier | Supplier of active pharmaceutical ingredients |
| 366 | FDF Manufacturer | Finished dosage form manufacturer |
| 367 | Exporter | Entity exporting goods |
| 368 | Importer | Entity importing goods |
| 369 | Distributor | Entity distributing products |
| 370 | Wholesaler | Bulk commercial seller |
| 371 | Stockist | Entity holding inventory for distribution |
| 372 | Agent | Representative acting for another party |
| 373 | Principal | Company represented by an agent/distributor |
| 374 | Tender | Competitive procurement process |
| 375 | RFQ | Request for Quotation |
| 376 | RFP | Request for Proposal |
| 377 | RFQ Response | Supplier’s quotation response |
| 378 | NDA | Non-Disclosure Agreement |
| 379 | MOU | Memorandum of Understanding |
| 380 | SLA | Service Level Agreement |
| 381 | Territory | Geographic market assigned to distributor |
| 382 | Exclusivity | Contractual exclusive distribution/manufacturing rights |
O. Pricing & Financial Terms
| No. | Term | Meaning |
|---|---|---|
| 383 | FOB Price | Price up to loading point under FOB terms |
| 384 | CIF Price | Cost + Insurance + Freight |
| 385 | EXW Price | Ex-works price |
| 386 | Landed Cost | Total cost after delivery/import-related costs |
| 387 | COGS | Cost of Goods Sold |
| 388 | GM | Gross Margin |
| 389 | GP | Gross Profit |
| 390 | ROI | Return on Investment |
| 391 | LC | Letter of Credit |
| 392 | TT | Telegraphic Transfer |
| 393 | Advance Payment | Payment made before shipment |
| 394 | Credit Terms | Agreed payment period |
| 395 | Payment Terms | Conditions under which buyer pays seller |
| 396 | Currency Risk | Risk from exchange-rate movements |
| 397 | FX | Foreign Exchange |
| 398 | Bank Charges | Banking costs associated with transaction |
| 399 | Insurance | Shipment/product insurance coverage |
| 400 | Credit Risk | Risk that buyer fails to pay |
P. Pharmacovigilance & Post-Marketing
| No. | Term | Meaning |
|---|---|---|
| 401 | PV | Pharmacovigilance |
| 402 | AE | Adverse Event |
| 403 | ADR | Adverse Drug Reaction |
| 404 | SAE | Serious Adverse Event |
| 405 | SUSAR | Suspected Unexpected Serious Adverse Reaction |
| 406 | PSUR | Periodic Safety Update Report |
| 407 | PBRER | Periodic Benefit-Risk Evaluation Report |
| 408 | RMP | Risk Management Plan |
| 409 | Signal Detection | Identification of potential safety signals |
| 410 | Safety Signal | Information suggesting a new safety concern |
| 411 | Post-Marketing Surveillance | Monitoring medicine after market launch |
| 412 | Recall | Removal of product from market |
| 413 | Product Complaint | Customer complaint regarding product |
| 414 | Medical Information | Scientific/medical information service |
| 415 | Adverse Event Reporting | Reporting suspected adverse events |
Q. Pharmaceutical Packaging & Labelling
| No. | Term | Meaning |
|---|---|---|
| 416 | Primary Packaging | Packaging directly contacting product |
| 417 | Secondary Packaging | Outer packaging containing primary pack |
| 418 | Tertiary Packaging | Transport/shipping packaging |
| 419 | Label Claim | Information stated on product label |
| 420 | Batch No. | Manufacturing batch identifier |
| 421 | MFG Date | Manufacturing date |
| 422 | EXP Date | Expiry date |
| 423 | MRP | Maximum Retail Price |
| 424 | GTIN | Global Trade Item Number |
| 425 | UDI | Unique Device Identification |
| 426 | Barcode | Machine-readable product identification |
| 427 | Serialization Code | Unique product-level identifier |
| 428 | PIL | Patient Information Leaflet |
| 429 | Artwork | Approved packaging/label design |
| 430 | Leaflet | Patient/user information document |
R. Pharmacopoeia & Standards
| No. | Term | Meaning |
|---|---|---|
| 431 | IP | Indian Pharmacopoeia |
| 432 | USP | United States Pharmacopeia |
| 433 | BP | British Pharmacopoeia |
| 434 | EP | European Pharmacopoeia |
| 435 | JP | Japanese Pharmacopoeia |
| 436 | Ph. Eur. | European Pharmacopoeia |
| 437 | NF | National Formulary |
| 438 | WHO | World Health Organization |
| 439 | ICH | International Council for Harmonisation |
| 440 | ISO | International Organization for Standardization |
| 441 | PIC/S | Pharmaceutical Inspection Co-operation Scheme |
| 442 | ASTM | American Society for Testing and Materials |
| 443 | Reference Standard | Standard used for analytical testing |
| 444 | Monograph | Official specification for a substance/product |
S. API & Raw Material Terminology
| No. | Term | Meaning |
|---|---|---|
| 445 | API | Active Pharmaceutical Ingredient |
| 446 | KSM | Key Starting Material |
| 447 | Starting Material | Material used in API manufacturing |
| 448 | Intermediate | Material formed during manufacturing process |
| 449 | Excipient | Inactive pharmaceutical ingredient |
| 450 | DMF | Drug Master File |
| 451 | CEP | Certificate of Suitability |
| 452 | ASMF | Active Substance Master File |
| 453 | Retest Date | Date for reassessment of material quality |
| 454 | Assay | Measurement of active substance content |
| 455 | Purity | Degree of freedom from impurities |
| 456 | Impurity | Unwanted component |
| 457 | Residual Solvent | Solvent remaining from manufacturing |
| 458 | Nitrosamine | Class of potentially concerning impurities |
| 459 | Genotoxic Impurity | Impurity with potential genetic toxicity |
| 460 | Elemental Impurity | Metallic/inorganic impurity |
| 461 | Specification | Defined quality requirements |
| 462 | Analytical Method | Laboratory method used to test material/product |
T. Regulatory Submission / Dossier Terms
| No. | Term | Meaning |
|---|---|---|
| 463 | CTD | Common Technical Document |
| 464 | eCTD | Electronic Common Technical Document |
| 465 | ACTD | ASEAN Common Technical Dossier |
| 466 | Module 1 | Administrative/regional information |
| 467 | Module 2 | CTD summaries |
| 468 | Module 3 | Quality information |
| 469 | Module 4 | Nonclinical information |
| 470 | Module 5 | Clinical information |
| 471 | Dossier | Complete regulatory submission |
| 472 | Regulatory Submission | Application submitted to regulator |
| 473 | MA | Marketing Authorisation |
| 474 | MAA | Marketing Authorisation Application |
| 475 | Variation | Regulatory change to an approved product |
| 476 | Renewal | Application to continue authorisation |
| 477 | Registration | Regulatory approval/listing of product |
| 478 | Product Licence | Authorisation to market product |
| 479 | Site Registration | Registration/approval of manufacturing site |
| 480 | Regulatory Pathway | Route used to obtain market authorization |
U. Important Business & Export Abbreviations
| No. | Term | Meaning |
|---|---|---|
| 481 | B2B | Business to Business |
| 482 | B2C | Business to Consumer |
| 483 | B2G | Business to Government |
| 484 | OEM | Original Equipment Manufacturer |
| 485 | ODM | Original Design Manufacturer |
| 486 | CMO | Contract Manufacturing Organization |
| 487 | CDMO | Contract Development and Manufacturing Organization |
| 488 | CRO | Contract Research Organization |
| 489 | KOL | Key Opinion Leader |
| 490 | CRM | Customer Relationship Management |
| 491 | ERP | Enterprise Resource Planning |
| 492 | SKU | Stock Keeping Unit |
| 493 | UPC | Universal Product Code |
| 494 | GTIN | Global Trade Item Number |
| 495 | MOQ | Minimum Order Quantity |
| 496 | MPQ | Minimum Packaging Quantity |
| 497 | Lead Time | Time required to fulfil an order |
| 498 | RFQ | Request for Quotation |
| 499 | RFP | Request for Proposal |
| 500 | PO | Purchase Order |
Complete Pharmaceutical Export Terminology & Glossary
- INDIAN PHARMA EXPORT TERMS
No. | Term | Full Form | Detailed Meaning / Use in Pharma Export |
1 | DGFT | Directorate General of Foreign Trade | Indian government authority responsible for India’s foreign-trade policy, IEC issuance and various export/import procedures. |
2 | IEC | Importer Exporter Code | Unique code generally required for carrying out import/export activities from India. |
3 | ICEGATE | Indian Customs Electronic Gateway | Indian Customs’ electronic platform used for customs-related filings and services. |
4 | AD Code | Authorised Dealer Code | Bank-related code registered with Customs for export/import transactions through an authorised dealer bank. |
5 | RCMC | Registration-Cum-Membership Certificate | Certificate issued by the relevant Export Promotion Council or authority to eligible exporters. |
6 | PHARMEXCIL | Pharmaceuticals Export Promotion Council of India | Export promotion body supporting India’s pharmaceutical export sector. |
7 | GST | Goods and Services Tax | Indian indirect tax system applicable to goods/services; export supplies generally receive specific GST treatment. |
8 | GSTIN | Goods and Services Tax Identification Number | Identification number issued to a GST-registered business. |
9 | LUT | Letter of Undertaking | Undertaking used by eligible exporters for exporting without payment of IGST, subject to applicable GST rules. |
10 | e-BRC | Electronic Bank Realisation Certificate | Electronic evidence related to realization of export proceeds through the banking system. |
11 | FEMA | Foreign Exchange Management Act | Indian law governing foreign exchange transactions, including export proceeds. |
12 | RBI | Reserve Bank of India | India’s central bank; regulates foreign-exchange and banking aspects relevant to exports. |
13 | ITC-HS | Indian Trade Classification – Harmonized System | Indian classification system used for identifying goods for trade/customs purposes. |
14 | HS Code | Harmonized System Code | International product classification system used for customs and trade. |
15 | HSN | Harmonized System of Nomenclature | Product classification terminology used particularly in Indian taxation and trade. |
16 | AD Bank | Authorised Dealer Bank | Bank authorised to handle specified foreign-exchange transactions. |
17 | Shipping Bill | — | Customs declaration submitted for export of goods from India. |
18 | EGM | Export General Manifest | Manifest information submitted to Customs concerning exported cargo. |
19 | LEO | Let Export Order | Customs order permitting goods to be exported after applicable examination/clearance. |
20 | CHA | Customs House Agent | Common industry term for a customs intermediary; formally, customs broker. |
- REGISTRATION & REGULATORY COMPLIANCE
No. | Term | Detailed Meaning |
21 | Marketing Authorisation (MA) | Regulatory authorization allowing a medicinal product to be marketed in a particular jurisdiction. |
22 | Marketing Authorisation Application (MAA) | Application submitted to a regulatory authority seeking marketing authorization. |
23 | Product Registration | Regulatory registration/approval of a pharmaceutical product in the destination market. |
24 | Site Registration | Registration or approval of a manufacturing/testing/distribution site where required by the destination regulator. |
25 | Establishment Registration | Regulatory registration of a pharmaceutical establishment or facility. |
26 | Foreign Manufacturer Registration | Registration of a foreign manufacturing establishment with the importing country’s regulator where applicable. |
27 | Import Licence | Authorization allowing an importer to import specified pharmaceutical products into a country. |
28 | Export Licence | Authorization required for exporting certain regulated products or controlled substances, where applicable. |
29 | Wholesale Licence | Authorization allowing an entity to conduct pharmaceutical wholesale activities. |
30 | Manufacturing Licence | Authorization permitting a company/facility to manufacture specified pharmaceutical products. |
31 | Controlled Drug Licence | Special authorization applicable to controlled/narcotic/psychotropic or otherwise restricted substances where required. |
32 | Certificate of Free Sale (CFS/FSC) | Certificate showing that a product is legally marketed or freely sold in the issuing jurisdiction, subject to the issuing authority’s rules. |
33 | GMP Certificate | Certificate demonstrating compliance with applicable Good Manufacturing Practice requirements. |
34 | CPP | Certificate of Pharmaceutical Product |
35 | COPP | Certificate of Pharmaceutical Product |
36 | CEP | Certificate of Suitability |
37 | DMF | Drug Master File |
38 | ASMF | Active Substance Master File |
39 | Letter of Access (LoA) | Letter of Access |
40 | Letter of Authorization (LoA) | Letter of Authorization |
41 | Regulatory Dossier | — |
42 | Variation | — |
43 | Renewal | — |
44 | Pharmacovigilance | PV |
45 | Recall | — |
46 | Regulatory Authority | — |
47 | Product Licence | — |
48 | Registration Certificate | — |
49 | Regulatory Pathway | — |
50 | Regulatory Submission | — |
- EXPORT DOCUMENTATION
No. | Document / Term | Full Form | Purpose |
51 | IEC | Importer Exporter Code | Identifies the Indian exporter/importer. |
52 | DGFT | Directorate General of Foreign Trade | Authority associated with India’s foreign-trade administration. |
53 | RCMC | Registration-Cum-Membership Certificate | Establishes relevant export-promotion-council membership/status where applicable. |
54 | Commercial Invoice | — | Final commercial document showing seller, buyer, products, quantities, prices and transaction value. |
55 | Proforma Invoice | PI | Preliminary quotation/invoice issued before the final commercial invoice. |
56 | Packing List | — | Provides package-level details such as cartons, quantities, weights and dimensions. |
57 | Shipping Bill | SB | Customs export declaration filed for shipment from India. |
58 | Bill of Lading | B/L or BL | Transport document commonly used for sea freight. |
59 | Air Waybill | AWB | Transport document used for air cargo. |
60 | Certificate of Origin | COO | Certifies the origin of exported goods. |
61 | Certificate of Analysis | COA | Shows analytical test results and conformity of a batch/product against specifications. |
62 | Certificate of Pharmaceutical Product | CPP | Regulatory certificate used in pharmaceutical registration/export processes. |
63 | Certificate of Free Sale | CFS/FSC | Provides evidence concerning legal sale/marketing status where accepted by the destination authority. |
64 | Insurance Certificate | — | Evidence of insurance coverage for the shipment where insurance is arranged. |
65 | Purchase Order | PO | Buyer-issued document specifying products, quantities, prices/terms and other requirements. |
66 | Letter of Credit | LC | Bank-supported payment mechanism subject to specified documentary conditions. |
67 | Bank Realisation Certificate | BRC | Evidence relating to realization of export proceeds. |
68 | e-BRC | Electronic Bank Realisation Certificate | Electronic version/system-record associated with export proceeds realization. |
69 | LUT | Letter of Undertaking | GST-related undertaking used by eligible exporters in applicable circumstances. |
70 | GST Documents | — | GST registration/invoice/export-related documents required according to the transaction. |
71 | Customs Declaration | — | Declaration of goods to Customs for export/import clearance. |
72 | Certificate of Conformity | COC | Document certifying conformity with specified standards/requirements where applicable. |
73 | GMP Certificate | — | Evidence of GMP compliance. |
74 | Batch Release Documentation | — | Documentation demonstrating release/quality approval of a particular batch. |
75 | Site Master File | SMF | Detailed information describing a manufacturing site’s organization, operations, quality system and facilities. |
76 | Product Dossier | — | Product-specific technical and regulatory documentation. |
77 | Stability Data | — | Data demonstrating product quality over its proposed storage period under defined conditions. |
78 | Certificate of Insurance | — | Evidence of shipment insurance coverage when required. |
79 | Purchase Contract | — | Contract defining commercial obligations between buyer and seller. |
80 | Export Declaration | — | Formal declaration submitted to relevant authorities concerning an export transaction. |
- COMMERCIAL & BUSINESS TERMS
No. | Term | Full Form / Meaning |
81 | MOQ | Minimum Order Quantity — smallest quantity a supplier agrees to manufacture/sell. |
82 | OEM | Original Equipment Manufacturer — manufacturer producing a product according to an agreed specification/brand arrangement. |
83 | ODM | Original Design Manufacturer — manufacturer that may design and manufacture a product for another company. |
84 | Private Label | Product manufactured by one company and marketed under another company’s brand. |
85 | Contract Manufacturing | Manufacturing performed by one company on behalf of another under contract. |
86 | CMO | Contract Manufacturing Organization |
87 | CDMO | Contract Development and Manufacturing Organization |
88 | Distributor | Business purchasing/selling/distributing pharmaceutical products within a market or territory. |
89 | Importer | Entity legally importing products into the destination country. |
90 | Wholesaler | Business purchasing and selling products in commercial quantities. |
91 | Stockist | Entity that holds pharmaceutical inventory for supply/distribution. |
92 | Tender | Formal competitive procurement process. |
93 | RFQ | Request for Quotation |
94 | RFP | Request for Proposal |
95 | FOB | Free On Board |
96 | CIF | Cost, Insurance and Freight |
97 | CFR | Cost and Freight |
98 | EXW | Ex Works |
99 | FCA | Free Carrier |
100 | DAP | Delivered at Place |
101 | DDP | Delivered Duty Paid |
102 | LC | Letter of Credit |
103 | TT | Telegraphic Transfer |
104 | Advance Payment | Payment received before shipment or before specified production stage. |
105 | Credit Terms | Agreed period/conditions under which buyer pays after invoicing or shipment. |
106 | Landed Cost | Total cost of product after relevant freight, insurance, duties, taxes, handling and other applicable costs. |
107 | Gross Margin | Revenue minus relevant cost of goods, usually expressed as a percentage or amount. |
108 | COGS | Cost of Goods Sold |
109 | ROI | Return on Investment |
110 | Territory | Geographic area assigned to a distributor/agent or covered by a commercial agreement. |
111 | Exclusivity | Contractual right restricting supply/representation to a specified party within a defined scope. |
112 | Lead Time | Time between order/production initiation and readiness or delivery. |
113 | Payment Terms | Agreed payment conditions between buyer and seller. |
114 | Credit Risk | Risk that a buyer does not pay according to agreed terms. |
115 | FX Risk | Foreign-exchange risk resulting from currency movements. |
- QUALITY ASSURANCE & QUALITY CONTROL
No. | Term | Full Form | Detailed Meaning |
116 | QA | Quality Assurance | Systematic activities ensuring pharmaceutical quality is consistently achieved. |
117 | QC | Quality Control | Testing and controls used to determine whether materials/products meet specifications. |
118 | GMP | Good Manufacturing Practice | Requirements designed to ensure medicines are consistently manufactured and controlled according to quality standards. |
119 | cGMP | Current Good Manufacturing Practice | Term emphasizing current applicable GMP requirements, especially in U.S. regulatory usage. |
120 | GLP | Good Laboratory Practice | Quality system principles for certain nonclinical laboratory studies. |
121 | GCP | Good Clinical Practice | International ethical and scientific quality standard for clinical trials. |
122 | GDP | Good Distribution Practice | Standards governing appropriate distribution/storage/handling of medicinal products. |
123 | GSP | Good Storage Practice | Principles governing proper storage of pharmaceutical products. |
124 | SOP | Standard Operating Procedure | Approved written procedure describing how an activity is performed. |
125 | CAPA | Corrective and Preventive Action | System for correcting identified problems and preventing recurrence. |
126 | OOS | Out of Specification | Test/result that does not meet an approved specification. |
127 | OOT | Out of Trend | Result that may remain within specification but shows an unexpected trend. |
128 | Deviation | — | Departure from an approved procedure, process, specification or expected condition. |
129 | Change Control | — | Formal system for evaluating, approving and documenting proposed changes. |
130 | Validation | — | Documented evidence demonstrating that a process/system performs consistently as intended. |
131 | Cleaning Validation | — | Evidence that cleaning procedures consistently remove residues to predetermined acceptable levels. |
132 | Process Validation | — | Evidence that a manufacturing process consistently produces product meeting predetermined requirements. |
133 | BMR | Batch Manufacturing Record | Batch-specific record documenting manufacturing operations. |
134 | BPR | Batch Packaging Record | Batch-specific documentation covering packaging operations. |
135 | MFR | Master Formula Record | Approved master manufacturing instructions/formula for a product. |
136 | MBR | Master Batch Record | Master document describing approved batch manufacturing requirements. |
137 | COA | Certificate of Analysis | Batch/product analytical results against specified standards. |
138 | COC | Certificate of Conformity | Certificate indicating conformity to specified requirements where applicable. |
139 | Specification | — | Defined acceptance criteria for material/product quality. |
140 | Assay | — | Analytical measurement of the quantity/content of a specified substance. |
141 | Impurity | — | Unwanted component present in a pharmaceutical material/product. |
142 | Stability | — | Ability of a product to maintain quality within specifications over time under defined conditions. |
143 | Qualification | — | Documented demonstration that equipment/facility/system is appropriately installed and operates as intended. |
144 | Audit | — | Systematic examination of records, systems, facilities or activities against defined criteria. |
145 | Supplier Qualification | — | Formal process for evaluating and approving suppliers. |
- MEDICINE & PHARMACEUTICAL TERMINOLOGY
No. | Term | Detailed Meaning |
146 | API | Active Pharmaceutical Ingredient — substance responsible for the pharmacological effect of a medicine. |
147 | FDF | Finished Dosage Form — final pharmaceutical dosage form ready for use/market supply. |
148 | FPP | Finished Pharmaceutical Product — finished medicinal product containing active ingredient(s) and excipients in its final form. |
149 | Generic Medicine | Medicine generally equivalent to a reference product in the relevant regulatory sense and marketed after applicable requirements are met. |
150 | Branded Generic | Generic medicine marketed under a proprietary/trade brand name. |
151 | Innovator Product | Original/reference pharmaceutical product developed and authorized by the innovator company. |
152 | Reference Product | Product used as the regulatory comparator/reference in relevant approval pathways. |
153 | Biosimilar | Biological product demonstrated to be highly similar to a reference biological product, subject to jurisdiction-specific requirements. |
154 | Biologic | Medicinal product derived from biological sources. |
155 | Excipient | Ingredient other than the active ingredient used for formulation, stability, delivery, appearance or other purposes. |
156 | Salt | Chemical form of an active pharmaceutical substance, often used to achieve suitable pharmaceutical properties. |
157 | Strength | Amount/concentration of active ingredient in a dosage unit or specified volume. |
158 | Dosage Form | Physical form in which a medicine is supplied, such as tablet, capsule, injection or cream. |
159 | Route of Administration | Method by which medicine enters the body, e.g. oral, intravenous, topical or inhaled. |
160 | Indication | Disease, condition or therapeutic purpose for which a medicine is authorized/recommended. |
161 | Contraindication | Situation in which a medicine should not be used because of unacceptable risk. |
162 | Drug Class | Group of medicines categorized according to pharmacological, chemical or therapeutic characteristics. |
163 | Therapeutic Class | Classification according to therapeutic use or disease/condition treated. |
164 | Pharmacological Class | Classification according to pharmacological action/mechanism. |
165 | Prescription Medicine | Medicine supplied under prescription requirements applicable in a jurisdiction. |
166 | OTC | Over-the-Counter |
167 | Controlled Substance | Substance subject to special legal controls because of abuse, dependence, diversion or other risks. |
168 | Dosage | Amount and frequency of medicine administered. |
169 | Regimen | Overall dosing schedule for a medicine. |
170 | Half-Life | Time required for the concentration/amount of a substance to decrease by approximately half under defined conditions. |
171 | Bioavailability | Rate and extent to which an active substance becomes available at the site/systemic circulation as applicable. |
172 | Bioequivalence | Demonstration that two pharmaceutical products meet specified criteria for equivalence in exposure/availability. |
173 | Pharmacokinetics | Study of what the body does to a drug — absorption, distribution, metabolism and excretion. |
174 | Pharmacodynamics | Study of what a drug does to the body and its effects/mechanisms. |
175 | Therapeutic Index | Relationship between effective and toxic exposure/dose used to characterize safety margin. |
- INTERNATIONAL REGULATORY AUTHORITIES
No. | Abbreviation | Full Name / Authority | Country/Region |
176 | FDA | Food and Drug Administration | USA |
177 | CDER | Center for Drug Evaluation and Research | USA |
178 | CBER | Center for Biologics Evaluation and Research | USA |
179 | DEA | Drug Enforcement Administration | USA |
180 | MHRA | Medicines and Healthcare products Regulatory Agency | UK |
181 | EMA | European Medicines Agency | European Union |
182 | EC | European Commission | European Union |
183 | PMDA | Pharmaceuticals and Medical Devices Agency | Japan |
184 | MHLW | Ministry of Health, Labour and Welfare | Japan |
185 | TGA | Therapeutic Goods Administration | Australia |
186 | Health Canada | Canadian federal health regulator | Canada |
187 | ANVISA | Agência Nacional de Vigilância Sanitária | Brazil |
188 | SAHPRA | South African Health Products Regulatory Authority | South Africa |
189 | NAFDAC | National Agency for Food and Drug Administration and Control | Nigeria |
190 | PPB | Pharmacy and Poisons Board | Kenya |
191 | TMDA | Tanzania Medicines and Medical Devices Authority | Tanzania |
192 | NDA | National Drug Authority | Uganda |
193 | FDA Ghana | Food and Drugs Authority | Ghana |
194 | EDA | Egyptian Drug Authority | Egypt |
195 | SFDA | Saudi Food and Drug Authority | Saudi Arabia |
196 | MOHAP | Ministry of Health and Prevention | UAE |
197 | EDE | Emirates Drug Establishment | UAE |
198 | DGDA | Directorate General of Drug Administration | Bangladesh |
199 | BPOM | Badan Pengawas Obat dan Makanan | Indonesia |
200 | NPRA | National Pharmaceutical Regulatory Agency | Malaysia |
201 | FDA Philippines | Food and Drug Administration | Philippines |
202 | DAV | Drug Administration of Vietnam | Vietnam |
203 | Medsafe | New Zealand Medicines and Medical Devices Safety Authority | New Zealand |
204 | BfArM | Federal Institute for Drugs and Medical Devices | Germany |
205 | ANSM | French National Agency for Medicines Safety | France |
206 | AIFA | Italian Medicines Agency | Italy |
207 | AEMPS | Spanish Agency of Medicines and Medical Devices | Spain |
208 | MEB | Medicines Evaluation Board | Netherlands |
209 | TİTCK | Turkish Medicines and Medical Devices Agency | Turkey |
- DRUG DEVELOPMENT & REGULATORY APPLICATIONS
No. | Term | Full Form / Meaning |
210 | IND | Investigational New Drug |
211 | NDA | New Drug Application |
212 | ANDA | Abbreviated New Drug Application |
213 | BLA | Biologics License Application |
214 | DMF | Drug Master File |
215 | CTD | Common Technical Document |
216 | eCTD | Electronic Common Technical Document |
217 | ACTD | ASEAN Common Technical Dossier |
218 | MAA | Marketing Authorisation Application |
219 | CTA | Clinical Trial Application |
220 | CRO | Contract Research Organization |
221 | CMC | Chemistry, Manufacturing and Controls |
222 | RLD | Reference Listed Drug |
223 | TE Code | Therapeutic Equivalence Code |
224 | Orange Book | Approved Drug Products with Therapeutic Equivalence Evaluations |
225 | Purple Book | — |
226 | PDUFA | Prescription Drug User Fee Act |
227 | GDUFA | Generic Drug User Fee Amendments |
228 | REMS | Risk Evaluation and Mitigation Strategy |
- SHIPPING, LOGISTICS & INCOTERMS
No. | Term | Full Form / Meaning |
229 | EXW | Ex Works |
230 | FCA | Free Carrier |
231 | FOB | Free On Board |
232 | CFR | Cost and Freight |
233 | CIF | Cost, Insurance and Freight |
234 | CPT | Carriage Paid To |
235 | CIP | Carriage and Insurance Paid To |
236 | DAP | Delivered at Place |
237 | DPU | Delivered at Place Unloaded |
238 | DDP | Delivered Duty Paid |
239 | Incoterms | International Commercial Terms published by the International Chamber of Commerce |
240 | BL/BOL | Bill of Lading |
241 | AWB | Air Waybill |
242 | FCL | Full Container Load |
243 | LCL | Less than Container Load |
244 | ETA | Estimated Time of Arrival |
245 | ETD | Estimated Time of Departure |
246 | Freight Forwarder | Company arranging transportation/logistics for shipments. |
247 | Customs Broker | Authorized intermediary assisting with customs clearance. |
248 | 3PL | Third-Party Logistics Provider |
249 | Cold Chain | Temperature-controlled supply chain. |
250 | Data Logger | Device recording temperature/humidity or other environmental conditions. |
251 | Temperature Mapping | Assessment of temperature distribution within a storage/transport area. |
252 | FEFO | First Expiry, First Out |
253 | FIFO | First In, First Out |
254 | Demurrage | Charges associated with exceeding permitted terminal/container time, depending on the applicable arrangement. |
255 | Detention | Charges associated with retaining carrier equipment beyond permitted free time. |
256 | Port of Loading | Location where cargo is loaded for transportation. |
257 | Port of Discharge | Location where cargo is discharged from the transporting vessel. |
- DOCUMENTATION ABBREVIATIONS — QUICK REFERENCE
No. | Abbreviation | Meaning |
258 | COA | Certificate of Analysis |
259 | COC | Certificate of Conformity |
260 | CPP | Certificate of Pharmaceutical Product |
261 | COPP | Certificate of Pharmaceutical Product |
262 | FSC | Free Sale Certificate |
263 | CFS | Certificate of Free Sale |
264 | COO | Certificate of Origin |
265 | PI | Proforma Invoice |
266 | PO | Purchase Order |
267 | CI | Commercial Invoice |
268 | PL | Packing List |
269 | BL | Bill of Lading |
270 | BOL | Bill of Lading |
271 | AWB | Air Waybill |
272 | LC | Letter of Credit |
273 | BRC | Bank Realisation Certificate |
274 | e-BRC | Electronic Bank Realisation Certificate |
275 | LUT | Letter of Undertaking |
276 | LOA | Letter of Authorization |
277 | LOA | Letter of Access — context dependent |
278 | SMF | Site Master File |
279 | DMF | Drug Master File |
280 | ASMF | Active Substance Master File |
281 | CEP | Certificate of Suitability |
- PHARMACOVIGILANCE & DRUG SAFETY
No. | Term | Full Form / Meaning |
282 | PV | Pharmacovigilance |
283 | AE | Adverse Event |
284 | ADR | Adverse Drug Reaction |
285 | SAE | Serious Adverse Event |
286 | SUSAR | Suspected Unexpected Serious Adverse Reaction |
287 | PSUR | Periodic Safety Update Report |
288 | PBRER | Periodic Benefit-Risk Evaluation Report |
289 | RMP | Risk Management Plan |
290 | DSUR | Development Safety Update Report |
291 | Signal Detection | Process of identifying potential safety signals from available data. |
292 | Safety Signal | Information suggesting a possible new association or safety concern. |
293 | Post-Marketing Surveillance | Monitoring product safety and performance after authorization. |
294 | Risk-Benefit Assessment | Evaluation comparing therapeutic benefits with identified/potential risks. |
295 | Product Recall | Removal of affected product from the market. |
296 | Medical Information | Scientific/medical information provided regarding a medicinal product. |
297 | Adverse Event Reporting | Process of receiving, assessing and reporting suspected adverse events. |
- PACKAGING & LABELLING
No. | Term | Meaning |
298 | Primary Packaging | Packaging directly in contact with the medicine. |
299 | Secondary Packaging | Outer packaging surrounding the primary package. |
300 | Tertiary Packaging | Packaging used primarily for transportation/logistics. |
301 | Label Claim | Information/statement appearing on the product label. |
302 | Batch No. | Unique identification number assigned to a manufacturing batch. |
303 | MFG Date | Manufacturing date. |
304 | EXP Date | Expiry date. |
305 | MRP | Maximum Retail Price, where applicable. |
306 | GTIN | Global Trade Item Number. |
307 | Barcode | Machine-readable identification code. |
308 | Serialization | Assignment of unique identifiers to individual saleable units where required. |
309 | Artwork | Approved design/layout of packaging and labelling. |
310 | Leaflet | Information document supplied with a medicine. |
311 | PIL | Patient Information Leaflet. |
312 | SmPC | Summary of Product Characteristics. |
313 | Tamper-Evident Packaging | Packaging designed to show visible evidence of unauthorized opening/tampering. |
- PHARMACOPOEIA & INTERNATIONAL STANDARDS
No. | Term | Full Form / Meaning |
314 | IP | Indian Pharmacopoeia |
315 | USP | United States Pharmacopeia |
316 | BP | British Pharmacopoeia |
317 | Ph. Eur. | European Pharmacopoeia |
318 | EP | European Pharmacopoeia |
319 | JP | Japanese Pharmacopoeia |
320 | NF | National Formulary |
321 | WHO | World Health Organization |
322 | ICH | International Council for Harmonisation |
323 | ISO | International Organization for Standardization |
324 | PIC/S | Pharmaceutical Inspection Co-operation Scheme |
325 | ASTM | ASTM International |
326 | Monograph | Official standard/specification for a substance or pharmaceutical product. |
327 | Reference Standard | Material of established quality used for analytical comparison/testing. |
- API, RAW MATERIAL & EXCIPIENT TERMINOLOGY
No. | Term | Meaning |
328 | API | Active Pharmaceutical Ingredient |
329 | KSM | Key Starting Material |
330 | Starting Material | Material used in the manufacturing process of an API/product. |
331 | Intermediate | Substance produced during manufacturing and subsequently processed. |
332 | Excipient | Non-active ingredient used in pharmaceutical formulation. |
333 | DMF | Drug Master File |
334 | ASMF | Active Substance Master File |
335 | CEP | Certificate of Suitability |
336 | Assay | Quantitative measurement of a specified substance. |
337 | Purity | Degree to which a material is free from unwanted substances. |
338 | Impurity | Unwanted component present in a material/product. |
339 | Residual Solvent | Solvent remaining from manufacturing processes. |
340 | Elemental Impurity | Elemental/metallic impurity requiring control according to applicable standards. |
341 | Nitrosamine | A class of compounds subject to regulatory risk assessment/control in pharmaceuticals. |
342 | Genotoxic Impurity | Impurity with potential to cause genetic damage. |
343 | Retest Date | Date by which an API/material should be retested to confirm continued suitability where applicable. |
344 | Specification | Defined set of tests, analytical procedures and acceptance criteria. |
345 | Analytical Method | Procedure used to test and characterize pharmaceutical materials/products. |
- REGULATORY DOSSIER STRUCTURE
No. | Term | Meaning |
346 | CTD | Common Technical Document |
347 | eCTD | Electronic Common Technical Document |
348 | ACTD | ASEAN Common Technical Dossier |
349 | Module 1 | Administrative/regional information. |
350 | Module 2 | CTD summaries and overviews. |
351 | Module 3 | Quality/CMC information. |
352 | Module 4 | Nonclinical study information. |
353 | Module 5 | Clinical study information. |
354 | Dossier | Complete collection of regulatory documentation. |
355 | CMC | Chemistry, Manufacturing and Controls |
356 | Quality Overall Summary | Summary of the quality portion of a regulatory submission. |
357 | Clinical Overview | Summary/assessment of clinical evidence. |
358 | Nonclinical Overview | Summary/assessment of nonclinical evidence. |
359 | Regulatory Submission | Formal submission made to a regulatory authority. |
360 | Variation | Change to an approved product/authorization. |
361 | Renewal | Process for continuation of an authorization where applicable. |
- BUYER, SUPPLIER & CONTRACT TERMINOLOGY
No. | Term | Meaning |
362 | Manufacturer | Company producing pharmaceutical products. |
363 | Supplier | Company supplying goods/materials to another business. |
364 | Trader | Entity buying and reselling products rather than necessarily manufacturing them. |
365 | Exporter | Entity exporting products from the origin country. |
366 | Importer | Entity importing products into destination country. |
367 | Distributor | Entity distributing products within a market. |
368 | Wholesaler | Entity dealing in products in wholesale quantities. |
369 | Stockist | Entity holding stock for onward distribution/sale. |
370 | Agent | Representative acting on behalf of another company. |
371 | Principal | Company represented by an agent/distributor. |
372 | OEM | Original Equipment Manufacturer. |
373 | ODM | Original Design Manufacturer. |
374 | CMO | Contract Manufacturing Organization. |
375 | CDMO | Contract Development and Manufacturing Organization. |
376 | Private Label | Product marketed under customer’s own brand. |
377 | Contract Manufacturing | Manufacturing under a contractual arrangement. |
378 | Tender | Competitive procurement process. |
379 | RFQ | Request for Quotation. |
380 | RFP | Request for Proposal. |
381 | NDA | Non-Disclosure Agreement. |
382 | MOU | Memorandum of Understanding. |
383 | SLA | Service Level Agreement. |
384 | KOL | Key Opinion Leader. |
- FINANCE & EXPORT PAYMENT TERMS
No. | Term | Meaning |
385 | LC | Letter of Credit |
386 | TT | Telegraphic Transfer |
387 | DP | Documents Against Payment |
388 | DA | Documents Against Acceptance |
389 | CAD | Cash Against Documents |
390 | Advance Payment | Payment received before shipment/production as agreed. |
391 | Open Account | Buyer pays after shipment according to agreed credit terms. |
392 | Credit Period | Agreed number of days before payment becomes due. |
393 | Credit Risk | Risk of non-payment by buyer. |
394 | FX | Foreign Exchange |
395 | FX Risk | Risk arising from currency fluctuations. |
396 | Landed Cost | Total delivered/imported cost after relevant charges. |
397 | COGS | Cost of Goods Sold |
398 | Gross Profit | Revenue less applicable cost of goods. |
399 | Gross Margin | Gross profit expressed as a percentage of revenue. |
400 | ROI | Return on Investment. |
- IMPORTANT GENERAL PHARMA TERMS
No. | Term | Meaning |
401 | Rx | Prescription |
402 | OTC | Over-the-Counter |
403 | Rx-only | Prescription-only medicine under applicable jurisdictional rules. |
404 | Controlled Drug | Medicine/substance subject to special legal controls. |
405 | Narcotic | Substance subject to specific legal controls and classification. |
406 | Psychotropic | Substance affecting the central nervous system and potentially subject to special controls. |
407 | Orphan Drug | Medicine intended for a rare disease/condition under applicable regulatory definitions. |
408 | Combination Product | Product containing two or more active ingredients or combining different therapeutic components. |
409 | Fixed-Dose Combination | Product containing specified active ingredients in fixed proportions. |
410 | Dosage Strength | Quantity/concentration of active ingredient in a dosage unit. |
411 | Route | Route by which the product is administered. |
412 | Oral | Administered through the mouth. |
413 | Parenteral | Administration that generally bypasses the gastrointestinal tract, such as injection. |
414 | Topical | Applied to a body surface/skin. |
415 | Ophthalmic | Intended for administration to/around the eye. |
416 | Inhalation | Administration through the respiratory tract. |
417 | Injectable | Pharmaceutical product administered by injection. |
418 | Tablet | Solid dosage form generally intended for oral administration. |
419 | Capsule | Dosage form containing drug substance/formulation within a shell. |
420 | Cream | Semisolid topical preparation. |
421 | Ointment | Semisolid preparation generally intended for application to skin. |
422 | Gel | Semisolid formulation with a gel structure. |
423 | Syrup | Liquid oral formulation, often containing dissolved ingredients. |
424 | Suspension | Liquid preparation containing dispersed insoluble particles. |
425 | Solution | Homogeneous liquid preparation in which ingredients are dissolved. |
- 26-COUNTRY REGULATORY TERMINOLOGY FOR YOUR NAWINZA BOOK
For your 26-country medicine export database, I recommend maintaining the following country-specific terminology.
No. | Country | Main Regulatory Authority / Terms to Track |
426 | USA | FDA, CDER, CBER, ANDA, NDA, BLA, IND, NDC, DMF, cGMP, DEA |
427 | UK | MHRA, Marketing Authorisation, WDA(H), GDP, POM, GSL, Pharmacovigilance |
428 | UAE | EDE/MOHAP, product registration, importer/manufacturer requirements, controlled medicines requirements |
429 | Saudi Arabia | SFDA, drug registration, importer/establishment requirements |
430 | Canada | Health Canada, DIN, NOC, Drug Submission, GMP, Drug Establishment Licence |
431 | Australia | TGA, ARTG, AUST-R, AUST-L, GMP, sponsor |
432 | Germany | BfArM/EMA, Marketing Authorisation, EU GMP, QP |
433 | France | ANSM/EMA, Marketing Authorisation, pharmacovigilance |
434 | Netherlands | MEB/EMA, Marketing Authorisation, GDP/GMP |
435 | Brazil | ANVISA, product registration, GMP, importer requirements |
436 | South Africa | SAHPRA, product registration, GMP, applicant/importer requirements |
437 | Nigeria | NAFDAC, product registration, import/registration requirements |
438 | Kenya | PPB, product registration, import/wholesale requirements |
439 | Tanzania | TMDA, registration, import permits, GMP |
440 | Uganda | NDA, product registration, import requirements |
441 | Ghana | FDA Ghana, product registration, importer requirements |
442 | Egypt | EDA, product registration, import/manufacturing requirements |
443 | Turkey | TİTCK, marketing authorization, product registration |
444 | Russia | Russian/EAEU registration framework, GMP and marketing authorization |
445 | Bangladesh | DGDA, product registration/import requirements |
446 | Indonesia | BPOM, product registration, importer/marketing authorization requirements |
447 | Malaysia | NPRA, product registration, importer/PRH requirements |
448 | Philippines | FDA Philippines, product registration, LTO/CPR-related requirements |
449 | Vietnam | Drug Administration of Vietnam, marketing authorization, import requirements |
450 | Japan | PMDA, MHLW, marketing authorization, MAH, GMP |
451 | New Zealand | Medsafe, medicine classification, product approval/notification requirements |
Professional Master Glossary of Pharmaceutical Export Terminology
This section is designed to function as a book-ready reference chapter for an Indian pharmaceutical exporter. The objective is not merely to give abbreviations, but to explain what each term means, why it matters, when it is used, and how it differs from related terminology.
Regulatory principle: A pharmaceutical product is not automatically exportable merely because it is legally manufactured in India. Exportability can depend on the product’s composition, dosage form, strength, controlled-substance status, manufacturing site, destination-country registration, importer licence, product authorization, labelling, documentation and applicable customs requirements.
PART I — INDIAN EXPORT & FOREIGN-TRADE TERMS
- DGFT
Full Form: Directorate General of Foreign Trade
Meaning
DGFT is the Indian government authority responsible for administering important aspects of India’s foreign-trade framework.
Importance to pharma exporters
An Indian pharmaceutical exporter may interact with DGFT for matters such as:
- Importer Exporter Code (IEC)
- Foreign Trade Policy
- export/import policy conditions
- restricted goods
- authorisations
- trade-related notifications
- export incentives or schemes where applicable
Difference
DGFT ≠ CDSCO.
- DGFT → foreign trade/export-import framework
- CDSCO → regulation of drugs and medical products in India
A pharma exporter may therefore need to satisfy both trade requirements and pharmaceutical regulatory requirements.
- IEC
Full Form: Importer Exporter Code
Meaning
IEC is the identification code associated with an Indian entity carrying out import/export activities, subject to applicable exemptions and rules.
Importance
For an Indian company exporting pharmaceutical products, IEC is one of the fundamental business/trade identifiers.
Example
An Indian pharmaceutical company may have:
Company → IEC → Customs/Trade documentation → Foreign buyer
Difference
IEC ≠ GSTIN
- IEC → foreign trade identification
- GSTIN → GST/tax identification
- ICEGATE
Full Form: Indian Customs Electronic Gateway
Meaning
ICEGATE is the electronic interface used for various Indian Customs-related activities and filings.
Importance
It is relevant to exporters because pharmaceutical shipments must pass through customs procedures.
Difference
DGFT deals primarily with foreign-trade administration.
ICEGATE/Customs systems deal with customs-related processing and electronic transactions.
- AD Code
Full Form: Authorised Dealer Code
Meaning
An AD Code is associated with an authorised dealer bank handling foreign-exchange transactions for an exporter/importer.
Importance
It is important for connecting export transactions with the appropriate banking/customs framework.
Related term
AD Bank = Authorised Dealer Bank
Difference
- IEC identifies the exporter/importer for foreign trade.
- AD Code relates to the authorised banking channel.
- GSTIN relates to GST taxation.
- RCMC
Full Form: Registration-Cum-Membership Certificate
Meaning
RCMC is issued by the relevant Export Promotion Council or competent organization to eligible exporters.
Pharma relevance
For pharmaceutical exporters, PHARMEXCIL may be relevant depending on the nature of the exporter’s business and applicable membership requirements.
Importance
It can support participation in export-promotion activities, trade facilitation and certain schemes/processes.
- PHARMEXCIL
Full Form: Pharmaceuticals Export Promotion Council of India
Meaning
PHARMEXCIL is India’s pharmaceutical export promotion council.
Importance
It is particularly relevant for companies involved in:
- pharmaceutical exports
- APIs
- formulations
- biotechnology products
- herbal/related healthcare products, depending on category
Difference
PHARMEXCIL ≠ CDSCO
- PHARMEXCIL → export promotion/trade support
- CDSCO → drug regulatory authority
- GST
Full Form: Goods and Services Tax
Meaning
GST is India’s indirect tax system covering supplies of goods and services.
Pharma export importance
Exports can receive specific GST treatment, including zero-rated supply mechanisms subject to applicable law and compliance.
Important distinction
Zero-rated export ≠ automatically tax-free in every procedural sense.
The exporter still has documentation and compliance obligations.
- GSTIN
Full Form: Goods and Services Tax Identification Number
Meaning
GSTIN identifies a GST-registered business.
Difference
Term | Purpose |
IEC | Foreign trade |
GSTIN | GST |
PAN | Income-tax/business identity |
AD Code | Banking/customs-related export framework |
- LUT
Full Form: Letter of Undertaking
Meaning
In GST export practice, an eligible exporter can use an LUT for exporting without payment of IGST, subject to applicable GST provisions.
Importance
It can improve export cash flow by avoiding payment of IGST upfront where the exporter is eligible to use the LUT route.
Difference
LUT is not an export licence.
It is a GST-related undertaking.
- e-BRC
Full Form: Electronic Bank Realisation Certificate
Meaning
e-BRC is an electronic record/certificate associated with realization of export proceeds.
Importance
It provides evidence relevant to:
- export proceeds realization
- banking records
- foreign-trade compliance
- certain export-related claims/benefits where applicable
Difference
Shipping Bill proves/records export customs declaration.
e-BRC relates to realization of export proceeds.
- RBI
Full Form: Reserve Bank of India
Meaning
RBI is India’s central bank.
Pharma-export relevance
Its importance to exporters arises particularly through:
- foreign exchange
- export proceeds
- banking channels
- authorized dealer banks
- reporting requirements
Difference
RBI does not approve pharmaceutical medicines for sale in foreign markets.
- FEMA
Full Form: Foreign Exchange Management Act, 1999
Meaning
FEMA provides India’s legal framework for foreign-exchange management.
Importance
Pharma exporters receiving foreign currency and conducting international transactions must understand the applicable FEMA/banking framework.
Difference
FEMA → foreign exchange
Drugs and Cosmetics framework → pharmaceutical regulation
- ITC-HS
Full Form: Indian Trade Classification based on Harmonized System
Meaning
ITC-HS is India’s trade classification system used for goods.
Importance
Correct classification affects:
- customs declarations
- export/import policy
- trade statistics
- applicable duties
- restrictions/conditions
Critical point
An HS code should not be guessed merely from the medicine’s brand name.
- HSN
Full Form: Harmonized System of Nomenclature
Meaning
HS/HSN terminology refers to internationally structured goods classification.
Difference
HS Code → international customs classification framework.
ITC-HS → India’s implementation/classification structure.
PART II — REGISTRATION & REGULATORY COMPLIANCE
- MA
Full Form: Marketing Authorisation
Meaning
Marketing Authorisation is regulatory authorization allowing a medicinal product to be marketed in a particular jurisdiction, subject to that jurisdiction’s law.
Importance
This is one of the most important concepts in pharmaceutical exports.
A medicine manufactured legally in India may still require separate authorization in the destination country before commercial marketing.
Difference
Manufacturing Licence → permission to manufacture.
Marketing Authorisation → permission to market/supply the product in the relevant jurisdiction.
- MAA
Full Form: Marketing Authorisation Application
Meaning
The application submitted to a regulatory authority seeking marketing authorization.
Relationship
MAA → regulatory review → MA
An MAA is an application.
MA is the authorization.
- Product Registration
Meaning
Formal registration/authorization of a pharmaceutical product with the destination country’s regulator.
Importance
It establishes the legal regulatory status of the specific product in that market.
Example
A company may manufacture:
Paracetamol 500 mg tablets
in India, but the product may still need to be registered with the relevant regulator before commercial sale in another country.
- Site Registration
Meaning
Registration or approval of a manufacturing, testing or other relevant site by a regulatory authority where required.
Importance
Regulators often need to know:
- where the medicine is manufactured
- who manufactures it
- whether the site complies with GMP
- what products/processes are performed there
Difference
Product registration concerns the product.
Site registration concerns the facility/site.
- Establishment Registration
Meaning
Registration of a pharmaceutical establishment/facility with the relevant authority.
Importance
It allows regulators to identify and oversee businesses involved in regulated pharmaceutical activities.
Difference
A company may have:
Company registration + establishment registration + product registration
These are not necessarily the same thing.
- Foreign Manufacturer Registration
Meaning
Registration of a manufacturer located outside the destination country, where required by the destination regulator.
Importance
An Indian manufacturer exporting medicines may need to be recognized by the destination country’s regulatory system.
Example
Indian manufacturer → foreign regulator → foreign establishment requirements
- Import Licence
Meaning
Authorization permitting an entity to import specified pharmaceutical products into a country.
Importance
The foreign buyer/importer may need an import authorization.
Key point
The Indian exporter should not assume that obtaining an Indian export document automatically gives the foreign buyer permission to import.
- Export Licence
Meaning
Authorization required for exporting certain goods/products where the law imposes such a requirement.
Pharma relevance
Particularly important for products that are:
- controlled
- narcotic/psychotropic
- restricted
- subject to special export controls
Difference
Export licence controls export from the exporting jurisdiction.
Import licence controls import into the destination jurisdiction.
- Wholesale Licence
Meaning
Authorization allowing an entity to conduct pharmaceutical wholesale activities under applicable law.
Importance
The foreign distributor/importer may require appropriate wholesale authorization.
Difference
Importer → legally brings product into country.
Wholesaler/distributor → distributes/sells within the market.
One organization can sometimes perform multiple roles if legally authorized.
- Manufacturing Licence
Meaning
Government authorization permitting manufacturing of specified pharmaceutical products at an approved facility.
Importance
It demonstrates that manufacturing is taking place under an authorized regulatory framework.
Difference
Manufacturing licence ≠ GMP certificate.
- Licence → legal authorization to manufacture.
- GMP certificate → evidence of compliance with applicable GMP requirements.
- Controlled Drug Licence
Meaning
Special authorization associated with controlled, narcotic, psychotropic or otherwise restricted substances where required.
Importance
Controlled products can have substantially stricter requirements for:
- manufacture
- storage
- possession
- distribution
- import
- export
- record keeping
Critical distinction
A product should not be labelled “controlled” merely because it is prescription-only.
Prescription status and controlled-drug status are different regulatory concepts.
- CFS / FSC
Full Form: Certificate of Free Sale / Free Sale Certificate
Meaning
A certificate providing evidence about a product’s legal sale/marketing status in the issuing jurisdiction, where the issuing authority uses such a certificate.
Importance
Some destination markets may request it as part of product registration.
Difference
GMP Certificate → manufacturing quality compliance.
CFS/FSC → evidence concerning free/legal sale or marketing status.
- GMP Certificate
Full Form: Good Manufacturing Practice Certificate
Meaning
A certificate or official evidence showing that a manufacturing facility complies with applicable GMP requirements, according to the issuing authority and scope.
Importance
GMP is fundamental to pharmaceutical manufacturing and international regulatory confidence.
Difference
GMP → standard/requirements.
GMP Certificate → evidence issued/recognized by an authority or competent body.
- CPP
Full Form: Certificate of Pharmaceutical Product
Meaning
A pharmaceutical regulatory certificate based on the WHO Certification Scheme for pharmaceutical products, used by participating authorities as applicable.
Importance
It can support registration of pharmaceutical products in importing countries.
Difference
CPP is a regulatory certificate, not a commercial invoice and not a manufacturing licence.
- COPP
Commonly used as: Certificate of Pharmaceutical Product
Meaning
COPP is frequently used in pharmaceutical-export terminology for a Certificate of Pharmaceutical Product.
Important distinction
Do not automatically create two completely separate concepts:
CPP ≠ COPP
In many contexts, they refer to the same general pharmaceutical certificate, with terminology varying according to authority/country/practice.
For your book, write:
CPP/COPP — Certificate of Pharmaceutical Product
and then explain the exact format/issuing authority applicable to the target country.
- CEP
Full Form: Certificate of Suitability
Meaning
A CEP is associated with demonstrating suitability of a substance with respect to relevant European Pharmacopoeia standards.
Importance
Particularly relevant to API manufacturers and regulatory submissions involving European markets.
Difference
CEP ≠ DMF
Both may contain technical information, but they are different regulatory mechanisms/documents.
- DMF
Full Form: Drug Master File
Meaning
A confidential technical file containing detailed information about manufacturing, processing, quality and controls of a substance or other regulated material, depending on the regulatory system.
Importance
It allows regulators to review confidential manufacturing information without necessarily disclosing it to the finished-product applicant.
Difference
DMF → confidential technical information
Marketing Authorisation → permission to market finished product
- ASMF
Full Form: Active Substance Master File
Meaning
ASMF is a European regulatory mechanism for protecting confidential information concerning an active substance while allowing regulators access to the necessary information.
Difference
DMF is a broader term used in several regulatory systems.
ASMF is particularly associated with the European regulatory framework for active substances.
- Letter of Access
Meaning
A Letter of Access authorizes a regulatory authority or relevant party to access/refer to confidential information contained in a technical file.
Example
An API manufacturer may permit a finished-product applicant to reference confidential API information held in a regulatory file.
Difference
Letter of Access ≠ Letter of Authorization.
- Letter of Authorization
Meaning
A formal document authorizing another party to perform an action, represent a company, submit information or act on behalf of the authorization holder, depending on the context.
Difference
Letter | Purpose |
Letter of Access | Access/reference confidential regulatory information |
Letter of Authorization | Authorize a person/company to perform specified actions |
- Regulatory Dossier
Meaning
A structured collection of regulatory, technical, quality, administrative, nonclinical and/or clinical information submitted to a regulatory authority.
Importance
A pharmaceutical product cannot normally be evaluated for authorization merely from a commercial brochure.
The regulator requires evidence.
Typical areas
- administrative information
- quality/CMC
- manufacturing
- specifications
- stability
- nonclinical information
- clinical information
- labelling
- Variation
Meaning
A regulatory change to an already authorized product, site, manufacturing process, documentation or other approved element.
Examples
- manufacturing-site change
- formulation change
- specification change
- packaging change
- manufacturing-process change
Difference
Variation = change to an existing authorization.
New application = authorization for a new product/pathway.
- Renewal
Meaning
Process through which a regulatory authorization is continued after a specified validity period, where applicable.
Difference
Renewal → continuation
Variation → change
New application → new authorization/pathway
- Pharmacovigilance
Abbreviation: PV
Meaning
The science and activities concerned with detecting, assessing, understanding and preventing adverse effects and other medicine-related safety problems.
Importance
Pharmacovigilance continues after the medicine reaches the market.
Difference
Clinical development studies safety before/around approval.
Pharmacovigilance monitors safety throughout the product lifecycle.
- Recall
Meaning
A process through which affected pharmaceutical products are removed from the market/supply chain because of a quality, safety, regulatory or other significant issue.
Possible triggers
- contamination
- incorrect strength
- labelling error
- stability problem
- manufacturing defect
- regulatory non-compliance
Difference
Recall ≠ routine product return.
A recall is a controlled corrective action addressing an identified risk/problem.
PART III — EXPORT DOCUMENTATION
- Commercial Invoice
Meaning
The principal commercial document describing the sale transaction.
Usually contains
- exporter
- buyer
- product
- quantity
- unit price
- total value
- currency
- Incoterm
- shipment details
Importance
Used by commercial, customs, banking and logistics parties.
- Proforma Invoice — PI
Meaning
A preliminary invoice/quotation issued before the final commercial transaction/shipment.
Uses
- quotation
- buyer approval
- advance payment
- LC arrangements
- order confirmation
Difference
PI → before/facilitates transaction
Commercial Invoice → final commercial transaction document
- Packing List
Meaning
Document describing how goods are physically packed.
Typical information
- number of cartons
- package type
- quantity
- gross weight
- net weight
- dimensions
- batch information where appropriate
Difference
Commercial Invoice → money/value
Packing List → physical shipment
- Shipping Bill
Meaning
Indian Customs export declaration for goods being exported.
Importance
Essential to customs clearance of the shipment.
- Bill of Lading — BL/BOL
Meaning
A transport document used mainly in sea freight.
Functions
Depending on the type and circumstances, it can serve as:
- evidence of carriage contract
- receipt for goods
- document with title functions in appropriate cases
Difference
B/L → sea transport
AWB → air transport
- Air Waybill — AWB
Meaning
Transport document for air cargo.
Difference
B/L | AWB |
Primarily sea freight | Air freight |
Can have negotiable/title characteristics depending on type | Generally non-negotiable |
Used by ocean carrier | Used by airline/air cargo carrier |
- Certificate of Origin — COO
Meaning
Certificate establishing the origin of goods for purposes determined by the destination country’s rules.
Importance
May be required for:
- customs
- preferential tariffs
- trade agreements
- buyer requirements
Difference
COO → origin of goods
COA → quality/test results
- Certificate of Analysis — COA
Meaning
A document showing analytical test results for a particular batch/product against specified standards.
Typical information
- product name
- batch number
- test parameters
- specifications
- actual results
- release status
- dates/signatures as applicable
Importance
Extremely important in pharmaceutical B2B transactions.
Difference
COA → product quality/test results
COO → country of origin
CPP → pharmaceutical regulatory status/product information
- Insurance Certificate
Meaning
Evidence that shipment insurance has been arranged.
Importance
Particularly relevant where the applicable Incoterm or sales contract requires the seller to arrange insurance.
- Purchase Order — PO
Meaning
Formal order issued by the buyer.
Typical details
- product
- quantity
- price
- delivery terms
- destination
- payment terms
- specifications
Difference
PO → buyer’s order
PI → seller’s preliminary commercial document
- Letter of Credit — LC
Meaning
A bank-based payment mechanism under which payment is made subject to specified terms and documentary conditions.
Importance
Can reduce certain payment risks, but documentary compliance is critical.
Difference
LC ≠ advance payment
With advance payment, seller receives funds before shipment.
With an LC, payment depends on the LC’s terms and compliant presentation.
PART IV — COMMERCIAL TERMS
- MOQ
Full Form: Minimum Order Quantity
Meaning
Smallest quantity a manufacturer/supplier agrees to supply or produce.
Example
MOQ = 10,000 tablets
Importance
Affects:
- working capital
- production economics
- packaging
- private-label viability
- inventory risk
Difference
MOQ → minimum quantity
Lead Time → time required
- OEM
Full Form: Original Equipment Manufacturer
Pharma context
A pharmaceutical manufacturer produces a product according to an agreed arrangement/specification for another company.
Importance
Useful when an exporter wants products manufactured under its own commercial brand or customer’s requirements.
- ODM
Full Form: Original Design Manufacturer
Meaning
An organization that may provide product design/development together with manufacturing.
Difference
OEM → manufacturing focus
ODM → design/development + manufacturing
The terminology is less standardized in pharmaceuticals than in electronics, so contracts should clearly define responsibilities.
- Private Label
Meaning
A product manufactured by one company and sold under another company’s brand.
Example
Manufacturer:
ABC Pharma Pvt. Ltd.
Brand:
NAWINZA
The commercial arrangement may be private-label manufacturing, subject to regulatory/legal requirements.
Important
Private labelling does not eliminate regulatory responsibilities.
- Contract Manufacturing
Meaning
A manufacturer produces pharmaceutical products for another company under a contractual arrangement.
Importance
Allows a company to enter markets without owning a complete manufacturing facility.
- CMO
Full Form: Contract Manufacturing Organization
Meaning
Organization providing manufacturing services to another company.
- CDMO
Full Form: Contract Development and Manufacturing Organization
Meaning
Organization providing development and manufacturing services.
Difference
CMO → primarily manufacturing
CDMO → development + manufacturing
- Distributor
Meaning
A company that purchases/receives pharmaceutical products and distributes them within a market or territory.
Importance
Often becomes the key commercial partner in foreign markets.
- Importer
Meaning
Entity responsible for importing goods into the destination country.
Importance
The importer may need:
- import authorization
- establishment authorization
- product registration
- customs capability
- storage/distribution authorization
depending on the jurisdiction.
- Wholesaler
Meaning
Business involved in buying and selling products in wholesale quantities.
Difference
Importer → brings goods into country
Wholesaler → sells/distributes in wholesale channel
One company can legally perform both functions where authorized.
- Stockist
Meaning
A business that holds pharmaceutical inventory for onward distribution.
Difference
A stockist is primarily characterized by its inventory/distribution role, while an importer is characterized by its import role.
- Tender
Meaning
Formal competitive procurement process.
Common buyers
- governments
- hospitals
- public procurement agencies
- international organizations
- large healthcare groups
Importance
Tender business can involve large volumes but generally has strict:
- technical specifications
- registration requirements
- pricing requirements
- documentation
- delivery conditions
- RFQ
Full Form: Request for Quotation
Meaning
Buyer asks suppliers to provide pricing and commercial terms.
Typical RFQ information
- product
- strength
- dosage form
- quantity
- destination
- packaging
- Incoterm
- required documents
- RFP
Full Form: Request for Proposal
Difference from RFQ
RFQ → mainly asks “What is your price/quotation?”
RFP → asks for a broader technical + commercial proposal.
- NDA
This abbreviation has two important meanings.
Pharmaceutical regulatory meaning
New Drug Application
Used particularly in the U.S. regulatory system.
Commercial/legal meaning
Non-Disclosure Agreement
Contract protecting confidential information.
Important rule
Never write simply “NDA” in a document where ambiguity is possible.
Write:
NDA — New Drug Application
or
NDA — Non-Disclosure Agreement
PART V — INCOTERMS & SHIPPING
- Incoterms®
Meaning: International Commercial Terms
Meaning
Incoterms are standardized international trade rules published by the International Chamber of Commerce.
They establish important responsibilities regarding:
- delivery
- costs
- risks
- transport
- insurance in specified terms
- customs responsibilities
Critical point
Incoterms do not by themselves determine:
- ownership/title transfer in every transaction
- payment terms
- product registration
- pharmaceutical regulatory authorization
- EXW
Full Form: Ex Works
Meaning
Seller makes goods available at the named place, generally with relatively limited seller responsibility for transportation.
Exporter consideration
Although commercially attractive for the seller, EXW can create practical difficulties where the buyer is expected to handle export formalities from another country.
- FCA
Full Form: Free Carrier
Meaning
Seller delivers goods to the carrier/person at the agreed place under the applicable Incoterms rule.
Use
Often useful where organized international transport is handled by the buyer.
- FOB
Full Form: Free On Board
Meaning
Under FOB, seller delivers goods on board the vessel at the named port of shipment, with risk transfer according to the Incoterms rule.
Important
FOB is designed for sea/inland waterway transport, not as a generic term for every shipment.
- CFR
Full Form: Cost and Freight
Meaning
Seller pays cost and freight to the named port of destination, with risk transferring according to the applicable Incoterms rule.
Difference from CIF
CIF additionally includes insurance arranged by the seller under the Incoterms rule.
- CIF
Full Form: Cost, Insurance and Freight
Meaning
Seller arranges cost, freight and the required insurance to the named port of destination according to the applicable Incoterms rule.
Difference
CFR = Cost + Freight
CIF = Cost + Insurance + Freight
- CPT
Full Form: Carriage Paid To
Meaning
Seller pays carriage to the named destination.
Difference from CIP
CIP additionally requires seller-arranged insurance according to the applicable Incoterms rule.
- CIP
Full Form: Carriage and Insurance Paid To
Meaning
Seller pays carriage and arranges insurance to the named destination according to the applicable Incoterms rule.
- DAP
Full Form: Delivered at Place
Meaning
Seller delivers goods to the named destination, ready for unloading.
Difference from DDP
Under DAP, import clearance/duties generally remain with the buyer.
- DPU
Full Form: Delivered at Place Unloaded
Meaning
Seller delivers and unloads goods at the named destination.
Difference
DAP → ready for unloading
DPU → unloaded
- DDP
Full Form: Delivered Duty Paid
Meaning
Seller assumes extensive responsibilities, including import formalities/duties where legally possible under the applicable rule.
Important pharma-export warning
DDP should not be selected casually for pharmaceutical exports because import-country regulatory and tax responsibilities may require the importer or locally established entity to perform certain functions.
PART VI — QUALITY
- QA
Full Form: Quality Assurance
Meaning
The overall system ensuring quality is built into pharmaceutical operations.
Focus
Prevention and systems.
- QC
Full Form: Quality Control
Meaning
Testing and analytical activities used to determine whether materials/products meet specifications.
Focus
Testing and verification.
Key difference
QA builds the quality system. QC tests the product/material against requirements.
- GMP
Full Form: Good Manufacturing Practice
Meaning
Requirements governing pharmaceutical manufacturing and quality systems.
Core objective
Ensure medicines are consistently:
- manufactured
- controlled
- documented
- tested
- stored
according to applicable requirements.
- cGMP
Full Form: Current Good Manufacturing Practice
Meaning
Emphasizes compliance with currently applicable GMP requirements.
Difference
GMP is the general concept.
cGMP is particularly common in U.S. regulatory terminology emphasizing current requirements.
- GLP
Full Form: Good Laboratory Practice
Meaning
Quality system principles for certain nonclinical laboratory studies.
Difference
GLP → laboratory/nonclinical studies
GCP → clinical trials
GMP → manufacturing
- GCP
Full Form: Good Clinical Practice
Meaning
International ethical and scientific quality standards for clinical trials involving human participants.
- GDP
Full Form: Good Distribution Practice
Meaning
Requirements governing proper distribution and handling of medicinal products.
Focus
- storage
- transportation
- traceability
- handling
- distribution quality
Important
In a pharmaceutical context:
GDP = Good Distribution Practice
not Gross Domestic Product.
- GSP
Full Form: Good Storage Practice
Meaning
Principles governing proper storage conditions for pharmaceutical products.
Difference
GSP → storage
GDP → broader distribution chain
- SOP
Full Form: Standard Operating Procedure
Meaning
Controlled written procedure describing how a particular activity must be performed.
Example
- warehouse SOP
- sampling SOP
- deviation SOP
- export documentation SOP
- CAPA
Full Form: Corrective and Preventive Action
Meaning
System for:
Corrective Action → fixing the existing problem
Preventive Action → preventing recurrence/potential recurrence
Example
Repeated packaging errors:
- identify root cause
- correct affected process
- implement preventive controls
- monitor effectiveness
- OOS
Full Form: Out of Specification
Meaning
A test result falls outside an approved specification.
Example
Specification:
Assay: 95–105%
Actual result:
92%
This may constitute an OOS result requiring formal investigation.
- OOT
Full Form: Out of Trend
Meaning
A result may remain within specification but shows an unusual or unexpected trend.
Difference
OOS → outside specification
OOT → potentially abnormal trend even within specification
- Deviation
Meaning
Departure from an approved procedure, specification, process or expected condition.
Example
A manufacturing step was performed outside the approved time range.
- Change Control
Meaning
Formal process for evaluating and approving changes before implementation.
Examples
- supplier change
- equipment change
- manufacturing-site change
- formulation change
- packaging change
Difference
Deviation → something departed from approved procedure.
Change control → planned/proposed change is evaluated before implementation.
- Validation
Meaning
Documented evidence demonstrating that a process/system consistently produces the intended result.
Difference from qualification
Qualification → equipment/system/facility
Validation → process/method/system performance
The terms can overlap depending on the context, so the applicable regulatory framework should be followed.
- Cleaning Validation
Meaning
Evidence that cleaning procedures consistently remove residues/contaminants to predetermined acceptable levels.
Importance
Critical for preventing:
- cross-contamination
- carryover
- microbial contamination
- Process Validation
Meaning
Evidence that a manufacturing process consistently produces product meeting predetermined requirements.
- BMR
Full Form: Batch Manufacturing Record
Meaning
Batch-specific documentation showing how a particular batch was manufactured.
Importance
Provides traceability of:
- materials
- equipment
- manufacturing steps
- quantities
- operators
- in-process checks
- BPR
Full Form: Batch Packaging Record
Meaning
Batch-specific documentation describing packaging operations.
- MFR
Full Form: Master Formula Record
Meaning
Approved master manufacturing instructions/formula for producing a pharmaceutical product.
- MBR
Full Form: Master Batch Record
Meaning
Master document containing approved instructions and requirements for batch manufacture.
Important
Terminology can vary between companies and regulatory systems. Your book should define the company’s/regulator’s specific usage when applicable.
PART VII — MEDICINE TERMINOLOGY
- API
Full Form: Active Pharmaceutical Ingredient
Meaning
The pharmacologically active substance responsible for the intended therapeutic effect.
Example
In a tablet containing paracetamol:
Paracetamol = API
Other ingredients are generally excipients.
- FDF
Full Form: Finished Dosage Form
Meaning
Final pharmaceutical dosage form presented for use.
Examples
- tablet
- capsule
- injection
- cream
- oral solution
- FPP
Full Form: Finished Pharmaceutical Product
Meaning
Finished pharmaceutical product containing the active pharmaceutical ingredient(s) together with appropriate excipients and presented in its final form.
Difference
API → active substance
FPP/FDF → finished medicine
- Generic Medicine
Meaning
A medicine that follows the relevant regulatory requirements for a generic product and is generally associated with the same active substance as a reference product.
Important
“Generic” does not mean:
“unregulated” or “lower quality.”
A legally approved generic must satisfy the applicable quality and regulatory requirements.
- Branded Generic
Meaning
A generic medicine marketed under a proprietary brand/trade name.
Example
Instead of marketing only by generic name, a company sells the product under its own brand.
- Innovator Product
Meaning
Original/reference medicinal product developed and brought to market by the innovator company.
Difference
Innovator → original/reference product
Generic → subsequent product using the relevant regulatory pathway
- Reference Product
Meaning
Product used as the comparator/reference in a regulatory pathway.
Importance
Particularly important in generic and bioequivalence development.
- Biosimilar
Meaning
A biological medicinal product demonstrated to be highly similar to a reference biological product, with no clinically meaningful differences in the relevant aspects under the applicable regulatory framework.
Difference
Generic → generally small-molecule pharmaceutical products
Biosimilar → biological products
- Biologic
Meaning
Medicinal product derived from biological sources.
Examples
Depending on regulatory classification:
- monoclonal antibodies
- recombinant proteins
- vaccines
- certain blood-derived products
- Excipient
Meaning
Ingredient other than the API used to formulate the medicine.
Functions
- tablet formation
- stability
- taste
- dissolution
- preservation
- colour
- delivery
- Salt
Meaning
A particular chemical form of an active substance created by combining it with an appropriate counter-ion.
Example
A medicine may contain:
Drug X hydrochloride
rather than the free-base form.
Export importance
The exact salt can affect:
- product identity
- specifications
- regulatory registration
- HS classification
- formulation
- documentation
- Strength
Meaning
Amount/concentration of active ingredient in a defined dosage unit or volume.
Example
Paracetamol 500 mg tablet
500 mg = strength per tablet.
Difference
Strength ≠ dosage
Strength is what the product contains per unit.
Dosage is how much/how often the patient takes it.
- Dosage Form
Meaning
Physical pharmaceutical form.
Examples
- tablet
- capsule
- injection
- cream
- ointment
- syrup
- suspension
- eye drops
- Route of Administration
Meaning
How a medicine is administered.
Examples
- oral
- intravenous
- intramuscular
- subcutaneous
- topical
- ophthalmic
- inhalation
Importance
The same API can have different regulatory and clinical characteristics depending on its route.
- Indication
Meaning
The disease/condition or therapeutic purpose for which a medicine is authorized or recommended.
Example
A medicine may be indicated for:
hypertension
or
type 2 diabetes
depending on its authorized use.
- Contraindication
Meaning
A circumstance in which a medicine should not be used because the potential risk is unacceptable.
Difference
Indication → when to use
Contraindication → when not to use
- Drug Class
Meaning
Group of medicines categorized according to pharmacological/chemical characteristics.
Example
ACE inhibitors, beta blockers, statins, etc.
- Therapeutic Class
Meaning
Classification according to the therapeutic condition or purpose.
Example
Antihypertensive medicines.
- Pharmacological Class
Meaning
Classification based primarily on pharmacological action/mechanism.
Important distinction
Therapeutic class → what condition it treats
Pharmacological class → how it acts/group of pharmacological action
- Rx
Meaning: Prescription medicine / prescription status
Meaning
Indicates that supply/use is subject to prescription requirements under the relevant jurisdiction.
Important
Rx status differs between countries.
- OTC
Full Form: Over-the-Counter
Meaning
Medicine that can be obtained without a prescription under the applicable country’s legal framework.
Important
A product may be OTC in one country and prescription-only in another.
- Controlled Substance
Meaning
A substance subject to special legal controls because of risks such as abuse, dependence, diversion or public-health concerns.
Critical difference
Prescription-only ≠ automatically controlled substance.
A controlled substance normally has an additional layer of legal control.
PART VIII — INTERNATIONAL REGULATORY AUTHORITIES
- FDA
Full Form: U.S. Food and Drug Administration
Role
U.S. federal regulator responsible for numerous products, including human drugs and biologics.
Pharma relevance
FDA regulates areas including:
- drug approval
- manufacturing
- labelling
- safety
- quality
- establishment requirements
- imports
Difference
FDA is the U.S. regulator; CDSCO is India’s principal central drug regulator.
- CDER
Full Form: Center for Drug Evaluation and Research
Meaning
FDA center primarily responsible for human drug evaluation and regulation.
Difference
FDA → overall agency
CDER → FDA center focused primarily on drugs
- CBER
Full Form: Center for Biologics Evaluation and Research
Meaning
FDA center responsible for many biological products.
Difference
CDER → many drugs
CBER → many biological products
The precise regulatory division depends on the product.
- DEA
Full Form: Drug Enforcement Administration
Meaning
U.S. federal agency responsible for enforcement relating to controlled substances.
Pharma relevance
Relevant when products/substances fall under U.S. controlled-substance laws.
Critical distinction
FDA approval does not mean DEA authorization where controlled-substance requirements apply.
- MHRA
Full Form: Medicines and Healthcare products Regulatory Agency
Country
United Kingdom.
Role
Regulates medicines, medical devices and other healthcare products within its statutory responsibilities.
- EMA
Full Form: European Medicines Agency
Region
European Union.
Role
Scientific/regulatory role within the EU medicines system.
Important
EMA is not simply the “FDA of Europe.”
The EU regulatory system involves:
- EMA
- European Commission
- national competent authorities
with different responsibilities.
- PMDA
Full Form: Pharmaceuticals and Medical Devices Agency
Country
Japan.
Role
Japan’s regulatory system includes PMDA and the Ministry of Health, Labour and Welfare.
- MHLW
Full Form: Ministry of Health, Labour and Welfare
Country
Japan.
Difference
PMDA → scientific/review/assessment functions
MHLW → governmental regulatory decision/policy functions
The exact division depends on the regulatory process.
- TGA
Full Form: Therapeutic Goods Administration
Country
Australia.
Role
Australian regulator for therapeutic goods.
Pharma relevance
Medicines may need appropriate Australian regulatory authorization/listing/registration depending on product classification.
- Health Canada
Meaning
Federal Canadian health regulator responsible for regulation of medicines and other health products.
Important Canadian term
DIN — Drug Identification Number
This should be added to your final glossary because it is important in the Canadian pharmaceutical market.
- ANVISA
Full Form: Agência Nacional de Vigilância Sanitária
Country
Brazil.
Role
Brazilian health regulatory authority.
Pharma relevance
Brazil has significant pharmaceutical registration and local regulatory requirements.
- SAHPRA
Full Form: South African Health Products Regulatory Authority
Country
South Africa.
Role
Regulates medicines and other health products.
- NAFDAC
Full Form: National Agency for Food and Drug Administration and Control
Country
Nigeria.
Pharma relevance
Important authority for pharmaceutical product registration and related regulatory requirements in Nigeria.
- PPB
Full Form: Pharmacy and Poisons Board
Country
Kenya.
Role
Regulatory authority for medicines/pharmaceutical products and related matters.
- TMDA
Full Form: Tanzania Medicines and Medical Devices Authority
Country
Tanzania.
- SFDA
Full Form: Saudi Food and Drug Authority
Country
Saudi Arabia.
Pharma relevance
Important for pharmaceutical registration, importation and related regulatory controls in Saudi Arabia.
- EDE
Full Form: Emirates Drug Establishment
Country
United Arab Emirates.
Importance
Important UAE federal pharmaceutical regulatory institution.
Note
UAE regulatory structures and responsibilities should always be checked against the current authority and product-specific pathway when your book is updated.
- DGDA
Full Form: Directorate General of Drug Administration
Country
Bangladesh.
- BPOM
Meaning: Indonesia’s Food and Drug Authority
Country
Indonesia.
Pharma relevance
Responsible for regulatory oversight of medicines and other regulated products.
- NPRA
Full Form: National Pharmaceutical Regulatory Agency
Country
Malaysia.
- FDA Philippines
Full Form: Food and Drug Administration
Country
Philippines.
- DAV
Full Form: Drug Administration of Vietnam
Country
Vietnam.
- Medsafe
Meaning: New Zealand’s medicines and medical devices safety/regulatory authority within the Ministry of Health framework.
Country
New Zealand.
PART IX — DRUG DEVELOPMENT & REGULATORY APPLICATIONS
- IND
Full Form: Investigational New Drug
Meaning
In the U.S., IND refers to the regulatory framework/application allowing investigation of a drug in humans, subject to applicable requirements.
Importance
Relevant primarily to clinical development rather than routine commercial export.
- NDA
Full Form: New Drug Application
Meaning
U.S. application for approval to market a new drug.
Difference
IND → investigate
NDA → seek marketing approval
- ANDA
Full Form: Abbreviated New Drug Application
Meaning
U.S. application pathway for qualifying generic drugs.
Difference
NDA → generally new drug approval pathway
ANDA → qualifying generic drug pathway
- BLA
Full Form: Biologics License Application
Meaning
U.S. application seeking approval for specified biological products.
Difference
ANDA → generic-drug pathway
BLA → biological products covered by the BLA framework
- CTD
Full Form: Common Technical Document
Meaning
Internationally harmonized format for organizing pharmaceutical regulatory information.
Five modules
- Administrative information
- Summaries
- Quality
- Nonclinical
- Clinical
Importance
Allows regulatory dossiers to be organized consistently across participating markets.
- eCTD
Full Form: Electronic Common Technical Document
Meaning
Electronic implementation of CTD submission architecture.
Difference
CTD → content/structure
eCTD → electronic submission format/technical framework
- ACTD
Full Form: ASEAN Common Technical Dossier
Meaning
Common technical dossier structure used in ASEAN regulatory submissions.
Importance
Particularly relevant to pharmaceutical registration in ASEAN markets.
- CMC
Full Form: Chemistry, Manufacturing and Controls
Meaning
Technical information describing:
- composition
- manufacturing process
- specifications
- analytical controls
- quality
- stability
- manufacturing consistency
Importance
CMC is central to demonstrating pharmaceutical product quality.
- CRO
Full Form: Contract Research Organization
Meaning
External organization contracted to perform research/clinical development services.
Difference
CRO → research
CMO → manufacturing
CDMO → development + manufacturing
- RLD
Full Form: Reference Listed Drug
Meaning
FDA terminology referring to the reference product used in certain generic drug approval pathways.
- NDC
Full Form: National Drug Code
Country
United States.
Meaning
FDA-associated product identification system/code structure for marketed drugs.
Important
NDC is not the same as FDA approval.
- Orange Book
Full Name: Approved Drug Products with Therapeutic Equivalence Evaluations
Meaning
FDA publication/database containing information about approved drug products and therapeutic-equivalence evaluations.
Importance
Important for understanding U.S. generic-drug regulatory relationships.
- Purple Book
Meaning
FDA resource containing information on licensed biological products, including relevant biosimilar/interchangeability information.
Difference
Orange Book → certain drug products
Purple Book → biological products
- PDUFA
Full Form: Prescription Drug User Fee Act
Meaning
U.S. legislation establishing user-fee mechanisms supporting FDA review activities for certain prescription drug applications.
- GDUFA
Full Form: Generic Drug User Fee Amendments
Meaning
U.S. user-fee framework associated with generic-drug application review.
PART X — PHARMACOVIGILANCE & SAFETY
- PV
Full Form: Pharmacovigilance
Meaning
System for monitoring medicine safety.
- AE
Full Form: Adverse Event
Meaning
Any untoward medical occurrence associated with use of a medicine, without necessarily establishing causation.
Important
AE does not automatically mean the medicine caused the event.
- ADR
Full Form: Adverse Drug Reaction
Meaning
A harmful/unintended response to a medicinal product where a causal relationship is at least a reasonable possibility under the applicable definition.
Difference
AE → occurrence associated with medicine use
ADR → stronger causal relationship concept
- SAE
Full Form: Serious Adverse Event
Meaning
An adverse event meeting defined seriousness criteria.
Important
Serious ≠ severe.
“Serious” is a regulatory classification; “severe” describes intensity.
- SUSAR
Full Form: Suspected Unexpected Serious Adverse Reaction
Meaning
A suspected adverse reaction that is:
- serious
- unexpected
- associated with a medicinal product
according to the applicable clinical-trial regulatory definitions.
- PSUR
Full Form: Periodic Safety Update Report
Meaning
Periodic regulatory safety report evaluating safety information and benefit-risk balance.
- PBRER
Full Form: Periodic Benefit-Risk Evaluation Report
Meaning
ICH-based periodic report assessing cumulative safety and benefit-risk information.
Difference
PSUR and PBRER are closely related regulatory safety-reporting concepts, with PBRER representing the harmonized ICH approach.
- RMP
Full Form: Risk Management Plan
Meaning
Document describing known/potential risks and planned activities to monitor/manage those risks.
- DSUR
Full Form: Development Safety Update Report
Meaning
Periodic safety report used during clinical development.
Difference
DSUR → development/clinical-trial stage
PBRER/PSUR → generally post-authorization safety reporting
- Signal Detection
Meaning
Process of identifying information that may indicate a new or changed safety concern.
Example
Unexpected pattern of adverse-event reports.
- Post-Marketing Surveillance
Meaning
Monitoring medicine safety, quality and performance after commercialization.
Importance
Regulatory responsibility does not necessarily end after product approval.
PART XI — PHARMACOPOEIA & STANDARDS
- IP
Full Form: Indian Pharmacopoeia
Meaning
Official pharmacopoeial standards applicable in India for relevant pharmaceutical substances/products.
- USP
Full Form: United States Pharmacopeia
Country
United States.
Importance
Contains recognized pharmaceutical quality standards/monographs.
- BP
Full Form: British Pharmacopoeia
Country
United Kingdom.
- Ph. Eur.
Full Form: European Pharmacopoeia
Region
Europe.
Difference
Ph. Eur. is the standard abbreviation for European Pharmacopoeia.
- EP
Meaning: European Pharmacopoeia
Important
In professional regulatory writing, Ph. Eur. is generally the clearer abbreviation for European Pharmacopoeia.
- JP
Full Form: Japanese Pharmacopoeia
Country
Japan.
- NF
Full Form: National Formulary
Importance
In pharmaceutical contexts, NF is particularly associated with the U.S. compendial system and should not be confused with an arbitrary national formulary in another country.
- WHO
Full Form: World Health Organization
Pharma relevance
WHO develops international standards, guidance and frameworks relevant to medicines, quality, public health and pharmaceutical regulation.
- ICH
Full Form: International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use
Importance
ICH develops harmonized technical guidelines covering areas such as:
- quality
- safety
- efficacy
- multidisciplinary regulatory topics
- ISO
Full Form: International Organization for Standardization
Meaning
International standards organization.
Important
ISO certification is not automatically equivalent to pharmaceutical GMP approval.
- PIC/S
Full Form: Pharmaceutical Inspection Co-operation Scheme
Meaning
International cooperation framework among participating pharmaceutical inspectorates.
Importance
Promotes harmonized GMP inspection and standards.
- ASTM
Full Form: ASTM International
Meaning
International standards organization developing technical standards across numerous industries.
Important
An ASTM standard should not automatically be described as a pharmaceutical regulatory approval.
- Monograph
Meaning
An official or recognized specification describing requirements for a particular substance/product.
Typically includes
- identity
- purity
- assay
- tests
- impurities
- analytical requirements
- Reference Standard
Meaning
A material of established quality used as a benchmark for analytical testing.
Example
A laboratory may compare a sample against a qualified reference standard.
PART XII — API & RAW MATERIAL TERMINOLOGY
- KSM
Full Form: Key Starting Material
Meaning
Important starting material used in API manufacturing.
Importance
Its control and qualification can affect API quality and regulatory compliance.
- Starting Material
Meaning
Material introduced into the manufacturing process at a defined stage.
Difference
A starting material is not necessarily the same thing as an API or finished product.
- Intermediate
Meaning
Material produced during a manufacturing process and subsequently processed further.
- Assay
Meaning
Quantitative determination of the amount/content of a specified substance.
Example
API assay:
99.2%
This indicates measured content according to the applicable analytical method.
- Purity
Meaning
Degree to which a substance is free from unwanted substances/impurities.
Difference
Assay → quantity of specified substance
Purity → broader assessment of absence/level of unwanted components
- Residual Solvent
Meaning
Solvent remaining in a pharmaceutical material after manufacturing.
Importance
Residual solvents must be appropriately controlled according to applicable quality standards.
- Elemental Impurity
Meaning
Unwanted elemental/metallic substances present in pharmaceutical materials/products.
Importance
Certain elements may pose toxicity risks and require risk-based control.
- Nitrosamine
Meaning
A class of compounds that has received significant pharmaceutical regulatory attention because some nitrosamines can pose carcinogenic risks.
Importance
Risk assessment and control may be required for affected products/processes.
- Genotoxic Impurity
Meaning
Impurity with potential to damage genetic material.
Importance
Such impurities can require particularly stringent assessment and control.
- Retest Date
Meaning
Date by which an API/material should be retested to confirm it continues to meet specifications, where applicable.
Difference
Expiry date → generally associated with finished product
Retest date → commonly associated with APIs/raw materials
PART XIII — REGULATORY DOSSIER
- Module 1
Meaning
Administrative and region-specific information.
May include
- application forms
- legal information
- labelling
- administrative documents
- Module 2
Meaning
CTD summaries and overviews.
- Module 3
Meaning
Quality information.
Major content
- API
- formulation
- manufacturing
- specifications
- analytical methods
- validation
- stability
- Module 4
Meaning
Nonclinical information.
Examples
- pharmacology
- toxicology
- Module 5
Meaning
Clinical information.
Examples
- clinical studies
- efficacy
- safety
- bioequivalence studies where applicable
PART XIV — BUYER, SUPPLIER & CONTRACT TERMINOLOGY
- Manufacturer
Meaning
Entity that actually manufactures the pharmaceutical product.
Important
Do not assume that every “supplier” is the manufacturer.
- Supplier
Meaning
Entity that supplies the product/material.
Difference
Manufacturer → makes product
Supplier/trader → may purchase and resell
- Trader
Meaning
Commercial intermediary that buys and sells products.
Importance
A trader may not own the manufacturing facility.
Due diligence
For pharma exports, verify:
- actual manufacturer
- manufacturing licence
- GMP status
- product authorization
- supply chain
- documentation
- Exporter
Meaning
Entity exporting goods from the origin country.
Important
Exporter and manufacturer can be different companies.
- Importer
Meaning
Entity bringing the product into the destination country.
Important
The importer often has country-specific legal/regulatory responsibilities.
- Agent
Meaning
Representative acting on behalf of another party.
Difference
Agent → represents
Distributor → normally purchases/distributes
The actual contractual structure determines the legal relationship.
- Principal
Meaning
The company on whose behalf an agent/distributor acts.
- NDA — Non-Disclosure Agreement
Meaning
Legal agreement protecting confidential information.
Pharma use
Can cover:
- formulation
- pricing
- customer information
- manufacturing information
- regulatory documents
- business plans
- MOU
Full Form: Memorandum of Understanding
Meaning
Document recording an understanding between parties.
Important
An MOU is not automatically a legally binding commercial contract in every respect. Its legal effect depends on its wording and applicable law.
- SLA
Full Form: Service Level Agreement
Meaning
Agreement defining service expectations and performance standards.
Example
A logistics provider may commit to defined delivery or reporting standards.
PART XV — FINANCE & PAYMENT
- TT
Full Form: Telegraphic Transfer
Meaning
Electronic bank transfer.
Common pharma-export practice
- 100% advance
- partial advance + balance before shipment
- other negotiated arrangements
The actual terms depend on commercial risk.
- DP
Full Form: Documents Against Payment
Meaning
Banking arrangement where documents are released against payment according to the agreed collection terms.
- DA
Full Form: Documents Against Acceptance
Meaning
Documents are released against buyer’s acceptance of a time draft/bill under the applicable collection arrangement.
Difference
DP → payment
DA → acceptance/credit arrangement
- CAD
Full Form: Cash Against Documents
Meaning
Commercial/banking expression referring to payment against presentation/release of documents, with exact structure defined by the transaction.
- Open Account
Meaning
Exporter ships goods and buyer pays later according to agreed credit terms.
Risk
Higher seller credit exposure than advance payment.
- Landed Cost
Meaning
Total cost of getting the product to the relevant destination, including applicable costs such as:
- product cost
- freight
- insurance
- duties
- taxes
- handling
- clearance
- other charges
Importance
A product can have a low FOB price but a high landed cost.
- COGS
Full Form: Cost of Goods Sold
Meaning
Direct costs associated with products sold.
- Gross Profit
Formula
Gross Profit = Sales Revenue − COGS
- Gross Margin
Formula
Gross Margin % = Gross Profit ÷ Sales Revenue × 100
Example
Sales = ₹10 lakh
COGS = ₹7 lakh
Gross Profit = ₹3 lakh
Gross Margin = 30%
- ROI
Full Form: Return on Investment
Meaning
Measures return relative to investment.
Importance
A pharmaceutical export business should not evaluate an opportunity only on sales value.
Also examine:
- margin
- working capital
- regulatory cost
- registration cost
- inventory
- payment risk
- logistics
- buyer risk
PART XVI — IMPORTANT DISTINCTIONS EVERY PHARMA EXPORTER MUST UNDERSTAND
- Approved vs Registered
Approved
A regulator has formally evaluated/authorized something under its legal framework.
Registered
A product/company/site has been entered into the applicable regulatory registration system.
Important
The exact meaning differs between jurisdictions.
Do not automatically treat “registered” and “approved” as identical legal terms.
- Permitted vs Approved
Permitted
An activity/product may legally be allowed under a particular condition.
Approved
A specific regulatory authorization has been granted.
Example
A product might be legally importable under certain circumstances but still not be authorized for commercial marketing.
- Restricted vs Banned
Restricted
Allowed subject to specified conditions.
Examples could include:
- licence
- quantity limit
- approved importer
- special documentation
- controlled-substance authorization
Banned
Prohibited by law for the relevant activity/use.
Critical rule
Never write “BANNED” in the Nawinza medicine database merely because a product is not approved or because registration is difficult.
Use the correct status:
- Not approved
- Registration required
- Restricted
- Controlled
- Not authorized for specified use
- Prohibited
- Product-specific review required
- Prescription vs Controlled
These are not the same.
Prescription
Requires a prescription.
Controlled
Subject to special legal controls.
A medicine can be:
Prescription-only but not controlled.
Some controlled medicines may also be prescription medicines, but the concepts remain distinct.
- GMP vs GMP Certificate
GMP
The quality/manufacturing standard.
GMP Certificate
Evidence issued/recognized by an appropriate authority/body regarding compliance with applicable GMP requirements.
- QA vs QC
QA | QC |
Quality Assurance | Quality Control |
System-oriented | Testing-oriented |
Prevention | Detection/verification |
Processes | Materials/products/test results |
Builds quality system | Checks conformity |
- OOS vs OOT
OOS | OOT |
Out of Specification | Out of Trend |
Result outside approved specification | Unexpected trend |
Clear specification failure | May still be within specification |
Formal investigation generally required | Trend evaluation/investigation may be required |
- CAPA vs Change Control
CAPA
Used to correct/prevent problems.
Change Control
Used to evaluate and control planned changes.
Example
Repeated tablet weight deviation:
Investigation → Root cause → CAPA
Changing manufacturing equipment:
Change Control
- DMF vs Regulatory Dossier
DMF
Focused confidential technical information.
Regulatory Dossier
Complete submission for regulatory approval/registration.
Relationship
A DMF can support a regulatory dossier without being the entire dossier.
- API vs FPP
API
Active ingredient.
FPP
Finished medicine.
Supply chain
API manufacturer → formulation manufacturer → finished product → exporter → importer/distributor → market
- Generic vs Branded Generic
Generic
Usually marketed using generic/non-proprietary name, depending on market.
Branded Generic
Generic product marketed under a proprietary brand.
Export importance
A branded generic strategy may require:
- trademark
- brand registration
- product registration
- local marketing authorization
- labelling compliance
- Manufacturer vs Supplier
Manufacturer
Actually produces the product.
Supplier
Provides the product.
Critical due-diligence question
“Are you the actual manufacturer? If not, who is the licensed manufacturer?”
This question is particularly important when sourcing from online B2B platforms.
- OEM vs Private Label
These terms overlap in commercial practice but are not identical.
OEM
Focuses on manufacturing according to another company’s requirements.
Private Label
Focuses on selling the manufactured product under another company’s brand.
A single pharmaceutical arrangement can therefore involve:
OEM manufacturing + Private Label branding.
- FOB vs CIF
FOB
Seller delivers goods on board vessel at named port of shipment.
CIF
Seller also arranges cost, freight and insurance to named destination port under the applicable rule.
Commercial consequence
CIF generally produces a higher seller quotation than FOB because additional transport/insurance costs are included.
- CIF vs CFR
CFR
Cost + Freight.
CIF
Cost + Freight + Insurance.
- DAP vs DDP
DAP
Seller delivers to destination; buyer generally handles import clearance/duties.
DDP
Seller takes on extensive import responsibilities, including duties, subject to legal feasibility.
Pharma caution
DDP can be problematic if the exporter cannot legally act as importer of record or perform required local regulatory obligations.
- COA vs CPP vs COO
Document | Main purpose |
COA | Batch/product analytical quality |
CPP/COPP | Pharmaceutical regulatory/product information |
COO | Country of origin |
These documents cannot normally substitute for one another.
- CPP vs GMP Certificate
CPP
Information about the pharmaceutical product and its regulatory/manufacturing status under the applicable certification scheme.
GMP Certificate
Evidence regarding GMP compliance of a manufacturing site.
- CFS vs CPP
CFS/FSC
Evidence concerning free/legal sale or marketing status, depending on issuing authority.
CPP
Pharmaceutical product certificate used for regulatory purposes.
- IND vs NDA vs ANDA
Term | Main purpose |
IND | Clinical investigation |
NDA | New drug marketing application |
ANDA | Qualifying generic drug application |
Think:
IND → Investigate
NDA → New drug approval
ANDA → Generic approval
- NDA vs BLA
NDA
Application for drugs within the NDA framework.
BLA
Application for biological products covered by the BLA framework.
- CTD vs eCTD
CTD
Common technical dossier structure.
eCTD
Electronic technical submission implementation.
- GMP vs GDP vs GSP
Term | Focus |
GMP | Manufacturing |
GDP | Distribution |
GSP | Storage |
- GLP vs GCP vs GMP
Term | Area |
GLP | Certain nonclinical laboratory studies |
GCP | Clinical trials |
GMP | Manufacturing |
- Pharmacovigilance vs Quality Control
Pharmacovigilance
Focuses primarily on medicine safety and risk after/during development and commercialization.
QC
Focuses on analytical/product/material quality testing.
- Recall vs Withdrawal
Recall
Removal of product because of an identified problem/risk, generally under a controlled corrective process.
Withdrawal
A broader term that can refer to removing/suspending a product from the market for various reasons.
The exact legal distinction depends on the jurisdiction.
- Importer vs Distributor
Importer
Legally brings product into the country.
Distributor
Distributes product within the market.
One company can potentially perform both roles if appropriately authorized.
- Wholesaler vs Stockist
Wholesaler
Commercial wholesale seller.
Stockist
Entity primarily characterized by holding inventory for distribution.
The terminology varies by market.
- RFQ vs RFP
RFQ
Primarily asks for price/quotation.
RFP
Requests a broader technical and commercial proposal.
- PO vs PI
PO
Issued by buyer.
PI
Issued by seller.
- Advance Payment vs LC
Advance
Seller receives money before shipment/production as agreed.
LC
Payment depends on compliance with the LC’s terms and documentary conditions.
- B/L vs AWB
B/L
Primarily sea freight.
AWB
Air freight.
- HS Code vs HSN
HS Code
International harmonized classification concept.
HSN
Harmonized System of Nomenclature terminology commonly used in India.
- PHARMEXCIL vs CDSCO
PHARMEXCIL
Export promotion/trade support.
CDSCO
Drug regulatory authority.
- DGFT vs CDSCO
DGFT
Foreign trade.
CDSCO
Drugs/regulatory control.
Example
For an Indian pharmaceutical export:
DGFT/Customs side
→ Can the goods legally be exported and properly declared?
Drug regulatory side
→ Does the product/manufacturer satisfy applicable pharmaceutical requirements?
Destination regulator
→ Can the product legally be imported/marketed there?
All three questions can matter.
PART XVII — A PROFESSIONAL WAY TO THINK ABOUT PHARMA EXPORT
For every medicine that Nawinza evaluates for export, use this sequence:
STEP 1 — Identify the product
Brand → Generic → API → Salt → Strength → Dosage Form → Route
STEP 2 — Identify the manufacturer
Manufacturer → Manufacturing licence → GMP → Site → Certifications
STEP 3 — Identify Indian export requirements
IEC → DGFT → Customs → HS Code → Banking → Export documentation
STEP 4 — Identify destination-country requirements
Importer → Establishment → Product registration → Marketing Authorisation → Import licence → Labelling
STEP 5 — Determine medicine status
OTC / Prescription / Controlled / Restricted / Special regulatory category
STEP 6 — Prepare technical documentation
COA → GMP → CPP/COPP → CFS/FSC → DMF/CEP/ASMF → Dossier
STEP 7 — Determine commercial model
Distributor / Importer / Wholesaler / Tender / Private Label / OEM / CDMO
STEP 8 — Determine logistics
EXW / FCA / FOB / CFR / CIF / CPT / CIP / DAP / DDP
STEP 9 — Determine payment risk
Advance / TT / LC / DP / DA / Open Account
STEP 10 — Verify before shipment
Product + Manufacturer + Buyer + Registration + Documentation + Customs + Payment + Logistics
PART XVIII — THE MOST IMPORTANT 25 TERMS FOR A NEW INDIAN PHARMA EXPORTER
If someone is completely new to pharma exports, I would make these the “First 25 Terms You Must Know” box in the Nawinza book:
Priority | Term | Why it matters |
1 | API | Identifies active pharmaceutical substance |
2 | FPP | Identifies finished medicine |
3 | CDSCO | Indian drug regulatory authority |
4 | DGFT | Indian foreign-trade authority |
5 | IEC | Core foreign-trade identification |
6 | GMP | Manufacturing quality requirement |
7 | COA | Batch quality evidence |
8 | CPP/COPP | Pharmaceutical regulatory certificate |
9 | DMF | Confidential technical information |
10 | MA | Permission to market |
11 | Product Registration | Destination-market regulatory status |
12 | Import Licence | Destination-country import authorization |
13 | MOQ | Minimum commercial quantity |
14 | OEM | Manufacturing arrangement |
15 | Private Label | Selling under another brand |
16 | CMO/CDMO | Contract manufacturing/development |
17 | Distributor | Foreign commercial partner |
18 | HS Code | Customs classification |
19 | FOB | Major shipping term |
20 | CIF | Shipping + insurance term |
21 | LC | Trade payment mechanism |
22 | QA/QC | Pharmaceutical quality system/testing |
23 | CAPA | Corrective/preventive quality action |
24 | Pharmacovigilance | Medicine safety monitoring |
25 | Recall | Controlled removal of affected product |
Additional Indian Export & Trade Terms
Term | Full Form | Meaning / Importance |
ICEGATE | Indian Customs Electronic Gateway | Indian Customs electronic portal used for customs filings, shipping bills, electronic communication and related processes. |
AD Code | Authorized Dealer Code | Bank-linked code used in export transactions and customs processes. It connects the exporter’s bank account with customs/export operations. |
RCMC | Registration-Cum-Membership Certificate | Exporter registration with the relevant Export Promotion Council; PHARMEXCIL is relevant for many pharmaceutical exporters. |
PHARMEXCIL | Pharmaceuticals Export Promotion Council of India | Government-recognized export promotion body for the Indian pharmaceutical sector. |
e-BRC | Electronic Bank Realisation Certificate | Electronic evidence that export proceeds have been realized through the banking system. |
LUT | Letter of Undertaking | GST mechanism allowing eligible exporters to export without payment of IGST, subject to applicable conditions. |
ITC-HS | Indian Trade Classification – Harmonized System | India’s classification system used for import/export policy and customs purposes. |
HS Code | Harmonized System Code | International product classification system used by customs; exact classification must be verified for the product and destination. |
LEO | Let Export Order | Customs authorization permitting goods to be exported after applicable examination/compliance. |
EGM | Export General Manifest | Carrier-level export manifest filed with Customs after shipment, subject to the applicable process. |
Additional Regulatory Terms
Term | Full Form | Meaning / Importance |
MAH | Marketing Authorisation Holder | Entity legally responsible for a medicinal product’s marketing authorization in a particular jurisdiction. |
MIA | Manufacturing Import Authorization / context-dependent | Must be interpreted according to the jurisdiction; do not use as a universal abbreviation. |
NRA | National Regulatory Authority | Government body responsible for regulating medicines in a country. |
NOC | No Objection Certificate | Official authorization/clearance issued where a particular regulatory or administrative process requires it. |
GMP Inspection | Good Manufacturing Practice Inspection | Regulatory inspection to assess whether manufacturing operations comply with applicable GMP requirements. |
Prequalification | Regulatory/quality prequalification | Formal assessment showing that a product, manufacturer or supplier meets specified requirements, often relevant to institutional/international procurement. |
Regulatory Reliance | — | A regulator uses or considers assessments performed by another trusted regulatory authority to improve efficiency. |
Reference Authority | — | A regulatory authority whose assessment may be relied upon or considered by another jurisdiction. |
Good Regulatory Practices (GRP) | Good Regulatory Practices | Principles intended to make regulatory decision-making consistent, transparent, risk-based and predictable. |
Additional Registration & Dossier Terms
Term | Full Form | Meaning / Difference |
MA | Marketing Authorization | Legal authorization allowing a medicinal product to be marketed in a jurisdiction. |
MAA | Marketing Authorisation Application | Application submitted to obtain marketing authorization. |
MA Number | Marketing Authorization Number | Identification number assigned to an approved product, where the jurisdiction uses such a system. |
Site Master File (SMF) | Site Master File | Document describing a manufacturing site’s organization, facilities, quality system and operations. |
PIL | Patient Information Leaflet | Patient-facing information supplied with a medicine in applicable markets. |
PI | Prescribing Information | Professional prescribing information; exact format and terminology vary by country. |
SmPC | Summary of Product Characteristics | UK/EU professional product information describing approved indications, dosage, warnings, pharmacology and other information. |
Package Insert (PI) | Package Insert | Information accompanying the medicine; terminology and legal requirements vary by market. |
Labeling | — | Legally regulated information appearing on the container, package and/or accompanying documentation. |
Artwork | — | Approved packaging/label design used for a specific market. |
Mock-up | — | Representative visual version of proposed packaging/labeling submitted for regulatory review where required. |
Additional Pharmaceutical Development Terms
Term | Full Form | Meaning / Importance |
QTPP | Quality Target Product Profile | Defines the desired quality characteristics of a pharmaceutical product. |
CQA | Critical Quality Attribute | Physical, chemical, biological or microbiological property that must remain within an appropriate limit/range. |
CPP | Critical Process Parameter | Process parameter whose variability can affect a CQA. |
QbD | Quality by Design | Systematic development approach based on predefined objectives, risk management and scientific understanding. |
QRM | Quality Risk Management | Systematic assessment, control, communication and review of pharmaceutical quality risks. |
DoE | Design of Experiments | Statistical method used to study process/product variables efficiently. |
PAT | Process Analytical Technology | Framework for monitoring and controlling pharmaceutical manufacturing processes. |
Bioavailability | — | Rate and extent to which an active ingredient becomes available at the site of action/systemic circulation. |
Bioequivalence | — | Demonstration that two medicinal products have sufficiently comparable bioavailability/exposure under specified conditions. |
BE Study | Bioequivalence Study | Study used to establish bioequivalence, commonly important for generic medicines. |
BA/BE | Bioavailability/Bioequivalence | Regulatory evidence frequently relevant to generic drug applications. |
Pharmaceutical Equivalence | — | Products contain the same active ingredient(s), strength and dosage form, subject to the applicable regulatory definition. |
Therapeutic Equivalence | — | Broader regulatory concept involving pharmaceutical equivalence plus evidence required to establish comparable therapeutic performance. |
Additional Quality-Control Terms
Term | Full Form | Meaning |
IPC | In-Process Control | Checks performed during manufacturing rather than only on the finished product. |
IPQC | In-Process Quality Control | Quality-control activities conducted during manufacturing. |
FP | Finished Product | Completed medicinal product ready for release after applicable testing and quality review. |
RM | Raw Material | Material used in pharmaceutical manufacturing. |
PM | Packaging Material | Material used to package a pharmaceutical product. |
AMV | Analytical Method Validation | Demonstration that an analytical method is suitable for its intended purpose. |
AMT | Analytical Method Transfer | Transfer of an analytical method from one laboratory/site to another. |
Stability Study | — | Study determining how product quality changes over time under defined environmental conditions. |
Accelerated Stability | — | Stability testing under stressed conditions to support development and regulatory assessment. |
Long-Term Stability | — | Stability testing under recommended storage conditions over the intended shelf-life period. |
Shelf Life | — | Period during which the product is expected to remain within approved specifications when stored as directed. |
Retest Period | — | Period after which an API/material should be retested before use, where applicable. |
Specification | — | Set of tests, references to analytical procedures and acceptance criteria defining product/material quality. |
Acceptance Criteria | — | Numerical or qualitative limits used to determine whether a test result passes. |
Additional Pharmacovigilance Terms
Term | Full Form | Meaning |
ICSR | Individual Case Safety Report | Report containing information about an individual suspected adverse reaction/event case. |
MedDRA | Medical Dictionary for Regulatory Activities | Standardized medical terminology widely used for coding regulatory safety information. |
PV Agreement / PVA | Pharmacovigilance Agreement | Agreement defining pharmacovigilance responsibilities between companies/partners. |
Safety Database | — | System used to collect, manage and evaluate safety information. |
Benefit-Risk Assessment | — | Evaluation comparing a medicine’s therapeutic benefits against identified or potential risks. |
Risk Minimization | — | Measures intended to prevent or reduce medicine-related risks. |
PASS | Post-Authorization Safety Study | Study conducted after authorization to obtain additional safety information. |
PAES | Post-Authorization Efficacy Study | Study performed after authorization to collect additional efficacy information. |
Additional Supply-Chain & Export Terms
Term | Full Form | Meaning |
GDP | Good Distribution Practice | Standards governing proper storage, transportation and distribution of medicinal products. Do not confuse with Gross Domestic Product. |
GSP | Good Storage Practice | Principles for maintaining appropriate storage conditions for medicines. |
FEFO | First Expiry, First Out | Inventory method where products with the earliest expiry are dispatched first. |
FIFO | First In, First Out | Inventory method based on earliest receipt date. |
Temperature Excursion | — | Situation where a product is exposed to temperatures outside its specified range. |
Data Logger | — | Device used to record environmental conditions such as temperature during storage or transportation. |
GDP Certificate | Good Distribution Practice Certificate | Evidence of compliance where the relevant authority/certification system issues such a certificate. |
CoA / COA | Certificate of Analysis | Document showing test results against specified quality requirements. |
CoC / COC | Certificate of Conformity | Certificate confirming conformity with specified requirements; exact meaning depends on the transaction/regulatory context. |
POD | Proof of Delivery | Evidence that shipment was delivered to the consignee/customer. |
Additional Commercial Terms
Term | Full Form | Meaning |
SKU | Stock Keeping Unit | Unique inventory/product identifier used commercially. |
RFQ | Request for Quotation | Buyer request asking suppliers for price and commercial terms. |
RFI | Request for Information | Preliminary request used to gather supplier/product information. |
RFP | Request for Proposal | Formal request seeking a detailed commercial/technical proposal. |
PO | Purchase Order | Buyer’s formal order specifying products, quantities and commercial terms. |
PI | Proforma Invoice | Preliminary commercial invoice used before shipment/payment; PI can also mean Prescribing Information, so context matters. |
CI | Commercial Invoice | Final commercial invoice used for customs and commercial purposes. |
PL | Packing List | Document showing package-level shipment details. |
DN | Delivery Note | Document accompanying/confirming delivery, depending on the transaction. |
Credit Limit | — | Maximum credit exposure permitted for a buyer. |
Due Diligence | — | Systematic verification of a supplier, buyer, product, licence, financial position or regulatory status. |
KYC | Know Your Customer | Process of identifying and verifying a business/customer. |
KYB | Know Your Business | Business-level verification of a company and its legitimacy. |
Critical Legal/Regulatory Distinctions to Add to the Book
These deserve their own glossary box, because exporters frequently confuse them:
Approved ≠ Registered ≠ Permitted ≠ Marketed ≠ Exportable ≠ Importable ≠ Banned
- Approved — regulator has granted the relevant approval.
- Registered — product/company/site has been entered into the applicable regulatory registration system.
- Permitted — activity/product is legally allowed under the relevant rules.
- Not approved — approval has not been granted; this does not automatically mean banned.
- Restricted — additional conditions or controls apply.
- Controlled — subject to specific legal controls, often including narcotic/psychotropic or other special regulatory requirements.
- Banned/Prohibited — law specifically prohibits the product/activity in the relevant context.
- Exportable from India — does not automatically mean legally importable or marketable in the destination country.
- Registered in India — does not automatically mean registered in the destination country.
- Manufactured in a GMP-compliant facility — does not automatically mean the product is approved for sale in another country.
Important Abbreviation Conflicts
These should be explicitly explained in the glossary:
Abbreviation | Possible Meaning | How to Interpret |
NDA | New Drug Application / Non-Disclosure Agreement | Regulatory context = New Drug Application; commercial/legal context = Non-Disclosure Agreement. |
IEC | Importer Exporter Code / Independent Ethics Committee | Indian trade context = Importer Exporter Code; clinical research context may mean Independent Ethics Committee. |
GDP | Good Distribution Practice / Gross Domestic Product | Pharma logistics = Good Distribution Practice; economics = Gross Domestic Product. |
PI | Proforma Invoice / Prescribing Information / Package Insert | Commercial, regulatory and medical contexts differ. |
MA | Marketing Authorization / other context-specific meanings | Pharma regulatory context normally refers to Marketing Authorization. |
LOA | Letter of Authorization / Letter of Access | Meaning depends on regulatory/commercial context. |
CPP | Certificate of Pharmaceutical Product / Critical Process Parameter | Regulatory export certificate vs pharmaceutical manufacturing terminology. |
BPR | Batch Packaging Record / other organization-specific terminology | Always check the company’s SOP/document-control terminology. |
BL/BOL | Bill of Lading | Usually the same shipping-document concept; terminology may vary by organization. |
EP/Ph. Eur. | European Pharmacopoeia | “Ph. Eur.” is the formal abbreviation commonly used for European Pharmacopoeia. |
One more section I strongly recommend for your book
26-Country Regulatory Authority Quick Reference
Country | Principal Authority / Regulatory Reference |
🇺🇸 USA | FDA — Food and Drug Administration |
🇬🇧 UK | MHRA — Medicines and Healthcare products Regulatory Agency |
🇦🇪 UAE | EDE — Emirates Drug Establishment |
🇸🇦 Saudi Arabia | SFDA — Saudi Food and Drug Authority |
🇨🇦 Canada | Health Canada |
🇦🇺 Australia | TGA — Therapeutic Goods Administration |
🇩🇪 Germany | BfArM / PEI, depending on product; EU framework also applies |
🇫🇷 France | ANSM; EU framework also applies |
🇳🇱 Netherlands | MEB; EU framework also applies |
🇧🇷 Brazil | ANVISA |
🇿🇦 South Africa | SAHPRA |
🇳🇬 Nigeria | NAFDAC |
🇰🇪 Kenya | Pharmacy and Poisons Board (PPB) |
🇹🇿 Tanzania | TMDA |
🇺🇬 Uganda | National Drug Authority (NDA) |
🇬🇭 Ghana | FDA Ghana |
🇪🇬 Egypt | Egyptian Drug Authority (EDA) |
🇹🇷 Türkiye | TITCK |
🇷🇺 Russia | Ministry of Health / Roszdravnadzor framework |
🇧🇩 Bangladesh | DGDA |
🇮🇩 Indonesia | BPOM |
🇲🇾 Malaysia | NPRA |
🇵🇭 Philippines | FDA Philippines |
🇻🇳 Vietnam | Drug Administration of Vietnam (DAV) |
🇯🇵 Japan | PMDA / MHLW |
🇳🇿 New Zealand | Medsafe |
Important: For Germany, France and the Netherlands, do not describe EMA as simply “the national regulator.” EMA is an EU-level agency and the applicable authorization route can involve EU centralized or national/mutual-recognition/decentralized procedures.
Final glossary addition: “Verification Required”
Regulatory terminology is jurisdiction-specific. An abbreviation, certificate, licence or regulatory pathway may have different meanings or legal effects in different countries. Exporters should verify the current requirement with the applicable national regulator, customs authority, importing-country authority and, where necessary, qualified regulatory counsel before shipment.
NAWINZA OPC PVT. LTD. — EDUCATIONAL & REGULATORY DISCLAIMER
Disclaimer — Educational, Informational & Reference Use Only
The information, articles, pharmaceutical terminology, medicine descriptions, regulatory information, country-specific guidance, export procedures, documentation requirements, product classifications, examples, tables, databases, and other materials published on this website by Nawinza OPC Pvt. Ltd. are provided solely for educational, informational, academic, research, training, and general reference purposes.
This website and its content are intended to help students, researchers, exporters, importers, pharmaceutical professionals, business learners, and other interested persons understand general concepts relating to pharmaceutical products, international pharmaceutical trade, regulatory terminology, export procedures, documentation, quality requirements, logistics, and global pharmaceutical markets.
No Offer or Intention to Sell
Nawinza OPC Pvt. Ltd. does not intend this educational content, by itself, to constitute an offer, solicitation, invitation, advertisement, quotation, commitment, or representation to sell or supply any pharmaceutical medicine, drug, API, formulation, controlled substance, medical product, or other regulated product.
The appearance of a medicine, pharmaceutical product, manufacturer, supplier, buyer, country, regulatory category, product example, trade term, HS code, or commercial reference on this website does not mean that Nawinza OPC Pvt. Ltd. is offering that product for sale or confirming its availability, legality, registration, approval, importability, exportability, or marketability in any particular country.
Regulatory Requirements May Differ
Pharmaceutical laws and regulatory requirements vary significantly between countries and may also vary according to:
- active ingredient/API;
- salt, strength and formulation;
- dosage form and route of administration;
- intended indication/use;
- prescription or OTC classification;
- controlled-substance status;
- product registration status;
- manufacturer and manufacturing site;
- importing country;
- intended buyer/importer;
- quantity and shipment purpose;
- clinical, commercial, research or other intended use; and
- applicable national, regional and international regulations.
Regulatory terminology is jurisdiction-specific. An abbreviation, certificate, licence, approval, registration, regulatory pathway or document may have different meanings or legal effects in different countries.
Accordingly, information presented on this website should not be interpreted as a guarantee that a particular pharmaceutical product is approved, registered, permitted, freely exportable, freely importable, or legally marketable in any particular jurisdiction.
No Legal, Regulatory or Professional Advice
The information provided is not intended to constitute legal, regulatory, medical, pharmaceutical, customs, tax, accounting, financial, investment, clinical, pharmacovigilance, or other professional advice.
Users should not rely solely on website content when making decisions involving pharmaceutical manufacturing, registration, importation, exportation, distribution, marketing, prescribing, procurement, customs clearance, licensing, or commercial transactions.
Where appropriate, users should obtain independent advice from:
- the relevant national medicines regulatory authority;
- customs authorities;
- DGFT and other applicable Indian authorities;
- the importing-country authority;
- qualified regulatory professionals;
- customs brokers or trade professionals;
- qualified legal professionals;
- licensed healthcare/pharmaceutical professionals; and
- other appropriately qualified advisers.
Verification of Current Information
Regulations, policies, licences, registration procedures, tariffs, customs requirements, regulatory classifications, product approvals and government procedures may change without notice.
Users are therefore responsible for independently verifying the latest applicable requirements before relying on any information or undertaking any transaction.
For pharmaceutical exports from India, verification may involve the relevant Indian authorities as well as the regulatory and customs authorities of the destination country.
Product-Specific Verification
The inclusion of a medicine or pharmaceutical product in an educational database does not constitute an endorsement, recommendation, approval, certification, or authorization of that product.
Product-specific information should be independently verified against the applicable official regulatory source before:
- manufacturing;
- purchasing;
- exporting;
- importing;
- registering;
- distributing;
- marketing;
- advertising; or
- otherwise dealing with the product.
Particular caution should be exercised for controlled substances, narcotic and psychotropic substances, hormones, anabolic steroids, prescription medicines, biologics, investigational products, veterinary medicines, products with special import restrictions, and other regulated or high-risk products.
No Guarantee of Accuracy or Completeness
Although reasonable efforts may be made to present useful and accurate educational information, Nawinza OPC Pvt. Ltd. does not warrant or guarantee that the information is complete, current, error-free, universally applicable, or suitable for a particular transaction or jurisdiction.
Examples, classifications, regulatory references, commercial information, supplier/buyer information, HS codes, prices, MOQs, timelines and other data may require independent verification.
Where information is marked “to be verified,” “indicative,” “example,” “preliminary,” “subject to confirmation,” or similar wording, users should treat it accordingly and should not consider it confirmed regulatory or commercial advice.
Website and Student Reference Use
Certain materials may be provided specifically to support students, researchers, trainees, exporters and educational users in understanding pharmaceutical export concepts.
Such material may be used as a learning and reference resource, but users should not treat educational examples as instructions to conduct a regulated pharmaceutical transaction without completing the appropriate independent regulatory and legal checks.
Third-Party Information
References to third-party companies, manufacturers, suppliers, buyers, distributors, websites, organizations, regulatory authorities, databases or commercial platforms are provided where applicable for identification, research or reference purposes only.
Such references do not necessarily constitute an endorsement, partnership, certification, recommendation, guarantee, or commercial relationship with Nawinza OPC Pvt. Ltd., unless expressly stated.
No Guarantee of Commercial Transaction
Nawinza OPC Pvt. Ltd. does not guarantee:
- product availability;
- supplier availability;
- buyer availability;
- product pricing;
- minimum order quantities;
- regulatory approval;
- registration;
- import permission;
- export permission;
- customs clearance;
- shipment acceptance;
- delivery timelines;
- payment;
- commercial profitability; or
- successful completion of any proposed transaction.
All commercial terms and regulatory requirements must be independently confirmed before entering into a transaction.
User Responsibility
By using this website, the user acknowledges that the responsibility for verifying applicable laws, regulations, licences, approvals, registrations, documentation and commercial requirements rests with the user and the relevant parties to the transaction.
Users should not use the information on this website as a substitute for professional regulatory or legal due diligence.
Final Statement
Nawinza OPC Pvt. Ltd. provides this material in good faith as an educational, informational and research resource. Nothing contained on this website should be interpreted as an offer to sell, a solicitation to purchase, a medical prescription, regulatory approval, legal advice, or a guarantee that any pharmaceutical product or transaction is lawful, approved, registered, importable, exportable or marketable in a particular jurisdiction.
Always verify the latest requirements directly with the applicable government authority, regulatory authority, customs authority and qualified professional before taking any regulatory, medical, export, import or commercial action.
© Nawinza OPC Pvt. Ltd. — All Rights Reserved.
